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Summary 
Mycoplasma nasistruthionis sp. nov. str. Ms03 (Ms03) is one of three Mycoplasma species 
that were identified from ostriches. Mycoplasmas infections have been implicated in ostrich 
chick mortalities, growth retardation and downgrading of ostrich carcasses. Currently there is 
no vaccine available for the treatment of mycoplasmosis in ostriches. This study investigated 
the development of DNA vaccines against Ms03 infections in ostriches. To this end, the 
Ms03 genome was sequenced and annotated. The vaccine candidate gene, oppA, was 
identified within the genome sequence and characterized before DNA vaccines containing 
the oppA were developed and tested.  
The genome of Ms03 was sequenced and the resulting 172 contigs were annotated. This 
dissertation presents the first Ms03 draft genome and annotation which contributed to the 
understanding of Ms03 as a miniature genetically independent organism. In Ms03, genome 
replication, cell division, RNA transcription, protein translation and glycolysis resemble that 
of the closely related Mycoplasma synoviae 53. Purine and pyrimidine metabolism was 
incomplete and de novo synthesis thereof was not possible. Amino acid synthesis in Ms03 
was mostly absent and only the genes that convert aspartate to asparagine and glycine to 
serine were found. More importers than exporters were annotated owing to the lack of 
synthesis pathways in Ms03, which is typical for mycoplasmas that have parasitic life styles. 
Two oligopeptide permease (opp) operons were annotated within the Ms03 genome.  
The potential of the oppA as a vaccine candidate gene was evaluated by investigating the 
need for a substrate-binding domain (OppA) as part of the OppBCDF transporter within 
Mycoplasma species. An oppA homologue could be identified for each oppBCDF operon in 
all species and therefore must play an essential role in oligopeptide transport. All 
mycoplasmas (except for hemoplasma) had one, two or three opp operons that could be 
divided into three types (Type A, B and C). Each type had unique InterPro and MEME 
domains and motifs which together with the phylogenetic analysis suggest unique roles in 
their survival under different conditions. Ms03 had a Type A and a Type B opp operon, the 
Type A oppA was used as vaccine candidate gene. 
The Type A oppA was cloned and site-directed mutagenesis was used for codon correction 
before the mutated gene was sub-cloned into three DNA vaccine vectors. The three DNA 
vaccines (pCI-neo_oppA, VR1012_oppA and VR1020_oppA) were used to vaccinate 
ostriches and the OppA-antibody response was analysed by ELISA. The VR1020_oppA and 
pCI-neo_oppA constructs elicited a primary immune response in ostriches, indicating that 
the OppA protein was expressed in vivo and was immunogenic. This can therefore be 
viewed as the first step in the development of a DNA vaccine for the control of mycoplasma 
infections in ostriches.   
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Opsomming 
Mycoplasma nasistruthionis sp. nov. str. Ms03 (Ms03) is een van drie mikoplasma spesies 
wat volstruise infekteer. Mikoplasma-infeksies in volstruise veroorsaak kuiken vrektes, 
vertraagde groei en afgradering van volstruis karkasse. Daar is tans geen geregistreerde 
mikoplasma entstof beskikbaar vir gebruik in volstruise nie. Hierdie studie het die 
ontwikkeling van DNS-entstowwe teen Ms03-infeksies in volstruise ondersoek. Vir hierdie 
doel was die Ms03-genoomvolgorde bepaal en geannoteer. Die entstofkandidaat-geen, 
oppA, was geïdentifiseer in die genoomvolgorde en gekarakteriseer voordat DNS-entstowwe 
(wat die oppA-geen bevat) ontwikkel en getoets is.  
Die Ms03-genoomvolgorde was bepaal en die gegenereerde 172 aaneenlopende volgordes 
was geannoteer. Hierdie proefskrif bied die eerste voorlopige volgorde en annotering van die 
Ms03-genoom wat bygedra het tot die kennis van Ms03 as 'n miniatuur geneties 
onafhanklike organisme. Genoom-replikasie, seldeling, RNS-transkripsie, proteïen-translasie 
en glikolise in Ms03 stem ooreen met dié prosesse in die naverwante Mycoplasma synoviae 
53. Die purien en pirimidien metabolisme was onvolledig en de novo sintese daarvan was 
nie moontlik in Ms03 nie. Aminosuursintese in Ms03 was meestal afwesig en net die gene 
wat aspartaat omskep na asparagien en glisien na serien was gevind in die annoteerde 
genoom. Meer invoerders as uitvoerders was geannoteer, wat dui op die gebrek aan 
sintesepadweë in Ms03. Dit is tipies van mikoplasmas wat ‘n parasitiese lewensstyle het. 
Twee oligopeptied-permeases (opp) operons was gevind in die Ms03-genoom. 
Die potensiaal van die oppA-geen as 'n entstofkandidaat-geen was geëvalueer deur die 
behoefte van 'n substraatbindingsdomein (OppA) as deel van die OppBCDF-vervoerder 
binne mikoplasma spesies te ondersoek. 'n Homoloog van die oppA-geen kon geïdentifiseer 
word vir elke oppBCDF-operon in al die spesies en behoort daarom 'n noodsaaklike rol te 
speel in die vervoer van oligopeptiede. Alle mikoplasmas (behalwe vir hemoplasmas) het 
een, twee of drie opp-operons, wat verdeel kan word in drie tipes (Tipe A, B en C). Elke tipe 
het unieke InterPro en MEME domeine en motiewe wat saam met die filogenetiese ontleding 
daarop dui dat hulle unieke rolle in oorlewing onder verskillende omstandighede speel. Ms03 
het 'n Tipe A en Tipe B opp-operon, die Tipe A oppA is gebruik as entstofkandidaat-geen. 
Die Tipe A oppA-geen was gekloneer en teikengerigte-mutagenese was gebruik vir 
kodonregstellings voordat die gemuteerde geen in drie DNS-entstof vektore gesubkloneer 
was. Die drie DNS-entstowwe (pCI-neo_oppA, VR1012_oppA en VR1020_oppA) was 
gebruik om volstruise in te ent en die OppA-teenliggaamsreaksie was geanaliseer deur 
ELISA. Inenting met die VR1020_oppA en pCI-neo_oppA entstowwe het tot 'n primêre 
immuniteitsreaksie in volstruise gelei. Dit dui daarop dat die OppA proteïen in vivo uitgedruk 
en immunogenies was. Dit kan beskou word as die eerste stap in die ontwikkeling van 'n 
DNS-entstof vir die beheer van mikoplasma-infeksies in volstruise.  
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Chapter 1  Introduction 
Struthio camelus, commonly known as the ostrich, is the largest living flightless bird in the 
world. Although endemic to Africa and Saudi Arabia, ostriches are farmed around the world 
for their meat, leather and feathers. South Africa is the world’s largest producer of ostrich 
products and contributes to about 75% of the global ostrich market. In South Africa, ostrich 
farms contribute significantly to the economy, with the average gross value amounting to 
approximately R1.5 billion annually and provide about 20 000 jobs in rural areas. Ostrich 
farming requires a dry climate making the arid Klein Karoo region in the Western Cape 
Province of South Africa ideal. Approximately 75% of the South African ostriches are found 
in the Klein Karoo region (DAFF 2014). However, the South African ostrich industry is largely 
dependent on the export of ostrich products. This makes it particularly vulnerable to 
internationally notifiable diseases such as avian influenza (AI). The industry has therefore 
invested in research into ostrich diseases that could lead to a reduction in international 
embargoes and production losses. 
An increased demand for ostrich meat has resulted in ostriches being reared under intensive 
farming conditions. Under these conditions ostriches are more exposed to diseases. In 
commercial ostrich farming, livestock is frequently moved since the eggs are hatched on a 
breeding farm or hatchery and day-old chicks (less than 72 hours) are moved to a second 
location where the chicks are reared for about three months (Figure 1.1). The three-month-
old ostriches are moved to adult rearing farms with larger enclosures to accommodate the 
increase in bird size. At nine to 12 months of age, ostriches are moved again to a quarantine 
area for a minimum of 14 days before slaughtering. This quarantine period is required by 
South African regulations and was implemented in response to the repeated outbreak of AI 
to ensure that ostrich meat is disease free.  
 
Figure 1.1 Ostrich production in South Africa (Moore et al. 2014).   
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In South Africa, AI is a notifiable disease and ostrich flocks are monitored bi-annually as well 
as before movement and slaughter as part of an official serological surveillance programme 
(Abolnik et al. 2013). When ostriches test positive for antibodies against AI, a stamping-out 
approach is followed and all ostriches on the farm are slaughtered, while all farms in a 10 km 
radius from the outbreak are quarantined. Export of fresh ostrich meat is immediately halted 
and the quarantine is only lifted once the farms in the quarantine area test negative in two 
rounds of testing, 28 days apart (Van Helden et al. 2012). South Africa implemented these 
measurements in 2013 in response to the repeated outbreaks of AI stating in 2004. The 
2011 outbreak of AI had a major impact on the industry and meat production decreased from 
9 000 tons in the 2009/2010 financial year to 3 000 tons in the 2012/2013 financial year 
(DAFF 2014) mainly as a result of the international embargo on ostrich meat.  
Although AI has had a very negative short term effect on the ostrich industry, an almost 
more serious long term problem in the intensive rearing of ostriches has been the incidence 
of mycoplasma infections. Mycoplasma infections have been implicated in ostrich chick 
mortalities, growth retardation and downgrading of carcasses (Botes 2004). Mycoplasmas 
are known to be host-specific and in 2005, three unique Mycoplasma species were identified 
in South African ostriches (Botes et al. 2005a). These were provisionally named Ms01, Ms02 
and Ms03. Ms01 and Ms03 have since been isolated from Namibian ostriches as well and 
have been described as Mycoplasma struthionis sp. nov. and Mycoplasma nasistruthionis 
sp. nov., respectively, but have not been formally published (Langer 2009).  
Mycoplasmas infect the mucosal membranes of the ostrich respiratory tract causing eye, 
nose and air sac infections (Botes et al. 2005b). These infections can be treated with 
antibiotics, but this is not always successful, since carrier conditions exist (infected ostriches 
without symptoms). Currently a combination of biosecurity practice and antibiotic treatment 
is used to control mycoplasma infections. As yet, there are no commercial vaccines 
available for the prevention of mycoplasma infections in ostrich. Chicken mycoplasma 
vaccines have proved to be ineffective (Pretorius 2009). The development of whole 
organism vaccines is hampered by the fact that these mycoplasmas are slow growing and 
require complex media for growth (Langer 2009), making such vaccine strategies ineffective 
and expensive. DNA vaccines present an attractive alternative to vaccine development for 
numerous reasons such as, economic large scale production and that the antigen is 
produced within the host’s own cells (Mahoney et al. 2000; Liu 2011). Recent developments 
in genome sequencing techniques provide a unique opportunity to characterize the genes of 
bacteria and inter alia mycoplasmas. This aids in the development of DNA vaccines by 
providing a repertoire of genes that can be used to select vaccine candidate genes. 
The overall objective of this study was to investigate the development of DNA vaccines 
against M. nasistruthionis sp. nov. infections in South African ostriches. The genome of 
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M. nasistruthionis sp. nov. str. Ms03 was sequenced and annotated to allow for a better 
understanding of its metabolic capacity as well as for the identification of the vaccine 
candidate gene, oppA. After cloning of the gene into appropriate DNA vaccine vectors, the 
ability of these DNA vaccines to elicit an immune response was evaluated.  
In Chapter 2 a literature overview of the genomic characteristics and essential processes in 
mycoplasmas is given. The second part of the literature overview focuses on the prevention 
of mycoplasma infections with the main focus on DNA vaccines. 
The first aim of this study was to expand the knowledge of M. nasistruthionis sp. nov. str. 
Ms03 by determining the genome sequence, annotating the genes and evaluating the 
metabolic pathways of essential processes. The second aim was to identify and characterize 
the oppA gene as potential vaccine candidate gene. The results from these analyses are 
presented in Chapter 3.  
The third aim was to investigate the prevalence of the oppA gene within all Mycoplasma 
species in order to assess its potential as a vaccine candidate gene. The results are 
presented in Chapter 4 as a published manuscript (Gene, 2015, Volume 558, Issue 1, pages 
31-40) and are preceded by background information on certain aspects of the experimental 
design. 
The fourth aim was to develop three DNA vaccines containing the M. nasistruthionis sp. nov. 
str. Ms03 oppA gene and to evaluate their potential to elicit an immune response in 
ostriches. The results from the DNA vaccine trial are presented as an independent 
manuscript in Chapter 5. This is once again preceded by background information on certain 
aspects of the experimental design and the negative influence an outbreak of AI had on it.  
The objectives of the different parts of this study are described in the introduction of the 
respective chapters. The dissertation ends with an overall conclusion in Chapter 6. The 
references for all the chapters are given at the end of Chapter 6 and relevant supplementary 
data are presented in Appendix 1 to 5.  
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Chapter 2  The mycoplasma genome: Implication of DNA vaccine design  
2.1 Introduction: Mycoplasmas in the genomic era 
With genome sequencing becoming an everyday technique, the question of what we have 
learnt from the increasing amount of available sequencing data has become more and more 
important. Being the self-replicating organisms with the smallest genomes, mycoplasmas 
have being given considerable attention in this genomic era and a total of 91 genomes from 
47 species in the class Mollicutes have been completely sequenced and annotated up to 
June 2015 (Appendix 1). The first bacterial genome, Mycoplasma genitalium, was 
sequenced in 1995 (Fraser et al. 1995) and is the smallest genome of all self-replicating 
organisms. Additionally, a mycoplasma genome has also served as the blueprint for the first 
synthetic organism (Gibson et al. 2010). Mycoplasma research aims to understand the 
genomic organization and composition of the mycoplasma cell. If we were to understand the 
smallest and “simplest” genome, it may aid in understanding more complex cell systems as 
well as aiding in the treatment and prevention of mycoplasma bacterial infections.  
Mycoplasmas are parasitic or commensal bacteria that are of medical and agricultural 
importance since they are associated with a number of diseases in humans and animals. 
Mycoplasmas belong to the phylum Firmicutes and the class Mollicutes, ‘mollis’ meaning 
soft and ‘cutes’ meaning skin, reflecting the lack of cell walls in this class (Razin et al. 1998) 
(Table 2.1). They therefore stain negative in the Gram stain test, although they have evolved 
from low guanine and cytosine (G+C) containing Gram-positive bacteria through a reductive 
evolutionary process with their closest relatives being Lactobacillus, Bacillus and Clostridium 
(Woese et al. 1980; Weisburg et al. 1989; Wolf et al. 2004). All of the members in the order 
Mycoplasmatales require exogenous sterol for maintenance of the bacterial cell membrane  
 
Table 2.1 Classification of the class Mollicutes 
Phylum  Firmicutes   
Class Bacilli 
Clostridia 
Mollicutes 
  
Class Order Family Genus 
Mollicutes Mycoplasmatales Mycoplasmataceae Mycoplasma 
Ureaplasma 
 Acholeplasmatales Acholeplasmataceae Incertae sedis 
Acholeplasma 
Phytoplasma Candidatus 
 Anaeroplasmatales Anaeroplasmataceae Anaeroplasma Asteroleplasma 
 Entomoplasmatales Spiroplasmataceae Spiroplasma 
  Entomoplasmataceae Entomoplasma Mesoplasma 
Reference: Razin et al. (1998); Wolf et al. (2004); Brown (2010).  
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which is reflected by the absence of these molecular pathways within their genomes (Brown 
2010). The genus Mycoplasma is divided into three phylogenetic groups based on the 
typical bacterial 16S ribosomal RNA (rRNA) phylogeny: the hominis, pneumoniae and 
spiroplasma groups as described by Wolf et al. (2004) (Figure 2.1). In general, members of 
the genus Mycoplasma are known for their low G+C content and small genome size.  
 
 
Figure 2.1 Maximum likelihood phylogeny the class Mollicutes based on 16S rRNA 
sequences. Bootstrap values (≥70%) are indicated above or below nodes. The columns on 
the right-hand side indicate the hosts for each Mycoplasma species as well as the 
phylogenetic group (hominis, pneumoniae and spiroplasma).   
Bacillus subtilis str. 168
Clostridium botulinum A
Clostridium tetani E88 str. Massach
Acholeplasma laidlawii
Anaeroplasma bactoclasticum
M. arthritidis 158L3-1 
M. hominis ATCC 23114
M. struthionis sp. nov. str. Ms01
M. mobile 163K
M. pulmonis UAB CTIP
M. hyorhinis HUB-1
M. conjunctivae HRC/583
M. hyopneumoniae 232
M. hyopneumoniae 7448 
M. hyopneumoniae J 
M. synoviae 53
M. nasistruthionis sp. nov. str. Ms03
Mycoplasma sp. Ms02
M. alligatoris A21JP2
M. crocodyli MP145
M. fermentans JER
M. fermentans M64
M. agalactiae
M. agalactiae PG2
M. bovis PG45
M. bovis Hubei-1
Hominis
group
Spiroplasma citri
Spiroplasma taiwanense CT-1
M. putrefaciens KS1
M. mycoides subsp. capri LC str. 95010
M. mycoides subsp. mycoides SC str. PG1
M. capricolum subsp. capricolum ATCC 27343
M. leachii PG50
Spiroplasma
group
M. haemocanis str. Illinois
M. haemofelis str. Langford 1
Candidatus M. haemominutum 'Birmingham 1'
M. ovis str. Michigan
M. wenyonii str. Massachusetts
Candidatus M. haemolamae str. Purdue
M. parvum str. Indiana
M. suis str. Illinois
Ureaplasma gallorale str. D6-1
Ureaplasma urealyticum serovar 13
M. iowae 695
M. penetrans HF-2
M. gallisepticum F 
M. gallisepticum R(high)
M. gallisepticum R(low)
M. genitalium G37
M. pneumoniae 309 
M. pneumoniae M129
Pneumoniae
group
100
100
85
100
99
100
100
74
86
100
100
100
100
100
98
100
100
100
100
69
100
100
100
100
93
80
100
100
100
100
100
72
100
0.05
Alligator 
Host species
Broad spectrum
Caprids
Crocodile
Plants (Citrus)
Dog
Poulty
Human
Pig
Poultry  
Human 
Rodents
Ostrich
Pig
Pig
Ostrich 
Human
Caprids
Caprids
Bovine
Bovine
Mosquitoes 
Caprids
Bovine
Bovine
Bovine
Caprids
Cat
Cat
Camelid
Sheep 
Bovine
Pig
Pig
Human
Human
Poultry 
Poultry
Human
Poultry
Human
Human 
Poultry
Bovine rumen
Fish
Ostrich
Mouse
Pig
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Genome size appears to be an indication of an organism’s life strategy, with small genomes 
associated with a parasitic life style (Moran 2002), allowing them to acquire complex 
metabolic building blocks from their host rather than synthesizing them. This is reflected in 
mycoplasma culturing studies in which a wide spectrum of substrates and factors is required 
for in vitro growth, with some species requiring undefined media components such as serum 
while other species are characterized as unculturable (Waites and Talkington 2004; 
Guimaraes et al. 2011; Flores-Medina et al. 2012; Citti and Blanchard 2013; Bueno et al. 
2014).  
The trivial name mycoplasma was previously used as a group term for all members in the 
class Mollicutes, however, “Bergey’s Manual® of Systematic Bacteriology” reports that the 
more appropriate term should be mollicute(s) so that the trivial name mycoplasma can be 
devoted to species within the genus Mycoplasma (Brown 2010). In this dissertation, the 
trivial name mycoplasma will be used to refer to species belonging to the genus 
Mycoplasma.  
The first part of this literature review investigates the genomes of mycoplasma with regard to 
genome characteristics, essential cellular pathways as well as pathogenicity. The second 
part focuses on vaccine design, in particular DNA vaccines. 
2.2 Organization of mycoplasma genomes 
Mycoplasmas have typical bacterial single, small circular chromosomes that range in sizes 
from 564 kilobase pairs (kbp) to 1 359 kbp with a G+C content between 24% and 40% 
(Table 2.2). Information in mycoplasma genomes is condensed with 92.54% to 99.10% 
(gene density) of the genome being transcribed to RNA (Table 2.2). As in other bacteria, 
genes in mycoplasmas frequently overlap (Fukuda et al. 1999; Fonseca et al. 2014). Most 
gene overlaps are short (less than 60 nucleotides), terminal unidirectional overlaps and the 
result of deletions resulting in the elongation of the 3' end of the genes. These overlaps are 
not associated with the reduction in mycoplasma genomes size (Fukuda et al. 1999; Fukuda 
et al. 2003).  
Within bacteria, genes are organised into groups that are arranged in tandem in the genome 
(Mao et al. 2009; Yin et al. 2010). These groups are typically called operons and share 
common promoter and terminator sequences that imply that they are co-transcribed into 
single RNA molecules (Simons et al. 1987; Siqueira et al. 2011). Perhaps the best known 
example of operon gene organization in bacteria is the rRNA cluster i.e. 16S, 23S and 5S 
rRNA genes including their intergenic spacers. The largest polycistronic operon in 
Mycoplasma pneumoniae contains 20 genes but most operons only encode two or three 
genes (Guell et al. 2009). It is estimated that as little as 5% of all the genes in Mycoplasma  
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Table 2.2 A summary of the complete genome sequences within the class Mollicutes and their 
features  
Genus * Number of 
Species 
Number of 
Genome# 
Genome 
Size (kbp) 
Gene 
Count 
G+C 
fraction 
Gene 
density (%)  
rRNA 
Count 
tRNA 
Count 
Acholeplasma 1  1  1 497  1 422 0.32 97.05 6 36 
Asteroleplasma No complete genome sequence available  
Phytoplasma 
Candidatus 
5  6  570-960  518-1 155 0.21-0.28 92.47-96.45 6 27-35 
Mesoplasma 1 2 793-825 721-768 0.27 94.59-95.44 6 29 
Entomoplasma No complete genome sequence available  
Spiroplasma 8 8 945-1 175 890-1 422 0.24-0.30 96.28-97.47 3-6 29-33 
Mycoplasma 30 71 564-1 359 523-1 580 0.24-0.40 92.54-99.10 3-8 28-37 
Ureaplasma 2 3 752-874 642-679 0.25-0.26 94.05-95.14 6 27-30 
Class: Mollicutes 47 91 564-1 497 518-1 580 0.21-0.40 92.47-99.10 3-8 27-37 
*  For the complete list of species within the class Mollicutes for which a complete genome sequence is available see Appendix 1. 
Data was downloaded from Integrated Microbial Genomes (IMG) system (http://www.jgi.doe.gov/) on 25 June 2015.  
#  In many cases more than one strain of the same species had a complete genome sequence available. 
 
hyopneumoniae are transcribed in monocistronic units (Siqueira et al. 2011), illustrating the 
abundance and importance of the operon gene organization in mycoplasma genomes.  
Genes organised into an operon are usually associated with a single metabolic pathway (Yin 
et al. 2010). When genes of an essential metabolic pathway are organised into more than 
one operon, these operons will normally cluster together in the genome (Guell et al. 2009; 
Yin et al. 2010). In bacteria (including mycoplasma), operons may, however, also contain 
genes of multiple pathways, which result in related operons being found further apart (Yin et 
al. 2010). The operons of more frequently activated pathways are closer together than less 
active pathways. This arrangement was proposed to reduce effort associated with finding, 
transcribing and translating all of the genes of a particular pathway (Yin et al. 2010). This 
genomic organizational level i.e. the operons, contributes to the regulation of protein 
expression, resulting in similar stoichiometry among proteins of the same pathway (Rocha 
2008). Depending on particular environmental conditions, a gene may be transcribed as part 
of more than one or different operons which is called alternative transcription. Alternative 
transcription is possible due to the presence of internal promoters and/or termination 
sequences within the transcribed sequence (Guell et al. 2009) and plays an important role in 
the adaption to a changing environment.  
Since replication and transcription, two fundamental processes, take place on the 
chromosome, the organization of genes and operons will have an effect on these processes. 
Studies in bacteria have shown that when transcription interrupts or stalls replication, it can 
contribute negatively towards survival and reproduction (Srivatsan et al. 2010; Lin and 
Pasero 2012). Genes therefore tend to be transcribed in the same direction as the leading 
strand, preventing “head-on” collisions of replication and transcription processes (Price et al. 
2005). Additionally frequently activated pathways and essential genes tend to be located on 
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the leading strand near the origin of replication to prevent the transcription of these genes to 
disrupt or stall replication. This allows for transcription during replication. In mycoplasmas, 
gene organization shows a strong bias towards the leading strand (Sirand-Pugnet et al. 
2007a). About 80% of all genes in M. genitalium are located on the leading strand (Rocha 
and Blanchard 2002; Lin and Zhang 2011). 
On an evolutionary time scale, mycoplasmas are located on some of the longest branches of 
the bacterial tree of life implying that as a group they evolve at a faster rate (Woese et al. 
1984; Ciccarelli et al. 2006; Sirand-Pugnet et al. 2007a). Genome “changes” are attributed to 
point mutations, genome rearrangement, gene deletions and horizontal gene transfer (HGT). 
Mycoplasmas have some of the highest rates of base substitution mutations of all unicellular 
organisms (Delaney et al. 2012; Sung et al. 2012). It has also been suggested that genome 
rearrangements in mycoplasmas occur more frequently than previously thought (Marenda 
2014). Large genome rearrangements have been observed within species by comparing the 
genomes of M. hyopneumoniae str. 232 to the J and 7448 strains (Vasconcelos et al. 2005) 
and also between species by comparing the genomes of Mycoplasma bovis Hubei-1 with 
Mycoplasma agalactiae PG2 (Li et al. 2011). Genome rearrangements contribute to the lack 
of gene order conservation among mycoplasmas (Sirand-Pugnet et al. 2007a).  
Mycoplasma genomes are subjected to significant gene decay (deletions) and the remnants 
of genes (pseudogenes) are often found in mycoplasma genomes. As much as 12.99% of 
the M. pneumoniae FH genome consists of pseudogenes while 5.91% of the M. bovis PG45 
genome consists of pseudogenes (Marenda 2014). This is in agreement with the hypothesis 
that mycoplasmas have evolved through a reductive evolutionary process from 
Lactobacillus, Bacillus and Clostridium. These events of gene deletions have played a 
significant role in the reduction of the genome size.  
HGT is a mechanism whereby genes or DNA regions are transferred from one bacterium to 
the next (Pereyre et al. 2009; Marenda 2014). A shared environment between co-infecting 
species can lead to the acquisition of new genes from one another. This is viewed to be a 
strategy to increase the gene pool for better adaption to environmental changes. In 
mycoplasmas, HGT has been postulated within human (Pereyre et al. 2009), ruminant 
(Sirand-Pugnet et al. 2007b) and chicken (Vasconcelos et al. 2005) mycoplasmas. 
Furthermore, a recent study has proved the concept under laboratory conditions (Dordet 
Frisoni et al. 2013). 
Both genome rearrangement and HGT are ascribed to the activity of mobile genetic 
elements. Mobile genetic elements are segments of DNA that encode for proteins that 
mediate the translocation of DNA regions. Mobile genetic elements in mycoplasmas include 
plasmids, bacteriophages, conjugative transposons and insertion sequences (IS) (Marenda 
2014). 
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Plasmids are rarely found in mycoplasmas and have only been reported in some species, 
such as Mycoplasma capricolum subsp. capricolum, Mycoplasma cottewii, Mycoplasma 
leachii, Mycoplasma mycoides subsp. capri and Mycoplasma yeatsii (Thiaucourt et al. 2011; 
Breton et al. 2012; Kent et al. 2012; Marenda 2014). These circular DNA molecules range 
from 1 kbp to 2 kbp in size and belong to the rolling circle replication plasmid family pMV158 
(Breton et al. 2012). They have similar organizations: two unidirectional open reading frames 
(ORFs) with the proteins of the one functioning in the replication of the plasmid and the other 
controlling the copy number of the plasmid in the cell (Thiaucourt et al. 2011; Breton et al. 
2012). The only exception (in the genus Mycoplasma) reported thus far is the 3.4 kbp M. 
yeatsii plasmid, pMyBK1, that belongs to a novel rolling circle replication plasmid family 
(Kent et al. 2012). The pMyBK1 plasmid has two unidirectional ORFs, one may function in 
the replication of the plasmid but the exact functions of the two proteins are speculative 
(Kent et al. 2012). The retention of these plasmids within mycoplasma cells, organisms with 
such drastically reduced genome sizes, implies a significant role in adaptation and survival. 
The role of retaining plasmids remains to be identified (Breton et al. 2012).  
As with plasmids, bacteriophages (prokaryotic viruses) are rarely found in mycoplasmas but 
have been reported in Mycoplasma pulmonis str. UAB 6510, Mycoplasma arthritidis, 
Mycoplasma fermentans and Mycoplasma hyorhinis (Tu et al. 2001; Röske et al. 2004; 
Marenda 2014). These bacteriophages have the ability to integrate into the mycoplasma 
genome and can contribute to genome rearrangements. The insertion of the bacteriophage 
into the genome may disrupt some gene functions. Interestingly in M. arthritidis, 
bacteriophages have been reported to convey virulence (Voelker et al. 1995; Marenda 2014) 
which is the same as in other bacteria (Penadés et al. 2015). 
Conjugative transposons, or integrated conjugative elements (ICEs), are clusters of genes 
that can translocate within and between genomes (Dordet Frisoni et al. 2013; Marenda 
2014). ICEs encode genes that assist in their excision, conjugative transfer and integration 
into the recipient genome (Dordet Frisoni et al. 2013). Mycoplasma ICEs are about 20 kbp to 
30 kbp long, encode for about 20 genes, occur in multiple copies within genomes and have 
been implicated in horizontal gene transfer (Dordet Frisoni et al. 2013; Marenda 2014). 
IS are short DNA elements that code for proteins with transposition activities such as 
transposases (Loreto et al. 2007; Lysnyansky et al. 2009; Marenda 2014). The activities of 
these proteins allow the insertion sequence to move within and between genomes. IS are 
widely found in bacteria (including mycoplasmas) and influence the genome by contributing 
to horizontal gene transfer and genome rearrangement that can result in acquiring new 
genes, deletions, insertions or gene amplification (Loreto et al. 2007; Lysnyansky et al. 
2009). In the genome of Mycoplasma mycoides subsp. mycoides SC, the insertion 
sequence IS1634, which is 1 872 base pairs (bp) long, is found 60 times, illustrating the 
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occurrence of this element within mycoplasma genomes (Vilei et al. 1999; Westberg et al. 
2004).  
In addition to the above, simple sequence repeats (SSRs) are also found within mycoplasma 
genomes. SSRs or microsatellites are mono- to hexanucleotide tandem repeats (Trivedi 
2010) and can play a role in antigenic variation (Citti et al. 2010).  
Even in these small genomes, the contribution of repetitive sequences cannot be ignored 
since they lead to genome rearrangement and horizontal gene transfer as well as 
contributing to the genome size (Marenda 2014). Repetitive regions account for 21% of the 
M. fermentans M64 genome (Shu et al. 2011) and 29% of the M. mycoides subsp. mycoides 
SC genome (Westberg et al. 2004). The contribution of mobile and repetitive elements to the 
fluency of mycoplasma genomes might explain the ability of mycoplasmas to adapt to 
environmental changes and to new hosts.  
2.3 Essential pathways in mycoplasma  
The reduction in the mycoplasma genome size has lead to the loss of several metabolic 
pathways while preserving others, leaving these organisms with the barely essential genes 
to support life. Within these small genomes, the number of predicted genes ranges from 523 
to 1 580 genes (Table 2.2). Through transposon mutagenesis studies, it was determined that 
387 of the 482 protein-encoding genes and all 43 of the structural RNA genes in 
M. genitalium are essential (Hutchison et al. 1999; Glass et al. 2006). In similar studies, 271 
of the 782 protein-encoding genes were identified as essential in M. pulmonis (French et al. 
2008; Dybvig et al. 2010) while in M. arthritidis, 417 of the 635 protein-encoding genes were 
found to be essential (Dybvig et al. 2008). Whether or not a gene is essential will depend on 
its environmental or growth conditions, implying that under a particular condition, a gene 
may be essential whereas under another, it may be non-essential.  
Some genes should be essential under all circumstances (fundamental for life) leading some 
authors to search for what are referred to as core-essential genes. Core-essential gene 
studies in mycoplasma have lead to the identification of between 153 to 196 genes that are 
conserved across Mycoplasma species’ genomes (Lin and Zhang 2011; Liu et al. 2012). 
These genes are generally involved in critical cellular processes such as genome replication, 
transcription and translation (Lin and Zhang 2011). Mycoplasmas are self sustaining thus 
they have the ability to replicate the genome, duplicate the cell, transcribe RNA and translate 
protein independently of their hosts. Energy metabolism pathways are used to produce the 
energy necessary for cell maintenance and growth, while transporters acquire the necessary 
building blocks for these processes from the environment. These fundamental processes will 
be reviewed in the next sections.  
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2 Literature review 
11 
2.3.1 Genome replication and cell division  
During genome replication the circular DNA chromosome of mycoplasmas is duplicated. The 
process of DNA replication is complex and includes a number of steps starting with site 
specific initiation at the origin of replication (ori), followed by the unwinding of the supercoiled 
double stranded genomic DNA and the assembly of the replication machinery before the 
DNA is replicated bidirectionally and finally terminated at the termination site or when the 
two replication forks reach each other.  
The ori is a well defined site where the replication forks open the parent DNA double helix. 
Bacterial genes in the vicinity of the ori tend to be conserved with regard to gene order as 
well as orientation. In most mycoplasmas, the ori is located in the vicinity of the dnaA and 
dnaN genes. In genome annotation, the ori is numbered as the first base of the circular 
chromosome and the ORFs would be numbered from the dnaA gene onwards. The ori has 
been determined experimentally for several mycoplasmas (M. mycoides subsp. mycoides 
LC str. Y-goat, M. mycoides subsp. mycoides SC str. PG1, M. capricolum subsp. capricolum 
str. California kid and M. pulmonis UAB CTIP and M. hyopneumoniae) (Cordova et al. 2002; 
Lartigue et al. 2003; Maglennon et al. 2013). DnaA proteins initiate replication by binding to 
the DnaA box sequences at the ori, which then causes the supercoiled DNA to unwind 
locally. DnaA boxes are 9 bp regions that are rich in adenine and thymine (A+T). The 
consensus sequence of mycoplasma DnaA boxes is more relaxed than in Escherichia coli 
(Cordova et al. 2002). Up to 10 putative DnaA boxes were identified in Mycoplasma species, 
however, for some mycoplasmas bioinformatic analysis could not identify any DnaA boxes 
(Cordova et al. 2002; Sasaki et al. 2002; Lartigue et al. 2003; Lee et al. 2008; Pereyre et al. 
2009). 
The replication machinery of mycoplasmas is similar to that of Bacillus subtilis. The leading 
strand is synthesized continuously while the second strand, the lagging strand, is 
synthesized semidiscontinuously. The leading strand requires 11 proteins to replicate while 
the lagging strand requires the same 11 proteins as well as DnaE and primase (Sanders et 
al. 2010). These different replication modes of the leading and lagging strands result in 
different mutation rates (Engelen et al. 2012) and as a consequence, the leading strand is 
rich in guanine (G) and thymine (T) while the lagging strand is rich in adenine (A) and 
cytosine (C) (Marín and Xia 2008). A shift from a G+T rich region to a C+A rich region is 
frequently observed at the ori in bacteria species and a GC plot can therefore be used to 
predict the ori in bacteria. This technique has been used to identify the ori in mycoplasma 
genomes with mixed success (Sirand-Pugnet et al. 2007a) most probably because 
mycoplasma genomes are generally A+T rich and genome rearrangement occurs frequently.  
In bacteria, replication is terminated when the replication forks progressing in opposite 
directions meet each other or when the replication forks reach a termination site (Kono et al. 
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2012). Specific termination sites or the involvement of termination proteins such as Tur 
protein in E. coli and RTP protein in B. subtilis have not been reported in all Firmicutes 
(Kono et al. 2012). In most bacteria, replication is symmetrical implying that the termination 
and ori is 180° from each other on the circular chromosome, but it has been reported that for 
slow growing bacteria such as mycoplasma, replication may be asymmetrical. As with the 
ori, the termination site can be predicted with a GC plot (Zheng and Liu 2008).  
Mycoplasma cells divide by binary fission and have a low number of conserved genes 
involved in cell division (Alarcon et al. 2007; Fisunov et al. 2011). Compared to B. subtilis 
that has 17 genes in the “cell division and cell wall synthesis” gene cluster, mycoplasma 
genomes only have mraZ, mraW, ftsZ and one gene encoding a hypothetical protein 
(Alarcon et al. 2007; Lluch-Senar et al. 2010). These four genes are usually but not always 
found (Alarcon et al. 2007; Lluch-Senar et al. 2010). The ftsZ gene is believed to play a 
central role in cell division by binary fission but has recently been shown to be non-essential 
in mycoplasma (Lluch-Senar et al. 2010). In the Mycoplasma mobile genome the ftsZ gene 
was not found (Jaffe et al. 2004) and in M. genitalium a ftsZ null mutation was viable (Lluch-
Senar et al. 2007), which implies that an alternative mechanism of cell division can occur 
without the FtsZ protein. Subsequently genes involved in movement have been implicated in 
cell division (Hatchel and Balish 2008; Erickson and Osawa 2010; Lluch-Senar et al. 2010). 
It was proposed that this alternative mechanism can function on its own but Erickson and 
Osawa (2010) suggested that the two mechanisms work together for more effective cell 
division.  
2.3.2 RNA transcription and protein translation 
Transcription is initiated by the binding of the RNA polymerase to the promoter region. The 
mycoplasma promoter regions resemble those of the standard σ70 promoter region with the 
transcription start within 100 bp upstream of the translational start site in transcribed regions 
(Guell et al. 2009; Weber et al. 2012; Siqueira et al. 2014). In M. hyopneumoniae, promoters 
consist of a σ70 -10 promoter element and a -16 element, also found in the low G+C Gram-
positive bacteria (Weber et al. 2012). The -35 promoter element was not identified which is 
typical for low G+C bacteria. Intergenic regions have also been found to transcribe and are 
the result of improper transcription termination as well as the initiation of transcription within 
these regions (Gardner and Minion 2010). The functions of these intergenic regions remain 
to be elucidated. Transcription is either terminated by the formation of a termination hairpin 
that tightly regulates the process (Guell et al. 2009) or by the gradual release of RNA 
polymerase from the DNA after the last gene is transcribed (Gardner and Minion 2010). 
Transcription and translation in bacteria may occur simultaneously since these two 
processes are not compartmentalised in bacteria. Translation relies on the complex 
interaction of multiple proteins and RNA molecules as described by Grosjean et al. (2014). 
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The total number of genes involved in translation for Mycoplasma species ranges from 116 
to 167 of which 104 are conserved in all mycoplasmas (Grosjean et al. 2014). These include 
genes encoding for ribosomal proteins (49), rRNA modification (4), ribosome assembly and 
protein maturation (8), RNA processing (4), tRNA modification (6), tRNA aminoacylation (20) 
and translation factors (13).  
2.3.3 Energy metabolism  
Glycolytic mycoplasmas use glycolysis as their main energy producing pathway while non-
glycolytic mycoplasmas utilise arginine as energy source. In glycolytic mycoplasmas, the 
complete glycolysis pathway (Embden-Meyerhoff-Parnas pathway) that converts glucose to 
pyruvate is present (Halbedel et al. 2007; Shu et al. 2012). Transporters and enzymes for 
connecting reactions to utilize alternative substrates are also present. Mycoplasmas can use 
D-glucose, fructose, glycerol, mannitol and glycerol-3-phosphate that lead into this pathway 
as energy sources (Halbedel et al. 2007; Shu et al. 2012). Both the citric acid cycle and 
pentose phosphate pathways are however partly or completely absent in mycoplasmas. 
Pyruvate is therefore degraded further into acetate, acetyl-coenzyme A or lactate (Halbedel 
et al. 2007; Guimaraes et al. 2011; Shu et al. 2012).  
In non-glycolytic mycoplasmas, ATP is provided by the arginine deiminase pathway encoded 
by the arcA (arginine deiminase), arcB (ornithine carbamoyltransferase) and arcC 
(carbamate kinase) genes as well the arginine transporter genes (Rechnitzer et al. 2011). 
Examples of mycoplasmas that use arginine as their major energy source are Mycoplasma 
hominis (Pereyre et al. 2009) and M. arthritidis (Dybvig et al. 2008). In non-glycolytic 
mycoplasmas some of the enzymes of glycolysis can be absent as is the case in 
M. arthritidis where hexokinase and phosphofructokinase are absent (Dybvig et al. 2008).  
All mycoplasmas have a typical F1F0 ATP synthase that consists of eight conserved genes 
found within an operon (Beven et al. 2012). Unlike mitochondrial ATP synthase of which the 
main function is the generation of ATP, the mycoplasma ATP synthase is thought to be 
involved in ATP hydrolysis and maintenance of the electrochemical gradient since 
mycoplasma lack a cytochrome-containing electron transport chain (Rechnitzer et al. 2011). 
In the absence of a cell wall, mycoplasmas depend on mechanisms such as this to maintain 
and regulate the osmotic balance between the external environment and intracellular space.  
2.3.4 Acquiring the necessary building blocks to maintain life  
Mycoplasmas have limited metabolic capabilities since the massive reduction in genome 
size has lead to the loss of many pathways, therefore nutritional building blocks need to be 
imported into the cell. Pathways evicted include de novo synthesis of purine and 
pyrimidines, some amino acids, Coenzyme A, cholesterol, lipids and cell wall synthesis 
(Razin et al. 1998; Arraes et al. 2007; Bizarro and Schuck 2007). In addition to the above, 
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energy sources such as glucose, fructose, glycerol and arginine are commonly required for 
maintenance and growth. Mycoplasmas need to scavenge these nutrients from the 
environment and therefore require a number of transporters to transport these molecules 
into the cell. About 10% of the genes within mycoplasma genomes code for transport 
proteins and of these ATP-binding cassette systems (ABC) are the most prominent (Nicolás 
et al. 2007). 
ABC transporters or traffic ATPases are conserved active membrane transport proteins that 
consist of four domains: two transmembrane domains that form a pore through which the 
substrate is transported and two cytosolic ATP-binding domains that hydrolyse ATP to 
provide the energy for the translocation (Berntsson et al. 2010). Additionally, ABC importers 
that are unique to plants, bacteria and archaea, have an extracellular substrate-binding 
domain (Berntsson et al. 2010; Rice et al. 2014). ABC transporters include the glycerol 
importer (gtsABC), putative glycerol-3-phosphate (ugpACE) importer, polyamine 
(putrescine/spermidine) importer (potABCD) and the oligopeptide permease importer 
(oppABCDF) (Vilei and Frey 2001; Pilo et al. 2005; Nicolás et al. 2007; Großhennig et al. 
2013; Szczepanek et al. 2014).  
Transporters other than ABC transporters include the glycerol uptake facilitator, glucose 
permease and the phosphoenolpyruvate-dependent sugar phosphotransferase transport 
system (PTS) that is responsible for import of glucose, fructose and mannitol (Halbedel et al. 
2007).  
2.4 Adaption towards living as a parasite 
A successful pathogen possesses the ability to enter its host, reach the target tissue and 
adhere to it, while evading the host’s immune system in order to grow, multiply and be 
transmitted to new hosts (Bradbury 2005; Pilo et al. 2007). With the reduced coding capacity 
of their small genome, mycoplasmas are remarkably well adapted to their hosts. 
Mycoplasma species have evolved to successfully live and multiply within numerous hosts. 
They have evolved the ability to adhere to their hosts through numerous surface proteins 
and are able to avoid the host’s immune system through surface antigen variation and phase 
switching. These pathogens are transmitted through inhalation, direct and indirect contact 
(Frey 2002; Batista et al. 2004; Faustino et al. 2004; Fox et al. 2005). In birds, mycoplasmas 
can also spread from one generation to the next through eggs (vertical transmission) 
(Bradbury 2005) while some mammal mycoplasmas be transmitted through the milk (Fox et 
al. 2005). Factors such as environmental stresses (e.g. weather conditions and extreme 
temperatures), commercial farming practices (high stocking densities) as well as genetic 
factors (susceptibility of animals to infections), all contribute to the intensity and transmission 
rate of these infections.  
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2.4.1 Colonization 
Mycoplasmas generally infect the mucosal membranes of the eyes, nose, respiratory- and 
urogenital tract as well as causing joint inflammation. Some species can, however, enter the 
host’s cells (Fürnkranz et al. 2013; Hegde et al. 2014) and others are blood born parasites 
(hemoplasma) (Messick 2004; do Nascimento et al. 2012). Adhesion of a bacterium to the 
host cell is the first step towards colonization. Adhesion ensures close contact between the 
mycoplasma and the host cell for effective import of nutrients (Fürnkranz et al. 2013). A 
number of surface proteins have been implicated in adhesion in mycoplasmas but these are 
only conserved in closely related strains and species (Browning et al. 2011). 
2.4.2 Avoiding the host’s immune system: Antigenic, size and phase variation 
Mycoplasmas face the constant challenge of recognition by the host’s immune system. To 
effectively avoid detection, bacteria can create hypervariable surface molecules through 
phase and antigenic variation. The variation events cause a highly dynamic repertoire of the 
major immunodominant surface proteins. This creates a flexible membrane surface that 
allows the mycoplasma to effectively escape the attacks of the host immune system’s 
antibodies. Mycoplasmas have a number of sophisticated systems that are associated with 
phase and antigenic surface variation that have been reviewed by Citti et al. (2010) and 
Zimmerman (2014). Mechanisms of antigenic variation include phase variation through 
ON/OFF expression switches, domain variation, epitope masking and locus duplication.  
Phase variation is usually the result of DNA slippage or rearrangements. The expression of 
a gene or gene set can be turned ON/OFF when DNA slippage occurs in the promoter 
region due to the presence of simple sequence repeats (SSRs) (Citti et al. 2010). In 
mycoplasmas, SSRs in the promoter regions of the M. hyorhinis vlp gene and the 
Mycoplasma gallisepticum vlhA gene cause DNA slippage that results in phase variation 
(Yogev et al. 1991; Liu et al. 2002). DNA rearrangements can also switch expression 
ON/OFF. Site specific recombination (cut and paste mechanism) can result in gene and/or 
promoter inversion that can alter expression. Expression of the hsd gene in M. pulmonis is 
regulated by the inversion of the gene (Dybvig et al. 1998) while the expression of the vpma 
gene in M. agalactiae is regulated by the inversion of the gene and the promoter (Chopra-
Dewasthaly et al. 2008). Phase variations occur at a high rate in mycoplasmas, for example, 
in M. hyorhinis phase variation occurs at 10-2 to 10-5 events/cell/generation (Rosengarten 
and Wise 1990). These events are reversible and inheritable which create a highly variable 
surface repertoire. 
In domain variation, a part of the protein sequence is altered by shuffling of the domains or 
altering the size. Gene recombination events can structurally change the domains within 
genes as is the case in the vlhA gene of Mycoplasma synoviae (Noormohammadi et al. 
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2000). DNA slippage associated with tandems of SSRs at the C-terminal of the protein can 
also cause size variation in the protein (Citti et al. 2010) as is the case in the vsa gene of 
M. pulmonis (Simmons et al. 1996).  
When constantly expressed protein is concealed by either a second protein blocking its 
exposure to the immune surveillance of the host or by variation of the protein size, it is called 
epitope masking. In M. hominis, the rapidly changing non-essential P120 protein conceals 
the constantly expressed surface protein, P56, from the host immune system by acting as a 
decoy (Zhang and Wise 2001).  
Additionally gene or locus duplication also contributes to variation in mycoplasmas. In the 
genome of the field strain M. agalactiae str. 5632, 23 copies of the vpma gene were found. 
In these copies both gene and locus duplication contributed to the variation (Nouvel et al. 
2009).  
Another interesting discovery is the presence of cysteine protease in M. gallisepticum and 
M. synoviae. Cysteine protease is a surface exposed protease and can digest chicken IgG 
into Fc and Fab fragments. This digestion may disable the chicken IgG to function properly 
and may play a role in host invasion (Cizelj et al. 2010). Recently an antibody-binding 
protein, protein M, has been discovered in M. genitalium that can bind IgG thereby 
neutralising the antibody (Grover et al. 2014). These approaches may also aid in avoiding 
detection. All the above mechanisms contribute to the success of Mycoplasma species as 
pathogens. 
2.4.3 Pathogenesis  
Not all mycoplasmas are pathogenic to the host, some live in the host without causing 
disease symptoms. A number of diseases in human and animals are, however, caused by 
pathogenic or opportunistic mycoplasmas. Symptoms associated with mycoplasmosis are 
rarely due to toxin production and rather a result of the host response to the infection or the 
depletion of nutrients (Pilo et al. 2005; Browning et al. 2014).  
In a few cases, toxins are however reported. Community-acquired respiratory distress 
syndrome (CARDS) toxin is an ADP-ribosylating and vacuolating toxin produced by 
M. pneumoniae. The CARDS toxin was linked to increased mucus production (mucus 
metaplasia), eosinophilia, vacuolation of the bronchial and bronchiolar epithelium which is 
suggestive of allergic airway hyperresponsiveness. Homologues of the toxin gene, mpn372, 
were also found in Mycoplasma penetrans and Mycoplasma iowae (Medina et al. 2012; 
Browning et al. 2014).  
The production of hydrogen peroxide (H2O2) in glycerol metabolism has been implicated in 
the virulence of M. mycoides subsp. mycoides SC, M. gallisepticum and M. pneumoniae 
(Figure 2.2) (Pilo et al. 2005; Großhennig et al. 2013; Szczepanek et al. 2014). The 
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particular enzyme implicated in this is glycerol-3-phosphate oxidase. Additionally 
transporters that lead to high import of glycerol, glycerol-3-phosphate and 
glycerolphosphochlorine also contribute to virulence of these mycoplasmas. Glycerol-3-
phosphate oxidase catalyses the oxidation reaction that converts glycerol-3-phosphate and 
H2O to dihydroxyacetone phosphate (DHAP) and H2O2. After attachment of M. gallisepticum 
and M. mycoides subsp. mycoides to the host cells, this enzyme acts as a transmembrane 
protein which releases the H2O2 during the conversion into the host cell. H2O2 and other 
reactive oxygen species (ROS) cause damage and inflammation in host tissue while DHAP 
enters the energy producing glycolytic pathway (Pilo et al. 2005). Even though the glycerol-
3-phosphate oxidase is a cytosolic protein in M. pneumoniae, H2O2 production was still 
implicated in virulence (Schmidl et al. 2011).  
OppA, the substrate-binding domain of the oligopeptide permease transporter may also play 
a role in pathogenicity of M. hominis. In addition to its role in oligopeptide transport, the 
OppA protein is also involved in cytoadhesion and is the major ecto-ATPase in M. hominis 
(Hopfe and Henrich 2008). The binding of OppA to the host cell induces the release of ATP 
from the host cell. Extracellular ATP is then hydrolysed by OppA (ecto-ATPase activity) to 
ADP and a phosphate group. This reduces proliferation and leads to apoptosis of the 
infected host cell (Hopfe and Henrich 2014). 
Mycoplasmas are host-specific, therefore it is possible that the genes involved in 
pathogenesis are species-specific and that this may be the reason for the lack of a general 
mechanism of pathogenesis in the Mycoplasma genus. The lesions produced in different 
hosts by different Mycoplasma species are, however, similar (Browning et al. 2014). This 
suggests that the underlining mechanisms may be similar.  
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Figure 2.2 Schematic representation of H2O2 production of the glycerol pathway in M. pneumoniae, 
M. mycoides subsp. mycoides and M. gallisepticum. The production of H2O2 causes damage to host 
cells. Compiled from Vilei and Frey (2001); Pilo et al. (2005); Großhennig et al. (2013) and 
Szczepanek et al. (2014).   
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2.5 Mycoplasma infections in ostriches 
Mycoplasma species infect mucosal membranes of the respiratory tract in ostriches and 
cause sinusitis, rhinitis, foaming conjunctivitis, tracheitis, coughing, laryngitis and air sac 
infections (Botes et al. 2005a; Botes et al. 2005b). Ostriches in intensive rearing systems are 
particular vulnerable to mycoplasma infections during extreme weather conditions and stress 
due to handling, transport or change in housing conditions. Mycoplasma infections lead to 
retardation of growth, downgrading of carcasses and even death in young chicks which has 
a major economical impact on the ostrich industry. Mycoplasma infections in ostriches are 
normally associated with secondary infections of other bacteria that occur in ostriches such 
as E. coli, Pseudomonas aeruginosa, Pasteurella species and Bordetella avium which 
elevate disease symptoms (Verwoerd 2000; Botes et al. 2005a).  
From a phylogenetic or evolutionary perspective, the three Mycoplasma species that infect 
ostriches (Mycoplasma struthionis sp. nov. str. Ms01, Mycoplasma sp. Ms02 and 
Mycoplasma nasistruthionis sp. nov. str. Ms03) belong to the hominis group within the genus 
Mycoplasma (Figure 2.1). M. struthionis sp. nov. str. Ms01 is closely related to M. hominis 
ATCC 23114 and M. arthritidis 158L3-1 while Mycoplasma sp. Ms02 and M. nasistruthionis 
sp. nov. Ms03, are closely related to M. synoviae 53, Mycoplasma alligatoris A21JP2 and 
Mycoplasma crocodyli MP145.  
M. nasistruthionis sp. nov. str. 2FIAT was recently isolated from ostriches in Namibia and 
was characterized as a non-motile mycoplasma that ferments glucose, but cannot hydrolyse 
arginine or metabolise urea (Langer 2009). Serum is required for in vitro growth, and this 
mycoplasma can be cultured between 28 to 37°C (Langer 2009). The experimental part of 
this dissertation will focus on M. nasistruthionis sp. nov. str. Ms03.  
2.6 Controlling mycoplasma infections  
Mycoplasma species can be controlled by: 1) prevention 2) treatment and 3) vaccination. 
Mycoplasma infections can be prevented by biosecurity practices. Biosecurity practices are 
used to prevent the spread of diseases. This includes quarantine of infected animals and all-
in-all-out approaches where a group of animals will be kept together throughout their life 
preventing close contact with other animals (same and/or other species) on the farm (Evans 
et al. 2005; Punyapornwithaya et al. 2012).  
South Africa is the world’s leader in the production of ostrich products (meat, leather and 
feathers) and biosecurity is of the upmost importance in order to ensure export of safe meat 
that meets international export standards. It is therefore enforced by law that all ostrich 
farms in South Africa must be registered and adhere to biosecurity regulation requirements 
(VPN/04/2012-01(Revision_6.0) 2012). South Africa implemented these regulations after the 
first outbreak avian influenza in 2004. These requirements include that poultry (excluding 
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ostriches) and pigs (specifically due to influenza viruses) may not be kept on registered 
ostrich farms, access for unauthorised persons, animals and vehicles should be restricted 
and contact between ostriches and wild birds should be limited by fencing off open water 
and constructing water troughs so that this will discourage wild water birds from perching on 
the sides or swimming inside them.  
Mycoplasmosis can be treated with antibiotics such as tetracyclines and macrolides 
(targeting protein synthesis). Treatment with antibiotics that target the cell wall (penicillin) or 
folic acid synthesis (sulfonamides and trimethoprim) fail since the cell wall and folic acid 
synthesis are absent in mycoplasmas (McCormack 1993). Antibiotic treatment is, however, 
believed to be mostly ineffective (Frey 2002). This is also the case in ostriches where 
antibiotic treatment is not always successful because ostriches carrying the disease can 
remain asymptomatic and are therefore not treated which aids in the spread of 
mycoplasmas. Additionally in many countries, including South Africa, antibiotic resistance 
has been reported in Mycoplasma species (excluding ostrich-infecting mycoplasma) and are 
of concern (Kibeida 2011; Zhao et al. 2012; Waites et al. 2014).  
Biosecurity practices and antibiotic treatment aid in limiting losses, but they do not provide 
optimum solutions to control mycoplasma infections. Vaccination provides the animal with 
the necessary defence to prevent the progression of infections and to fend off pathogens 
against which it has been vaccinated. This prevents or reduces the symptoms and severity 
of the disease. Ensuring healthy animals which can grow optimally thus increases 
commercial production. Vaccines not only protect the animal from the pathogen but also the 
human consumer from encountering the pathogen. It also decreases the associated risks of 
long term antibiotic use such as acquiring antibiotic resistance and of consuming 
pharmacological contaminants in food products (Nisha 2008; Darwish et al. 2013).  
Although there are registered vaccines against a few Mycoplasma species there are 
currently no means of preventing mycoplasma infections in ostriches. The sections that 
follow will explore the literature on vaccines in general in order to evaluate the approaches 
that can be followed specifically to develop a vaccine for the treatment of mycoplasmosis in 
ostriches.  
2.7 Live attenuated, inactivated whole organism and protein subunit vaccines 
Vaccines rely on the ability of the host to gain memory of the particular antigen after 
exposure. This equips the host with the necessary defences to combat future exposure to 
the pathogenic organism. The ideal vaccine should be highly efficient in activating both B-
cells and T-cells that lead to memory. It should be administered in a single dose and cause 
long term immunity. It should have no side effects in the immunized individuals, even in 
complicated cases such as immune-compromised, young or old individuals. The 
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manufacture of the ideal vaccine should also be inexpensive and quality control 
uncomplicated. It should be temperature stable for transport without a cold chain and have a 
long shelf-life. Additionally it should also be possible to differentiate infected from vaccinated 
animals, the so-called DIVA principle (Levine and Sztein 2004; Hoelzle et al. 2009; Uttenthal 
et al. 2010). Current vaccine approaches include live attenuated vaccines, inactivated whole 
organism vaccines, protein subunit vaccines and DNA vaccines. Most current vaccines only 
meet a few of the requirements for the ideal vaccine (Table 2.3).  
Currently, most licensed vaccines are live attenuated and inactivated whole organism 
vaccines while only a few protein subunit vaccines and DNA vaccines are registered (Kutzler 
and Weiner 2008; Unnikrishnan et al. 2012). Live attenuated vaccines are non-pathogenic or 
non-virulent strains of the organism that have the ability to stimulate the immune system 
without causing disease symptoms. Immunity is long-lived and the vaccine can be 
administrated in a single dose. This approach mimics the natural route of entry of the 
infective organism and stimulates local immunity (Table 2.5). Immunization with live 
attenuated vaccines often results in both cellular and humoral immunity (Detmer and 
Glenting 2006). Live attenuated vaccines have, however, the potential to become 
reactogenic to the host, especially to immune-compromised, young and old individuals and 
are transmissible from one individual to the next. However, in future, a better understanding 
of bacterial genetics and availability of improved molecular techniques may aid in the 
development of safer live attenuated vaccines that may present fewer side effects (Detmer 
and Glenting 2006). Live attenuated vaccines are temperature sensitive and therefore 
require a cold chain transport and storage. Additionally they have a relative short shelf-life. 
Since the immunized individual is exposed to the whole pathogen it is difficult to differentiate 
infected from vaccinated animals (DIVA principle). Approved and commercially available live  
Table 2.3 The characteristics of the ideal vaccine in comparison with current vaccine approaches 
Characteristics of the ideal 
vaccine 
Vaccine approaches 
Live 
attenuated 
vaccines 
Inactivated whole 
organism 
vaccines 
Protein 
subunit 
vaccines 
DNA 
vaccines 
Humoral response (B-cell) √ √ √ √ 
Cellular response (T-cell) √ Χ Χ √ 
Single dose √ Χ Χ Χ 
No negative side effects Χ Χ Χ √ 
Inexpensive to manufacture √ Χ Χ √ 
Uncomplicated quality controls Χ Χ Χ Χ 
Temperature stable for transport 
without cold chain 
Χ Χ Χ √ 
Long shelf-life Χ Χ Χ √ 
DIVA principle Χ Χ √ √ 
Compiled from Levine and Sztein (2004); Hoelzle et al. (2009); Uttenthal et al. (2010). 
  
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2 Literature review 
22 
attenuated vaccines for mycoplasma control include M. gallisepticum str. F (FVAX-MG, 
Schering-Plough Animal Health), M. gallisepticum str. 6/85 (Mycovac-L, Intervet Inc.) and M. 
gallisepticum str. ts-11 (MG vaccine, Merial Select) for vaccination in chickens (Evans et al. 
2005; Jacob et al. 2014). 
Inactivated whole organism vaccines are heat or chemically inactivated pathogens. These 
vaccines elicit a potent humoral immune response but do not elicit a cellular response. 
Booster injections are almost always required. Inactivated whole organism vaccines against 
bacteria are composed of the entire cell content and therefore may contain toxins that can 
lead to local inflammation at the injection site as well as other side effects (Table 2.5). It is  
 
Table 2.4 The advantages and disadvantages of current vaccine approaches 
Live attenuated vaccines 
Advantages Disadvantages 
1. Highly effective in eliciting both cellular and 
humoral immune response  
2. Long term memory 
3. Low cost  
4. Can be administered orally  
5. Single dose 
1. Potential safety risk for immune-compromised 
individuals  
2. Temperature sensitive, requires cold chain for 
transport and storage  
3. May convert into virulent forms 
4. Manufacturing is challenging, working with 
potential dangerous organisms 
Example of commercial license live attenuated vaccines:  
Product name (Supplier, attenuated strain) Vaccine target Animal 
FVAX-MG (Schering-Plough Animal Health, strain F) M. gallisepticum  Chicken 
Mycovac-L (Intervet Inc., strain 6/85) M. gallisepticum  Chicken 
MG vaccine (Merial Select, strain ts-11) M. gallisepticum  Chicken 
Inactivated whole organism vaccines 
Advantages Disadvantages 
1. Potent antibody response  
2. Safety: Cannot revert to virulent form 
1. No cellular immune response  
2. Potential risk of toxins and inflammation at the 
immunization site 
3. Temperature sensitive, requires cold chain for 
transport and storage  
4. Manufacturing is challenging, working with 
potentially dangerous organisms 
Example of commercial licence inactivated whole organism vaccines: 
Product name (Supplier) Vaccine target Animal 
Stellamune One (Pfizer Animal Health)  M. hyopneumoniae Swine  
Suvaxyn® MH One (Pfizer Animal Health)  M. hyopneumoniae Swine  
MG-Bac (Fort Dodge Animal Health) M. gallisepticum  Chicken 
Protein subunit vaccines 
Advantages Disadvantages 
1. Potent antibody response 
2. Manufacture with well established techniques 
3. Safety: Eliminate working with pathogens and 
exposing patients or animals to live pathogens 
and toxins within these organisms  
1. No cellular immune response  
2. Folding problems, protein antigens may be in 
the non-native form 
3. Temperature sensitive, requires cold chain for 
transport and storage  
4. Potential risk of inflammation at the 
immunization site  
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Table 2.5 (Continued). 
DNA vaccines 
Advantages Disadvantages 
1. Elicit cellular and humoral immune responses 
2. Endogenous antigen production  
3. Economic, large scale production 
4. More temperature stable than conventional 
vaccines, long shelf-life and require no cold 
chain for transport.  
5. Produce antibodies in neonates even in the 
presences of maternal antibodies 
6. Animal acts as a bioreactor- thus eliminating 
problems with protein folding and post-
translational modifications of protein antigens 
1. Potential problems with potency  
2. Would require more than one dose 
 
Example of commercial licence DNA vaccines: 
Product name (year, country) Vaccine target Animal 
West Nile Innovator (2005, USA) West Nile virus Horse 
Apex®-IHN (2005, Canada) Infectious haematopoietic necrosis virus Salmon 
Canine melanoma vaccine (2007, USA) Melanoma Dogs 
LifeTide-SW5 (2007, Australia) Growth hormone release hormone for foetal loss Swine  
Compiled from: Babiuk et al. (2003); Evans et al. (2005); Detmer and Glenting (2006); Kutzler and Weiner 
(2008); Villarreal et al. (2011); Marchioro et al. (2013); Bueno et al. (2014); Jacob et al. (2014). 
 
difficult to apply the DIVA principle to these vaccines since the immunized individual is 
exposed to the whole cell content. Production relies on the ability to culture bacteria in large 
quantities. Mycoplasmas are notorious for infecting cell cultures (Uphoff and Drexler 2014) 
creating the false impression that they are easy to culture. However for most species, the 
small genome size brings with it complex substrate requirements (Citti and Blanchard 2013). 
The implication is that some species are especially difficult to culture (Citti and Blanchard 
2013; Bueno et al. 2014) and renders inactivated whole organism vaccines expensive. 
Examples of inactivated whole organism vaccines are Suvaxyn® MH One (Pfizer Animal 
Health) and Stellamune One (Pfizer Animal Health) for the prevention of M. hyopneumoniae 
infections in pigs (Villarreal et al. 2011; Marchioro et al. 2013) and MG-Bac (Fort Dodge 
Animal Health) for the prevention of M. gallisepticum infections in chicken (Bueno et al. 
2014). 
Protein subunit vaccines consist of a specific protein/antigen that are isolated from the 
bacterial cell culture or produced recombinantly. As with whole organism vaccines, protein 
subunit vaccines can also elicit a strong humoral response but cannot elicit a cellular 
response and booster injections are required (Table 2.5). Protein subunit vaccines eliminate 
the presence of toxins within the vaccine and therefore are less likely to elicit inflammation at 
the injection site as well as other side effects associated with inactivated whole organism 
vaccines. Recombinant proteins are commonly produced in E. coli after which the protein is 
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isolated using chemical or chromatographical methods. Isolation methods may, however, 
lead to the incorrect folding of the antigenic protein. Expression of mycoplasma proteins 
within E. coli is also hampered because of codon usage differences in particularly the TGA 
codon that encodes for tryptophan in Mycoplasma species but for a universal stop codon in 
E. coli. This terminates translation of mycoplasma proteins in E. coli prematurely and 
warrants the need for an additional step before the expression to change the codon to TGG. 
Although there are no commercial licensed protein subunit vaccines available for 
mycoplasmosis, their potential use, development and efficacy has been extensively studied 
(Galli et al. 2012; Simionatto et al. 2012; Prysliak et al. 2013).  
Ostrich-infecting Mycoplasma species are slow growing bacteria that require serum for 
growth (Langer 2009). This makes traditional approaches such as inactivated whole 
organism vaccines for use in ostriches impractical and economically unfeasible for the 
relatively small vaccine market if compared to that of poultry. As an alternative DNA 
vaccines do not require large scale culturing and have also been reported to be cost 
effective (Mahoney et al. 2000).  
DNA vaccines have attracted considerable attention as an alternative vaccine strategy to 
eliminate some of the disadvantages of other vaccine strategies (Table 2.5). This approach 
to vaccination was recognized in the early 1990’s by Wolff et al. (1990) and will be reviewed 
in the following section. 
2.8 DNA vaccines 
A DNA vaccine is an antigen encoding double stranded circular deoxyribonucleic acid (DNA) 
molecule also referred to as a DNA plasmid or DNA vector. The molecules, encoding an 
antigenic pathogen protein, are delivered to the eukaryotic host cells. This leads to 
expression of the antigenic pathogen protein, which in turn is capable of eliciting a specific 
immune response within the immunized animal and leads to protection against the 
pathogen. DNA vaccines provided researches with the unique opportunity to utilize the cell’s 
own mechanisms to produce transgenic protein (Lewis and Babiuk 1999; Findik and Çiftci 
2012).  
The antigen is produced in situ and therefore can stimulate both humoral and cellular 
immune responses (Kutzler and Weiner 2008) (Table 2.5). DNA vaccines circumvent the 
need to work with dangerous pathogens in vaccine production laboratories as is the case in 
the production of live attenuated or inactivated whole organism vaccines. Production also 
has no protein isolation step that can lead to incorrect protein folding as is the case with the 
production of protein subunit vaccines. Additionally DNA vaccines are relatively stable in dry 
form or dissolved in buffer (Quaak et al. 2010), thus they do not require traditional cold 
transport and storage. As with protein subunit vaccines, the DIVA principle can be applied 
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after vaccination since the plasmid encodes for one or a small number of pathogen proteins. 
Thus it would be possible to distinguish between infected and vaccinated animals by testing 
the immune response towards other pathogen proteins.  
DNA vaccines can be produced and isolated from E. coli bacteria which is a relatively easy 
and cost effective way of producing a vaccine (Cai et al. 2009). DNA vaccines are also 
considered safe (Section 2.8.4). In general there are problems with the potency of DNA 
vaccines in large animals (Babiuk et al. 2003), but this has also been overcome in the 
commercial DNA vaccines available for pigs and horses.  
The design of DNA vaccines is based on a two part strategy: firstly, the production of the 
DNA vaccine within E. coli and secondly, the expression of the antigen within the eukaryotic 
host. The two parts are interlinked and changes in one part of the plasmid may influence 
both processes (Hartikka et al. 1996; Williams 2013). For prokaryotic production, the plasmid 
contains a high copy number origin of replication and a prokaryotic marker (Figure 2.3). The 
prokaryotic origin of replication influences the copy number of the plasmid within the 
bacterial cells and therefore has a direct effect on the amount of DNA vaccine produced per 
unit culture. Prokaryotic markers ensure selection during the cloning process as well as 
stable inheritance of the plasmid DNA during bacterial growth (Oliveira and Mairhofer 2013). 
In general this conveys resistance to a drug, typically an antibiotic. The most used resistant 
marker is the neomycin phosphotransferase II (nptII) gene because it is tolerated by 
regulatory authorities (FDA 1996). The nptII gene encodes the enzyme aminoglycoside-3'-
phosphotransferase that phosphorylates aminoglycoside antibiotics such as kanamycin and 
G418 thereby inactivating them. Kanamycin is not commonly use to treat human infections 
because of side effects (Vandermeulen et al. 2011) and it is therefore safe to use these 
resistance genes from the vaccine production perspective. 
When DNA vaccines were first discovered all plasmids used antibiotic markers since it 
provided an easy way to select for bacteria containing DNA vaccines. However due to public 
concern about the possible horizontal transfer of these markers to other bacteria and 
integration into the host genome, the general perspective is to move away from using 
antibiotics for selection. New generations of DNA vaccine plasmids are partially or totally 
devoid of prokaryotic elements (Vandermeulen et al. 2011; Oliveira and Mairhofer 2013). 
Selection of these vectors is based either on the complementation of auxotrophic strains, 
toxin–antitoxin systems, operator–repressor titration, RNA markers, or on the 
overexpression of a growth essential gene (Vandermeulen et al. 2011; Oliveira and 
Mairhofer 2013). Progress had been made to remove the prokaryotic elements from DNA 
vaccines although there are still problems with cost effective isolation for some of the 
alternatives (Faurez et al. 2010). 
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For eukaryotic protein expression, the DNA vaccine contains a strong eukaryotic promoter, 
enhancer, intron and transcription terminator/polyadenylation signal in addition to the 
antigenic gene (Figure 2.3). The plasmid is engineered to contain has a strong and 
ubiquitous viral promoter that confers optimal expression of the vaccine candidate gene in 
eukaryotic cells (Faurez et al. 2010; Okuda et al. 2014). Additionally transcriptional 
transactivators, introns and other enhancer elements are included to increase transcription 
activity and expression (Flingai et al. 2013; Williams 2013). The polyadenylation signals 
ensure proper termination of transcription and RNA maturation. 
 
 
 
 
Figure 2.3 A diagram of the typical DNA vaccine vector showing the origin of replication and the 
selective marker which are needed for prokaryotic production, as well as the promoter, intron and 
polyadenylation signal, in addition to the vaccine candidate gene that is required for eukaryotic 
expression  
2.8.1 Routes of immunization  
DNA vaccines can be formulated as an aqueous solution (naked DNA vaccine), in complex 
with cationic liposomes and polymers, or packed within virus and bacteria vectors (Faurez et 
al. 2010). Naked DNA vaccines can by administrated by intramuscular or intradermal 
injection. Physical methods such as gene gun, electroporation and a CO2-powered Biojector 
can also be used for administration of the vaccine (Escoffre et al. 2013; Manjila et al. 2013). 
Each method proved to have certain advantages and disadvantages, providing a range of 
approaches that can be applied keeping the outcome in mind (Table 2.5). For example, with 
bacterial carriers it is possible to administer the vaccine orally. This elicits mucosal immunity, 
which can be of value if the pathogen attacks/gains entrance via the airways such as in the 
case of mycoplasmas. These techniques are to overcome the problems associated with the 
low transfection rate of DNA vaccines. It is, however, important to note that because of the 
Eukaryotic promoter, intron 
and regulatory elements 
Bacterial origin of replication 
Vaccine candidate gene  
Polyadenylation signal  
Prokaryotic selective marker 
Prokaryotic production                                       Eukaryotic expression  
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effectiveness of the immune system, protein expression in the nanogram range is sufficient 
to elicit an effective immune response (Chastain et al. 2001).  
Table 2.5 Advantages and disadvantages of DNA vaccine administration methods 
Delivery method Advantages Disadvantages 
Bacterial or viral carrier  Easy to administer 
 Secretory IgA production 
 Possible risk due to live 
bacteria 
Biojector injection (id)  Induces cellular immune response 
 Easy to administer 
 Induce weak humoral 
immune response 
DNA with adjuvants  Can manipulate to get desired cellular or 
humoral immune response 
 Unknown side effects 
Electroporation (id, im)  High level of immune response 
 Long duration of immune response 
 Possible risk due to 
high voltage  
Gene Gun (id)  Small amount of DNA injected 
 Dominance of humoral immune response 
 Induce weak cellular 
immune response 
Intranasal immunization  Easy to administer 
 Secretory IgA production 
 Effective for lung immunity 
 Weak overall 
immunogenicity 
Needle injection (im)  Activate cellular immune response 
 pDNA spreads widely 
 Most commonly studied 
 Large amount of DNA can be injected 
 Muscle pain 
Abbreviations: id intradermal, im intramuscular. 
Table from Bermúdez-Humarán et al. (2011); Okuda et al. (2014).
 
2.8.2 The journey into the cell nucleus  
Understanding the mechanism of transfection into the nucleus as well as the mechanism of 
inducing an immune response is critical for the rational design of DNA vaccines. The 
proportion of DNA vaccine plasmid molecules that reach the nucleus is affected by 
numerous factors such as the route of administration, size and conformation of the plasmid. 
The tissue distribution of DNA vaccines as well as the cell type transfected will depend on 
the route of immunization. After intramuscular immunization, the DNA vaccine molecules will 
be positioned within the extracellular spaces and be transfected mainly into mycocytes. 
Intradermal or subcutaneous administration, on the other hand, will predominately lead to 
transfection of keratinocytes. Additionally a small portion will also be directly transfected into 
professional antigen presenting cells (APCs), dendritic cells (DC) in the muscle and the 
epidermal Langerhans cells or dermal dendritic cells in the skin (Kutzler and Weiner 2008; 
Palumbo et al. 2012).  
Studies evaluating the anatomical distribution of DNA vaccines within a body have shown 
that after immunization most DNA vaccines either remain at the injection site, where they are 
taken up by cells or degraded by nuclease enzymes, or they are distributed through the 
blood and lymph system to various tissues (Tadokoro et al. 2001). In the blood and lymph, 
the plasmid will also either be degraded or taken up by APCs. Transfection occurs at a very 
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low frequency because the extracellular space, blood, lymph and cytoplasm are equipped 
with enzymes that degrade DNA.  
The half-life of DNA vaccines within the blood of rats after intravenous injections ranges from 
0.15 to 21 minutes depending on the topoform (linear, open circle or supercoiled) of the DNA 
vaccines (Houk et al. 2001). In addition to nuclease enzymes, the liver nonparenchymal cells 
such as Kupffer (liver resident macrophage) and liver sinusoidal endothelial cells contribute 
to the degradation of DNA vaccines. These cells use scavenger receptors to internalize and 
degraded large anionic molecules. Trace amounts of plasmids could still be detected after 
28 days in rats (Tuomela et al. 2005) and pigs (Kanellos et al. 1999), 54 days in sheep 
(Mena et al. 2001), 70 days in goldfish (Kanellos et al. 1999) and turkeys (Kanellos et al. 
1999) and 90 days in rainbow trout (Garver et al. 2005). 
In order for the antigen to be expressed, the vaccine plasmid should be transfected into the 
nucleus. To enter the nucleus, the vaccine plasmid needs to overcome three obstacles, 
crossing the cell plasma membrane, travelling to the nucleus and crossing the nuclear 
membrane, as illustrated in Figure 2.4. 
The cell membrane as well as the DNA vaccine plasmid have an overall negative charge 
implying that the two do not associate with each other. Despite this, DNA vaccines do cross 
the cell membrane and it has been proposed that it happens via endocytosis although the 
precise mechanism is not known (Tonheim et al. 2008). Once inside the cell, DNA vaccines  
 
 
Figure 2.4 Path of a DNA vaccine into the cell nucleus and the expression of the antigenic protein. The 
vector is imported into the cell through endocytosis (Step 1). The DNA vector travels through the 
dense cytoplasm to the nucleus (Step 2) where it crosses the nucleus membrane to enter the nucleus 
(Step 3). Within the nucleus the antigenic gene is transcribed to RNA (Step 4) which is processed to 
mRNA (Step 5) and exported to the cytoplasma (Step 6) for translation of the antigen protein (Step 7). 
The antigenic protein can either be exported (Step 8) or it can be tagged for protein degradation (Step 
9), which leads to the presentation of antigenic peptides by the major histocompatibility complex I 
(MHC I) on the cell membrane (Step 10).   
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are hardly stable, it is estimated that the half-life for DNA vaccines within the cytoplasma of 
HeLa and COS cells is 50 to 90 minutes (Lechardeur et al. 1999). The eukaryotic cytosol 
has dense and viscose characteristics with proteins, organelles and the cytoskeleton making 
diffusion of large molecules such as DNA vaccines slow (Lukacs et al. 2000). DNA vaccines 
use the microtubule network of the cytoskeleton and the molecular motor, dynein, to move to 
the nucleus (Vaughan and Dean 2006). A multiprotein complex is involved in this transport 
since the DNA vaccine does not directly bind to the dynein. 
The DNA vaccine cross the nuclear membrane through a nuclear pore complex (Lechardeur 
and Lukacs 2006). About 0.1% of the plasmid DNA microinjected into the cytoplasma of 
COS-7 cells reached the nucleus and resulted in expression (Pollard et al. 1998).  
2.8.3 How does the DNA vaccine result in immunity? 
The antigen gene of the DNA vaccine is transcribed to RNA within the nucleus. Sequentially, 
the RNA is processed to remove introns (if present) and a 5' cap and 3' polyadenylate tail is 
added. The mature messenger RNA (mRNA) is then exported to the cytoplasma where it is 
translated to the antigenic protein (Figure 2.4).  
Our understanding of how DNA vaccines lead to immunity is far from complete. The 
mechanism, as outlined in Figure 2.5 is based on the current understanding (Kutzler and 
Weiner 2008; Moss 2009; Liu 2011; Li et al. 2012; Pereira et al. 2014; Xu et al. 2014). After 
immunization, the DNA vaccine is internalized by somatic cells (myocytes or keratinocytes), 
as well as APC cells, leading to the expression of the protein antigen (Ag). The host-
synthesized Ag molecules are subjected to immune surveillance and will be tagged by 
ubiquitylation for proteolysis that will degrade the antigenic protein into small fragments. The 
fragments enter the endoplasmic reticulum where they are loaded onto major 
histocompatibility complex class I (MHC I) molecules. The Ag-MHC I complex is transported 
via the Golgi complex to the cell surface where it facilitates binding with CD8+ T-cells (Vyas 
et al. 2008; Wang et al. 2011). CD8+ T-cells recognize the Ag-MHC I complex as non-self 
and elicit a cellular immune response that results in the formation of memory T-cells as well 
as cell death of the infected cell.  
APC can either be directly transfected and produce the Ag or the Ag can be internalised by 
sample part of the extracellular milieu by a process called phagocytosis. This results in the 
display of the antigenic peptides on major histocompatibility complex class II (MHC II) 
molecules. This activates CD4+ T-cells leading to the activation and maturation of B-cells 
which will produce antibodies, as well as memory B-cells, and thereby elicits humoral 
immunity.   
Stellenbosch University  https://scholar.sun.ac.za
Chapter 2 Literature review 
30 
Figure 2.5 A) Design of a DNA vaccine against mycoplasmas and the immune responses elicited by it. 
Genomic DNA of the mycoplasma is isolated and sequenced with a next-generation sequencing 
platform. The vaccine candidate gene is identified from the genomic data. Site-directed mutagenesis is 
performed to correct for codon differences between the mycoplasma and its host, thereafter the gene 
is inserted into a vaccine vector for subsequent immunization trials. B) The immune response. Cellular 
immune response: The DNA vaccine enters myocytes or APC leading to the expression of the antigen 
(Ag). If a signal peptide is present the Ag may also be exported. Fragments of the antigen produced 
within cells are displayed by the MHC I on the cell surface for self-recognition. CD8+ T-cells recognize 
the Ag-MHC I complex as non-self and elicits a cellular immune response that results in the formation 
of memory T-cells as well as cell death of the infected cell. Humoral immune response: APC cells 
engulf or produce Ag that leads to the presentation of Ag on MHC II molecules. This activates CD4+ T-
cells leading to the maturation of B-cell which will produce antibodies as well as memory B-cells. 
Figure complied from Kutzler and Weiner (2008); Moss (2009); Liu (2011); Li et al. (2012); Pereira et 
al. (2014); and Xu et al. (2014).  
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2.8.4 DNA vaccines and safety 
Safety is an important concern with any vaccine and as such should be considered in full. It 
is important to understand that DNA vaccines cannot replicate within eukaryotic cells and 
that the transfection percentage of the cells is extremely low. This coupled with the low half-
life of the vaccine within blood and tissue implies that most of the DNA vaccine degrades 
within the body within minutes to hours. Additionally, DNA vaccines are non-living thus 
cannot revert to a disease state or cause secondary infection and inflammatory responses 
(Ferraro et al. 2011; Xu et al. 2014). For these reasons, DNA vaccines are considered to be 
safe and environmentally friendly (Ferraro et al. 2011; Williams 2013; Xu et al. 2014).  
Safety concerns about the use of DNA vaccines are integration into the host genome, 
vertical transmission, the production of anti-DNA antibodies (autoimmunity), the possible 
spread of selective markers leading to antibiotic resistance and the effect of consuming 
vaccinated food animals. Integration into the host genome may result in suppression or 
activation of genes, which may have devastating effects such as cancer. Preclinical and 
clinical studies have, however, proven the rate of integration of plasmid DNA into the 
genome is lower than that of spontaneous mutations (Wang et al. 2004; Sheets et al. 2006). 
Vertical transmission of the DNA vaccines from one generation to the next is of concern, but 
has not been reported yet (Langer et al. 2013; Williams 2013; Xu et al. 2014). Animal studies 
showed no increase in anti-DNA antibodies after DNA vaccination and there was no 
evidence that DNA vaccination resulted in autoimmunity (MacGregor et al. 1998; Tavel et al. 
2007; Kutzler and Weiner 2008; Fioretti et al. 2014). In the production of DNA vaccines an 
antibiotic selective marker is generally used and concerns exist about the spread of 
antibiotic resistance through horizontal gene transfer. The use of antibiotic resistance genes 
should therefore be restricted to exclude antibiotics generally used in treatment of human 
disease such as kanamycin (FDA 1996) or alternatively an antibiotic free production system 
should be used. Humans consume DNA of plant, animal and bacterial origin daily as a part 
of their food. The risk of consuming plasmid DNA from vaccines should pose no greater risk 
than natural DNA (Schalk et al. 2006).  
2.8.5 The choice of DNA vaccine candidate gene 
Choosing a vaccine candidate gene for a DNA vaccine is critical as it determines the 
success of the vaccine. The gene candidates should conform to the following requirements: 
1. It should be a unique gene with no homologous or paralogous genes within the 
pathogen’s genome or within the host’s genome (Galperin and Koonin 1999). 
2. The protein product must have an essential function in the pathogen thus life without 
the protein should be impossible (Allan and Wren 2003). Essential functions in 
pathogens include nutrient uptake, DNA replication, cell division, RNA transcription, 
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protein translation, virulence and pathogenicity. Proteins that are involved in more 
than one pathway can make more potent targets since more than one pathway will 
be affected.  
3. The protein product must not be hypermutable or involved in antigen variation thus 
serving as decoys in preventing an effective immune response (Liu 2011).  
4. The protein product must be accessible. Critical epitopes must not be masked 
thereby preventing an effective immune response (Liu 2011). Surface proteins 
generically have good accessibility since these proteins are exposed to the immune 
system of the host. An added advantage is that some have the essential role of host 
attachment, the first step in pathogenicity. Surface proteins are also involved in 
transport of essential nutrients, which in the case of mycoplasma, makes life 
possible. 
In addition to the above, in silico prediction programs also use the availability of 3D 
structures and protein size as parameters to select suitable vaccine candidate genes 
(Agüero et al. 2008; Caffrey et al. 2009). This however does not mean that larger proteins 
without resolved 3D structures cannot make good and effective vaccines, it simply means 
that the experimental procedure may be more complicated.  
2.9 DNA vaccine strategies for ostrich-infecting mycoplamas  
The process of designing and developing a DNA vaccine for mycoplasmas is outlined in 
Figure 2.5 A. The steps include the identification of a vaccine candidate gene from a 
sequenced and annotated genome of the pathogen, the cloning of the vaccine candidate 
gene into a vaccine vector and the production of the DNA vaccine in E. coli before the DNA 
vaccine can be evaluated. Additionally for mycoplasmas, codon optimization is also 
required.  
2.9.1 Codon usage in Mycoplasma species 
Tryptophan is coded as UGG in the universal genetic code whilst UGA is one of the three 
universal stop codons. In the class Mollicutes, however, the universal stop codon UGA, 
encodes for the amino acid tryptophan (Inamine et al. 1990). The use of UGA as an 
additional tryptophan codon is attributed to the reduced guanine and cytosine (G+C) content 
in mycoplasma genomes (Halbedel and Stulke 2007). Consequently the expression of 
mycoplasma genes in E. coli, avian or mammalian cells is jeopardized by the occurrence of 
the TGA codon within genes (UGA in RNA sequences) that result in premature termination 
of protein expression (Halbedel and Stulke 2007). To circumvent this problem a number of 
approaches can be used. Firstly, an expression system that employs the same codon can 
be used. The expression of mycoplasma proteins in Spiroplasma citri has been reported but 
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this bacterium is difficult to cultivate (Stamburski et al. 1991). Secondly, an E. coli 
suppressor strain that expresses UGA suppressor tRNA codons can be used to express 
mycoplasma proteins but they fail if the gene contains multiple UGA codons (Smiley and 
Minion 1993). Thirdly, genes can be synthesized in vitro with appropriate codons but this is 
expensive for long genes. Lastly, the codons can be changed by site-directed mutagenesis 
(SDM). SDM is a polymerase chain reaction (PCR) based technique in which primers that 
contain the mutated sites, are used to amplify the gene as well as the vector. After PCR 
amplification, the original template is removed with DpnI endonuclease enzyme digestion. 
DpnI endonuclease digests methylated and hemimethylated DNA i.e. the DNA of bacterial 
origin. The product is then transformed into E. coli and the mutation sites confirmed by 
sequencing (Ishii et al. 1998).  
The influence of a low G+C content can further be observed in codon preferences in 
mycoplasma. The occurrence of rare codons may influence the expression of recombinant 
protein in E. coli as well as in the ostrich (targeted host) after DNA vaccination. Each animal 
and bacterium has its own codon preferences that result in optimal expression within the 
organism (Babiuk et al. 2003). No codon preference table is, however, currently available for 
the optimization of expression in ostrich. Although codon optimization can lead to increased 
protein expression, synonymous codon changes may also affect the protein conformation 
and stability, change sites of post-translational modifications and even alter protein function 
(Tsai et al. 2008; Zhang et al. 2010; Spencer et al. 2012; Zhou et al. 2013; Mauro and 
Chappell 2014). The immune system is, however, very effective and protein expression in 
the nanogram range can elicit an effective immune response (Chastain et al. 2001).  
For the above reasons the only codon optimization done in the current study was the 
mutation of TGA codons to TGG by using SDM within the vaccine candidate gene.  
2.9.2 DNA vaccine vectors for use in ostrich 
The three vaccine vectors chosen for this study were pCI-neo, VR1012 and VR1020 (Figure 
2.6). These were selected based on DNA vaccine studies in other birds (Lee et al. 2003; 
McCutchan et al. 2004; Klotz et al. 2007) and on special characteristics such as a tissue 
plasminogen activator (TPA) signal peptide in VR1020. The TPA signal should result in the 
export of the translated protein from the cell in which it is produced and thus better activation 
of the immune system. The prokaryotic elements in these vectors include an origin of 
replication and a prokaryotic selection marker. These elements are required for the 
production of the DNA vaccines within E. coli. The prokaryotic selection marker in pCI-neo is 
ampicillin resistance while in both VR1012 and VR1020 the prokaryotic selection marker is 
kanamycin resistance. The use of kanamycin resistance is preferable because kanamycin 
not commonly use to treat human infections due to side effects (Vandermeulen et al. 2011).  
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Figure 2.6 The DNA vaccine vector map of pCI-neo, VR1012 and VR1020.  
The eukaryotic elements in all of these vectors include a promoter region, intron and 
polyadenylation signal. These regions are required for optimal expression in eukaryotic cells. 
All three of these vectors use a cytomegalovirus (CMV) immediate-early (IE) 
enhancer/promoter region. The CMV promoter is a virally-derived promoter that leads to a 
high-level of transgenic expression in a wide range of eukaryotic cells making it an ideal 
choice for DNA vaccines (Garmory et al. 2003; Kutzler and Weiner 2008). Furthermore pCI-
neo has a chimeric intron and a simian virus 40 (SV40) late polyadenylation signal while 
both VR1012 and VR1020 have the intron A from CMV and the bovine growth hormone 
(BGH) terminator site. Introns have been reported to increase expression (Sridhar et al. 
2008) while the polyadenylation signal or terminator site is required for proper termination of 
transcription and export of the mRNA from the nucleus (Kutzler and Weiner 2008). 
Polyadenylation sequences such as BGH or SV40 also increase the stability of mRNA 
transcripts (Garmory et al. 2003).  
2.9.3  DNA vaccine candidate gene, oppA  
Numerous potential target genes for DNA vaccines are described in the literature and 
amongst these are the ABC transporters. ABC importers are involved in the active import of 
nutrients and are located on the surface of the cell membrane of mycoplasma.  
One such importer is the oligopeptide permease (Opp) transporter that is responsible for the 
active import of oligopeptides due to the absence of de novo amino acid synthesis. The Opp 
transporter contains a substrate-binding domain referred to as OppA. The OppA proteins of 
Brachyspira pilosicoli (Movahedi and Hampson 2010), Moraxella catarrhalis (Yang et al. 
2011) and Yersinia pestis (Tanabe et al. 2006) have been evaluated as candidate vaccine 
antigens and could similarly be a potential vaccine antigen in Ms03. 
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The oppA gene and its corresponding protein product have several characteristics that make 
it a suitable vaccine candidate gene: 
 The substrate-binding domain is unique to plants, bacteria and archaea (Berntsson 
et al. 2010; Rice et al. 2014) which implies that the oppA gene should have no 
homologous genes in the ostrich genome.  
 Oligopeptide transport is an essential function in mycoplasmas and the substrate-
binding domain is a prominent part of the transporter. Furthermore, transposon 
mutagenesis studies in M. genitalium and M. pulmonis found the oppA gene to be 
essential for survival (Glass et al. 2006; French et al. 2008).  
 The OppA is not involved in antigen variation due to its essential function in 
oligopeptide binding.  
 The substrate-binding domain OppA is surface located and therefore exposed to the 
immune system of the host.  
Additionally the OppA of M. hominis has been reported to function in cytoadhesion (Henrich 
et al. 1999; Hopfe and Henrich 2004). If this is also the case in M. nasistruthionis sp. nov. 
str. Ms03, then antibodies against the OppA would not only limit or prevent oligopeptide 
transport but also cytoadhesion and therefore infections. In order to identify an oppA gene in 
M. nasistruthionis sp. nov. str. Ms03, the genome was sequenced and annotated. The 
sequencing and annotation results are presented in the following chapter together with the 
identification and characterization of the opp operon. 
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Chapter 3  The sequencing and annotation of the Mycoplasma 
nasistruthionis sp. nov. str. Ms03 genome and the identification 
and characterization of the proposed vaccine candidate gene, 
oppA  
3.1 Introduction  
Recent developments in genome sequencing techniques provide a unique opportunity to 
characterize individual genes of bacteria and thereby obtain an overview of their metabolic 
capacities. Knowledge of the genome also allows for a reverse vaccinology approach to be 
taken where bioinformatic tools are used to identify genes that conform to the requirements 
for a vaccine candidate gene. Having an annotated genome further enables the quick and 
effective identification of a vaccine candidate gene. 
The first aim of this study was therefore to expand the knowledge of Mycoplasma 
nasistruthionis sp. nov. str. Ms03 (Ms03, this abbreviation is used in this chapter for brevity) 
by determining the Ms03 genome sequence, annotating the genes and evaluating the 
metabolic pathways of essential processes. This would also allow future identification of 
vaccine candidate genes. The objectives were therefore set as follows: 
 To sequence and assemble the Ms03 genome. 
 To annotate the Ms03 genome using two annotation programs. 
 To generate a metabolic overview of Ms03. 
A number of next-generation sequencing (NGS) platforms are available for genome 
sequencing. These include the Roche 454 GS FLX Titanium, Illumina Solexa GAII, Life APG 
SOLiD 3 and Pacific Biosciences PacBio RS; these are compared in Table 3.1. 
Pyrosequencing (such as the Roche 454 platform) is a sequence-by-synthesis technique 
that relies on the detection of pyrophosphate release during nucleotide incorporation. The 
released inorganic pyrophosphate initiates a chain of enzyme reactions that ultimately 
produces light. The sequential nucleotide specific light signals are then used to determine 
the nucleotide sequence (Harrington et al. 2013). The Roche 454 GS FLX Titanium platform 
was used in this study because the longer read length is beneficial for de novo sequencing 
of genomes in which repeats frequently occur as in the case of mycoplasmas. De novo 
sequencing was used to determine the Ms03 genome sequence since no reference genome 
was available for Ms03. Pyrosequencing produces reads that can be assembled into 
contiguous sequences (contigs) and these contigs can then be used as a draft genome.  
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Table 3.1 Comparison of next-generation sequencing techniques 
Platform Library 
(Template 
preparation) 
NGS chemistry  
(Read length) 
Advantages and disadvantages  
Roche 454 
GS FLX 
Titanium 
Fragment, 
paired-end 
(emPCR) 
Pyrosequencing 
(400 bases) 
Advantage: Longer reads improve 
mapping in repetitive regions; fast run 
times 
Disadvantage: High reagent cost; high 
error rates in homopolymer repeats 
Illumina 
Solexa GAII 
Fragment, 
mate-pair 
(emPCR) 
Sequencing by 
synthesis with reversible 
terminators  
(75 or 100 bases) 
Advantage: Low cost per Mb of data 
generated 
Disadvantage: Low multiplexing 
capability of samples 
Life APG 
SOLiD 3 
Fragment, 
mate-pair 
(solid-phase) 
Cleavable probe 
sequencing by ligation  
(50 bases) 
Advantage: Two-base encoding 
provides inherent error correction 
Disadvantage: Long run times 
Pacific 
Biosciences 
PacBio RS  
Fragment 
(single 
molecule) 
Single DNA polymerase 
detection 
(mean 2246 bases, 
maximum 23000 bases) 
Advantage: Longer reads improve 
mapping in repetitive regions and de 
novo sequencing  
Disadvantage: Highest error rates 
compared with other NGS chemistries 
Abbreviation emPCR: emulsion-based clonal amplification.  
Adapted from Metzker (2009); Glenn (2011); van Dijk et al. (2014).
 
For genome annotation, two automatic prokaryotic servers were used, namely the Institute 
for Genome Sciences (IGS) prokaryotic annotation pipeline and the Rapid Annotations using 
Subsystem Technology (RAST) annotation pipeline. IGS and RAST annotation servers are 
both web-base analyses for the annotation of bacterial and archaeal genomes that allow the 
user to manually curate data (Table 3.2). The two servers use different approaches to 
annotation as outlined in Table 3.3 and Table 3.4. Automated annotation results from 
different servers are often reported to provide different and sometimes conflicting predictions 
(Ederveen et al. 2013). The two annotation pipelines were therefore compared in attempt to 
generate a more complete/accurate annotation of the Ms03 genome. Additionally RAST 
allows for a metabolic reconstruction of the annotated data using KEGG pathways. An 
overview of the metabolic capacity of Ms03 could therefore be generated using the gene 
annotation of both annotation servers as basis.  
Traditional whole organism vaccine development against ostrich-infecting mycoplasmas is 
impractical and expensive because Ms03 is a slow growing bacterium that requires 
undefined medium components such as serum for in vivo growth. Knowledge of the Ms03 
genome makes a DNA vaccine approach against Ms03 infections in ostriches possible. DNA 
vaccine development requires knowledge of the mycoplasma genome in order to identify a 
vaccine candidate gene that can be used in the DNA vaccine.  
The oppA gene (substrate-binding domain of the oligopeptide permease (Opp) transporter) 
was chosen as vaccine candidate gene in previous Mycoplasma struthionis sp. nov. str. 
Ms01 and Mycoplasma sp. Ms02 studies within our research group (Pretorius 2009; 
Steenmans 2010).  
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The second aim of this study was therefore to identify an oppA gene within the Ms03 
genome for use as a DNA vaccine candidate gene. The objectives were therefore: 
 To identify an opp operon and its associated oppA gene within the Ms03 draft 
genome sequence. 
 To confirm the identity of the opp operon and therefore the oppA gene by using 
bioinformatic analysis.  
The opp operon in Ms03 was identified using tBLASTn and Glimmer searches. Furthermore, 
the identity of the opp genes was confirmed by identifying the functional protein motifs within 
their respective protein products.  
Table 3.2 Comparison of the IGS and RAST annotation servers 
 IGS annotation server RAST annotation server 
Developed by Institute for Genome Sciences, University 
of Maryland School of Medicine 
The National Microbial Pathogen Data 
Resource 
Website http://ae.igs.umaryland.edu/cgi/index  http://rast.nmpdr.org/  
Annotation of Bacteria and archaea Bacteria and archaea 
Prediction of non-
coding RNA and 
coding protein 
Search for non-coding RNA and protein 
coding genes simultaneously 
Search for non-coding RNA first then 
protein-encoding genes 
Do not allow protein-encoding genes 
to overlap with non-coding RNA  
Programs used for 
rRNA prediction 
RNAmmer search-for-rrna  
BLASTn against RNA database for 
endpoint adjustments  
Programs used for 
tRNA prediction 
tRNAscanSE tRNAscanSE 
Prediction of protein-
encoding genes 
Self-training method with Glimmer3* Self-training method with Glimmer3* 
Metabolic 
reconstruction  
No Yes 
* Note the self-training methods are different between the two programs, see Table 3.3 and Table 3.4. 
  Compiled from Aziz et al. (2008); Galens et al. (2011); Overbeek et al. (2013).
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Table 3.3 The IGS annotation pipeline  
The IGS annotation pipeline can be used to annotate both draft and finished genomes. The pipeline 
includes a number of steps for gene finding, protein searching and functional assignment (Galens et al. 
2011). These steps are: 
1. Parallel prediction of non-coding RNA and protein-encoding genes: 
 Non-coding RNA genes are identified by using tRNAscanSE for transfer RNA (tRNA) gene 
identification and RNAmmer for ribosomal RNA (rRNA) gene identification.  
 Protein-encoding genes are predicted with an ab initio Glimmer3 search. A set of long non-
overlapping genes are generated. From this set the relative frequencies of start sites are 
calculated and an upstream position weight matrix is created to aid in the identification ribosomal 
binding sites. These along with the set of long non-overlapping genes are used as input for the 
second Glimmer3 iteration. The predicted genes from this second round of Glimmer3 are used 
for downstream annotation. 
2. Similarity searches (Round 1) using the predicted genes (Round 2 of Glimmer3) as queries:  
 An initial BLASTx search is performed against the UniRef100 database.  
 The resulting pairwise alignments are used as input into BER (Blast Extend Repraze). BER 
translates the extended nucleotide query (300 nucleotides (nt) up- and downstream from the 
predicted gene) to protein and aligns it to each protein match found in the BLASTx search. This 
may result in up to 150 alignments for each predicted gene. By aligning the extended nucleotide, 
it is possible to adjust for frameshifts or in-frame stop codons due to sequencing errors. The BER 
tool aligns the sequence through the error and allows for better curation. One round of extension 
is performed; further manual curation is needed if the predicted gene needs to be extended more 
than 300 nt.  
 HMMER package is used to search the predicted polypeptide sequences against the TIGRFAM 
and Pfam databases. 
3. Refinement of the gene predictions based on automated evidence-directed structural curation:  
 The start and stop codons are adjusted based on the BER analysis and the presence of a 
ribosomal binding site upstream of the start codon. 
 All overlapping genes (non-coding RNA and protein-encoding) are identified. The BER analysis 
is evaluated for overlaps larger than 60 nt. If no evidence from a BER or HMM (Hidden Markov 
Model) search are found for one of the overlapping genes, it suggests a false positive and the 
gene is removed from the gene set. The same principle is applied to RNA genes overlapping 
protein-encoding genes. All other overlaps greater than 60 nt are flagged for manual reviewing. 
 Regions between genes are explored with BLASTx searches against the UniRef100 database to 
identify possible false negatives.  
4. Similarity searches (Round 2) using the newly identified or curated genes as queries:  
 Similarity searches include an initial BLASTx search as well as BER and HMM searches (against 
the TIGRFAM and Pfam databases). In the second round of similarity searches the genes are 
not extended with 300 nt as is the case within the first round of similarity searches.  
5. Motif searches on each predicted polypeptide:  
 Protein motif searches include SignalP (for prediction of signal peptide cleavage sites), LipoP 
(for prediction of lipoprotein signal peptides), TMHMM (for prediction of transmembrane helices), 
PROSITE using ScanProsite (for prediction of binding sites, active sites etc.), NCBI COGs (for 
assessment of orthologous groups) and Priam (to assign enzyme commission (EC) numbers) 
analyses are performed on each predicted polypeptide.  
6. Assignment of a common name, gene symbol, Gene Ontology (GO) terms, EC number and 
TIGRFAM roles to each polypeptide is based on the results of the similarity and motif searches 
using the program pFunc (prokaryotic protein functional prediction).  
7. All evidences are presented for online manual curation in Manatee.  
 
 
Table 3.4 The RAST annotation pipeline  
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The RAST annotation pipeline can be used to annotate both draft and finished prokaryotic genomes. 
The pipeline uses the FIGFam and subsystem approach to annotation (Aziz et al. 2008; Overbeek et 
al. 2013). The steps within the RAST annotation are as follows: 
1. Special case genes (such as the genes for selenoproteins and pyrrolysoproteins) are identified 
first. These genes require domain-specific knowledge for identification.  
2. Non-coding RNAs are identified using tRNAscanSE for tRNA gene identification and “search-for-
rrna” for rRNA gene identification. BLASTn searches against an rRNA database are used for 
endpoint adjustments of the rRNA genes.  
3. An ab initio Glimmer3 search is used to identify gene-candidates. The resulting gene-candidates 
are compared to a set of universal, plus up to 200 “unduplicated”, proteins in order to determine the 
30 closest phylogenetic neighbours.  
4. All gene-candidates are searched against proteins in the subsystems of the 30 closest 
phylogenetic neighbours. Subsystems are based on the FIGfam database. Genes are retained if 
they are similar to proteins in a subsystem and do not overlap significantly with a gene previously 
called. These genes are assigned a functional role base on these similarities.  
5. Glimmer is retrained based on the retained genes. The gene-candidates from this iteration are 
searched against proteins in the subsystems as in step 4. This is repeated until no new gene-
candidates are found to be similar to subsystem proteins.  
6. The remaining gene-candidates that do not match subsystem proteins and do not overlap with 
existing called genes are retained if they are similar to any protein in the 30 closest phylogenetic 
neighbours. 
7. The rest of the gene-candidates are now retained if they do not overlap with the genes called in 
step 4 to 6. This reduces the false negative gene calling.  
8. Gene fragments that may contain frameshifts due to low quality sequencing are detected by 
comparing it to the genes from the 30 closest phylogenetic neighbours. Upon user request, the 
fragments are joined to a single gene.  
9. Stretches of DNA longer than 1 500 base pairs (bp) that do not contain any genes are compared to 
the proteins of the 30 closest phylogenetic neighbours using BLASTx in order to identify missing 
genes. 
10. Functions for the genes that did not have subsystem matches are assigned base on BLASTp 
similarities.  
11. If a gene-candidate lacks subsystem assignment but the genes flanking it have subsystem 
assignments, then it is compared to the 30 closest phylogenetic neighbours. The gene may then be 
assigned into a subsystem provided that the three genes have bidirectional-best-hits in a 
neighbouring genome.  
12. Additionally gaps are re-examined if they are flanked by genes with bidirectional-best-hits to genes 
that are in a subsystem in one of the neighbouring genomes. This aids in the identification of 
missing genes.  
13. Gene-candidates are removed from the annotation if 1) they do not have subsystem or BLAST 
support, 2) are embedded in another gene, 3) significantly overlap with another gene or 4) are 
extremely short (>90 nt).  
14. Subsystem analysis and initial metabolic reconstruction (using the KEGG pathways) are 
performed.  
15. Pairs of close bidirectional-best-hits are computed against the genomes in PubSEED to support 
estimates of functional coupling based on conserved contiguity.  
16. Results are presented online in SEED Viewer that provides the opportunity for viewing and manual 
curation of the annotated genome.  
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3.2 Material and methods  
3.2.1 DNA isolation and confirming the identity of Ms03 genomic DNA 
Cultures of Ms03 were obtained from Mr J.J. Gouws (Faculty of Veterinary Science, 
Onderstepoort, University of Pretoria). Genomic DNA (gDNA) was isolated from these 
cultures using a method described by Hempstead (1990) with the following modifications: 
The cells were collected from 25 ml of culture by centrifugation and directly resuspended in 
1 ml concentrated TE buffer (50 mM Tris-HCl, pH 7.5, 10 mM EDTA). Following the sodium 
acetate/ethanol precipitation step, samples were incubated overnight at -20°C before 
collecting the gDNA by centrifugation at 16 000 × g for 1 h at 4°C. The pellet was washed 
twice by adding 1.5 ml 70% ethanol and incubation for 20 min at room temperature before 
centrifugation at 16 000 × g for 10 min at 4°C. The pellet was air dried at room temperature 
and dissolved in 50 μl Milli-Q® water. The gDNA concentration was determined 
spectrophotometrically (NanoDrop spectrophotometer, ND-1000), while the integrity of the 
gDNA samples was assessed on a 1% (w/v) agarose gel (Lonza, Switzerland). 
Electrophoresis was performed in 1 × TAE buffer (40 mM Tris-acetate, 1 mM EDTA, pH 8, 
20 mM glacial acetic acid) at 100 V for 5 min followed by 12 h at 12 V. After electrophoresis 
the agarose gel was stained for 10 min in 0.5 μg/ml ethidium bromide solution and visualised 
under UV light.  
Polymerase chain reactions (PCR) were performed to confirm the identity of Ms03 gDNA 
and the absence of possible contamination from the other ostrich mycoplasmas, 
M. struthionis sp. nov. str. Ms01 and Mycoplasma sp. Ms02. The primer sets used to identify 
the specific ostrich mycoplasmas was based on 16S rRNA gene sequences (Botes et al. 
2005a) (Table 3.5). Each PCR reaction contained 1 × reaction buffer, 0.2 mM of each 
deoxynucleotide (dATP, dCTP, dGTP and dTTP, Kapa Biosystems, South Africa) 2 mM 
MgCl2, 1 pmol/ml of each primer (Table 3.5), 0.2 units of Super-Therm Taq DNA polymerase 
(JMR Holdings, USA) and 2 μl gDNA (diluted 1:100) in a total volume of 10 μl. Positive 
controls containing M. struthionis sp. nov. str. Ms01, Mycoplasma sp. Ms02 and Ms03 gDNA 
as well as a negative control without template were included. PCR fragments were amplified 
with 25 cycles of denaturation at 94°C for 30 sec, annealing at 57°C for 15 sec and 
elongation at 72°C for 1 min followed by a final extension step at 72°C for 6 min in a Veriti 
96 well Thermal Cycler (Applied Biosystems, USA). PCR products were separated using 2% 
(w/v) agarose gel containing 0.5 μg/ml ethidium bromide. Electrophoresis was carried out at 
100 V for 40 min in 1 × TAE buffer and products were visualised under UV light. The 100 bp 
DNA ladder (Promega, USA) was used for size determination.   
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Table 3.5 Primer sequences, based on 16S rRNA sequences, for the identification of ostrich 
Mycoplasma species 
 Primer Sequence Fragment size (bp) 
M. struthionis sp. nov. 
str. Ms01 specific 
primers 
MS012 (F) 5'-AACATTAGTTAATGCCGGATACGC-3' 
499 
MS01D (R) 5'-GCCAGTATCCAAAGCGAGCC-3' 
Mycoplasma sp. Ms02 
specific primers 
MS02H (F) 5'-AATATAAAAGGAGCGTTTGC-3' 
247 
MS02A (R) 5'-AAGGCAATAGCATTTCCTCTACT-3' 
Ms03 specific primers 
MS03A (F) 5'-AGTGCTAATGCCGGATACTTATAC-3' 
521 
MS03C (R) 5'-CGTTAACCTCTATACAATTCTAGCG-3' 
Reference: Botes et al. (2005a). 
 
3.2.2 Ms03 genome sequencing and assembly 
The gDNA was sequenced using the Roche 454 GS FLX Titanium system by inqaba biotec 
(South Africa). Due to low gDNA concentrations, whole genome amplification was performed 
using the GenomiPhi kit (GE Healthcare, UK). In attempt to obtain a complete assembly, a 
second run, using the same library, as well as a third and a fourth run with newly isolated 
gDNA were done. Reads were assembled into contigs using the GS de novo assembler in 
Newbler (Roche) with default parameters. The genome parameters were also calculated 
with this program to assess the quality of the assembly. The quality parameters of the Ms03 
draft genome were compared to that of M. struthionis sp. nov. str. Ms01 (Pretorius 2009) 
and Mycoplasma sp. Ms02 (Steenmans 2010). 
3.2.3 IGS and RAST annotations and comparison of the annotations for the Ms03 
genome 
The IGS annotation engine was used for structural and functional annotation of the 
sequences (http://ae.igs.umaryland.edu/cgi/index.cgi, Galens et al. (2011)) and Manatee 
was used to view annotations (http://manatee.sourceforge.net/). Upon submission of the 
contigs to the IGS annotation engine, contigs were arranged from longest to shortest and 
assembled together into a pseudomolecule. The contigs were separated by a spacer 
(NNNNNCACACACTTAATTAATTAAGTGTGTGNNNNN) that introduces stop and start 
codons in all six reading frames. All the contigs (≥ 100 bp) in the final assembly was used to 
generated the pseudomolecule.  
Annotation was also performed with a second automatic annotation platform: RAST 
prokaryotic genome annotation server (http://rast.nmpdr.org, Aziz et al. (2008)). For 
comparison purposes, the same pseudomolecule generated by assembling all contigs was 
used as input for the RAST annotation.  
Both the IGS and RAST are online annotation servers which allow easy access to an 
annotation pipeline. All analyses and results are provided online which means that extensive 
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computer capacity is not required by the user. In the case of IGS, annotation results can be 
viewed online in Manatee that has a results page for each gene showing the evidence from 
the BER-searches and the protein bioinformatic analyses (SignalP, LipoP, TMHMM, 
PROSITE, NCBI COGs and Priam) on which the annotation was based. This information is 
presented in a clear systematic manner with links to the BER-alignments or to websites with 
the necessary motif information. The alignments are also provided for manual curation of the 
start and stop codons (Galens et al. 2011). Annotation results from RAST can be viewed 
online in The SEED Viewer. The viewer has options to browse the genome, to compare the 
genome based on function, sequence or KEGG pathways as well as the option for manual 
curation. The evidence that the annotation was based on, is provided on the gene’s feature 
page (Aziz et al. 2008; Overbeek et al. 2013). 
A metabolic pathway reconstruction (using KEGG reference pathways) was automatically 
done within the Seed Viewer of RAST using the RAST-annotated genes. The IGS-annotated 
genes were added to the constructed metabolic pathways in order to use as basis for 
comparing the IGS and RAST annotation servers. The reconstructed pathways based on the 
gene annotations were further compared to the KEGG pathways of the closes related 
species, Mycoplasma synoviae 53 (NC_007294), to determine the extent of missing genes 
due to incomplete sequencing or annotation of the Ms03 genome.  
3.2.4 Identification of the Ms03 origin of replication 
The origin of replication (ori) as well as the DnaA boxes were predicted using the web-based 
tool, Ori-Finder (Gao and Zhang 2008). DnaA boxes were identified using the consensus 
sequence TT(A/T/C)TCCACA and allowing 1 or 2 mismatches.  
3.2.5 Identification and bioinformatic characterization of the Ms03 opp operon 
Genes within the oligopeptide permease (opp) transporter operon (oppABCDF) were 
identified by using the operon of Mycoplasma hominis (YP_003302688.1) as query 
sequence in tBLASTn searches against the initial assembly of the Ms03 draft genome within 
CLC-bio. Glimmer v3.02 (Delcher et al. 1999; Delcher et al. 2007) was used to identify open 
reading frames (ORFs) in the contigs that contained the opp genes. Results were compared 
to that obtained after annotation of the draft Ms03 genome. The detailed analysis of 
functional motifs in the Opp proteins of M. hominis (Henrich et al. 1999) was used together 
with InterPro (Hunter et al. 2012) to identity the functional motifs in the Ms03 oppABCDF 
genes. Additionally, the similarity and identity between the Opp proteins of Ms03 and 
M. hominis was calculated using the EMBOSS WATER pairwise alignment algorithm 
(http://www.ebi.ac.uk/Tools/psa/emboss_water/). The program was set to use the 
BLOSUM62 matrix with a gap penalty of 10 and an extension penalty of 0.5.  
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3.3 Results and discussion 
3.3.1 DNA isolation and confirming the identity of Ms03 genomic DNA 
gDNA was isolated from Ms03 cultures to use as template in genome sequencing. Nanodrop 
analysis indicated adequate purity, but low concentration while the agarose gel 
electrophoresis confirmed the presence and integrity of the gDNA. No contamination with 
M. struthionis sp. nov. str. Ms01 and Mycoplasma sp. Ms02 gDNA was detected within the 
Ms03 gDNA samples by PCR. Multiple isolations were needed due to low yields. The purity 
and concentration of the gDNA was also assessed by inqaba biotec before genome 
sequencing. Due to low yield, whole genome amplification (GenomiPhi kit) was performed 
by inqaba biotec prior to genome sequencing.  
3.3.2 Ms03 genome sequencing and assembly 
The genome of Ms03 was sequenced with the GS FLX Titanium system by inqaba biotec. 
The first three Titanium runs produced 21.6 Mb of data that consist of 104 488 reads (Table 
3.6). Using the GS de novo assembler, the reads could be assembled into 427 contigs larger 
or equal to 100 bp of which 212 contigs were equal or larger than 500 bp. In an attempt to 
decrease the number of large contigs, a fourth Titanium run was performed which produced 
3.6 Mb of data that consist of 13 117 reads. In total, 25.2 Mb of data that consisted of 
117 605 reads was generated (Table 3.6). This was assembled together with the initial data 
into 314 contigs larger or equal to 100 bp. The larger contigs (≥ 500 bp) were only reduced 
from 212 to 172 contigs. All contigs from the final assembly are listed in Appendix 2 
Supplementary Table 2.1.  
Table 3.6 The 454 sequencing data of the four 454 Titanium sequencing runs and the de novo 
assembly of Ms03 genome 
454 Titanium sequencing run Data per run (Mb) Reads  
1st Run 15.4 71 383  
2nd Run 5.1 28 994  
3rd Run 1.1 4 111  
4th Run 3.6 13 117  
Newbler Assembly Total Mb Data Total reads Number of contigs ≥500 
Data from 1st run 15.4 71 383 221 
1st and 2nd  20.5 100 377 220 
1st, 2nd and 3rd  21.6 104 488 212 
All data 25.2 117 605 172 
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The 172 large contigs (≥ 500 bp) had a total length of 845 856 bp with an average size of 
4 917 bp (Table 3.7). The longest contig was 39 354 bp in length. The N50 contig size was 
9 874 bp. This implies that more than half of the assembled sequence length (845 856 bp / 2 
= 422 928 bp) is in contigs longer or equal to 9 874 bp. Q40 plus indicated that 99.3% 
(839 779 bp) of the bases had Phred-like consensus quality scores higher than 40. 
Therefore the probability of these bases being incorrect was less than 1 in 10 000. The Q39 
minus was 0.72% indicating that 6 077 bp of the 845 856 bp had Phred-like consensus 
quality scores less than 40 thus had a higher probability of being incorrect (>1 in 10 000).  
During in vitro culture, the Ms03 mycoplasma grows slowly and does not reach a high cell 
density. As a result it was difficult to isolate intact gDNA at high concentrations. This may 
have contributed to the quantity and quality of the reads generated. Whole genome 
amplification using the GenomiPhi kit was required to obtain an adequate concentration of 
gDNA for sequencing. This amplification step may have introduced a small amount of bias 
into the data (Pinard et al. 2006), that may have caused areas of the genome not to be 
sequenced. Problems with the generation of the sequencing library cannot be excluded 
since coverage of the individual contigs was irregular (uneven) as visualized in Newbler.  
Table 3.7 Comparison of the de novo assemble genomes of Ms03, Mycoplasma sp. Ms02 and 
M. struthionis sp. nov. str. Ms01  
De novo genome assemble 
parameters 
Ostrich-infecting mycoplasma genome assembles 
Ms03 Mycoplasma sp. Ms02 
M. struthionis sp. 
nov. str. Ms01 
454 instrument used to sequence 
genome (read length) 
GS FLX Titanium 
(400 bases) 
GS FLX 
(200 bases) 
GS20 
(100 bases) 
Amount sequencing data 
generated 25.2 Mb 15.8 Mb 30 Mb 
Number of reads 117 605 reads 70 115 reads 345 863 reads 
Number of contigs ≥500 bp 172 contigs 28 contigs 65 contigs 
Number of bases (≥500 bp) 845 856 bp 895 119 bp 693 513 bp  
Average contig size      4 917 bp   31 968 bp   10 669 bp 
N50 contig size     9 874 bp   71 894 bp   44 778 bp 
Largest contig size   39 354 bp 127 294 bp   86 684 bp 
Q40 plus bases 839 779 bp, 99.3% 893 151 bp, 99.8% 691 611 bp, 99.7% 
Q39 minus bases     6 077 bp, 0.72%     1 968 bp, 0.22%     1 902 bp,   0.3% 
Number of contigs ≥100 bp 314 contigs - - 
Number of bases (≥100 bp) 881 370 bp - - 
Reference This study Steenmans (2010) Pretorius (2009) 
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The genomes of ostrich-infecting mycoplasmas, M. struthionis sp. nov. str. Ms01 and 
Mycoplasma sp. Ms02 were previously sequenced by Pretorius (2009) and Steenmans 
(2010), respectively. In spite of the improvements in 454 sequencing chemistry (read length 
increased from 100 bases to 400 bases), the Ms03 genome assembly had more contigs and 
a lower N50 contig length compared to the assembly of M. struthionis sp. nov. str. Ms01 or 
Mycoplasma sp. Ms02 (Table 3.7). Results were also not significantly improved by 
generating more data. This may indicate that the full assembly of the Ms03 genome was not 
only influenced by the read length and chemistry (454 short gun) used, but also the 
sequence characteristics of the genome.  
A+T rich genomes with numerous runs and repeats (as found in mycoplasmas) cause 
anomalies that result in incomplete genome drafts. A limitation of 454 sequencing 
technology is the inability to accurately detect runs of identical bases (mononucleotide 
repeats or homopolymer runs). During 454 sequencing, nucleotide bases that are 
incorporated into the newly synthesised DNA, release inorganic pyrophosphate. This release 
initiates a chain of enzymatic reactions leading to the production of a light signal. There is 
however no termination that would prevent multiple consecutive incorporation of the same 
base; therefore the technology relies on the intensity of the light signal to detect multiple 
incorporations of the same base (Shendure and Ji 2008; Kircher and Kelso 2010). Multiple 
incorporation of long homopolymer runs (>10Ԝnt) are prone to error and may have 
contributed to the state of the A+T rich Ms03 genome assembly.  
Additionally, repeats longer than the read length creates gaps since they are erroneously 
collapsed on top of one another during the assembly of reads into contigs (Treangen and 
Salzberg 2011). Attempts to complete the Mycoplasma sp. Ms02 genome by using thermal 
asymmetric interlaced (TAIL) PCR failed due to numerous long repeats within the contigs 
(Strydom 2013). If the incomplete assembly of the Ms03 draft genome was the result of 
repetitive regions, generating paired-end or longer (>1 000 bases) reads may solve the 
genome assembly problems. Paired-end reads are generated from a single DNA fragment of 
a fixed size, from which both ends are sequenced. An assembler can then use the expected 
distance and the orientation of the reads to reconstruct the genome (Treangen and Salzberg 
2011). Additionally, sequencing data from platforms such as PacBio that generate longer 
read lengths (up to 23 000 bp) can be combined with the 454 reads. Combining data from 
PacBio with 454 data have been reported to overcome the assembly problems due to 
repeats and sequence bias (Koren et al. 2012). 
The absence of a reference genome, that would make a comparative approach to the Ms03 
genome assembly possible, further contributes to the incomplete state of the assembly. A 
number of complete mycoplasma genome sequences (Appendix 1) are available, but the 
lack of gene order conservation amongst Mycoplasma species, due to genome 
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rearrangements (Sirand-Pugnet et al. 2007a), implies that closely related species cannot 
serve as suitable reference genomes for the assembly of the Ms03 genome.  
3.3.3 IGS and RAST annotations of the Ms03 draft genome 
For annotation, a pseudomolecule was generated by joining all the contigs larger or equal to 
100 bp together with spacers between them. The spacers introduced stop and start codons, 
in all six reading frames, between each contig. This aids in identifying possible gene 
fragments on the ends of contigs. The generated pseudomolecule was 852 084 bp in length 
and had a G+C content of 28.7% with base frequencies of 35.8% adenine (A), 14.4% 
cytosine (C), 14.3% guanine (G) and 35.5% thymine (T) (Table 3.8). This is similar to other 
members of the genus Mycoplasma which typically have genome sizes ranging from 564 kb 
to 1 359 kb and a G+C content of 24% to 40% (Chapter 2, Table 2.2).  
Table 3.8 A summary of the Ms03 draft genome annotation as provided by the IGS and RAST 
annotation servers*  
Pseudomolecule generated by the IGS annotation server 
Pseudomolecule length 852 084 bp 
G+C content 28.7% 
Base frequencies (A)              35.8% 
(C)             14.4%  
(G)             14.3%  
(T)              35.5% 
IGS annotation server  
Protein-encoding sequences 763 genes 
Conserved hypothetical genes 46 genes (5.9%) 
Hypothetical genes 227 genes (29.0%) 
Total hypothetical genes 273 genes (34.8%) 
tRNA 19 
rRNA 3  
Average gene length 998 nt 
Percent coding 91.9% 
Percent coding, tRNA, rRNA, or repeat 92.9%  
Frequency of the translational start sites  
(excluding hypothetical genes) 
ATG:   79.3% 
GTG:    18.5% 
TTG:    2.2% 
RAST annotation server  
Protein-encoding sequences 635 genes 
Total RNAs 24 (5 rRNAs and 19 tRNAs) 
Number of subsystems 115 
Hypothetical genes 244 genes (38.4%) 
* The parameters for each annotations server differ, however, this is an output of the summary provided by the 
annotation server itself.  
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The IGS server annotated 763 genes in the Ms03 draft genome of which 273 were 
annotated as hypothetical genes (Table 3.8). The RAST server annotated 635 genes in the 
Ms03 draft genome of which 244 genes were annotated as hypothetical genes (Table 3.8). 
The number of predicted genes in the complete mycoplasma genomes ranges from 525 to 
1 580 annotated genes, which is similar to what was annotated by IGS and RAST.  
The most common start codon within the IGS annotation was ATG, the average gene length 
was 998 nt and 92.9% of the genome was predicted to be transcribed to RNA (Table 3.8). 
This information was not provided in the summary generated by the RAST analysis.  
All the genes annotated with the IGS and RAST annotation pipeline are listed in a 
comparative manner (based on the location on the pseudomolecule) in Appendix 2 
Supplementary Table 2.2. Annotated protein-encoding and non-coding RNA genes were 
named mnas (abbreviation for Ms03 chosen by the IGS server) followed by a number in the 
IGS annotation. In the RAST annotation protein-encoding and non-coding RNA genes were 
named peg (abbreviation for protein-encoding gene) and rna, respectively, followed by a 
number. Genes in IGS were numbered according to the position of the ORF on the 
pseudomolecule (i.e. the first gene was mnas_1, the second mnas_2, the third mnas_3), 
while in RAST this was not the case.  
3.3.4 Comparison of IGS and RAST annotation  
The IGS platform provided more information regarding the overall characteristics of the 
Ms03 draft genome than RAST (Table 3.8). The information was also easily available and 
included the number of conserved hypothetical genes, gene density (percent coding) and 
the frequency of the translational starting sites that were not provided by RAST. The only 
genome characteristics provided by RAST were number of protein-encoding sequences, 
number of RNAs, number of subsystems and total number of hypothetical genes (Table 3.8). 
It is possible to calculate all the additional parameters for the RAST annotation, except for 
number of conserved hypothetical genes (conserved hypothetical genes are defined as 
genes found in several phylogenetic lineages but have not been assigned function).  
The actual Ms03 annotation results of the IGS and RAST servers differ with regards to: 
• Number of protein-encoding and rRNA genes predicted  
• Start and stop positions of some genes 
• Names assigned to an annotated genes  
• IGS assigns gene abbreviations to the annotated genes, where possible.  
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3.3.4.1 Genes annotated  
The IGS annotation found 128 genes more than the RAST annotation while the hypothetical 
genes were 273 in the IGS annotation compared to 244 in the RAST annotation (Table 3.8). 
This implies that many of the genes annotated in IGS were discarded in the RAST 
annotation. Both IGS and RAST use the self-training method, Glimmer3, to identify genes. 
The results of the initial Glimmer3 searches were, however, implemented in a different 
manner as shown in Table 3.3 and Table 3.4. In the IGS pipeline, an initial Glimmer3 ORF 
search was performed to identify 1) non-overlapping long ORFs, 2) the frequency of the 
translational start sites and 3) an upstream position weight matrix for ribosomal binding sites. 
These results were used as input for the second Glimmer3 iteration. All ORFs predicted in 
the second run were used for downstream analysis (Galens et al. 2011). In the RAST 
pipeline, the ORF results from the initial Glimmer3 search were used to identify the 30 
closest phylogenetic neighbours. All gene-candidates were then vetted to identify genes that 
were similar to proteins in the subsystems of the 30 closest phylogenetic neighbours. In 
RAST, a subsystem is a set of related functional roles to which genes were assigned. These 
functional roles frequently make up a metabolic pathway, a complex (like a ribosome) or a 
class of proteins. The ORFs with subsystem matches were retained and used to retrain 
Glimmer3. This process was repeated until no new gene-candidates were found to belong to 
a subsystem. At this point new gene-candidates were retained if they matched genes called 
in the 30 closest phylogenetic neighbours, but did not overlap significantly with previously 
called genes (Overbeek et al. 2013). Although both methods (IGS and RAST) had additional 
steps to limit false positive and negative gene calling, most genes were called from these 
Glimmer3 iterations. RAST retained most genes based on matches with subsystem genes 
(provided that they do not overlap) whereas IGS predicted a gene irrespective of functional 
assignment or overlap with each other which leads to a larger number of genes identified 
within IGS.  
The IGS annotation found all three rRNAs (5S rRNA, 16S rRNA and 23S rRNA). Within the 
RAST annotation, however, five rRNAs were found, three (rna.5, rna.8 and rna.12) 
corresponding to the 5S rRNA, 16S rRNA and 23S rRNA (Appendix 2 Supplementary Table 
2.3) while the additional two were annotated as “Large subunit ribosomal RNA” genes. IGS 
predicted rRNA genes with the program RNAmmer that uses HMM datasets to locate rRNA 
genes. RAST, on the other hand, uses “search-for-rrna” followed by endpoint adjustments 
using a BLASTn search against a RNA database. The number of predicted rRNA genes was 
also similar to that annotated in complete mycoplasma genomes where the rRNA genes 
range from 3 to 8 (Chapter 2, Table 2.2). 
Both annotation servers use the same program to identify tRNA and both annotated 19 
tRNAs in the Ms03 draft genome (Appendix 2 Supplementary Table 2.4) which was lower 
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than in complete mycoplasma genomes where the tRNA genes range from 28 to 37 
(Chapter 2, Table 2.2). This was probably a result of the incomplete Ms03 genome 
sequence. 
3.3.4.2 Functional categories  
Of the 763 genes predicted in the IGS annotation, 54% were assigned to functional 
categories (Figure 3.1). Of the genes not assigned to functional categories (46%), most (273 
genes, 35%) were annotated as hypothetical genes while the remainder had a functional 
annotation but was not assigned to a functional category.  
Of the 635 genes predicted in the RAST annotation, 42% (265 genes) were assigned to 
functional categories (Figure 3.2), this included five genes annotated as hypothetical. The 
remaining 58% (370 genes) was not assigned into a functional category. Of these, most 
(238 genes, 37%) were annotated as hypothetical while 132 genes (21%) had a functional 
annotation even though they were not assigned into functional categories. 
IGS uses a more elaborate system to confirm and therefore assign function to a predicted 
gene. In IGS, functional categories are based on TIGRFAM roles and genes are assigned to 
a category using the program pFunc (uses BER and HMMER searches against TIGRFAM 
and Pfam databases as well as SignalP, LipoP, TMHMM and PROSITE searches), while in 
RAST functional categories are based on subsystems as defined by the FIGfam database 
and genes are assigned based on similarity searches. As a result more genes were 
assigned to functional categories using the IGS analysis. 
The IGS category for protein synthesis (95 genes, 12.1%) and the category transport and 
binding proteins (86 genes, 11.0%) account for 23% of all genes within the Ms03 draft 
genome (Figure 3.1). Other major categories were cellular processes (46 genes, 5.9%), 
DNA metabolism (44 genes, 5.6%), cell envelope (39 genes, 5.0%), protein fate (36 genes, 
4.6%) and energy metabolism (29 genes, 3.7%). The main categories in the RAST 
annotation were protein metabolism (125 genes, 19.7%), DNA metabolism (58 genes, 
9.1%), RNA metabolism (40 genes, 6.3%) and carbohydrate metabolism (21 genes, 3.3%) 
(Figure 3.2). In spite of the absence of a cell wall in mycoplasmas, two genes were present 
in the subcategory cell wall and capsule within the RAST annotation. These genes, tsaB 
(peg.484) and tsaE (peg.483), are found in many mycoplasmas. According to the RAST 
annotation website, placement of these genes into another category is being considered. In 
IGS these genes were annotated as “tRNA threonylcarbamoyl adenosine modification 
protein YeaZ” and “tRNA threonylcarbamoyl adenosine modification protein YjeE” and 
placed into the category “Transport and binding proteins” and “Unknown: conserved”, 
respectively.  
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Protein metabolism (125)
DNA metabolism (58)
RNA metabolism (40)
Carbohydrates (21)
Cofactors, vitamins, prosthetic groups, pigments (17)
Virulence, disease and defense (13)
Membrane transport (11)
Fatty acids, lipids, and isoprenoids (9)
Stress response (9)
Nucleosides and nucleotides (8)
Cell division and cell cycle (5)
Sulfur metabolism (5)
Potassium metabolism (3)
Phages, prophages, transposable elements, plasmids (3)
Cell wall and capsule (2)
Regulation and cell signaling (2)
Amino acids and derivatives (2)
Miscellaneous (1)
Dormancy and sporulation (1)
Phosphorus metabolism (1)
54%
46%
Protein synthesis (95)
Transport and binding proteins (86)
Cellular processes (46)
DNA metabolism (44)
Cell envelope (39)
Protein fate (36)
Energy metabolism (29)
Purines, pyrimidines, nucleosides, and nucleotides (17)
Transcription (15)
Biosynthesis of cofactors, prosthetic groups, and carriers (7)
Fatty acid and phospholipid metabolism (4)
Regulatory functions (4)
Signal transduction (3)
Mobile and extrachromosomal element functions (3)
Central intermediary metabolism (2)
Amino acid biosynthesis (1)
42%
58%
Role category coverage                                                         Category (number of genes) 
 
 
 
 
 
 
 
Figure 3.1 The IGS annotation role category breakdown of the Ms03 draft genome. The role 
categories are defined by TIGRfam. The bar-graph indicates the percentage genes assigned into a 
functional category in blue and the percentage genes not assigned into a functional category in green. 
The pie-chart displays the portions of each category. The categories are indicated on the right hand 
side with the number of genes in the category in brackets. The chart was generated in Microsoft Excel 
from the IGS data. Genes can be assigned into more than one functional category. 
Role category coverage                                                       Category (number of genes) 
 
 
 
 
 
 
 
Figure 3.2 The RAST annotation role category breakdown of the Ms03 draft genome. The bar-graph 
indicates the percentage genes assigned into a functional subsystem category in blue and the 
percentage genes not assigned into a functional category in green. The pie-chart displays the portions 
of each category. The categories are indicated on the right hand side with the number of genes in the 
category in brackets. The chart was generated in Microsoft Excel from the RAST data. Genes can be 
assigned to more than one subsystem category.  
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It should be noted that role categories in the two annotation programs differ and that this 
complicates direct comparisons. For example the largest category in the IGS annotation was 
“protein synthesis” (95 genes) while the largest category for the RAST annotation was 
“protein metabolism” (125 genes). But the RAST category “protein metabolism” contained 
most of the genes within the IGS categories “protein synthesis” as well as “protein fate” (36 
genes). For this reason the results from the two annotations were further compared using 
metabolic pathways. 
3.3.5 Metabolic overview of Ms03 
RAST allowed the construction of metabolic pathways for the annotated Ms03 draft genome 
using KEGG reference pathways. Construction of the metabolic pathways not only gave an 
overview of the metabolic capacity of Ms03 but also allowed a comparison of the annotation 
ability of IGS and RAST servers. The IGS annotation data was therefore added to each of 
the metabolic pathway reconstructions. The pathways of essential processes namely 
genome replication, cell division, RNA transcription, protein translation, energy metabolism 
and transport were used as basis for the comparison of the two annotation servers.  
From the gene annotation it could be seen that genes were missing in both annotations. To 
determine the extent to which genes were possibly missing and therefore the extent to which 
the genome sequence was incomplete, genes annotated within the M. synoviae 53 genome 
were added to each metabolic pathway. The M. synoviae 53 genome is a closely related 
species to Ms03 (Chapter 2, Figure 2.1) for which the complete genome sequence as well 
as its annotation is available.  
3.3.5.1 Genome replication and cell division in Ms03 
Genome replication is initiated by the binding of DnaA proteins to conserved regions (called 
DnaA boxes) at the ori (Brown 2002). The ori is a well defined site at which the replication 
forks open and is usually located in the vicinity of the dnaA and dnaN genes. In Ms03, the 
dnaA gene (mnas_99 or peg.9), encoding for the chromosomal replication initiator protein, 
was located from 142 051 to 143 460 nt on the DNA pseudomolecule as annotated by both 
IGS and RAST (Appendix 2 Supplementary Table 2.5). The dnaN gene (mnas_100 or 
peg.10) that encodes for the beta subunit of DNA polymerase III (EC 2.7.7.7) was located 
adjacent to the dnaA gene. This arrangement is conserved across Mycoplasma species 
(Figure 3.3). The Ms03 ori was predicted with Ori-Finder to be located between 141 769 and 
142 049 nt (length 281 nt) (Figure 3.4, Table 3.9). This region was between the mnas_98 
(peg.8, RecD-like DNA helicase YrrC) and dnaA gene (indicated with an orange arrow in 
Figure 3.3) and had an A+T content of 85.05%. A high A+T content for the ori is typical since 
it reduces the energy associated with opening the double stranded DNA molecule for 
replication. This confirms the position of the predicted ori.  
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DnaA boxes are A+T rich 9 bp regions that are usually found in the ori. Ori-Finder identified 
two DnaA boxes in this region when allowing one mismatch to the consensus sequence 
(TT(A/T/C)TCCACA), however when relaxing the conditions to allow two mismatches, nine 
DnaA boxes could be identified (Figure 3.4, Table 3.9). This was in range with other 
Mycoplasma species in which up to 10 DnaA boxes were identified (Cordova et al. 2002; 
Lartigue et al. 2003; Lee et al. 2008; Pereyre et al. 2009).  
A change in gene direction in the Ms03 draft genome annotations (both the IGS and RAST 
annotations) was observed at the ori (Figure 3.3). This is typically observed at the ori since it 
would prevent the head-on collision of replication and translation. Head-on collisions could 
stall replication and lead to a decrease in fitness (Price et al. 2005; Srivatsan et al. 2010; Lin 
and Pasero 2012). In the annotation of complete genomes, genes are numbered from the 
dnaA gene. The Ms03 annotation was, however, only a draft and the contig order was 
unknown therefore the gene numbers were not re-assigned based on the dnaA gene’s 
position. The linear genome sequences of Mycoplasma agalatiae PG2, Mycoplasma 
pulmonis UAB CTIP, Mycoplasma arthritidis 158L3-1, Mycoplasma hyopneumoniae 232 and 
M. synoviae 53 were used to generate Figure 3.3 therefore the dnaA gene was the first gene 
in the genome sequence. As such the figure shows no genes upstream of the dnaA gene for 
these genomes, but bacterial genomes are obviously circular and there will be genes 
upstream. It should be mentioned that the dnaA, dnaN genes, the predicted ori as well as all 
the genes shown for Ms03 in Figure 3.3 were located on one contig (contig00350) therefore 
the arrangement and orientation of genes in this regions is not due to the linking of contigs 
into the pseudomolecule.  
 
Figure 3.3 The annotated genes at the ori. The coloured genes indicate the same function with the red 
genes being dnaA and the green genes being dnaN. The grey boxes around the genes indicate similar 
function to the dnaA gene. The orange arrow indicates the ori as predicted with Ori-Finder. The linear 
genome sequences with the first gene being the dnaA gene of M. agalatiae PG2, M. pulmonis UAB 
CTIP, M. arthritidis 158L3-1, M. hyopneumoniae 232 and M. synoviae 53 were used to generate the 
figure. The figure was generated within RAST, results for the IGS annotation are not shown but the 
gene order, orientation and strand for all genes in both analyses are listed in Appendix 2, 
Supplementary Table 2.2. 
Ms03 
M. agalatiae PG2 
M. pulmonis UAB CTIP 
M. arthritidis 158L3-1 
M. hyopneumoniae 232 
M. synoviae 53 
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Figure 3.4 The Ms03 ori as predicted with Ori-Finder. The graph shows the Z-curves (AT, MK, RY and 
GC disparity curves) for the first 330000 nt of the Ms03 pseudomolecule sequence. The short vertical 
red line indicates the location of the indicator genes (dnaA, dnaN) and the short vertical dark orange 
arrow indicates the location of the predicted ori. The purple peaks with the diamonds indicate DnaA 
box clusters (allowing 1 mismatch from the consensus). The extremes for the AT disparity was 
142 029 nt (minimum) and 316 379 nt (maximum), for MK disparity 142 053 nt (minimum) and 316 382 
nt (maximum), for RY disparity 142 029 nt (minimum) and 316 379 nt (maximum) and for GC disparity 
39 426 nt (minimum) and 86 718 nt (maximum). Abbreviations of nucleotides: A, adenine; T, thymine; 
G, guanine; C, cytosine; M, amino (A and C); K, keto (G and T); R, purine (A and G) and Y, pyrimidine 
(C and T). 
Table 3.9 Characteristics of the Ms03 ori as predicted in Ori-Finder  
Ori-Finder parameter  
Ori length  281 nt  
A+T content of ori 85.05% 
The location of ori region  141 769..142 049 nt  
The location of dnaA gene  142 051..143 460 nt 
The number of DnaA boxes allowing one mismatch* 2 
Location of DnaA boxes (sequence) 141 841 (TTATTCACA) 
141 911 (TTATTCACA) 
The number of DnaA boxes allowing two mismatches* 9  
Location of DnaA boxes (sequence) 141 828 (TTTTGCACC) 
141 841 (TTATTCACA) 
141 853 (TTATTAACA) 
141 888 (TTATTAACA) 
141 911 (TTATTCACA) 
141 922 (TTATTAACA) 
141 964 (TAATTCACA) 
142 033 (TTATACACT) 
142 035 (TTTTATACA) 
* Consensus sequence TT(A/T/C)TCCACA  
  
AT disparity  
MK disparity  
RY disparity  
GC disparity  
DnaA box clusters
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Following site specific initiation of genome replication at the ori, the supercoiled DNA 
unwinds and the replication machinery is assembled. This proposed process in Ms03 is 
outlined in Figure 3.5. In total 14 DNA replication proteins were annotated in the Ms03 draft 
genome with both the IGS and RAST annotations (Figure 3.5 and Appendix 2 
Supplementary Table 2.5). These include, DnaA, two helicase (DnaB), DNA primase 
(DnaG), single-stranded DNA-binding protein (SSB), ribonuclease HII (RNase HII), DNA 
ligase (LigA), DNA polymerase I (DpoI) and six genes for the DNA polymerase III 
holoenzyme. The six DNA polymerase III holoenzyme subunits annotated were beta (dnaN 
gene), delta (holA gene), delta' (holB gene), gamma/tau (dnaX gene) and two alpha (dnaE 
and polC genes) subunits (Figure 3.5). Binding of DnaA proteins to the ori initiates 
replication by causing melting or opening of the double stranded DNA chromosome. 
Helicase separates the double stranded DNA and the binding of the SSB proteins stabilize 
the single stranded parental DNA. Subsequently, the DNA polymerase holoenzyme 
synthesizes the new strand complementary to the single strand parent DNA. The two DNA 
polymerase III alpha subunits, PolC and DnaE are responsible for the synthesis of the 
leading and lagging strand, respectively. This would likely represent all the genes for 
replication within the Ms03 genome since the same DNA replication proteins were annotated 
in the M. synoviae 53 genome (Figure 3.5) as well as Mycoplasma bovis str. Hubei-1 (Li et 
al. 2011).  
 
Figure 3.5 Proposed DNA replication in Ms03. The proteins (rectangular blocks on the right hand side) 
coloured in green were found in both the IGS and RAST annotations while proteins coloured in white 
were not found in the Ms03 draft genome annotations. For comparison, the annotated proteins of the 
complete M. synoviae 53 genome are indicated with red boxes. The schematic was downloaded from 
the Ms03 metabolic analysis in RAST and adapted to include the Ms03 IGS annotated proteins as well 
as the KEGG pathway of the M. synoviae 53 genome (msy03030). This schematic represents the 
KEGG reference pathway 03030. 
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During replication the circular chromosome of the mycoplasma is duplicated through DNA 
synthesis for which purine and pyrimidine bases are required. These bases can either be 
generated by de novo synthesis or recovered by the salvage pathways. Purine and 
pyrimidine metabolism in Ms03 is shown in Figure 3.6 and Figure 3.7 respectively using the 
KEGG reference pathways as basis with the purine and pyrimidine de novo synthesis 
pathways indicated with pink arrows.  
In the de novo synthesis of purine bases, inosine monophosphate (IMP) is synthesised from 
glycine, aspartate, glutamine, formate, HCO3⎯ and ribose-5-phosphate. AMP and GMP are 
subsequently synthesised from IMP. In the de novo synthesis of pyrimidine bases, UTP and 
CTP are synthesised from glutamine, HCO3⎯ and aspartate. Like most mycoplasmas (Bizarro 
and Schuck 2007), Ms03 is unable to synthesised purine (Figure 3.6, Appendix 2 
Supplementary Table 2.6) and pyrimidine bases (Figure 3.7, Appendix 2 Supplementary 
Table 2.7) de novo and have to rely on the respective salvage pathways.  
For purine and pyrimidine metabolism in Ms03, the IGS and RAST analysis annotated the 
same genes (Figure 3.6, Figure 3.7, Appendix 2 Supplementary Table 2.6 and 
Supplementary Table 2.7). These genes encode for enzymes that form part of the purine 
and pyrimidine salvage pathways. The enzyme, EC 3.1.3.5, that catalyses several reversible 
reactions was annotated by RAST (peg.299) as a “5'-nucleotidase”. In IGS, however, this 
gene (mnas_205) was only annotated as a “calcineurin-like phosphoesterase family protein”. 
The nucleotidase enzyme belongs to the “calcineurin-like phosphoesterase family protein” 
and therefore was indicated as annotated in both the IGS and RAST analysis. This enzyme, 
5'-nucleotidase, was however not annotated in the M. synoviae 53 genome although it is 
found within all other members of the hominis group (Vasconcelos et al. 2005). 
The purine metabolic pathway (Figure 3.6) of M. synoviae 53 had two enzymes that were 
not annotated in the Ms03 draft genome, ribonucleoside-diphosphate reductase 
(EC 1.17.4.1) and purine-nucleoside phosphorylase (EC 2.4.2.1). In addition to these two 
enzymes, the pyrimidine metabolic pathway in M. synoviae 53 also had the enzymes 
thymidylate synthase (EC 2.1.1.45) and dCMP deaminase (EC 3.5.4.12) annotated that 
were absent in the Ms03 draft genome annotations (Figure 3.7). The ribonucleoside-
diphosphate reductase enzyme and thymidylate synthase were also absent in M. hominis 
(KEGG pathways mho00230 and mho00240). Given the absence of the ribonucleoside-
diphosphate reductase enzyme and thymidylate synthase in M. hominis, it is possible that 
only the absence of purine-nucleoside phosphorylase and dCMP deaminase in the Ms03 
draft genome was due to incomplete genome sequence or the incomplete annotation (genes 
annotated as hypothetical).  
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Figure 3.6 Proposed purine metabolism in Ms03. The enzymes coloured in green were found in both the IGS and RAST annotations while the enzymes in white 
were not found in the Ms03 draft genome annotations. For comparison, annotated enzymes of the complete M. synoviae 53 genome are indicated with red boxes. 
The purine de novo synthesis pathway is indicated with pink arrows. The schematic was downloaded from the Ms03 metabolic analysis in RAST and adapted to 
include the Ms03 IGS annotated proteins as well as the KEGG pathway of the M. synoviae 53 genome (msy00230). This schematic represents the KEGG reference 
pathway 00230. 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3 Genome sequencing and annotation   
58 
Figure 3.7 Proposed pyrimidine metabolism in Ms03. The enzymes coloured in green were found in both the IGS and RAST annotations while the enzymes in white 
were not found in the Ms03 draft genome annotations. For comparison, annotated enzymes of the complete M. synoviae 53 genome are indicated with red boxes. 
The pyrimidine de novo synthesis pathway is indicated with pink arrows. The schematic was downloaded from the Ms03 metabolic analysis in RAST and adapted to 
include the Ms03 IGS annotated proteins as well as the KEGG pathway of the M. synoviae 53 genome (msy00240). This schematic represents the KEGG reference 
pathway 00240. 
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The purine salvage pathways in Ms03 include the stepwise conversion of deoxyadenosine to 
dAMP, to dADP, to dATP as well as the stepwise conversion of deoxyguanosine to dGMP, 
to dGDP, to dGTP (Figure 3.6). The pyrimidine salvage pathways in Ms03 include the 
stepwise conversion of thymine to thymidine, to dTMP, to dTDP as well as the stepwise 
conversion of uracil to deoxyuridine, to deoxycytidine, to dCMP, to dCDP (Figure 3.7). The 
enzyme nucleoside diphosphate kinase (EC 2.7.4.6) that is needed to convert dTDP to 
dTTP and dCDP to dCTP was, however, not annotated. This enzyme is also absent in the 
M. synoviae 53 genome annotation as is the case in all Mollicutes (Bizarro and Schuck 
2007). It has been reported that this function can be replaced by the glycolytic kinases, 6-
phosphofructokinase (EC 2.7.1.11), phosphoglycerate kinase (EC 2.7.2.3) and pyruvate 
kinase (EC 2.7.1.40) although these enzymes have a lower substrate-specificity for 
nucleosides other than ATP (Pollack et al. 2002; Bizarro and Schuck 2007; Pachkov et al. 
2007). The bases dATP, dGTP, dCTP and dTTP are incorporated into the newly 
synthesised DNA by the DNA polymerase III holoenzyme (EC 2.7.7.7).  
The limited purine and pyrimidine metabolic capacity suggests that Ms03 would be 
dependent on environment-derived nucleotides and precursors. It also implies the need to 
import these bases for DNA synthesis. 
Mycoplasmas have a low level of conservation of proteins related to cell division (Alarcon et 
al. 2007; Fisunov et al. 2011). Seven genes were annotated that encode for proteins 
involved in cell division with both the IGS and RAST annotations (Table 3.10). The genes 
are ftsH, era, scpA, scpB and ftsY that were annotated in both the IGS and RAST 
annotations. The FtsH protein plays a role in the quality control of integral membrane 
proteins and also influences cell division (Ito and Akiyama 2005), the GTP-binding protein, 
Era, may contribute to cell cycle regulation (Gollop and March 1991), the segregation and 
condensation protein A (ScpA) and B (ScpB) play a role in chromosomal segregation during 
cell division (Soppa et al. 2002), while the signal recognition particle-docking protein, FtsY, 
plays a role in protein targeting and also influences the cell cycle (Macao et al. 1997; 
Alarcon et al. 2007).  
In addition to these five genes, the IGS annotation had two additional genes (mnas_318 and 
mnas_803) that were both annotated as “recF/RecN/SMC N-terminal domain proteins” 
(Table 3.10). The mnas_318 protein was annotated as “chromosome partition protein smc” 
(peg.446) in the RAST annotation (Table 3.10) while the ORF for the mnas_803 gene was 
not predicted in RAST. An additional protein, peg.192, was also annotated as “chromosome 
partition protein smc” in the RAST annotation, but was only annotated as a conserved 
hypothetical protein in the IGS annotation. The ftsH and smc genes are found in all 
mycoplasma genomes (Alarcon et al. 2007).   
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Table 3.10 Cell division genes annotated with the Ms03 draft genome  
IGS RAST 
Gene_id Gene name  Gene symbol EC Gene_id Gene name  
mnas_95 
ATP-dependent zinc 
metalloprotease FtsH 
domain protein  
ftsH 3.4.24.- peg.5 Cell division protein FtsH  
mnas_167 Conserved hypothetical 
protein   peg.192 
Chromosome partition 
protein smc 
mnas_291 GTP-binding protein Era era  peg.404 GTP-binding protein Era 
mnas_318 RecF/RecN/SMC N terminal domain protein   peg.446 
Chromosome partition 
protein smc 
mnas_329 Segregation and condensation protein B scpB  peg.455 
Segregation and 
condensation protein B 
mnas_330 Segregation and condensation protein A scpA  peg.456 
Segregation and 
condensation protein A 
mnas_803 RecF/RecN/SMC N terminal domain protein     
mnas_606 
Signal recognition 
particle-docking protein 
FtsY 
ftsY  peg.115 
Signal recognition particle 
receptor protein FtsY (alpha 
subunit) (TC 3.A.5.1.1) 
 
Mycoplasmas divide by binary fission and the cell division protein. FtsZ is believed to play a 
central role in cell division by binary fission (Lluch-Senar et al. 2010). In Ms03, the ftsZ gene 
was, however, not found in either the IGS or RAST annotations. The ftsZ gene was also not 
found in the genome of Mycoplasma mobile (Jaffe et al. 2004) and in Mycoplasma 
genitalium a ftsZ null mutation was viable (Lluch-Senar et al. 2007). The ftsZ gene is, 
however, found in almost all mycoplasmas, including the close related species, M. synoviae 
53. In the absences of the fstZ gene, proteins involved in cell movement were found to be 
implicated in cell division (Hatchel and Balish 2008; Erickson and Osawa 2010; Lluch-Senar 
et al. 2010). However, Ms03 has been characterised as a non-motile Mycoplasma species 
(Langer 2009) which questions the absence of the ftsZ gene. Furthermore, the cell division 
genes mraZ and mraW were also not annotated in the Ms03 draft genome. The mraZ and 
mraW genes are conserved in Mycoplasma species (Alarcon et al. 2007). The absence of 
these genes (fstZ, mraZ and mraW) may be a result of the incomplete genome sequence or 
these genes may be annotated as hypothetical genes. The possibility that one or more of 
these gene are not found in Ms03 can however not be excluded.  
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3.3.5.2 RNA transcription and protein translation in Ms03  
RNA polymerase is essential for life and is found in all organisms including bacteria. This 
enzyme is responsible for the DNA-directed synthesis of RNA, i.e. transcription. In 
mycoplasma, the core subunits of RNA polymerase resemble that of other bacteria and are 
encoded by the rpoA, rpoB and rpoC genes. Genes for the alpha (rpoA), beta (rpoB) and 
beta' (rpoC) subunits of RNA polymerase, were annotated within both the IGS and RAST 
annotations of Ms03 (Figure 3.8, Appendix 2 Supplementary Table 2.8). In addition, the 
transcription initiation sigma factor (rpoD gene) that assists binding of the RNA polymerase 
to the promoter sequence was also annotated (Appendix 2 Supplementary Table 2.8). Only 
one sigma factor is common in mycoplasmas (Dorman 2011). The annotated genes 
correspond to that annotated in M. synoviae 53 (Figure 3.8). The omega (ω) subunit of RNA 
polymerase is absent in mycoplasmas while the delta (δ) is found in some but not all 
mycoplasma genomes (Madeira and Gabriel 2007). The delta subunit that is required for the 
expression of several stress-responses is found in M. pneumoniae, M. genitalium, 
Mycoplasma gallisepticum and Ureaplasma urealyticum (Fraser et al. 1995; Himmelreich et 
al. 1996; Madeira and Gabriel 2007).  
 
Figure 3.8 Proposed RNA polymerase in Ms03. The proteins coloured in green were found in both IGS 
and RAST annotations while the enzymes in white were not found in the Ms03 draft genome 
annotations. For comparison, annotated enzymes of the complete M. synoviae 53 genome are 
indicated with red boxes. The schematic was downloaded from the Ms03 metabolic analysis in RAST 
and adapted to include the Ms03 IGS annotated proteins as well as the KEGG pathway of the 
M. synoviae 53 genome (msy03020). This schematic represents the KEGG reference pathway 03020. 
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Transcription relies on the availability of nucleotides to be incorporated into the newly 
synthesised RNA molecule. As with DNA synthesis these nucleotides need to be salvaged 
from the environment because de novo synthesis of purines and pyrimidines is absent 
(Figure 3.6 and Figure 3.7). The purine salvage pathways for RNA bases in Ms03 include 
the stepwise conversion of adenine to adenosine, to AMP, to ADP, to ATP as well as the 
stepwise conversion of guanine to guanosine, to GMP, to GDP, to GTP (Figure 3.6). The 
pyrimidine salvage pathways for RNA bases in Ms03 include the stepwise conversion of 
uracil to uridine, to cytidine, to CMP, to CDP as well as the stepwise conversion of uridine to 
UMP, to UDP (Figure 3.7). The enzyme nucleoside diphosphate kinase (EC 2.7.4.6) that 
converts CDP to CTP and UDP to UTP was not annotated in the Ms03 draft genome and 
was also not present in the M. synoviae 53 genome annotation, although the function may 
be performed by other enzymes (Section 3.3.5.1). The bases ATP, GTP, CTP and UTP can 
be incorporated into the newly synthesised RNA by the RNA polymerase (EC 2.7.7.6). This 
limited metabolic capacity of Ms03 suggests that it depends on the import of ribonucleotide 
bases for RNA synthesis.  
Ribosomes are responsible for the RNA-directed synthesis of proteins, i.e. translation. A 
ribosome is a RNA-protein complex that uses tRNA molecules as adaptors to translate RNA 
to protein. The IGS annotation as well as the RAST annotation had 50 ribosomal proteins 
annotated (Figure 3.9, Appendix 2 Supplementary Table 2.9). This is equivalent to the 
ribosomal proteins annotated in the M. synoviae 53 genome (Figure 3.9). Additionally the 
rRNA genes 5S rRNA, 16S rRNA and 23S rRNA were annotated (Figure 3.9, Appendix 2 
Supplementary Table 2.3) as described above (Section 3.3.4.1).  
The two annotation programs, IGS and RAST both use the same tRNA prediction tool, 
tRNAscan-SE (Aziz et al. 2008; Galens et al. 2011) and annotated the same tRNA genes in 
the Ms03 draft genome. In Ms03, 19 tRNA genes were found that cover 14 of the 20 
standard amino acids as well as tRNA-SeC for the translation of the amino acid 
selenocysteine (Figure 3.10, Appendix 2 Supplementary Table 2.4). Selenocysteine is the 
21st amino acid and is incorporated into selenoproteins (Commans and Böck 1999). The 
tRNA for selenocysteine is reported in Mycoplasma alligatoris, Mycoplasma capricolum, 
Mycoplasma crocodyli, M. gallisepticum, M. genitalium, Mycoplasma hyorhinis, Mycoplasma 
suis and M. synoviae 53 as well as many other bacteria (Commans and Böck 1999; 
Guimaraes et al. 2011).  
The tRNA genes for alanine, aspartate, isoleucine, methionine, phenylalanine and proline 
were not annotated (Figure 3.10, Appendix 2 Supplementary Table 2.4). In M. synoviae 53, 
however, tRNA genes for all 20 amino acids as well as the tRNA-Sec are found (Figure 
3.10).  
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In Ms03 aminoacyl-tRNA synthetase genes were annotated for 19 of the 20 amino acids 
(Figure 3.10, Appendix 2 Supplementary Table 2.10). Only 18 aminoacyl-tRNA synthetase 
genes were, however, annotated in the RAST annotation. The enzyme for serine tRNA 
synthesis (EC 6.1.1.11) was annotated in IGS however the ORF was not found in the RAST 
analysis. The RAST enzyme for glutamine tRNA synthesis (EC 6.1.1.24) was annotated in 
IGS as “tRNA synthetases class I (E and Q), catalytic domain protein“ and was therefore 
added to the IGS pathway in Figure 3.10. The enzyme for asparagine tRNA synthesis (EC 
6.1.1.23 or EC 6.1.1.22) was not annotated in either annotation. In the aminoacyl-tRNA 
biosynthesis pathway of M. synoviae 53 (msy00970) the enzyme EC 6.1.1.22 was however 
annotated.  
 
Figure 3.9 The proposed ribosomal genes in Ms03. The proteins coloured in green were found in both 
IGS and RAST annotations while the proteins in white were not found in the Ms03 draft genome 
annotations. For comparison, annotated proteins of the complete M. synoviae 53 genome are 
indicated with red boxes. The schematic was downloaded from the Ms03 metabolic analysis in RAST 
and adapted to include the Ms03 IGS annotated proteins as well as the KEGG pathway of the 
M. synoviae 53 genome (msy03010). This schematic represents the KEGG reference pathway 03010. 
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Figure 3.10 The proposed aminoacyl-tRNA biosynthesis in Ms03. The tRNA genes found with both 
IGS and RAST annotations are coloured in pink. The aminoacyl-tRNA synthetase enzymes coloured 
in yellow were only found within the IGS annotation, the enzymes coloured in green were annotated in 
both IGS and RAST annotations while the enzymes coloured in white were not found in the Ms03 draft 
genome annotations. For comparison, annotated tRNAs and enzymes of the complete M. synoviae 53 
genome are indicated with red boxes. The schematic was downloaded from the Ms03 metabolic 
analysis in RAST and adapted to include the Ms03 IGS annotated proteins as well as the KEGG 
pathway of the M. synoviae 53 genome (msy00970). This schematic represents the KEGG reference 
pathway 00970.  
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The aminoacyl-tRNA biosynthesis of all standard 20 amino acids are essential to most 
organisms (Sheppard et al. 2008). The tRNA genes and aminoacyl tRNA synthetase 
enzymes that were not found in the Ms03 draft annotation do not overlap with each other 
(Figure 3.10). This indicates that it is likely that all the tRNA and synthetase enzymes for all 
20 amino acids will be present in a completely assembled and annotated genome of Ms03. 
In general, tRNA genes range from 71 to 91 nt in size. The absences of these small genes 
are likely an effect of the incomplete assembly of the genome. Additionally, detailed manual 
curation of the hypothetical and annotated genes may lead to the assignment or re-
assignment of function to some genes which could include some of the “missing” functions.  
Translation, the synthesis of protein, relies on the availability of amino acids to incorporate/ 
build into the protein molecule. Annotated Ms03 genes for de novo amino acid synthesis 
paint a rather incomplete picture. Table 3.11 provides an overview of the amino acid 
metabolism pathways, with only six genes annotated in the Ms03 draft genome.  
Table 3.11 Overview of the number of genes annotated in amino acid metabolic pathways in the 
Ms03 draft genome 
KEGG pathway maps for amino acid metabolism  
(Reference pathway number) 
Number of genes annotated in 
the genome  
Ms03  M. synoviae 53 
Alanine, aspartate and glutamate metabolism (00250) 1 0 
Glycine, serine and threonine metabolism (00260) 2 3 
Cysteine and methionine metabolism (00270) 2 2 
Valine, leucine and isoleucine degradation (00280) 0 1 
Valine, leucine and isoleucine biosynthesis (00290) 0 0 
Lysine biosynthesis (00300) 0 0 
Lysine degradation (00310) 0 0 
Arginine and proline metabolism (00330) 1 0 
Histidine metabolism (00340) 0 0 
Tyrosine metabolism (00350) 0 0 
Phenylalanine metabolism (00360) 0 0 
Tryptophan metabolism (00380) 0 0 
Phenylalanine, tyrosine and tryptophan biosynthesis (00400) 0 0 
Total number of genes 6 6 
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The enzyme L-aspartate:ammonia ligase (EC 6.3.1.1) that catalyses the conversion of 
aspartate to asparagines was the only enzyme annotated in the alanine, aspartate and 
glutamate metabolic pathway in both the IGS and RAST annotations of Ms03 (Table 3.12, 
Appendix 2 Supplementary Figure 2.1). In the genomes of M. synoviae 53 (Appendix 2 
Supplementary Figure 2.1) and M. hominis no enzymes were annotated for this pathway. 
The enzyme serine hydroxymethyltransferase (EC 2.1.2.1) was annotated in IGS but not in 
the RAST annotation (Table 3.12, Appendix 2 Supplementary Figure 2.2). In RAST the ORF 
for this gene was not predicted. This enzyme forms part of the glycine, serine and threonine 
metabolic pathway and catalyses the conversion of glycine to serine. In addition, 
phosphoglyceromutase (EC 5.4.2.12) was annotated within both the IGS and RAST 
annotations. Phosphoglyceromutase also takes part in glycolysis (Section 3.3.5.3). Both 
these enzymes were present in the genome of M. synoviae 53 (Appendix 2 Supplementary 
Figure 2.2). 
Table 3.12 Genes annotated in the amino acid metabolic pathways of the Ms03 draft genome 
Reaction  
(KEGG reaction number) 
IGS RAST 
Gene_id Description  
(EC number) 
Gene 
symbol
Gene_id Description  
(EC number) 
Alanine, aspartate and glutamate metabolism (KEGG reference pathway 00250) 
ATP + NH3 + L-Aspartate 
<=> PPi + AMP + L-
Asparagine 
(R00483) 
mnas_499 Aspartate-ammonia 
ligase  
(EC 6.3.1.1) 
asnA peg.628 L-Aspartate: 
ammonia ligase 
(AMP-forming)  
(EC 6.3.1.1) 
Glycine, serine and threonine metabolism (KEGG reference pathway 00260) 
5,10-
Methylenetetrahydrofolat
e + Glycine + H2O <=> 
Tetrahydrofolate + L-
Serine 
(R00945) 
mnas_278 Serine 
hydroxymethyltransferas
e  
(EC 2.1.2.1) 
glyA      
Cysteine and methionine metabolism (KEGG reference pathway 00270) 
H2O + ATP + L-
Methionine <=> 
Phosphate + PPi + S-
Adenosyl-L-methionine 
(R00177) 
mnas_482 Methionine 
adenosyltransferase  
(EC 2.5.1.6) 
metK  peg.617 ATP:L-methione 
S-
adenosyltransferas
e  
(EC 2.5.1.6) 
S-Adenosyl-L-methionine 
+ DNA <=> S-Adenosyl-
L-homocysteine + DNA 5-
methylcytosine 
(R00380) 
mnas_497 Modification methylase 
BanI  
(EC 2.1.1.37) 
banIM peg.626 DNA-cytosine 
methyltransferase 
(EC 2.1.1.37) 
Arginine and proline metabolism (KEGG reference pathway 00330) 
Peptide with N-terminal 
proline + H2O <=> L-
Proline + Peptide 
(R00135) 
mnas_42 prolyl aminopeptidase  
(EC 3.4.11.5) 
pip peg.422 Proline 
iminopeptidase  
(EC 3.4.11.5) 
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The enzyme methionine adenosyltransferase (EC 2.5.1.6) that catalyses the conversion of 
methionine to adenosyl-L-methionine and the enzyme DNA-cytosine methyltransferase 
(EC 2.1.1.37) that catalyses the methylation of the cytosine base in DNA were the only two 
enzymes annotated in the cysteine and methionine metabolism pathway of the Ms03 draft 
genome (Table 3.12, Appendix 2 Supplementary Figure 2.3). These two enzymes were also 
found in the M. synoviae 53 genome (Appendix 2 Supplementary Figure 2.3).  
In the arginine and proline metabolism pathway, the enzyme prolyl aminopeptidase 
(EC 3.4.11.5) was the only enzyme annotated in the Ms03 draft genome (Table 3.12, 
Appendix 2 Supplementary Figure 2.4). This enzyme catalyses the release of an N-terminal 
proline from a peptide and is also found in the M. synoviae 53 genome (Appendix 2 
Supplementary Figure 2.4).  
To conclude this section, annotation of the genes in the amino acid metabolism pathways 
indicated that Ms03 can convert aspartate to asparagine and glycine to serine and imply that 
most amino acids must be imported for protein synthesis. Ms03, like other mycoplasmas, is 
unable to synthesise de novo amino acids.  
3.3.5.3 Energy metabolism in Ms03 
From experimental evidence it is known that Ms03 uses glucose as its main energy source 
(Langer 2009). Ten glycolysis enzymes were annotated in the IGS annotation and nine in 
the RAST annotation (Figure 3.11, Appendix 2 Supplementary Table 2.11). The enzyme 
phosphoglycerate kinase (EC 2.7.2.3) was annotated in the IGS annotation, however in the 
RAST analysis, the ORF of this gene was not predicted. Two glucose-6-phosphate 
isomerase (EC 5.3.1.9) genes were annotated in both analyses although in IGS one of these 
was only annotated as a “phosphoglucose isomerase family protein”. Enzyme II of the 
phosphoenolpyruvate-dependent sugar phosphotransferase transport system (PTS) 
(EC 2.7.1.69) was included in the glycolysis pathway. The PTS system phosphorylates 
extracellular glucose and other sugars upon transport into the cell. This circumvents the 
need for glucokinase (EC 2.7.1.2) that was not annotated in Ms03 as is the case in 
M. synoviae 53 (Figure 3.11).  
Both the IGS and RAST annotations lack the gene for phosphofructokinase (EC 2.7.1.11) 
that converts β-D-fructose-6-phosphate to β-D-fructose-1,6-bisphosphate (Figure 3.11). In 
the M. synoviae 53 genome, this enzyme was annotated, however in the genome of 
M. hominis phosphofructokinase is also absent (KEGG mho0010) (Pereyre et al. 2009). 
M. hominis is a non-glycolytic mycoplasma that uses arginine as its main energy source but 
can also utilize glucose. In M. hominis, the steps to circumvent the need for 
phosphofructokinase form part of the pentose phosphate pathway (KEGG mho00030). The  
 
Stellenbosch University  https://scholar.sun.ac.za
Chapter 3 Genome sequencing and annotation   
68 
 
Figure 3.11 Glycolysis / gluconeogenesis pathway in Ms03. The enzymes coloured in yellow were only 
found within the IGS annotation, enzymes coloured in green were found in both IGS and RAST 
annotations while the enzymes in white were not found in the Ms03 draft genome annotations. For 
comparison, annotated enzymes of the complete M. synoviae 53 genome are indicated with red boxes. 
The schematic was downloaded from the Ms03 metabolic analysis in RAST and adapted to include 
the Ms03 IGS annotated proteins as well as the KEGG pathway of the M. synoviae 53 genome 
(msy00010). This schematic represents the KEGG reference pathway 00010. 
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pentose phosphate pathway for MS03 is presented in Figure 3.12 (Appendix 2 
Supplementary Table 2.12). In this pathway, β-D-fructose-6-phosphate from glycolysis is 
converted to xylulose-5-phosphate (transketolase EC 2.2.1.1). Xylulose-5-phosphate can 
follow one of two paths to continue with glycolysis. Firstly xylulose-5-phosphate can be 
converted directly to glyceraldehyde-3-phosphate by phosphoketolase (EC 4.1.2.9). 
Secondly xylulose-5-phosphate can be converted to ribulose-5-phosphate by ribulose-5-
phosphate 3-epimerase (EC 5.1.3.1), ribulose-5-phosphate to ribose-5-phosphate by ribose-
5-phosphate isomerase B (EC 5.3.1.6) and ribose-5-phosphate to glyceraldehyde-3-
phosphate by transketolase (EC 2.2.1.1). Glyceraldehyde-3-phosphate can then enter 
glycolysis. Although most of the enzymes to circumvent the need for phosphofructokinase 
were annotated in Ms03, transketolase (EC 2.2.1.1) was not annotated. In order to catalyse 
the degradation of glucose to pyruvate, either phosphofructokinase or transketolase would 
be needed. Although these “missing” genes could likely be due to the incomplete assembly 
that complicates accurate ORF calling or the incomplete annotation with genes annotated as 
hypothetical, the possibility that one of these genes is absent in the Ms03 genome cannot be 
excluded.  
Pyruvate is further metabolised to D-lactate (Figure 3.13, Appendix 2 Supplementary Table 
2.13). In contrast to M. synoviae 53, enzymes to convert pyruvate to acetyl-CoA were not 
annotated in Ms03 (Figure 3.11 and Figure 3.13). These enzymes were however also not 
annotated in M. hominis (KEGG mho0010). Additionally no genes were annotated with roles 
in the citric acid cycle pathway, which suggest that the citric acid cycle is absent in Ms03. 
This is expected as the citric acid cycle is absent in most mycoplasmas (Razin et al. 1998; 
Jaffe et al. 2004; Chen et al. 2012).  
The pentose phosphate pathway that regenerates NADPH from NADP+ was incomplete 
(Figure 3.12). The enzymes glucose-6-phosphate dehydrogenase (EC 1.1.1.49) and 6-
phosphogluconate dehydrogenase (EC 1.1.1.44) that produce NADPH were not annotated 
in the Ms03 genome as in the case of M. synoviae 53. The pentose phosphate pathway is, 
however, also incomplete in many other mycoplasmas (Himmelreich et al. 1996; Razin et al. 
1998; Halbedel et al. 2007; Pereyre et al. 2009). The absence of these genes is therefore 
not necessarily related to the incomplete genome sequence of Ms03.  
As in the M. synoviae 53 genome, no genes were annotated within the Ms03 draft genome 
for the arginine deiminase pathway and the urea cycle. This was consistent with the finding 
that Ms03 is unable to utilize arginine and urea as energy source during in vitro culture 
(Langer 2009).  
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Figure 3.12 The proposed pentose phosphate pathway in Ms03. The enzymes coloured in green were found in both the IGS and RAST annotations while the 
enzymes in white were not found in the Ms03 draft genome annotations. For comparison, annotated enzymes of the complete M. synoviae 53 genome are indicated 
with red boxes. The schematic was downloaded from the Ms03 metabolic analysis in RAST and adapted to include the Ms03 IGS annotated proteins as well as the 
KEGG pathway of the M. synoviae 53 genome (msy00030). This schematic represents the KEGG reference pathway 00030. 
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Figure 3.13 The proposed pyruvate metabolism in Ms03. The enzymes coloured in green were found 
in both IGS and RAST annotations while the enzymes in white were not found in the Ms03 draft 
genome annotations. For comparison, annotated enzymes of the complete M. synoviae 53 genome 
are indicated with red boxes. The schematic was downloaded from the Ms03 metabolic analysis in 
RAST and adapted to include the Ms03 IGS annotated proteins as well as the KEGG pathway of the 
M. synoviae 53 genome (msy00620). This schematic represents the KEGG reference pathway 00620. 
In mycoplasma, ATP synthase is thought to be involved in ATP hydrolysis and the 
maintenance of the electrochemical gradient (Rechnitzer et al. 2011). IGS annotated 15 
genes that encode for ATP synthase subunits, while RAST annotated 10 genes (Figure 3.14 
and Table 3.13). All mycoplasmas have a typical F1F0 ATP synthase that consists of eight 
conserved genes found within an operon (Beven et al. 2012). In the IGS annotation, six of 
the ATP synthase subunit genes were found adjacent to each other (atpB, atpE, atpF, atpH, 
atpA and atpG; mnas_84 to mnas_89). The atpD and atpC (mnas_767 and mnas_766) were 
found next to each other but in a separate location (Table 3.13). The first six genes are 
located on contig00408 while the atpD and atpC genes were on contig00433. In a complete 
assembly of the Ms03 genome, these genes would likely be located next to each other in an 
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operon system as in other Mycoplasma species. The ORFs for the IGS genes, atpG 
(mnas_89), atpD (mnas_765), atpD (mnas_767), mnas_630 and mnas_643 were not 
predicted in the RAST annotation. Extra copies of the ATP synthase subunits (atpA and 
atpD) have been reported in many mycoplasmas although it is not the case in most bacteria 
(Beven et al. 2012).  
3.3.5.4 Acquiring the necessary building blocks to maintain life: Transport  
The transporters annotated in the Ms03 draft genome are illustrated in Figure 3.14 and the 
proteins involved are listed in Appendix 2 Supplementary Table 2.14. The F1F0 ATP 
synthase (Section 3.3.5.3, Table 3.13) is a transmembrane protein complex (Figure 3.14 A) 
and has been reported to play a role in ATP hydrolysis and maintaining the electrochemical 
gradient (Rechnitzer et al. 2011). 
Putative potassium, magnesium and cation (possibly for copper, lead, cadmium, zinc and 
mercury ions) importers were annotated in both the Ms03 IGS and RAST annotations 
(Figure 3.14 B-D, Appendix 2 Supplementary Table 2.14). These ions play an important role 
as cofactors in enzymatic reactions as well as in maintaining an electrochemical gradient for 
osmotic balance.  
Table 3.13 The annotated genes for ATP synthase (EC 3.6.3.14) in the Ms03 draft genome 
IGS annotation RAST annotation  
Gene_id Gene name  Gene symbol Gene_id Gene name  
mnas_84 ATP synthase A chain atpB peg.590 ATP synthase F0 sector subunit a 
mnas_85 ATP synthase F0, C subunit atpE peg.591 ATP synthase F0 sector subunit c 
mnas_86 ATP synthase F0, B subunit atpF peg.592 ATP synthase F0 sector subunit b 
mnas_87 ATP synthase F1, delta subunit atpH peg.593 ATP synthase delta chain  
mnas_88 ATP synthase F1, alpha subunit atpA peg.594 ATP synthase alpha chain  
mnas_89 ATP synthase family protein atpG   
mnas_293 
ATP synthase alpha/beta 
family, nucleotide-binding 
domain protein 
 peg.405 ATP synthase alpha chain 
mnas_294 ATP synthase F1, beta subunit atpD peg.406 ATP synthase beta chain  
mnas_614 
ATP synthase alpha/beta 
family, nucleotide-binding 
domain protein 
atpA peg.141 ATP synthase alpha chain  
mnas_615  ATP synthase F1, beta subunit atpD peg.142 ATP synthase beta chain 
mnas_765 ATP synthase F1, beta subunit atpD   
mnas_766 ATP synthase F1, epsilon subunit atpC peg.347 ATP synthase epsilon chain 
mnas_767 ATP synthase, subunit beta atpD   
mnas_630 Putative ATP synthase alpha 
chain domain protein    
mnas_643 Putative ATP synthase alpha 
chain domain protein 
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The phosphoenolpyruvate-dependent sugar phosphotransferase transport system (PTS) 
imports and phoshorylates sugars (Clore and Venditti 2013). This transport involves a series 
of phosphorylation events of enzyme I (EI), histidine-containing phospho-carrier protein 
(HPr) and enzyme II (EII). EII consists out of three components, IIA, IIB and IIC. A high-
energy phosphate moiety from phosphoenolpyruvate (PEP) is transferred to EI in the 
cytoplasma, subsequently to HPr and to IIA (cytoplasma) then to IIB which is associated with 
the membrane embedded IIC component. Finally the transmembrane domain IIC catalyzes 
the coupled translocation and phosphorylation (phosphate group from IIB) of the incoming 
sugar (Clore and Venditti 2013). In both the IGS and RAST annotations of the Ms03 draft 
genome, two HPr, glucose/glucosamine/beta-glucoside-specific IIA, IIB and IIC components 
(EC 2.7.1.69) and an additional putative PTS system glucose-specific enzyme IIB 
component were annotated (Figure 3.14 E, Appendix 2 Supplementary Table 2.14). 
Furthermore, an enzyme was annotated as ”HPr(Ser) kinase/phosphatise” (EC 2.7.1.-) 
which could possibly be the Ms03 EI. The glycolytic mycoplasma M. genitalium had two 
complete glucose and fructose PTS systems while in the non-glycolytic mycoplasmas, 
M. hominis and Ureaplasma parvum, EI is absent (Glass et al. 2000; Pereyre et al. 2009). In 
vitro culturing has shown that Ms03 mainly uses glucose as energy source (Langer 2009) 
and with the absence of glucokinase (EC 2.7.1.2) in glycolysis (Figure 3.11), the 
phosphorylation of extracellular glucose could be required by Ms03.  
ATP-binding cassette (ABC) transporters are present in all organisms and play an important 
role in the active transport of substrate across the cell membrane (Rice et al. 2014). All ABC 
transporters have two transmembrane domains that form a pore and two intracellular 
domains that bind and hydrolyze ATP thereby supplying energy for substrate transport. 
Additionally, ABC importers in bacteria have an extracellular substrate-binding domain (Rice 
et al. 2014).  
Energy-coupling factor (ECF) transporters are a type of ABC transporter that mediate the 
uptake of micronutrients. ECF transporters are present in approximately 50% of prokaryotic 
species but are particularly abundant in the phylum Firmicutes of Gram-positive bacteria 
(Slotboom 2014). The transporter consists of an integral membrane protein, EcfT (the T 
component) and integral membrane substrate-binding domain (the S component) as well as 
two similar or identical cytosolic ATP synthases, EcfA and EcfA′ (the A components). A 
substrate-binding domain for different substrates can interact with the same T and A 
components. In the Ms03 draft genome, an ECF transporter was annotated (Figure 3.14 F). 
Two EcfA proteins were found in both the IGS and RAST annotations. An EcfT protein was 
annotated within IGS, however in the RAST annotation, this ORF was not predicted. Only 
one S component was annotated with both programs. The annotated S component was  
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Figure 3.14 Transporters annotated in the Ms03 draft genome. A) The F1F0 ATP synthase, B) Putative 
potassium uptake protein (KtrB/KtrA), C) Magnesium transporter, D) Putative cation transporting P-
type ATP synthase (copper, lead, cadmium, zinc and mercury), E) Phosphoenolpyruvate-dependent 
sugar phosphotransferase system, F) Putative energy-coupling factor transporter, G) Putative 
spermidine/putrescine ABC transporter, H) Putative glycerol-3-phosphate ABC transporter, I) Putative 
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phosphonate ABC transporter, J) Oligopeptide permease ABC transporters and K) Lipid A export 
permease protein MsbA. Abbreviation: PEP phosphoenolpyruvate.  
predicted to have the substrate specificity for riboflavin with the IGS server but folate with the 
RAST server. In general, the S components share low sequence similarity (10 to 20% 
identity) (Slotboom 2014) which may explain the difference in the annotations.  
Within the Ms03 draft genome, ABC importers for spermidine/putrescine, glycerol-3-
phosphate, phosphonate and two Opp transporters were annotated (Figure 3.14 G-J, 
Appendix 2 Supplementary Table 2.14). A complete spermidine/putrescine (Pot) transporter 
consists of two transmembrane domains (PotB and PotC), two homodimeric intracellular 
nucleotide binding domains (PotA) as well as the substrate-binding domain (PotD) (Figure 
3.14 G). In the IGS annotation, eight genes were denoted as components of a 
spermidine/putrescine (PotABCD) transporter while the RAST annotation had only three 
genes (Appendix 2 Supplementary Table 2.14). The ORFs for the additional genes 
annotated in IGS were not predicted in the RAST annotation. In the IGS annotation, a 
complete gene set, potABCD was annotated with two additional potA genes, one potC and 
potD gene.  
In both the IGS and RAST annotations, the putative glycerol-3-phosphate ABC transporter 
consisted of UgpA, UgpC and UgpE (Figure 3.14 H). The IGS annotation had annotated an 
additional ugpC gene. The substrate-binding domain, UgpB was not annotated. In 
M. gallisepticum and M. pneumoniae, the UgpACE transporter has been implicated in 
virulence (Szczepanek et al. 2014).  
P37 is an extracytoplasmic thiamine-binding lipoprotein that forms part of the ABC transport 
system and has been proposed to be the putative phosphonate substrate-binding protein 
(Sippel et al. 2009; Sippel et al. 2011). It was found to be part of the operon that included a 
transmembrane domain and an intracellular ATPase domain. In both the IGS and RAST 
annotations all three of the components were annotated (Figure 3.14 I, Appendix 2 
Supplementary Table 2.14).  
In the absences of de novo synthesis of amino acids (Section 3.3.5.2), import of 
oligopeptides will be required. The oligopeptide permease (Opp) transport system consists 
of a substrate-binding domain (OppA), two transmembrane domains (OppB and OppC) and 
two ATP-binding domains (OppD and OppF). Two complete Opp transporters were 
annotated with the IGS annotation server (Figure 3.14 J, Appendix 2 Supplementary Table 
2.14). The RAST annotation, however, did not predict an ORF for the second oppB gene. 
Additionally, the RAST annotation had a gene annotated as “Oligopeptide ABC transporter 
ATP-binding protein” (peg.424) but the IGS annotated the same region as a hypothetical 
protein (mnas_50). The IGS annotation also had a “putative oligopeptide ABC transporter, 
ATP binding protein OppF C-terminal” (mnas_806) protein annotated; this region did not 
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have an ORF prediction in RAST. Both these proteins (mnas_806 and mnas_50) were 
truncated and were located on different contigs.  
In the RAST annotation two proteins were annotated as “lipid A export ATP-
binding/permease protein MsbA” Figure 3.14 K, Appendix 2 Supplementary Table 2.14) 
These were only annotated as “ABC transporter family protein” in the IGS annotation. In 
E. coli, MsbA is a homodimer ABC exporter that plays a role in translocation of 
lipopolysaccharide and had also been characterized as a multidrug resistance (MDR) efflux 
system. Putative ABC MDR genes were also identified in the genomes of M. genitalium, 
M. pneumoniae and M. hominis (Van Veen and Konings 1998; Paulsen et al. 2000; 
Raherison et al. 2002; Raherison et al. 2005). 
Both IGS and RAST annotations include four membrane proteins predicted to have β-
galactosidase activity (EC 3.2.1.23) (Appendix 2 Supplementary Table 2.14). In 
mycoplasmas, a very small minority of species have β-galactosidase activity and annotated 
genes are only found in M. alligatoris (Brown et al. 2011; May and Brown 2014) a close 
related species to Ms03. β-Galactosidase is a large membrane bound protein that hydrolysis 
terminal β-D-galactosides attached to glycoproteins and glycosaminoglycans. It also 
hydrolyses free lactose to galactose and glucose (May and Brown 2014; Singh et al. 2014). 
In Streptococcus pneumoniae β-galactosidase is postulated to play a role in adhesion 
(Singh et al. 2014). 
As illustrated in Figure 3.14, a larger number of importers were annotated compared to 
exporters. Mycoplasmas, with such a reduced genome, have limited biosynthetic capacity 
and therefore rely on the import of nutrients, cofactors and other building blocks.  
In addition to the above annotated transporters, both annotation analyses identified a 
number of substrate-binding, transmembrane and ATP-binding domains of putative ABC 
transporters (Appendix 2, Supplementary Table 2.14). These were components of 
transporters and/or the functions were unknown and as such are not discussed.  
Furthermore, no transporter for nucleoside or nucleotide bases (Section 3.3.5.1) was found 
in both the IGS and RAST annotations. This may be an effect of the incomplete assembly of 
the Ms03 genome or the genes involved may be annotated as hypothetical in the current 
annotation. Transporters for these bases were, however, also not found in the genomes of 
M. genitalium and M. pneumoniae although they are essential components of mycoplasma 
growth medium (Himmelreich et al. 1996; Mushegian and Koonin 1996; Castellanos et al. 
2004). Additionally, the loss of specificity and broadened substrate selectivity so that a single 
carrier can transport several metabolites across the cell membrane could explain the lack of 
some transport systems in mycoplasmas (Saurin and Dassa 1996).  
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3.3.6 Identification and bioinformatic characterization of the Ms03 opp operon 
The Ms03 opp operon of which the oppA gene forms part was identified. Contigs that 
contain opp genes were identified by using the opp operon of M. hominis as query in a 
tBLASTn search with the initial assembly of Ms03 draft genome as database. Two contigs 
were identified to contain opp genes and the ORFs within these two contigs were predicted. 
The identities of the genes were confirmed with BLAST searches in NCBI. Two opp operons 
were subsequently identified (Figure 3.15) and submitted to NCBI with the following 
accession numbers, KM410300.1 and KM410301.1. Genes within the opp1 operon were 
only named oppA, oppB, oppC, oppD and oppF while the genes in the opp2 operon were 
numbered oppA2, oppB2, oppC2 oppD2 and oppF2. 
The first draft assembly (15.4 Mb, Table 3.6) of the Ms03 genome was used to identify the 
opp genes, however for the annotation, the pseudomolecule was generated from the contigs 
in the final assembly (25.2 Mb, Table 3.6). In the first draft assembly each set of opp genes 
(oppA, oppB, oppC, oppD, oppF) was located adjacent to each other within an operon. This 
was not the case in the automated annotation of the final assembly. The parameters in the 
assembly program, Newbler, that was used to assemble the 454 reads into contigs, are 
conserved. If the program is unsure whether or not two regions are adjacent to each other, it 
would rather split the regions than link them erroneously. In an attempt to decrease the 
number of contigs, more data was generated using the 454 platform. This did decrease the 
total number of contigs, however in the region of one of the two opp operons (opp1 operon) 
more data may have introduced uncertainty which led to the genes of this opp operon to be 
distributed over more than one contig.  
 
Figure 3.15 The opp operons in Ms03. A) The organization of the opp1 operon (KM410300.1) B) The 
organization of the opp2 operon (KM410301.1).   
A opp1 operon 
B opp2 operon 
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Table 3.14 A sequence comparison of the Ms03 opp1 and opp2 operon proteins with that of 
M. hominis  
Gene  
(Gene size, Protein size) 
Ms03_OppA Ms03_OppA2 
Mho_OppA 
(2 886 bp, 961 aa) 
Protein identity:          27.1% 
Protein similarity:       45.7% 
Gaps:                         14.5% 
Protein identity:           19.0% 
Protein similarity:        32.6% 
Gaps:                          34.6% 
Ms03_OppA 
(3 867 bp, 1 288 aa) 
 Protein identity:           19.7% 
Protein similarity:        33.1% 
Gaps:                          35.0% 
Ms03_OppA2 
(3 093 bp, 1 030 aa) 
  
 Ms03_OppB Ms03_OppB2 
Mho_OppB 
(1 146 bp, 381 aa) 
Protein identity:           47.4% 
Protein similarity:        64.7% 
Gaps:                          12.0% 
Protein identity:           28.1% 
Protein similarity:        50.9% 
Gaps:                          14.6% 
Ms03_OppB  
(1 164 bp, 387 aa) 
 Protein identity:           26.3% 
Protein similarity:        42.2% 
Gaps:                          18.2% 
Ms03_OppB2 
(1 056 bp, 351 aa) 
  
 Ms03_OppC Ms03_OppC2 
Mho_OppC  
(1 275 bp,424 aa) 
Protein identity:          38.1% 
Protein similarity:       57.9% 
Gaps:                         16.5% 
Protein identity:           26.1% 
Protein similarity:        46.6% 
Gaps:                            5.0% 
Ms03_OppC 
(1 362 bp, 453 aa)  
Protein identity:           25.3% 
Protein similarity:        44.8% 
Gaps:                          12.5% 
Ms03_OppC2 
(1 083 bp, 360 aa) 
  
 Ms03_OppD Ms03_OppD2 
Mho_OppD 
(1 167 bp, 388 aa) 
Protein identity:           71.2% 
Protein similarity:        84.3% 
Gaps:                            0.0% 
Protein identity:           36.4% 
Protein similarity:        60.2% 
Gaps:                            7.8% 
Ms03_OppD 
(1 047 bp, 348 aa)  
Protein identity:           42.6% 
Protein similarity:        63.6% 
Gaps:                            8.0% 
Ms03_OppD2 
(1 209 bp, 402 aa)   
 Ms03_OppF Ms03_OppF2 
Mho_OppF 
(2 529 bp, 842 aa) 
Protein identity:           45.5% 
Protein similarity:        62.5% 
Gaps:                            8.6% 
Protein identity:           19.4% 
Protein similarity:        30.8% 
Gaps:                          53.8% 
Ms03_OppF 
(2 388 bp, 795 aa)  
Protein identity:           19.8% 
Protein similarity:        31.5% 
Gaps:                          52.1% 
Ms03_OppF2 
(1 332 bp, 443 aa)   
Similarity and Identity calculated with EMBOSS WATER Pairwise alignment 
(http://www.ebi.ac.uk/Tools/psa/emboss_water/ ) using the BLOSUM62 matrix with a gap penalty of 
10 and extension penalty of 0.5 
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Compared to M. hominis, the gene organization of the two Ms03 opp operons was found to 
be the same (ABCDF) and the sizes of the genes and their protein products similar, except 
for the Ms03 oppA that was 981 bp larger than the M. hominis oppA and the Ms03 oppF2 
that was 1 217 bp smaller than the M. hominis oppF gene (Figure 3.15 and Table 3.14). The 
percentage protein identity and similarity between the M. hominis Opp proteins and that of 
the Ms03 Opp1 were higher than that between M. hominis and Ms03 Opp2 proteins or 
between Ms03 Opp1 and Ms03 Opp2 proteins (Table 3.14).  
Vaccine candidate genes should be unique to the pathogen, with no homologous or 
paralogous genes within the genome of the host. The genome of the ostrich was sequenced 
and published recently and it was confirmed with tBLASTx searches that the two opp 
operons of Ms03 had no protein homologues or paralogues within the ostrich genome.  
To confirm the identity of the predicted opp genes, functional motifs and domains were 
identified within the protein products using the online program, InterPro. InterPro combines 
protein signatures from 11 databases into one resource (McDowall and Hunter 2011). A 
summary of the InterPro analyses of the Opp proteins are provided in Table 3.15 while a 
detailed report of the individual motifs and their locations is provided in Appendix 2 
Supplementary Table 2.15. Additionally the Opp proteins were manually examined for the 
same protein motifs as found in the Opp proteins of M. hominis. 
Table 3.15 Bioinformatic analyses of the Opp proteins  
 Ms03 opp1 operon Ms03 opp2 operon 
 OppA (1 288 aa) OppA2 (1 030 aa) 
Protein family 
membership 
None predicted ABC-type oligopeptide transport 
system, solute-binding component, 
Mycoplasmataceae, predicted 
(IPR016880) 
InterPro domains None predicted Solute-binding protein family 5 
domain (IPR000914) 
GO term prediction None predicted None predicted 
 OppB (387 aa) OppB2 (351 aa) 
Protein family 
membership 
None predicted None predicted 
InterPro domains ABC transporter type 1, 
transmembrane domain MetI-like 
(IPR000515) 
ABC transporter type 1, 
transmembrane domain MetI-like 
(IPR000515) 
GO term    
Biological process GO:0006810 transport GO:0006810 transport 
Molecular function GO:0005215 transporter activity None predicted 
Cellular component GO:0016020 membrane GO:0016020 membrane 
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Table 3.15 (Continued). 
 Ms03 opp1 operon Ms03 opp2 operon 
 OppC (453 aa)  OppC2 (360 aa) 
Protein family 
membership 
None predicted None predicted 
InterPro domains Oligopeptide transport permease C-
like, N- terminal domain 
(IPR025966) 
Oligopeptide transport permease C-
like, N- terminal domain 
(IPR025966) 
ABC transporter type 1, 
transmembrane domain MetI-like 
(IPR000515) 
ABC transporter type 1, 
transmembrane domain MetI-like 
(IPR000515) 
GO term prediction    
Biological process GO:0006810 transport GO:0006810 transport 
Molecular function None predicted None predicted 
Cellular component GO:0016020 membrane GO:0016020 membrane 
 OppD (348 aa) OppD2 (402 aa) 
Protein family 
membership:  
None predicted. None predicted. 
InterPro domains P-loop containing nucleoside 
triphosphate hydrolase 
(IPR027417) 
P-loop containing nucleoside 
triphosphate hydrolase 
(IPR027417) 
AAA+ ATPase domain (IPR003593) AAA+ ATPase domain (IPR003593) 
ABC transporter-like (IPR003439) ABC transporter-like (IPR003439) 
Oligopeptide/dipeptide ABC 
transporter, C- terminal 
(IPR013563) 
Oligopeptide/dipeptide ABC 
transporter, C- terminal 
(IPR013563) 
Oligopeptide/dipeptide ABC 
transporter, ATP-binding protein, C-
terminal (IPR010066) 
Oligopeptide/dipeptide ABC 
transporter, ATP-binding protein, C-
terminal (IPR010066) 
GO term prediction    
Biological process GO:0015833 peptide transport  GO:0015833 peptide transport  
Molecular function GO:0000166 nucleotide binding  
GO:0005524 ATP binding  
GO:0015197 peptide transporter 
activity  
GO:0016887 ATPase activity  
GO:0000166 nucleotide binding  
GO:0005524 ATP binding  
GO:0015197 peptide transporter 
activity  
GO:0016887 ATPase activity 
Cellular component GO:0016020 membrane GO:0016020 membrane 
 OppF (795 aa) OppF2 (443 aa) 
Protein family 
membership 
None predicted None predicted 
InterPro domains P-loop containing nucleoside 
triphosphate hydrolase 
(IPR027417) 
P-loop containing nucleoside 
triphosphate hydrolase 
(IPR027417) 
AAA+ ATPase domain (IPR003593) AAA+ ATPase domain (IPR003593) 
ABC transporter-like (IPR003439) ABC transporter-like (IPR003439) 
Oligopeptide/dipeptide ABC 
transporter, C- terminal 
(IPR013563) 
Oligopeptide/dipeptide ABC 
transporter, C- terminal 
(IPR013563) 
GO term prediction    
Biological process GO:0015833 peptide transport  GO:0015833 peptide transport  
Molecular function GO:0000166 nucleotide binding  
GO:0005524 ATP binding  
GO:0016887 ATPase activity  
GO:0017111 nucleoside-
triphosphatase activity  
GO:0000166 nucleotide binding  
GO:0005524 ATP binding  
GO:0016887 ATPase activity  
Cellular component None predicted None predicted 
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OppA 
No protein family, domains or GO terms were predicted with InterPro for the OppA protein of 
the opp1 operon. InterPro predicted the OppA2 protein of the opp2 operon to belong to the 
protein family: ABC-type oligopeptide transport system, solute-binding component of 
Mycoplasmataceae (IPR016880), pertaining to the solute-binding protein family 5 domain 
(IPR000914) (Table 3.15). GO terms were however not predicted for the OppA2 protein. For 
both OppA proteins the PROSITE prokaryotic lipoprotein (PS51257) and the PHOBIUS 
signal peptide motifs were found within the first 23 (OppA) or 27 (OppA2) amino acids 
(Appendix 2 Supplementary Table 2.15).  
In the OppA protein of M. hominis four functional sites were identified: a signal peptide, an 
oligopeptide binding site and Walker B and A motifs (Henrich et al. 1999). Through manual 
alignment of the Ms03 OppA proteins with that of M. hominis, a putative signal peptide could 
be identified in both OppA (first 23 aa) and OppA2 (first 27 aa). The liposignal peptide motif 
with a conserved cysteine residue at position 23 of OppA and 27 of OppA2 should result in 
the proteins being anchored to the cell via a lipo anchor. These signal peptides were also 
predicted with InterPro (Appendix 2 Supplementary Table 2.15). Manual alignment also 
allowed the identification of a putative oligopeptide binding site (552-FRVRPGHFW-560) as 
well as putative Walker B (1 074-YWTGTSPFSLAGWGYD-1 089) and putative Walker A 
(1 094-GSGIDGYS-1 101) motifs in the Ms03 OppA (opp1 operon). These motifs could not 
be found in the OppA2 protein.  
In bacterial OppA proteins, the oligopeptide-binding site determines substrate specificity 
(Doeven et al. 2005) and is in general less conserved which may explain the wide range of 
oligopeptides that can be transported. The Walker B and A motifs are responsible for the 
ecto-ATPase activity of M. hominis OppA. The consensus sequence for the Walker A motif 
is -GXXXXGK[S/T]- where Lys (K) is essential for nucleotide-binding. A mutation of the Lys 
to an Arg (both large and positively charged) resulted in a loss of ATPase activity (Hopfe and 
Henrich 2004). In Ms03 OppA the amino acid at this position is Tyr (large and possessing 
polar hydroxyl group) therefore although the motif is present in the Ms03 OppA sequence, it 
is likely not functional.  
Based on the identified functional motifs and domains, the identity of the OppA (opp1 
operon) and the OppA2 (opp2 operon) proteins could be confirmed as the proposed 
substrate-binding domains of the Opp transporters in Ms03.  
OppB and OppC 
InterPro could not predict the protein family for either Ms03 OppB or OppB2 however the 
InterPro domain “ABC transporter type 1, transmembrane domain MetI-like” (IPR000515) 
was found in both proteins (Table 3.15). The GO terms predicted for these two proteins were 
transport (GO:0006810) for biological process and membrane (GO:0016020) for cellular 
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component. Additionally the GO term transporter activity (GO:0005215) for molecular 
function was only predicted for the Ms03 OppB protein.  
In Ms03 OppC and OppC2, InterPro detected two domains: oligopeptide transport permease 
C-like, N- terminal domain (IPR025966) and ABC transporter type 1, transmembrane 
domain MetI-like (IPR000515) (Table 3.15) The GO term for biological process was 
transport (GO:0006810) and for cellular component was membrane (GO:0016020). 
In the Opp transporter, OppB and OppC domains form the pore through which the substrate 
is imported into the cell. Six transmembrane-spanning segments were predicted with 
InterPro in OppB, OppB2, OppC and OppC2 of Ms03 (Appendix 2 Supplementary Table 
2.15) which should result in a membrane pore with 12 membrane spanning segments (six 
from the OppB domain and six from OppC domain) which is typical for ABC transporters 
(Rees et al. 2009).  
In addition manual alignment revealed the OppB conserved motif (RTAK-
KGLXXXXI/VZXXHZLR, with Z representing a hydrophobic residue and X any residue) in 
OppB (256-IAKSKGLSRKEIFFKYVLR-274) and OppB2 (250-FAYLKGVSKNRFVWKHALK-
268) and the OppC conserved motif (XAAXXZGAXXXRXIFXHILP) in the OppC (346-
TASKSVGASKARLIYKHALP-365) and OppC2 (257-VSASKILGTPTWKILKNYVP-276). 
These motifs were found between the fourth and fifth membrane-spanning segments as 
predicted in the OppB and OppC proteins and correspond to the proposed interaction sites 
with OppD and OppF domains on the cytoplasmic side of the membrane (Mourez et al. 
1997; Henrich et al. 1999). These motifs and domains confirmed the identity of OppB and 
OppC as well as the OppB2 and OppC2 proteins as the proposed transmembrane pores of 
the Opp transporters in Ms03.  
OppD and OppF 
In each of the OppD, OppD2, OppF and OppF2 proteins, the following InterPro domains 
were identified: P-loop containing nucleoside triphosphate hydrolase (IPR027417); AAA+ 
ATPase domain (IPR003593); ABC transporter-like (IPR003439) and oligopeptide/dipeptide 
ABC transporter, C-terminal (IPR013563). Additionally the oligopeptide/dipeptide ABC 
transporter and ATP-binding protein, C-terminal (IPR010066) domain was also found in the 
OppD and OppD2 (Table 3.15). For these four proteins the GO term for biological process 
was peptide transport (GO:0015833) and for molecular function was nucleotide binding 
(GO:0000166), ATP binding (GO:0005524), and ATPase activity (GO:0016887). Additionally 
for molecular function, the GO term, nucleoside-triphosphatase activity (GO:0017111) was 
only found in OppF and the GO term, peptide transporter activity (GO:0015197) was only 
predicted for OppD and OppD2. The GO term membrane (GO:0016020) for cellular 
component was found in OppD and OppD2 but not in OppF and OppF2.  
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In the Opp transporter, the OppD and OppF domains hydrolyse ATP to provide the energy 
needed for the translocation of the oligopeptide across the membrane. This activity is 
attributed to the presence of protein motifs such as the Walker A and Walker B motifs. The 
Walker A motif (GXXGXGK[T/S]) was present in OppD (43-GESGSGKS-50), OppD2 (95-
GESGSGKS-102), OppF (42-GESGSGKT-49) and OppF2 (79-GESGSGKS-86). The Walker 
B motif (RXXXGXXXLZZZZD) was also found in OppD (180-LIIADEPTTALD-191), OppD2 
(234-ILVMDEPTTALD-243), OppF (303-VIVADEPIASLD-336) and OppF2 (305-
LLIADEPISALD-316). Furthermore, the ABC signature motif (LSGGQ) was also present in 
OppD (160-LSGGM-164), OppD2 (212-MSGGM-216), OppF (632-FSGGQ-636) and OppF2 
(285-FSGGQ-289). The presence of these motifs was reflected in the InterPro motifs 
identified, that correspond to ATPase activity and family domains for ABC transporters. 
These motifs and domains confirmed the identity of the OppD and OppF as well as the 
OppD2 and OppF2 proteins as the proposed cytosolic ATP-binding domains of the Opp 
transporters in Ms03.  
3.4 Conclusion  
The genome of Ms03 was sequenced and assembled into 172 large contigs. It was however 
not possible to generate the complete genome sequence of Ms03. Two annotation servers, 
IGS and RAST, were used to annotate the Ms03 draft genome and predicted 763 and 635 
protein-encoding genes, respectively. In spite of the differences, the two annotations 
augment to each other to generate a more complete annotation of the Ms03 draft genome. 
The IGS annotation yielded more annotated genes which resulted in a more complete 
representation of the Ms03 metabolic pathways. The RAST annotation provided the option 
for metabolic analysis which benefits the interpretation of the annotation result. Each 
annotation pipeline (IGS and RAST) has strengths and weaknesses. The combinational 
approach described here not only provided the opportunity to compare the pipelines, but 
also increased the confidence in the gene annotation of Ms03 and resulted in a more 
complete overview of the Ms03 metabolic capacity. 
Although some of the genes within the Ms03 pathways analysed are potentially “missing”, 
most annotated genes within the Ms03 draft genome correspond with the gene functions 
annotated in the complete genome of M. synoviae 53. This indicates that the annotation of 
the Ms03 genome is mostly complete. The generation of a complete genome sequence may 
however be advantageous when considering the number of genes that are potentially 
truncated because the Ms03 draft genome consists of 172 contigs.  
Genome replication, cell division, RNA transcription and protein translation in Ms03 is similar 
to that of M. synoviae 53. From the annotations it is likely that Ms03 is a glycolytic 
mycoplasma that cannot utilize arginine and urea which is in agreement with the 
experimental results of Langer (2009). Like other mycoplasmas, Ms03 cannot synthesise 
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purines and pyrimidines or amino acids using de novo pathways. Most of the annotated 
transporters were importers which is a reflection of the reduced metabolic capacity of the 
mycoplasma and the need to obtain nutrients from the environment.  
The current annotation of the Ms03 genes together with the metabolic analysis can assist in 
the identification of future vaccine gene targets. Two Opp transporters were found in the 
Ms03 genome. The genes for each transporter are located in an operon that consists of five 
adjacent genes with the order ABCDF. Protein motifs within the respective genes confirmed 
the functional annotations of the respective genes as oppA, oppB, oppC, oppD and oppF. 
These proteins were characterized in an attempt to confirm the identity of the opp operon 
and also the chosen vaccine candidate gene, oppA. Two opp operons (two oppA genes) 
were however identified within the Ms03 genome. Additionally, oppA genes in mycoplasma 
genomes are not always annotated, which questions the need for the substrate-binding 
domain in Opp transporter (Staats et al. 2007). The above warranted a more detailed 
analysis of the opp operons with special reference to the oppA gene within Mycoplasma 
species. 
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Chapter 4  The identification of oppA gene homologues as part of the 
oligopeptide transport system in mycoplasmas 
4.1 Introduction 
The oppA gene was chosen as a vaccine candidate gene in this dissertation, however it 
would only be a suitable target if it plays a prominent part in oligopeptide transport in 
mycoplasma. The oligopeptide permease (Opp) transport system is responsible for the 
import of oligopeptides into the bacterial cell. This transporter belongs to the ATP-binding 
cassette (ABC) family and consists of five components; a substrate-binding domain, OppA, 
two transmembrane domains, OppB and OppC that form a pore for transport and two 
cytoplasmic domains, OppD and OppF that hydrolyse ATP to provide the energy necessary 
for the translocation of the oligopeptide. In Gram-positive bacteria, OppA is anchored to the 
membrane through a lipid anchor, while in Gram-negative bacteria it is located in the 
periplasmic space. The oligopeptide-binding site (and therefore OppA) determines the 
specificity of the transporter. This site is in general less conserved and has a wide size 
range of peptides that are transported in different bacteria. The OppA of Escherichia coli has 
a preference for oligopeptides that contain positively charged amino acids and are 3 to 4 
residues in length (Klepsch et al. 2011) while the OppA of Lactoccocus lactis can transport 
oligopeptides between 4 and 35 residues in size and has a preference for proline-rich 
peptides containing at least one isoleucine (Berntsson et al. 2009). This illustrates the 
diversity in substrates that can be transported by bacterial OppA proteins. As a result low 
sequence similarity is, in general, reported between oppA genes and their protein products 
(Doeven et al. 2005).  
In Mycoplasma species, the need for an OppA in oligopeptide transport was, however, 
questioned because of the absence of an annotated oppA gene as part of some oppBCDF 
operons in mycoplasma genomes (Staats et al. 2007). The progress in genome sequencing 
has led significantly increase in the number of available and annotated mycoplasma 
genomes. Within these genomes, oppA genes are not always found as part of the oppBCDF 
operons.  
In order to assess whether the oppA gene of Ms03 has the potential to serve as a vaccine 
candidate gene the oligopeptide transporter systems in Mycoplasma species was assessed. 
The aim was therefore to investigate the prevalence of the oppA gene as part of the 
oppBCDF operon in Mycoplasma species. To this end, the following objectives were set: 
 To identify opp genes in the annotated genomes of Mycoplasma species available on 
NCBI.  
 To identify an oppA gene for each oppBCDF operon.  
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 To determine the phylogenetic relationships amongst the Mycoplasma species as 
well as their respective OppABCDF operons.  
 To identify conserved and functional motifs in the annotated and newly postulated 
OppA proteins, in order to confirm that the postulated oppA genes annotated as 
“hypothetical protein” are indeed oppA genes. 
The results obtained are presented in an independent manuscript following this introduction 
with the supplementary data presented in Appendix 3 at the end of this dissertation. The 
following sections will highlight certain aspects of the experimental design.  
4.2 Phylogenetic analysis  
Phylogenies are used to address various questions such as the relationships among genes 
or species, epidemiological dynamics of pathogens and the evolutionary histories of 
populations (Hartfield et al. 2014). The relationships of species can be determined by using 
a marker gene or protein. The selection of this gene is critical; it should be present in all the 
species in the assessment, have the same function within the species and be under the 
same selective pressure.  
The 16S rRNA gene is highly conserved and universally distributed in the different species 
of bacteria and archaea (Brocchieri 2001). Ribosomes are present in all self-replicating cells 
and function in protein synthesis (Schuwirth et al. 2005; Kitahara et al. 2012). The 16S rRNA 
genes have the same structural role in the ribosomes irrespective of species and are under 
approximately the same selective evolutionary pressure. Although other phylogenetic 
markers such as the RNA polymerase subunit B (rpoB) gene, 16S–23S intergenic 
transcribed spacers and phosphoglycerate kinase amino acid sequence have been 
evaluated, the 16S rRNA gene sequences are currently recommended for description of 
Mollicutes species (Wolf et al. 2004; Brown 2010; Volokhov et al. 2012). For the above 
reasons, the 16S rRNA gene is an ideal marker to analyse the relationships among 
Mycoplasma species and was used in the current study.  
A phylogeny was also constructed from the OppABCDF proteins to analyse the functional 
relationship amongst different copies of the oppABCDF operon within and between species. 
These genes are not necessarily under the same selective pressure but are subjected to the 
selection constraints of protein function and protein structure. The amino acid sequences 
rather than the nucleotide sequences were aligned because at nucleotide level the 
sequences were heterogeneous and could not by aligned with confidence.  
The 16S rRNA gene and the OppABCDF protein sequences were first aligned with the 
online alignment program T-Coffee (tree-based consistency objective function for alignment 
evaluation, Notredame et al. (2000)) followed by further manual refinement. T-Coffee is a 
multiple sequence alignment program that uses a progressive approach to combine local 
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and global pair-wise alignments creating a reliable alignment of the sequences (Notredame 
et al. 2000). This allows for the alignment of genes or proteins that differ in length as was the 
case with the OppA and OppF proteins in the current study.  
The construction of phylogenies is either distance or tree-searching based. In distance 
based methods, such as neighbour-joining, distances are calculated between pairs of 
sequences (within the larger alignment) resulting in a distance matrix. The distance matrix is 
then used to construct the phylogenetic tree. Although distance analyses are computer 
efficient, they perform poorly for very divergent sequences and are sensitive to gaps in the 
alignment (Yang and Rannala 2012). Tree-searching methods consider all characters of the 
entire alignment one site (column) at a time and calculate a score for each possible tree. 
The tree with the best score is retained. Examples of tree-searching methods are parsimony, 
maximum likelihood and Bayesian inference. In parsimony “tree-scores” are minimum 
number of changes, in maximum likelihood, log-likelihood values and in Bayesian inference, 
posterior probability (Wiley and Lieberman 2011b; Wiley and Lieberman 2011a). Each of 
these analyses uses their own formulas, algorithms and models that contribute to the 
outcome.  
The major weakness of a parsimony analysis such as the software package PAUP* 
(Phylogenetic Analysis Using Parsimony* and other methods, Swofford (2002)) is its lack of 
explicit assumptions which makes it nearly impossible to incorporate any knowledge of 
sequence evolution into the tree reconstruction (Yang and Rannala 2012). Maximum 
likelihood is an exhaustive analysis that searches for the best tree. Maximum likelihood is a 
powerful framework for estimating parameters and testing hypotheses and can 
accommodate variable amino acid substitution rates among sites and other evolutionary 
models. Exhaustive searches require a large amount of computational power, however 
online platforms such as the Cipres Web portal (Miller et al. 2010) are available for these 
analyses. RAxML (Randomized Axelerated Maximum Likelihood) is a program for maximum 
likelihood phylogenetic analysis of large datasets (Stamatakis 2014) that is available from 
the Cipres Web portal.  
OppA proteins in mycoplasma have low sequence identity and gaps were introduced to 
allow alignment. Since distance based methods perform poor with very divergent sequences 
and gaps, the phylogenies were generated using both RAxML (maximum likelihood analysis) 
and PAUP (parsimony analysis). The generated phylogenies had the same topology and 
only the RAxML phylogenies are shown.  
Stellenbosch University  https://scholar.sun.ac.za
Chapter 4 Identification of oppA homologues 
88 
4.3 Bioinformatic analysis of annotated and newly postulated oppA homologues 
genes 
In order to confirm that newly postulated oppA genes annotated as “hypothetical protein” 
were indeed oppA genes, a number of bioinformatic programs were used to evaluate the 
annotated and newly postulated OppA protein sequences. OppA is located on the surface of 
the mycoplasma cell and the location of the postulated and annotated OppA proteins were 
predicted with PSORTb version 3.0.2 (Yu et al. 2010). This program is specific for bacterial 
proteins and has five subcellular categories, namely cytoplasmic, cytoplasmic membrane, 
cell wall, extracellular or unknown. Additionally the presences of signal peptides were 
predicted using SignalP (Petersen et al. 2011) and PRED-LIPO (Bagos et al. 2008). SignalP 
predicts whether or not a protein has a signal peptide while PRED-LIPO specifically predicts 
signal peptidase I (secretory protein) and signal peptidase II (lipoproteins). A signal 
peptidase II was found in the OppA of M. hominis (the best described OppA in the 
Mycoplasma genus). 
InterPro (Hunter et al. 2012) was used to predict the functional domains of the postulated 
and annotated OppA proteins. The InterPro consortium includes the following databases: 
PROSITE, HAMAP (high-quality automated and manual annotation of proteins), Pfam 
(protein families), PRINTS, ProDom (protein domain families), SMART (simple modular 
architecture research tool), TIGRFAMs, PIRSF (protein information resource superfamily), 
SUPERFAMILY, CATH-Gene3D (class architecture topology homology) and PANTHER 
(protein analysis through evolutionary relationships). Using InterPro the information of these 
databases can be searched simultaneously to predict the function, domains and important 
sites within postulated and annotated OppA proteins. 
It was however not always possible to predicted function, domains or important sites within 
the postulated and annotated OppA proteins. Therefore the motif discovery program, MEME 
(Multiple expectation maximization for motif elicitation) (Bailey et al. 2009) was used to 
locate conserved motifs within the protein sequences. MEME locates repeated patterns 
within a group of related proteins and does not require functional or database information to 
identify these motifs. 
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4.4 The identification of oppA gene homologues as part of the oligopeptide 
transport system in mycoplasmas 
4.4.1 Contributions of co-authors 
The following manuscript contains the original work of the author of this dissertation. The 
contributions of each of the co-authors were as follows: 
Dr. Annelise Botes is a lecturer of Biochemistry at the University of Stellenbosch and the 
supervisor of this dissertation. In this capacity, she was involved in the conceptual 
development and execution of all aspects of this study.  
Prof. Dirk U. Bellstedt is a professor of Biochemistry at the University of Stellenbosch and 
the co-supervisor of this dissertation. In this capacity, he was involved in the conceptual 
development and execution of this study.  
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Chapter 5  Evaluation of the Mycoplasma nasistruthionis sp. nov. str. 
Ms03 oligopeptide permease substrate-binding domain (OppA) 
as a DNA vaccine candidate in ostriches 
5.1 Introduction  
DNA vaccines provide researchers with the unique opportunity to utilise the cell’s own 
mechanisms to produce transgenic protein antigens. DNA vaccines are DNA vectors that 
are constructed to have a combination of prokaryotic and eukaryotic elements. This 
allows for the production of the DNA vaccine in a prokaryotic organism such as 
Escherichia coli as well as the expression of antigenic protein within eukaryotic cells. The 
expressed antigenic protein, originating from the gene encoding it in the pathogen, can 
then in turn elicit a specific immune response that can lead to protection against the 
pathogen.  
The aim of this part of the study was to evaluate the potential of using a DNA vaccine 
containing the Mycoplasma nasistruthionis sp. nov. str. Ms03 oppA gene to elicit an 
immune response in ostriches. The objectives were as follows: 
 To clone the oppA gene of M. nasistruthionis sp. nov. str. Ms03 into the pGEM®-T 
Easy vector and to use site-directed mutagenesis (SDM) to change all the 
mycoplasma tryptophan encoding TGA codons to universal tryptophan encoding 
TGG codons in the Ms03 oppA gene. 
 To sub-clone the mutated oppA gene into the pCI-neo, VR1012 and VR1020 
vectors for use as DNA vaccines. 
 To sub-clone the mutated oppA gene into pGEX-4T-1 in order to express and 
isolate the recombinant OppA protein for use as coating antigen in an anti-OppA 
ELISA. 
 To evaluate the potential of the three DNA vaccines (pCI-neo_oppA, 
VR1012_oppA and VR1020_oppA) to elicit an anti-OppA humoral immune 
response in ostriches during a vaccination trial.  
The results obtained are presented in an independent manuscript in this chapter with the 
supplementary data in Appendix 4 and 5 at the end of this dissertation. The following 
sections will give additional background to certain aspects of the experimental design 
described in the manuscript and the negative influence an outbreak of AI had on it. 
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5.2 Primer design 
Primers were designed for SDM, oppA gene amplification and sequencing for the DNA 
vaccine development described in this chapter. Primers are polynucleotide sequences 
that are usually 18 to 30 nucleotides (nt) long. They are designed for the specific 
amplification of a unique region. For optimal amplification, the G+C content of primers 
should be higher than 40% and the G+C content of the forward and reverse primers 
should not differ by more than 5%. Binding of the primer to the template may be 
promoted with a G or C in the 3' end position (GC-clamp). The annealing temperature 
should be between 60°C and 75°C and the annealing temperature of the forward and 
reverse primers should be within 5°C of each other. Secondary structures and 
mononucleotide repeats (runs) within a primer should be avoided. Furthermore, 
interactions within (self-dimerizing) and between primers should be avoided as they 
cause primer dimer formation during PCR amplification. The primer sequence should be 
unique, thus homologue sequences should not be present within the template. This will 
ensure that the binding of the primer is specific to the region it was designed to bind to. 
For cloning, restriction enzyme sites can be added to the 5' end of the primers for 
cloning.  
When designing primers for SDM, the mutagenesis site should be more or less in the 
middle of the primer sequence and the annealing temperature of the portion (18 to 24 nt) 
on both sides of the mutagenesis site should be similar (within 5°C).  
5.3 Aspects of the vaccine trial  
In this study, the ability of DNA vaccines to elicit an immune response in ostriches was 
assessed in a vaccination trial. In this trial, ostriches were vaccinated at three months of 
age before they were introduced into feedlot systems where mycoplasma exposure 
increases. The vaccine trial was conducted on a commercial ostrich farm near 
Oudtshoorn (the Klein Karoo region, Western Cape, South Africa). This implies that the 
exposure of the ostriches to pathogens and weather conditions could not be controlled. 
These are however the conditions under which a commercial vaccine would be used.  
The vaccine trial consisted of three experimental groups that were vaccinated with pCI-
neo_oppA, VR1012_oppA and VR1012_oppA constructs respectively, and a control 
group that did not receive any vaccine. The initial aim was to collect samples every three 
weeks up to 12 weeks after the first vaccination at day 0 with a second booster 
immunization at week 6. The objective of the first vaccination was to stimulate a primary 
immune response against the OppA protein. The objective of the second booster 
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injection was to stimulate a larger and more rapid secondary immune response implying 
that memory cells were formed due to the first vaccination.  
An outbreak of highly pathogenic avian influenza (AI) was reported in the Oudtshoorn 
region in March 2011 (Van Helden et al. 2012) which coincided with the vaccination trial. 
AI is a notifiable disease and in ostrich symptoms include conjunctivitis, ocular discharge, 
nasal discharge, tracheal foam, pharyngitis, coughing and green urine (Toffan et al. 
2010). High mortality rates (>80%) are reported in ostrich chicks under one month while 
the mortality rate in young birds (up to eight months) is between 15% and 60% whilst 
adults seldom show clinical symptoms of AI (Allwright et al. 1993). Ostriches (non-trial 
birds) were tested positive for AI on the farm where the vaccine trial was conducted and 
in accordance with South African legislation all ostriches on the farm were slaughtered. 
This included all the ostriches that were part of the trial. No further sampling was 
therefore possible. It was therefore only possible to collect blood and saliva samples at 
week 0 and week 3. At the start of the trial there were 30 ostriches in each group. Due to 
deaths amongst the trial birds in all groups, only 25 ostriches within the pCI-neo_oppA 
group, 21 ostriches within the VR1012_oppA group, 21 ostriches within the 
VR1020_oppA group and 23 ostriches within the control group survived which could be 
sampled. None of the trial birds were confirmed positive for AI and no symptoms were 
observed, although AI as a cause for the high mortality in the test birds cannot be 
excluded.  
However, mortality of ostriches is affected by many factors such as stress, nutrition, 
temperature fluctuations and other diseases. Temperature fluctuations may have been a 
contributing factor since the trial was conducted in autumn (March to April) when there is 
a sudden drop in temperatures in the region. High mortality is reported in ostrich chicks 
(up to three months) with the mortality ranging between 10% to 50% while in three- to six-
month-old ostriches the mortality ranges between 10% to 30% (Black and Glatz 2011; 
Wang 2012). The mortality within the trial groups of the current study ranged from 16% to 
30% which is therefore not higher than normal. It should be noted that although the 
reasons for the deaths were unknown, the mortality in the control group was also high 
(23%). It can therefore be concluded that mortalities during the trial cannot be ascribed to 
the vaccination that the birds received.  
For these reasons, the manuscript that follows contains only data from week 0 and 
week 3 and it was therefore only possible to test whether the DNA vaccine elicited a 
primary immune response against OppA.  
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5.4 Evaluation of the Mycoplasma nasistruthionis sp. nov. str. Ms03 
oligopeptide permease substrate-binding domain (OppA) as a DNA 
vaccine candidate in ostriches 
5.4.1 Contributions of co-authors 
The following manuscript contains the original work of the author of this dissertation. 
The contributions of each of the co-authors were as follows: 
Dr. Annelise Botes is a lecturer of Biochemistry at the University of Stellenbosch and 
the supervisor of this dissertation. In this capacity, she was involved in the conceptual 
development and execution of all aspects of this study.  
Prof. Dirk U. Bellstedt is a professor of Biochemistry at the University of 
Stellenbosch and the co-supervisor of this dissertation. In this capacity, he was 
involved in the conceptual development and execution of this study.   
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Evaluation of the Mycoplasma nasistruthionis sp. nov. str. 
Ms03 oligopeptide permease substrate-binding domain 
(OppA) as a DNA vaccine candidate in ostriches 
Martha Wium, Annelise Botes and Dirk U. Bellstedt 
Abstract 
DNA vaccines containing the oppA gene of Mycoplasma nasistruthionis sp. nov. str. 
Ms03, were developed and the potential of these DNA vaccine to elicit an immune 
response in ostriches was evaluated. The oppA gene was cloned and site-directed 
mutagenesis was used for codon correction. The mutated oppA gene was then sub-
cloned into the DNA vaccine vectors: pCI-neo, VR1012 and VR1020. Three-month-old 
ostriches were vaccinated with these vaccines and the ability to elicit an anti-OppA 
immune response was evaluated by enzyme-linked immunosorbent assay (ELISA) in 
which recombinant OppA protein was used as coating antigen. The VR1020_oppA and 
pCI-neo_oppA constructs elicited a statistically significant immune response indicating 
their ability to induce a primary immune response in ostriches. This can therefore be 
viewed as the first step in the development of a DNA vaccine for the control of 
mycoplasma infections in ostriches. 
Introduction  
Mycoplasmas are a unique group of bacteria that can be distinguished from other 
bacteria by their lack of a cell wall and small A+T (adenine and thymine) rich genome 
(Razin et al. 1998). Mycoplasmas are host-specific (Pitcher and Nicholas 2005) and can 
infect the mucosal membranes of the eyes, nose, respiratory- and urogenital tract as well 
as causing joint inflammation. These infections cause numerous diseases in humans, 
animals and birds (Razin et al. 1998). Three ostrich-infecting Mycoplasma species have 
been identified, Ms01, Ms02 and Ms03 (Botes et al. 2005a) of which two Ms01 and Ms03 
have been provisionally described and given the species names, Mycoplasma struthionis 
sp. nov. and Mycoplasma nasistruthionis sp. nov., respectively (Langer 2009). These 
mycoplasmas cause upper respiratory tract infections in ostriches. Mycoplasmas are 
specifically problematic amongst feedlot ostriches where infections can cause retardation 
of growth, mortalities and carcass downgrading, which have a financial impact on rearing 
of slaughter birds. The majority of ostriches destined for slaughter are reared in feedlots 
from three months of age (Hoffman and Lambrechts 2011).  
Infections can be treated with antibiotics, but due to carrier conditions long-term 
treatment may be required. Long-term antibiotic treatment can lead to unwanted 
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accumulation of antibiotic residues in meat with concomitant risks for consumers (Nisha 
2008; Darwish et al. 2013). An alternative control measure would be the use of vaccines. 
Live attenuated and inactivated whole organism mycoplasma vaccines are available for 
commercial use in chickens (Kleven 2008; Jacob et al. 2014), but chicken vaccines were 
found to be ineffective in treating mycoplasmosis in ostriches (Pretorius 2009). Traditional 
approaches for mycoplasma vaccine development for use in ostriches is hampered by 
the fact that ostrich-infecting Mycoplasma species are difficult to culture in large volumes 
and require complex medium for growth. This makes whole organism vaccines 
impractical and economically unfeasible for the relatively small ostrich vaccine market if 
compared to that of poultry.  
As an alternative to whole organism vaccines, DNA vaccines are an attractive option. 
Over the past two decades, four DNA vaccines were registered for veterinary use in 
salmon, swine, horse and dogs (Kutzler and Weiner 2008; Giese 2012). Compared to 
inactivated whole organism vaccines and protein subunit vaccines, DNA vaccines have 
the advantage of being able to stimulate both humoral and cellular immune responses 
(Liu 2011). DNA vaccines also have an excellent safety profile (Schalk et al. 2006; Giese 
2012) and can be produced at relatively low cost (Mahoney et al. 2000). Production of 
DNA vaccines also does not rely on large scale culturing of the pathogen which is 
problematic in some mycoplasmas including Ms03 (Waites and Talkington 2004; Flores-
Medina et al. 2012; Citti and Blanchard 2013; Bueno et al. 2014). Furthermore, they are 
more temperature stable than other vaccines (Giese 1998) making them a particular 
attractive option for veterinary use under extensive farming conditions. Ostriches are 
usually farmed in semi-desert and desert regions where high temperatures are frequently 
found making cold storage of vaccines problematic.  
The Mycoplasma genus is known for its small genome size ranging from 564 kbp in 
Mycoplasma parvum (do Nascimento et al. 2013) to 1 359 kbp in Mycoplasma penetrans 
(Sasaki et al. 2002). With it comes a parasitic lifestyle and dependence on the host for 
nutrients. Mycoplasmas therefore have a wide range of transporters that are essential for 
survival. Transport proteins have been indicated as possible targets in vaccine 
development (Garmory and Titball 2004; Grandi 2010). Among these are ATP binding 
cassette (ABC) transporters that play a crucial role in the energy dependent import of 
nutrients. The oligopeptide permease transport (Opp) system is an ABC transporter that 
is responsible for the import of oligopeptides. Similar to other ABC transporters 
(Berntsson et al. 2010) this transporter has five domains: OppA is the substrate-binding 
domain, OppB and OppC form a pore within the cell membrane and OppD and OppF 
hydrolyse ATP to provide energy for translocation of the oligopeptide. These domains are 
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each encoded by an open reading frame (ORF), which is usually found in tandem within 
an operon structure in the genome.  
In bacteria, OppA has also been reported to play a role in spore formation (Rudner et al. 
1991), cytadherence (Henrich et al. 1999), antibiotic resistance (Mistry et al. 2013), 
biofilm formation (Lee et al. 2004) and ecto-ATPase activity (Hopfe and Henrich 2004). 
OppA is an attractive target for vaccine development because of its essential function as 
well as its location on the external bacterial membrane surface, which exposes the 
protein to the immune system of the host. To this end OppA has been evaluated as a 
target in subunit vaccines for Brachyspira pilosicoli (Movahedi and Hampson 2010), 
Moraxella catarrhalis (Yang et al. 2011) and Yersinia pestis (Tanabe et al. 2006).  
The genome of M. nasistruthionis sp. nov. str. Ms03 (Ms03, this abbreviation is used for 
brevity) was found to have two complete opp operons and therefore two possible oppA 
genes that could be used as vaccine candidates. Phylogenetic analysis of Opp proteins 
in Mycoplasma species allowed opp operons to be grouped into three types; A, B and C 
(See Chapter 3 of this dissertation, Wium et al. (2015)). Only Type A is found in all 
Mycoplasma species of the pneumoniae and hominis groups indicating an essential 
biological role for this operon. Furthermore, the immunogenicity and essential nature of 
the Type A OppA protein in M. hominis was experimentally confirmed (Henrich et al. 
1993; Henrich et al. 1999). The oppA gene that forms part of the Type A opp operon of 
Ms03 was therefore selected as vaccine candidate gene (KM410300). 
This study investigated the potential of using the Ms03 Type A oppA gene in the 
development of a DNA vaccine for the control of Ms03 infections in ostriches. For this 
purpose, the Ms03 oppA gene was cloned into the pGEM®-T Easy vector followed by 
codon correction using site-directed mutagenesis (SDM). The mutated oppA gene was 
sub-cloned into an expression vector and the gene product was expressed as a GST-
fusion protein that was used to develop an anti-OppA enzyme-linked immunosorbent 
assay (ELISA). The mutated oppA gene was also sub-cloned into three different DNA 
vaccine vectors that were assessed for their ability to elicit an anti-OppA humoral immune 
response in ostriches using the aforementioned ELISA.  
Materials and methods  
Mycoplasma cultivation and DNA isolation  
Cultures of Ms03 were obtained from Mr J.J. Gouws (Faculty of Veterinary Science, 
Onderstepoort, University of Pretoria). Genomic DNA (gDNA) was isolated from these 
cultures using a method described by Hempstead (1990). In short: The cells were 
harvested from 25 ml of Chanock’s medium by centrifugation at 27 200 × g for 60 min at 
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4°C (Beckman Model J2-21 centrifuge, JA-20 rotor). The harvested cells were washed by 
resuspension in 1 ml concentrated TE buffer (50 mM Tris-HCl, pH 7.5, 10 mM EDTA) 
followed by centrifugation, 10 000 × g for 30 min at 4°C (Biofuge Fresco, Heraeus). The 
pellet was resuspended in 100 μl concentrated TE buffer and incubated at -20°C for 
60 min or stored overnight. The frozen cells were lysed by a rapid thaw step at 55°C for 2 
to 5 min. The contaminating proteins within the lysed cell sample was digested by adding 
1 ml of SDS TE buffer (50 mM Tris-HCl, 10 mM EDTA, 1% (w/v) SDS, pH 7.5) and 
proteinase K (Roche, Switzerland) to a final concentration of 20 mg/ml. This was followed 
by an incubation step at 55°C for 30 min to allow the cell suspense to clarify. Proteins are 
denatured by the combination of high detergent concentration (SDS) and proteinase K 
(Hilz et al. 1975). RNA was digested by adding 6 μl RNase A (20 mg/ml, PureLinkTM 
RNase A, Invitrogen, USA) and 100 μl concentrated TE buffer followed by incubation for 
60 min at 37°C. The SDS was precipitated from the solution by adding 100 μl of 
potassium acetate (5 M) and incubating it on ice for 30 min. The SDS precipitation was 
removed by centrifugation, 16 000 × g for 10 min at 4°C. Contaminating proteins were 
removed from the supernatant by three equal volume extractions with chloroform: 
isopropanol (24:1, v/v). In each extraction, the solutions were mixed by inverting them for 
10 min followed by centrifugation, 16 000 × g for 2 min at room temperature. gDNA was 
precipitated by adding 1/10 of a volume of sodium acetate solution (3 M) and 2 volumes 
of 95% ethanol followed by an overnight incubation at -20°C. The precipitated gDNA was 
collected by centrifugation, 16 000 × g for 60 min at 4°C, and was washed by adding 1.5 
ml 70% ethanol followed by incubation for 20 min at room temperature. gDNA was 
collected by centrifugation, 16 000 × g for 10 min at 4°C and air dried at room 
temperature before dissolving it in 50 μl Milli-Q® water by incubation at 4°C overnight.  
The concentrations of gDNA samples were determined spectrophotometrically 
(NanoDrop spectrophotometer, ND-1000), while the integrity of the gDNA samples were 
assessed on a 1% (w/v) agarose gel. 
Cloning and site-directed mutagenesis of the oppA gene  
The oppA gene was amplified from Ms03 gDNA using proof-reading Kapa HiFi DNA 
polymerase (Kapa Biosystems, South Africa) according to the manufacturer’s 
instructions. Restriction enzyme sites of MluI and AccI were added to the Ms03_P100F 
and Ms03_P100R primers respectively (Table 5.1). All primers used within this study 
were synthesized and purified by Integrated DNA Technologies (IDT, USA). PCR 
products were separated and visualised using a 1% (w/v) agarose gel containing 0.5 
μg/ml ethidium bromide under UV light. PCR products were purified using the GFX™ 
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PCR DNA and gel band purification kit (GE Healthcare Life Science, UK) according to the 
manufacturer’s instructions.  
For SDM the purified PCR product was cloned into the pGEM®-T Easy vector (Promega, 
USA). To this end, 3' terminal deoxyadenosine residues were added to the blunt ends of 
the purified PCR product using the A-tailing procedure as described in the pGEM®-T 
Easy system I manual. A DNA clean and concentrator™-5 kit (ZYMO Research, USA) 
was used to clean and concentrate the A-tailing product followed by overnight ligation 
(vector: insert ration 1:1 and 1:3) at 4°C into the pGEM®–T Easy vector, according to the 
manufacturer’s instructions. The ligation products (pGEM_oppA) were transformed into 
E. coli JM109 cells and grown on Luria-Bertani (LB) agar plates (15 g/L) containing 100 
μg/ml ampicillin (Sigma-Aldrich, USA), 0.16 mM isopropyl β-D-1-thiogalactopyranoside 
(IPTG, Bioline, UK) and 0.04 mg/ml X-Gal (Bioline, UK) for 16-18 h at 37°C.  
Table 5.1 Primers used in this study  
Primer name Sequence* Anneal. Temp Comment 
Ms03_P100F 5'-ACGCGTATGAAAAAATGATGATTATT-3' 
55 
For cloning into pCI-neo (5' 
MluI restriction enzyme site) 
Ms03_P100R 5'-GTCGACCTATTTAGGTCTTACACCGT-3' For cloning into pCI-neo (5' AccI restriction enzyme site) 
Ms03_P100SalI_F 5'-GTCGACATGAAAAAATGGTGGTTAT-3'  
55 
For cloning into VR1012 (5' 
SalI restriction enzyme site) 
Ms03_P100NotI_R2 5'-ATGCGGCCGCCTATTTAGGTCTTACAC-3' 
For cloning into VR1012 and 
pGEX-4T-1 (5' NotI 
restriction enzyme site) 
Ms03_P100BamHI_
F 5'-GGATCCATGAAAAAATGGTGGTTAT-3' 
60 
For cloning into VR1020 and 
pGEX-4T-1 (5' BamIH 
restriction enzyme site)  
Ms03_P100BamHI_
R 5'-GGATCCCTATTTAGGTCTTACACCG-3' 
For cloning into VR1020 (5' 
BamIH restriction enzyme 
site)  
T7_R 5'-GCTGTAATTTGGGCATTTTCTTG-3' 74 Internal oppA primers, position 592-615 
P100_1F 5'-CATTAATTTAGCTTTATTAAAAGAT-3' 64 Internal oppA primers, position 549-573 
P100_1R 5'-GAAACAAATGAAATTGAAACAGTAT-3' 68 Internal oppA primers, position 1 220-1 244 
P100_2F 5'-GACAACACTGTAAGTTTTGGAAATC-3' 70 Internal oppA primers, position 1 177-1 201 
P100_2R 5'-ATTTTTCTGGTTTTAATAAGTCATC-3' 67 Internal oppA primers, position 1 906-1 930 
P100_3F 5'-CCCTAGAGCAAACTATGGAAATAAA-3' 72 Internal oppA primers, position 1 851-1 875 
P100_3R 5'-CAGAAGAAGGTATTTACTAATGTGT-3' 65 Internal oppA primers, position 2 525-2 549 
P100_4F 5'-AGAGATGCTGTAAATAAAGATCCTG-3' 69 Internal oppA primers, position 2 461-2 485 
P100_4R 5'-TGTTCAGTAGTTGGTTTAACAAAGT-3' 68 Internal oppA primers, position 3 185-3 209 
SP6_F 5'-GCTTTAGATTTAGTAATTGCTGCTT-3' 70 Internal oppA primers, position 3 130-3 154 
pGEM-T Easy_T7 5'-TAATACGACTCACTATAGGG-3' 
pGEM®-T Easy vector 
pGEM-T Easy_SP6 5'-ATTTAGGTGACACTATAGAA-3' 
pGEX_F 5'-GGGCTGGCAAGCCACGTTTGGTG-3' 
pGEX-4T-1 vector 
pGEX_R 5'-CCGGGAGCTGCATGTGTCAGAGG-3' 
pCI-neo_T7EEV 5'-AAGGCTAGAGTACTTAATACGA-3' 
pCI-neo vector 
pCI-neo_T3 5'-AATTAACCCTCACTAAAGGG-3' 
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Table 5.1 (Continued). 
  Primer name   Sequence Anneal. Temp Comment 
VR1012_F 5'-CGCGCCACCAGACATAATAG-3' 
VR1012 vector  
VR1012_R 5'-AACAACAGATGGCTGGCAAC-3' 
VR1020_F 5'-CGTCGACAGAGCTGAGATCCTACAG-3' 
VR1020 vector 
VR1020_R 5'-GACACCTACTCAGACAATGCGATGC-3' 
    
Site1&2_F 5'-ACGCGTATGAAAAAATGGTGGTTATTACCAGTAGCTAGTACA-3' 
66 
SDM reaction 1, mutate 
positions 12 &15 Site1&2_R 5'-TGTACTAGCTACTGGTAATAACCACCATTTTTTCATACGCGT-3' 
Site10_F 5'-TTTTAACAGCAGCTATTGACTGGAACTCAATCGCTTCAATT-3' SDM reaction 1, mutate 
position 2 727 Site10_R 5'-AATTGAAGCGATTGAGTTCCAGTCAATAGCTGCTGTTAAAA-3' 
Site9_F 5'-TGATGAATATGCTTACACAATGTGGGGAATGTCAGCAGCAGA-3' 
68 
SDM reaction 2, mutate 
position 2 626 Site9_R 5'-TCTGCTGCTGACATTCCCCACATTGTGTAAGCATATTCATCA-3' 
Site13&14_F 5'-AACCAACTACTGAACAATGGAGAAATTACTGGACAGGAACTTC TCCATT-3' SDM reaction 2, mutate 
positions 3 213 & 3 225 Site13&14_R 5'-AATGGAGAAGTTCCTGTCCAGTAATTTCTCCATTGTTCAGTAG TTGGTT-3' 
Site3_F 5'-ACTTAAAGCATCTGATAAGTGGGAATTAAATGAAAACG-3' 
61 
SDM reaction 3, mutate 
position 1 290 Site3_R 5'-CGTTTTCATTTAATTCCCACTTATCAGATGCTTTAAGT-3' 
Site7_F 5'-ACAGTAATTAATAAGAATTACTGGGACACAGAATATGTTAAT-3' SDM reaction 3, mutate 
position 2 301 Site7_R 5'-ATTAACATATTCTGTGTCCCAGTAATTCTTATTAATTACTGT-3' 
Site4_F 5'-GAGTTAGACCAGGTCATTTCTGGACCGATGCTAAAGGAAA-3' 
65 
SDM reaction 4, mutate 
position 1 680 Site4_R 5'-TTTCCTTTAGCATCGGTCCAGAAATGACCTGGTCTAACTC-3' 
Site12_F 5'-TTAGATTTAGTAATTGCTGCTTGGAACGGATTAGATCCAAGA-3' SDM reaction 4, mutate 
position 3 156 Site12_R 5'-TCTTGGATCTAATCCGTTCCAAGCAGCAATTACTAAATCTAA-3' 
Site5_F 5'-GATTATTAAGAACACAAATGTGGGACACACCTTATAGGCTA-3' 
64 
SDM reaction 5, mutate 
position 1 762 Site5_R 5'-TAGCCTATAAGGTGTGTCCCACATTTGTGTTCTTAATAATC-3' 
Site8_F 5'-CACATTAGTAAATACCTTCTTCTGGTCAATTCTGCCAAAAGA-3' SDM reaction 5, mutate 
position 2 550 Site8_R 5'-TCTTTTGGCAGAATTGACCAGAAGAAGGTATTTACTAATGTG-3' 
Site6_F 5'-CTAAATTGAGTGGTATTTACTGGTATGGACTTTCAGTTGAT-3' 
62 
SDM reaction 6, mutate 
position 2 196 Site6_R 5'-ATCAACTGAAAGTCCATACCAGTAAATACCACTCAATTTAG-3' 
Site16_F -TGTATTTAGTTCAAGATTCTGGCTAAACTATACAACATCAC-3' SDM reaction 6, mutate 
position 3 609 Site16_R 5'-GTGATGTTGTATAGTTTAGCCAGAATCTTGAACTAAATACA-3' 
Site11_F 5'-CCTCAACCGGTTAAACCTTGGATTACAGGATTGTCTCCTGAC-3' 
68 
SDM reaction 7, mutate 
position 2 775 Site11_R 5'-GTCAGGAGACAATCCTGTAATCCAAGGTTTAACCGGTTGAGG-3'
Site15_F 5'-TCCATTTTCACTAGCAGGTTGGGGTTATGACTACGATGGTAT-3' SDM reaction 7, mutate 
position 3 258 Site15_R 5'-ATACCATCGTAGTCATAACCCCAACCTGCTAGTGAAAATGGA-3' 
*Restriction enzyme sites, included for cloning purposes, are underlined, the start and termination codon are bold and the nucleotides 
change by site-directed mutagenesis are bold and underlined.  
White colonies were screened with colony PCR to confirm the presence of the insert 
using the pGEM–T Easy_T7 and P100_2R primers (Table 5.1). Each colony PCR 
reaction contained 1 × reaction buffer, 0.2 mM of each dNTP (Kapa Biosystems, South 
Africa), 2 mM MgCl2, 1 pmol/ml of each primer and 0.2 units of Super-Therm Taq DNA 
polymerase (JMR Holdings, USA) in a final volume of 10 μl. Bacteria from a single colony 
were transferred with a sterilized toothpick into the PCR mixture. PCR conditions were as 
follows: 25 cycles of 94°C for 30 sec, 55°C for 15 sec and 72°C for 1 min, followed by a 
final step at 72°C for 6 min in a Veriti 96 well Thermal Cycler (Applied Biosystems, USA). 
Positive colonies were inoculated into 5 ml LB medium containing 100 μg/ml ampicillin 
and grown at 37°C for 16 h, shaking at 250 rpm. Plasmid DNA (pDNA) was isolated from 
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2 ml culture with the Invisorb® spin plasmid mini two kit (Invitek GmbH, Germany), 
according to the manufacturer’s instruction. All pDNA samples were stored at 4°C. 
Freezer stocks were prepared from left over culture by diluting 1:1 with 80% glycerol and 
stored at -80°C.  
Accurate insertion of the gene into the vector was confirmed by sequencing. Each 
sequencing reaction contained 1 μl BigDye® Terminator mix (v3.1, Applied Biosystems, 
USA), 3 μl Halfdye (Bioline, UK), 300 ng pDNA, 1 pmol primer (Table 5.1) and Milli-Q® 
water to a final volume of 10 μl. PCR conditions were as follows: 35 cycles of 94°C for 10 
sec, 55°C for 30 sec and 60°C for 4 min, followed by a final step at 60°C for 10 min. The 
Central Analytical Facility (CAF) of the University of Stellenbosch, South Africa analysed 
the products with an ABI® 3100 Genetic Analyser (Applied Biosystems, USA). The 
resulting sequences were edited and aligned against the vector and the gene sequence 
of Ms03 oppA using BioEdit v7.0.5.2 (Hall 1999).  
Seven consecutive SDM steps were carried out to change all 16 of TGA codons to the 
universal codon for tryptophan i.e. TGG. The positions of the nucleotides mutated within 
the oppA gene were 12, 15, 1 290, 1 680, 1 762, 2 196, 2 301, 2 550, 2 626, 2 727, 
2 775, 3 156, 3 213, 3 225, 3 258 and 3 609. A strategy of using two primer pairs that 
bound to the oppA gene at distant positions and possessed very similar annealing 
temperatures was followed, to allow combinations of primers to be used in order to 
reduce the number of SDM steps to seven in total. In each step, the pGEM_oppA vector 
was amplified with two sets of SDM primers (Table 5.1) with Kapa HiFi DNA polymerase 
according to the manufacturer’s instructions using 2.25 mM MgCl2. The SDM PCR 
products were treated with DpnI (Promega, USA) according to the manufacturer’s 
instructions and the enzymes removed with the DNA clean and concentrator™-5 kit 
(ZYMO Research, USA) before transforming the plasmids into E. coli JM109 cells. 
Colony PCR was used to select positive colonies and the plasmid was subsequently 
isolated and the insert sequenced as before to confirm the success of each SDM step. 
Expression and purification of recombinant OppA protein 
Recombinant OppA protein was produced for use as coating antigen in an enzyme-linked 
immunosorbent assay (ELISA). For expression, the SDM oppA gene was sub-cloned 
from SDM pGEM_oppA vector into the pGEX-4T-1 vector (GE Healthcare Life Science, 
UK). The mutated oppA gene was first amplified by PCR from the pGEM_oppA vector 
using the Ms03_P100BamHI_F and Ms03_P100NotI_R2 primers with BamHI and NotI 
restriction sites (Table 5.1). The PCR product was next sub-cloned into a pGEM®-T Easy 
vector and the pGEM plasmid containing oppA and the BamHI and NotI restriction sites 
(pGEM_oppABamNot) isolated as describe above. Double digests of pGEM_oppABamNot and 
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the pGEX-4T-1 vector were performed with BamHI and NotI (FastDigest, Thermo 
Scientific, USA) and the digested products purified with the Zymo-DNA clean and 
concentrator™-5 kit (Zymo Research, USA). The BamHI/NotI digested linear pGEX-4T-1 
product was further treated with shrimp alkaline phosphatase (SAP, Promega, USA) 
according to the manufacturer’s instructions and purified as before. Ligation was 
performed overnight at 4°C with a vector to insert ration of 1:1 and 1:3 using T4 DNA 
ligase (Promega, USA) before transforming the plasmids into E. coli JM109 cells. A 
control was included which contained digested pGEX-4T-1 without insert. Positive 
colonies were identified using colony PCR with the pGEX_F and P100_2R primers (Table 
5.1) as described above followed by plasmid sequencing as before to confirm accurate 
insertion.  
The pGEX-4T-1_oppA plasmid was transformed into E. coli BL21(DE3)pLysS cells. 
Expression of the glutathione S-transferase (GST) OppA fusion protein was induced at 
an OD600 of 0.3 by the addition of 0.4 mM IPTG and cells harvested after 6 h. Terrific 
broth with 100 μg/ml ampicillin, 1% (w/v) glucose and 34 μg/ml chloramphenicol was 
used for expression experiments. The GST-OppA protein was isolated using glutathione-
agarose chromatography (Sigma-Aldrich, USA) within a gravity flow column system at 
4°C according to the manufacturer’s instructions. An extra 50 ml phosphate-buffered 
saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 and 1.5 mM KH2PO4, pH 7.2) 
wash step was added before bound GST-OppA protein was eluted with 10 mM reduced 
L-glutathione in Tris-HCl buffer (50 mM , pH 9.5). Fractions (1 ml) were collected and 
their protein concentration determined using a Bradford assay. In brief, 5 μl the protein 
fractions or BSA standards (concentrations in the range of 0 to 1.75 mg/ml) were diluted 
in 250 μl Bradford reagent (8.5% (w/v) phosphoric acid, 0.01% (w/v) Coomassie Brilliant 
Blue G-250 and 4.7% (v/v) ethanol) and incubated for 5 min at room temperature within 
96-well microtitre plate. Absorbance was measured at 620 nm. A standard curve using 
BSA was generated in order to calculate the protein concentrations of the fractions. 
Expression and isolation products were analysed using SDS-PAGE and Coomassie blue 
staining.  
For western blot analysis the proteins were transferred to a 0.45 μm nitrocellulose 
membrane (Schleicher and Schuel, Sigma-Aldrich) by electrophoresis (20 mA for 16 h), 
followed by three 1 h incubation steps at 37°C: blocking with casein buffer (10 mM Tris-
HCl, 150 mM NaCl, 0.5% casein and 0.02% Thiomersal), 1:12 000 dilution of primary 
antibody (goat anti-GST, GE Healthcare Life Science, UK) and a 1:10 000 dilution of 
secondary antibody (rabbit anti-goat IgG (whole molecule) peroxidase conjugate, Sigma-
Aldrich, USA). Antibodies were diluted with casein-Tween buffer (0.5% casein buffer 
containing 0.1% (v/v) Tween 20). After each binding step the membrane was washed 
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three times with PBS-Tween 20 (0.1%). The membrane was developed for 20 min in a 
solution containing 0.05% (w/v) 4-chloro-1-naphthol, 16.6% (v/v) methanol, 114 mM 
NaCl, 2.25 mM KCl, 8.3 mM Na2HPO4 and 1.25 mM KH2PO4 and 0.025 μl/ml H2O2 (30%). 
The colour reaction was stopped by washing the membrane in Milli-Q® water.  
Preparation of DNA vaccines 
The SDM oppA gene was sub-cloned into pCI-neo (Promega, USA), VR1012 and 
VR1020 (Vical Inc., USA). For sub-cloning into pCI-neo single consecutive digests of the 
pCI-neo and the SDM pGEM_oppA vectors were performed with AccI and MluI 
(FastDigest, Thermo Scientific, USA). AccI and MluI sites were previously added to 
amplification primers (Table 5.1) Digested products were purified and pCI-neo further 
treated with SAP followed by ligation and transformation as described above. A control 
was included which contained pCI-neo without insert. Positive colonies were identified 
using T7EEV and P100_2R primers (Table 5.1) by colony PCR and the insert sequenced 
as described above to confirm accurate insertion.  
For sub-cloning into VR1012 and VR1020, the oppA gene was PCR amplified from the 
SDM pGEM_oppA vector. For cloning into VR1012, SalI and NotI restriction enzyme sites 
were included in the forward and reverse primers, respectively and for cloning into 
VR1020, BamIH restriction enzyme sites were included in both the forward and reverse 
primers (Table 5.1). The PCR product with appropriate restriction sites was cloned into a 
pGEM®-T Easy vector as describe above. Plasmid DNA was isolated (as above) and a 
double digest was performed with SalI and NotI for VR1012 and a single digest with 
BamHI for VR1020. Purification, SAP treatment, ligation and transformation were 
performed as described above except that a different antibiotic was used (kanamycin, 50 
μg/ml). Positive colonies were identified in VR1012 using VR1012_F and P100_2R 
primers and in VR1020 using VR1020_F and P100_2R primers (Table 5.1) followed by 
sequencing of the insert as described above to confirm accurate insertion. 
For large scale production of the pCI-neo_oppA vaccine, five large scale cultures were 
used, while four large scale cultures were used for both the VR1012_oppA and 
VR1020_oppA vaccines. For each large scale culture, 450 ml of LB medium was 
inoculated with E. coli JM109 cells that contain the respective vaccine plasmids and 
cultivated for 16 h (A600 between 0.650 and 1.150). The DNA vaccine plasmids (pCI-
neo_oppA, VR1012_oppA and VR1020_oppA) were purified with an Endotoxin-free 
plasmid DNA purification kit (NucleoBond® Xtra Maxi plus EF, Macherey-Nagel, 
Germany). The yields were determined using a Nanodrop (Thermo Scientific, USA) while 
the integrity of the plasmid DNA was confirmed with electrophoresis on a 1% agarose 
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gel. The DNA vaccines were diluted to final concentrations of 100 μg/ml in sterile PBS 
buffer for use as vaccines. 
DNA vaccine trial 
A vaccine trial on ostriches in the Oudtshoorn district (Western Cape) in South Africa in 
which of all three vaccines were to be tested was planned. Ethical clearance to perform 
this trial was obtained from the University of Stellenbosch Animal Ethics Committee (Ref: 
10NB_BOT01) prior to the start of the trial. Three-month-old ostriches used for the trial 
were from, and housed on, a commercial ostrich farm near Oudtshoorn in the Klein Karoo 
region. Trial ostriches were not kept in isolation, but were housed and treated in the same 
manner as non-trial ostriches on the farm, receiving food and water ad libitum. Each 
ostrich was tagged with a unique number according to standard ostrich farming practices. 
The trial was therefore conducted under similar conditions to which a commercial vaccine 
would be administered.  
The vaccine trial consisted of three experimental groups. Group 1 (25 ostriches) was 
vaccinated with pCI-neo_oppA, group 2 (21 ostriches) with VR1012_oppA, group 3 (21 
ostriches) with VR1020_oppA and the control group (23 ostriches) received no 
vaccination. Ostriches were vaccinated intramuscularly in the upper thigh with a single 
dose (100 μg in 1 ml PBS) at week 0. Blood (4 ml) was drawn from the jugular vein in 
Vacuette® Z serum sep clot activator tubes with 18G x 1” needles (Vacuette, UK). Serum 
was separated by centrifugation at low speed for 20 min and transferred to a 1.5 ml 
microcentrifuge tube before storage at -20°C. Blood samples were collected and the 
weight of each ostrich recorded before vaccination at week 0 and after vaccination at 
week 3 (The reader is referred to page 101 where the implications of an outbreak of 
avian influenza during this trial are outlined). 
Monitoring of existing mycoplasma infections 
Saliva samples were used to monitor existing mycoplasma infections in the trial ostriches 
in order to interpret immune responses after vaccination, as existing infections may have 
influenced the results. Saliva samples were collected before vaccination at week 0 and at 
week 3 after vaccination. Saliva samples were collected from all ostriches by swabbing 
the trachea with a sterile transport swab (plain rayon tipped with plastic applicator, 
Copan, Italy) after which the swab was again placed in its sterile polypropylene tube. In 
the laboratory, each swab was rinsed in a microcentrifuge tube containing 200 μl PBS 
buffer followed by PCR testing with species-specific primers for the three ostrich-infecting 
mycoplasmas, M. struthionis sp. nov. str. Ms01 (Ms01), Mycoplasma sp. Ms02 (Ms02) 
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and Ms03 using Super-Therm Taq DNA polymerase (JMR Holdings, USA) as described 
by Botes et al. (2005a).  
Evaluation of the immune response 
Microtiter plates (Maxisorp, Nunc) were coated overnight at 4°C with 100 μl of 
recombinant GST-OppA protein diluted to 10 μg/ml in carbonate buffer (50 mM, pH 9.6). 
Non-specific binding was prevented by blocking with 300 μl/well of 0.5% casein buffer for 
2 h at 37°C after which the casein buffer was decanted. Serum samples were diluted 
1:100 with casein-Tween buffer (0.5% casein buffer containing 0.1% (v/v) Tween 20) and 
100 μl/well loaded in triplicate before incubation for 1 h at 37°C. The plate was decanted 
and washed eight times with PBS-Tween (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 
and 1.5 mM KH2PO4, pH 7.2, 0.1% (v/v) Tween 20), before 100 μl/well of biotinylated 
rabbit anti-ostrich IgG antibodies (Blignaut et al. 2000) (diluted 1:100 with casein-Tween 
buffer) was added followed by incubation for 1 h at 37°C. After decantation and washing 
(as above), a 100 μl/well streptavidin horseradish peroxidase (HRP) conjugate mixture (2 
ml Streptavidin (Invitrogen), 38 ml 0.5% casein buffer and 40 ml (50%) glycerol) diluted 
1:100 with casein-Tween buffer was added and incubated for 1 h at 37°C. After 
decantation and washing, 100 μl of substrate solution (0.5 mg/ml ABTS, 0.5 μl/ml H2O2, 
0.1 M citrate buffer, pH 5) was added. Absorbances were read at 405 nm after 30 min 
incubation at 37°C.  
Serum collected from ostrich 7736 (VR1020_oppA group) at week 0 and 3 was used as 
internal control and column blanks (containing all components except ostrich serum) 
were used to standardize the results.  
Statistical analysis of data 
Statistical analysis of the data was performed with the Agrobase Generation II® 
(Agronomix Software Inc.) software. ANOVA and least significant differences (LDS) 
between the groups were calculated.  
Results 
Mycoplasma cultivation and DNA isolation  
Ms03 cultures were successfully cultivated by Mr J.J. Gouws (Faculty of Veterinary 
Science, Onderstepoort, University of Pretoria). In medium, Ms03 grew slowly and did not 
reach high cell densities. Genomic DNA was successfully isolated from the cultured 
Ms03. The concentration of the gDNA samples range from 755 to 1022 ng/μl and the 
260/280 ratio range from 2.00 to 2.05. The higher 260/280 ratios (above 2) are not 
surprising since absorbance is depend on the nucleotide composition of the DNA sample. 
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Mycoplasma genomes are A+T rich and the nucleotide, adenine has a high 260/280 
ratio.  
Cloning, site-directed mutagenesis, expression and purification of OppA 
Subsequently, the gDNA was used as template for the amplification of the oppA gene. 
The oppA gene was successfully cloned into the pGEM®-T Easy vector which was 
confirmed by sequencing (results shown in Appendix 4). The 16 TGA codons were 
mutated successfully to TGG in seven consecutive steps of site-directed mutagenesis as 
confirmed by sequencing. The results of each consecutive step are shown in Appendix 4. 
This therefore gave an oppA gene that was suitable for transcription according to the 
universal code, cloned into the pGEM®-T Easy vector.  
Restriction enzyme sites (BamHI and NotI) were added to mutated oppA gene by PCR 
amplification before it was again cloned into the pGEM®-T Easy vector. The success of 
the resulting pGEM_oppABamNot vector was confirmed by sequencing (Appendix 4). 
Restriction digestion and ligation was used to sub-clone the oppABamNot gene into the 
prokaryotic pGEX-T4-1 expression vector as confirmed by sequencing (results shown in 
Appendix 4).  
SDS-PAGE analysis showed that the recombinant OppA protein was expressed successfully as an 
N-terminal GST-fusion protein of the predicted size of about 170 kDa (26 kDa due to the GST tag), 
Figure 5.1 A, lane 2. The isolation of the GST-OppA fusion protein was achieved by affinity 
purification as shown in Figure 5.1 A, lane 3. This fraction was shown to contain free GST and 
GST-OppA fusion protein (Figure 5.1 A, lane 3). This could have resulted from enzymatic cleavage 
during isolation and storage (Braun et al. 2002). Success of the isolation was confirmed by western 
blot analysis using anti-GST antibodies (Figure 5.1 B). The concentration of the isolated 
recombinant OppA protein was determined by Bradford analysis using BSA as a standard. An 
additional PBS wash step was introduced during isolation due to interference of Triton-X in the first 
wash step with the Bradford analysis. Protein was eluted between fraction 7 and 12 with the 
highest concentration obtained in the 9th fraction (Figure 5.2). 
Preparation of DNA vaccines 
The mutated oppA gene was successfully sub-cloned into pCI-neo with the use of the 
restriction enzyme sites (MluI and AccI) previously added. The results were confirmed by 
sequencing as shown in Appendix 4. 
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Figure 5.1 Expression of recombinant GST-OppA protein. SDS-PAGE (A) and western blot (B) 
analysis of the expressed OppA protein. Lane 1 E. coli BL21(DE3)pLysS cells expressing GST-
control, lane 2 E. coli BL21(DE3)pLysS cells expressing GST-OppA protein and lane 3 isolated 
recombinant GST-OppA protein. MM is the GE Healthcare full-range rainbow molecular weight 
marker, molecular sizes indicated in kDa. 
 
Figure 5.2 Protein isolation profile of the recombinant GST-OppA. Inserted in top right-hand corner 
is the BSA standard curve used to calculate protein concentrations.  
For sub-cloning into VR1012, restriction enzyme sites (SalI and NotI) were added to the 
mutated oppA gene with PCR amplification before it was successfully cloned into the 
pGEM®-T Easy vector. The success of the resulting pGEM_oppASalNot vector was 
confirmed by sequencing (Appendix 4). The mutated oppASalNot was sub-cloned into 
VR1012 with success as confirmed by sequencing (Appendix 4).  
For sub-cloning into VR1020, PCR amplification was used to add restriction enzyme sites 
to the mutated oppA gene before it was cloned into the pGEM®-T Easy vector. The 
success of the resulting pGEM_oppABamBam vector was confirmed by sequencing 
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(Appendix 4). The mutated oppABamBam gene was sub-cloned into VR1020 as confirmed 
by sequencing (Appendix 4).  
Large scale production of the DNA vaccines was achieved. In total 3522 μg of pCI-
neo_oppA plasmid DNA was isolated from 2 250 ml of medium, 6303 μg of 
VR1012_oppA plasmid DNA was isolated from 1 800 ml of medium and 4572 μg of 
VR1020_oppA plasmid DNA was isolated from 1 800 ml of medium. The 260/280 ratio of 
the isolated plasmids ranged from 1.89 to 1.95. These were used to dilute the three 
vaccines to the required concentration of 100 μg/ml for vaccination. 
DNA vaccine trial 
Ostriches were successfully vaccinated with the prepared DNA vaccines. No adverse 
reactions were observed at the injection sites. Blood and saliva samples were 
successfully collected. It was observed that within minutes after vaccination and sample 
collection (saliva and blood), the ostriches resumed normal behaviour such as eating, 
walking around and exploring, which indicates that the procedure did not have an 
immediate effect on the birds’ behaviour. Later adverse behaviour and inflammation at 
the vaccination sites was also not observed.  
Monitoring of existing mycoplasma infections 
The results of the mycoplasma infections that were monitored with PCR during the trial 
are presented in Table 5.2. At week 0, 43 of the 90 birds (48%) had mycoplasma 
infections (Table 5.2). Of the ostriches, 34 (38%) were infected with Ms03 and 33 (36%) 
with Ms02. This includes 24 ostriches that were not only infected with a single species, 
but had dual infections of Ms02 and Ms03. No Ms01 infections could be detected. These 
infections were spread over the different vaccine and control groups. At week 3, the total 
number of infections were 38 (42%) with 21 of the 90 ostriches (23%) being infected with 
Ms03, 25 (28%) with Ms02 and 3 ostriches infected with Ms01. Once again multiple 
infections were present in some birds, with seven ostriches being infected with Ms02 and 
Ms03 infections and two ostriches were infected with Ms01, Ms02 and Ms03. Infections 
at week 3 were spread over all groups, but the three Ms01 infections were only found in 
the VR1012_oppA group (Appendix 5, Supplementary Table 5.1).  
Overall the number of infections decreased from week 0 to week 3 within the control and 
VR1012_oppA groups but increased for pCI-neo_oppA and VR1020_oppA groups. 
These changes in infection status could not be related to the vaccines since the 
VR1012_oppA and control group received a non-scheduled treatment with Terramycin 
four days before the week 3 sampling point. This was prompted by lack of weight 
increase of ostriches in the control group and a weight decrease in the VR1012_oppA 
Stellenbosch University  https://scholar.sun.ac.za
 118 
group (Table 5.3) with an overall poor condition in both of these groups that could have 
been due to an underlying infection other than just mycoplasma. Terramycin is commonly 
used under field conditions to treat birds with physical signs of infection and thereby limit 
possible disease progression. It is a long-acting tetracycline with a broad-spectrum 
antibiotic activity, which also has some activity against mycoplasma.  
Table 5.2 Summary of the mycoplasma infections during the vaccine trial as determined by PCR  
 Ms01 Ms02 Ms03 Total number of infected birds* 
Number of 
birds with 
infections in 
week 0 and/or 
week 3* 
Week 0 3 0 3 0 3 0 3  
Control 0/23 0/23 15/23 5/23 19/23 1/23 21/23∆ 6/23 21/23 
pCI-neo_oppA 0/25 0/25 1/25 7/25 1/25 13/25 2/25 16/25# 16/25 
VR1012_oppA 0/21 3/21 16/21 9/21 13/21 4/21 18/21♦ 10/21Ω 18/21 
VR1020_oppA 0/21 0/21 1/21 4/21 1/21 3/21 2/21 6/21¥ 7/21 
Total 0/90 3/90 33/90 25/90 34/90 21/90 43/90 38/90 62/90 
*Since ostriches were infected with more than one Mycoplasma species, total numbers of infected birds are 
not the sum of the individual infections.  ∆ 13 dual infections of Ms02 and Ms03 in the control group in week 0 
# 4 dual infections of Ms02 and Ms03 in the pCI-neo_oppA group in week 3  ♦ 11 dual infections of Ms02 and Ms03 in the VR1012_oppA group in week 0  
Ω 2 dual infections of Ms02 and Ms03 as well as 2 infected with Ms01, Ms02 and Ms03 in the VR1012_oppA 
group in week 3  
¥ 1 dual infections of Ms02 and Ms03 in the VR1020_oppA group in week 3  
 
 
Evaluation of the immune response 
The ELISA was successfully optimized with regard to the coating concentration of the 
recombinant OppA protein as well as the serum dilution. It was found that when serum 
samples of ostrich 7736 were used they gave consistent absorbance values of about 
0.750 (week 0) and 1.750 (week 3) repeatedly. Consequently these serum samples were 
included on each plate as internal controls to monitor plate-to-plate variation. Plate-to-
plate variation was within 20% of the mean. The number of freeze-thaw cycles of the 
7736 serum sample may have increased the variation. The negative controls gave 
consistent low absorbance values.  
The results of the vaccination trial are shown in Figure 5.3. Mean titre values are shown 
for week 0 (before vaccination) and week 3 (after vaccination). At week 0, the mean 
ELISA titre values (405 nm) for the control and vaccinated groups ranged between 0.938 
and 1.142, but these differences were not statistically significant. The titre value for the 
control group was maintained at week 3 with a mean of 0.958. High absorbance values 
for all of the groups at the start of the trial and the control group at week 3 may be a 
result of mycoplasma infections occurring before and during the trial. This may be due to 
possible existing antibodies against OppA in the serum or due to increased background 
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values of the ELISA. The ANOVA analysis showed a significant treatment x time 
interaction (P=0.0428) between the vaccinated groups. However using the calculated 
least significant difference (LSD, P≤ 0.05) as basis for determining statistically significant 
differences, only the pCI-neo_oppA and VR1020_oppA treatment groups differed 
significantly from that of the control group. This implied that the ostriches were 
responding to vaccination. The OppA protein was therefore expressed in vivo and was 
sufficiently immunogenic to induce a primary antibody response. 
The weight of the ostriches was monitored during the vaccine trial as an indication of the 
birds’ health. An ANOVA analysis was performed for the recorded ostrich weights at 
week 0 and week 3. The average weight per group remained constant or increased 
slightly from week 0 to week 3 (except for VR1012_oppA which showed a slight 
decrease). No statistically significant difference over time or treatment x time interaction 
was found. A significant difference was found between treatments (P=0.0000) with a LSD 
value of 2.713, but this difference was not significant over time as it was already present 
at the onset of the trial due to the variation in weight between groups (Appendix 5, 
Supplementary Table 5.2). At the start of the trial the average weight per group ranged 
from 28.4 to 38.9 kg (Table 5.3) with the VR1012_oppA and VR1020_oppA groups not 
differing significantly. All weights were, however, in the expected range for the age group 
used since the weight of three-month-old ostriches can range from 4 to 44 kg (Bunter and 
Cloete 2004). The lack of an increase in weight between groups during the trial could 
therefore not be ascribed to the DNA vaccine administered as the unvaccinated control 
group also did not gain weight. 
Figure 5.3 Anti-OppA immune response of ostriches vaccinated with three different DNA 
vaccine vectors containing the mutated oppA gene of M. nasistruthionis sp. nov. str. 
Ms03. Vaccinated ostriches received a single DNA vaccine dose (100 μg/ml) at week 0 
and the control group did not receive any vaccine. Statistical parameters are indicated in 
the top right-hand corner. Additional ANOVA statistical data are available in Appendix 5, 
Supplementary Table 5.3.   
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Table 5.3 Summary of the mean weight recorded per vaccine group during the vaccine trial 
 Mean weight Week 0 Week 3 
Control 28.4 28.6 
pCI-neo_oppA 38.9 39.9 
VR1012_oppA 35.1 34.9 
VR1020_oppA 33.6 36.8 
   
Discussion  
In this study, DNA vaccines were developed using the Ms03 oppA gene as vaccine 
candidate gene. The codon optimization was required due to the use of the universal stop 
codon TGA as a tryptophan codon in mycoplasmas. The Ms03 oppA gene contains 16 
TGA codons. A strategy of combining two primer pairs to amplify the vector and oppA 
gene during SDM PCR was successfully employed to reduce the number of consecutive 
steps from 14 to 7 and to thereby correct all 16 TGA codons within oppA to TGG codons.  
Three different eukaryotic expression vectors (pCI-neo, VR1012 and VR1020) were used 
to develop the DNA vaccines within this study. They were selected based on DNA 
vaccine studies in other birds (Lee et al. 2003; McCutchan et al. 2004; Klotz et al. 2007) 
and on special characteristics such as a TPA-signal peptide in VR1020 that should result 
in the export of the translated protein from the cell and thus better activation of the 
immune system. The oppA gene was cloned into each vector using different restriction 
enzymes to ensure that the oppA gene is in-frame for in vivo protein expression. Large 
scale production of the constructs (pCI-neo_oppA, VR1012_oppA and VR1020_oppA) 
was successfully achieved, indicating that scaling up for commercial production should 
be possible.  
The humoral immune response elicited by the ostriches against these DNA vaccines was 
evaluated with an ELISA that was developed to using recombinant OppA protein as 
coating antigen. ELISA titre values were already raised at the start of the vaccination trial. 
The same observation was made by Yang et al. (2011) when using recombinant OppA 
protein as subunit vaccine against M. catarrhalis in mice. They suggested that the high 
titres were due to background and not recombinant OppA reacting to native OppA 
antibodies. Negative controls in our ELISA (serum replaced with casein buffer containing 
Tween 20) were used to test for nonspecific background and gave consistent low 
absorbance values (0.078-0.150). The raised titre values can therefore not be ascribed to 
non-specific binding.  
Yang et al. (2011) also postulated the possible presence of existing systemic antibodies 
to OppA as a result of existing infections. In this study, a large proportion of the ostriches 
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in all groups had existing mycoplasma infections at the start of the trial, which could 
account for the presence of anti-OppA antibodies. There were, however, ostriches that 
tested negative for mycoplasma with high titre values.  
Possible existing antibodies did, however, not mask the detection of an immune response 
to the OppA during vaccination. Vaccination resulted in a statistical significant increase in 
ELISA titre values for both the VR1020_oppA and pCI-neo_oppA vaccines with the 
VR1020_oppA construct resulting in the largest increase from week 0 to week 3. No 
significant increase was observed for VR1012_oppA. The DNA vaccine vectors 
(VR1020_oppA and pCI-neo_oppA) were therefore able to express the OppA protein in 
vivo, which in turn was sufficiently immunogenic to induce an anti-OppA immune 
response.  
Despite the fact that all three the vaccine vectors contain a CMV promoter, which is 
known to enhance the expression of genes, this may not have occurred in all three 
vaccines as an increase in anti-OppA antibodies was not observed in the VR1012_oppA 
vaccinated birds. The CMV promoter of VR1012 is optimized for use in mice and could 
therefore possibly not function in ostriches (Suarez and Schultz-Cherry 2000). However 
the main difference between the VR1012 and VR1020 vectors is the presence of the 
TPA-signal peptide within VR1020 vector. The export of the expressed OppA protein may 
therefore explain the significant antibody response following vaccination with the 
VR1020_oppA vaccine compared to the VR1012_oppA vaccine.  
An increase or decrease of PCR-detected infections did not correlate with immune 
responses. Ostriches typically produce a maximum primary immune response upon 
vaccination after 21 days, irrespective of the vaccine used (Blignaut et al. 2000; Bonato 
et al. 2009). The PCR was used to detect the presence or absents of mycoplasmas in the 
trial ostriches, but the technique does not quantify the bacterial load within the ostriches. 
Although a decrease in mycoplasma infections was not observed within the duration of 
this vaccine trial, it does not exclude the possibility that the bacterial load within the 
infected ostriches might have decreased. Thus the DNA vaccines may prove to be 
effective in eliminating existing mycoplasma infections given a longer duration, optimum 
dose or a second booster immunization. In future studies, the use of a quantitative 
technique such as real-time PCR to determine the bacterial load during vaccination trials 
may be advantageous. 
Although not statistically significant, the weight of the pCI-neo_oppA and VR1020_oppA 
vaccine groups increased while that of VR1012_oppA group decreased and the control 
group showed no change. Growth rate of birds is affected by many factors such as 
stress, nutrition, temperature fluctuations and diseases. Before the age of three months, 
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chicks were kept in small camps where chick numbers were low and they receive stimuli 
to encourage eating. At three months of age they were moved in to larger camps where 
there were a larger number of birds. In the new camps food ration as well as food and 
water bowls were different. The changes in social dynamic along with their housing 
environment result in birds being stressed and not eating sufficiently which can impact on 
growth. Ostriches are known to be severely affected by stress (Hoffman and Lambrechts 
2011) and during this adaption period retardation in weight gain and even weight loss in 
some case is therefore normal among farm ostriches. Furthermore stress is known to 
depress immune responses. This indicates that, in future trials, serious attention should 
be given to reducing stress. Ostriches have only been farmed intensively since about 
1860 and this may indicated that stress may play a major role in reducing immune 
responses in ostriches in general.  
Due to an outbreak of avian influenza, it was not possible to evaluate a secondary 
immune response during this study (the reader is referred to page 101 where the 
implications of an outbreak of avian influenza during this trial are outlined). This would 
have indicated whether or not the vaccinations had lead to immune memory. Further 
trials are now required to establish the optimal doses for immune memory and whether or 
not these vaccines will lead to protection against mycoplasma infections. 
In conclusion, this study developed three DNA vaccines using the oppA gene as vaccine 
candidate gene. These DNA vaccines were produced on large scale and used to 
immunize ostriches. The pCI-neo_oppA and VR1020_oppA vaccines elicited an immune 
response in the vaccinated ostriches which implies that the OppA protein was expressed 
in vivo. As antigen, the OppA protein was therefore sufficiently immunogenic to elicit a 
primary immune response. This is the first study that shown a DNA vaccine was capable 
of eliciting an immune response in ostriches. This study can therefore be viewed as the 
first step in the development of a DNA vaccine for the control of mycoplasma infections in 
ostriches.  
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Chapter 6  Conclusion 
Vaccines are one of the great achievements of modern medicine. The discovery of DNA 
vaccines, more than two decades ago, has opened a new economical and safe possibility 
for the treatment of diseases.  
This study set out to explore the genome of Mycoplasma nasistruthionis sp. nov. str. 
Ms03 in terms of its metabolic capacity (Chapter 3) and found that i) genome replication, 
cell division, RNA transcription, protein translation and glycolysis in Ms03 resembles that 
of the closely related Mycoplasma synoviae 53, ii) purine and pyrimidine metabolism is 
incomplete and de novo synthesis is not possible, iii) amino acid synthesis is mostly 
absent, with Ms03 only able to convert aspartate to asparagine and glycine to serine and 
iv) more importers than exporters were annotated owing to the lack of synthesis 
pathways in Ms03. This is typical for mycoplasmas that have parasitic life styles.  
This study was unable to generate a complete genome sequence for Ms03. Considering 
that 25.2 Mb of 454 sequencing data was used to assemble the Ms03 genome and that 
the genome size of the genus Mycoplasma ranges from 564 to 1 359 kbp, the coverage 
of the Ms03 genome would be about 25 times which should have been sufficient to 
generate a complete or near complete genome. The characteristics of the genome (A+T 
content as well as the occurrence of repeats and runs) and the technology used to 
sequence the genome (454 pyrosequencing in this case) influenced the assembly 
outcome. Two approaches to overcome this may be to generate data with longer read 
lengths (like PacBio) or to generate paired-end data. 
The KEGG pathways generated from the Ms03 genome annotation were comparable to 
that of M. synoviae 53 and the annotation mostly completed. The absence of some genes 
within pathways is, however, questionable since it would render the pathways 
incomplete. The incomplete genome sequence of the Ms03 genome could have resulted 
in some ORFs not being predicted by the annotation programs. Additionally ORFs may 
also have been truncated due to the incomplete genome sequence. Annotation of these 
truncated proteins would be complicated as some functional motifs may be located on the 
“missing” part of the sequence. A large number of genes were annotated as “hypothetical 
protein” implying that it was not possible to predict the function of these proteins due to a 
lack of evidence. A more comprehensive annotation may assign function to some of 
these hypothetical proteins and lead to the identification of some of the genes which 
absence is questionable. 
This study sought to identify and characterize the opp operon and associated oppA gene 
within the Ms03 genome and found that the Ms03 genome had two opp operons, 
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therefore two oppA genes and that each of the identified opp genes (A, B, C, D and F) 
had typical motifs associated with the respective function of the protein products in Opp 
transporters.  
Furthermore the prevalence of oppA genes as part of the oppBCDF operons within 
Mycoplasma species was evaluated (Chapter 4) and it was confirmed that the substrate-
binding domain is present in all species and therefore must play an essential part in 
oligopeptide transport. All mycoplasmas (except for hemoplasma) had one to three opp 
operons that could be divided into three types (Type A, B and C). Each type had unique 
InterPro and MEME domains and motifs which together with the phylogenetic analysis 
suggest a unique role that may be a strategy towards survival under different conditions. 
Ms03 had a Type A and a Type B opp operon, the Type A oppA was used as vaccine 
candidate gene. 
The Ms03 Type A oppA is a suitable vaccine candidate choice because:  
 The importers of the ATP-binding cassette (ABC) family are unique to plants, 
bacteria and archaea (Berntsson et al. 2010; Rice et al. 2014). This implies that no 
homologue of the sequence should be found in the ostrich. At the time this study 
was initiated the genome sequence of the ostrich was not available. It was however 
recently published and it was confirmed with a tBLASTx search that no homologues 
of the oppA gene were present in the ostrich genome (3).  
 OppA is located on the outer surface of the mycoplasma cell membrane 
(Chapter 4). 
 Oligopeptide import is an essential process in Ms03 as deducted from the lack of 
genes for amino acid synthesis in the Ms03 draft genome (Chapter 3). Additionally 
transposon mutagenesis studies in Mycoplasma genitalium and Mycoplasma 
pulmonis had found the oppA gene to be essential (Glass et al. 2006; French et al. 
2008). Furthermore the Mycoplasma hominis OppA protein not only acts as a 
substrate-binding protein but also possesses a cytoadherence function and has 
ecto-ATPase activity (Henrich et al. 1993; Hopfe and Henrich 2004). The M. 
hominis opp operon belongs to Type A.  
 The two OppA proteins of Ms03 only share 19.7% amino acid identity (Chapter 3). 
This along with the phylogenetic and other bioinformatic analyses suggest that 
each type of OppABCDF transporter should have a unique role (Chapter 4).  
Lastly the study aimed to develop and evaluate DNA vaccines containing the Ms03 Type 
A oppA gene for the treatment of Ms03 infections in ostriches and found that DNA 
vaccines were able to elicit a primary immune response in the ostriches. Due to an 
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outbreak of avian influenza only two sample points were included in the DNA vaccine trial 
which was unfortunate. As a result, a second booster vaccination was not possible which 
could have contributed positively to the vaccine study. However this study shown that, 
the use of DNA vaccines may be a viable approach for the control of mycoplasma 
infections in ostriches in future.  
In this dissertation, the first Ms03 draft genome and annotation was presented which 
contributed to our understanding of Ms03 as a miniature genetically independent 
bacterium. The analysis of the opp operons provides insight into the organization and 
relationships amongst oligopeptide transporters in Mycoplasma species. Three DNA 
vaccines were developed using the oppA gene as vaccine candidate gene. This is the 
first study to show that DNA vaccines are capable of eliciting an immune response in 
ostriches. 
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Appendix 1 A inventory of Mollicutes species with an available complete genome sequence and their 
genome characteristics 
Species Strain IMG Genome ID  
Release 
Date Host Name 
Genome 
Size  
Gene 
Count  GC  
CDS 
Count  CDS % 
rRNA 
Count 
tRNA 
Count 
w/o function 
prediction % 
Order: Acholeplasmatales             Family: Acholeplasmataceae                Genus: Acholeplasma 
Acholeplasma laidlawii PG-8A 641522601 01/08/2008   1 496 992 1 422 0.32 1 380 97.05 6 36 25.74 
Order: Acholeplasmatales             Family: Acholeplasmataceae                Genus: Candidatus Phytoplasma 
Aster yellows witches'-broom 
phytoplasma AY-WB 2606217303 10/03/2015 Plant: Lettuce 723 970 706 0.27 665 94.19 6 32 32.58 
Candidatus Phytoplasma 
australiense 
  642555117 01/12/2008   879 959 727 0.27 684 94.09 6 35 37.55 
NZSb11 2554235337 01/01/2014   959 779 1 155 0.27 1 114 96.45 6 35 45.97 
Candidatus Phytoplasma mali AT 642555118 01/12/2008   601 943 518 0.21 479 92.47 6 32 29.54 
Candidatus Phytoplasma solani 284/09 2558309089 26/02/2014   570 238 547 0.28 520 95.06 - 27 23.58 
Onion yellows phytoplasma OY-M 2606217364 10/03/2015   853 092 977 0.28 935 95.70 6 32 39.00 
Order: Entomoplasmatales           Family: Entomoplasmataceae                Genus: Mesoplasma 
Mesoplasma florum L1 2606217385 10/03/2015 Plant: Solidago 793 224 721 0.27 682 94.59 6 29 19.00 W37 2558309067 26/02/2014 Plant: Solidago 825 824 768 0.27 733 95.44 6 29 20.05 
Order: Entomoplasmatales           Family: Spiroplasmataceae                   Genus: Spiroplasma
Spiroplasma apis B31 2563366575 14/04/2014 1 160 554 1 030 0.28 998 96.89 3 29 30.39 
Spiroplasma chrysopicola DF-1 2554235371 01/01/2014 1 123 322 1 051 0.29 1 015 96.57 3 33 30.54 
Spiroplasma culicicola AES-1 2558860239 07/03/2014 Mosquito 1 175 131 1 103 0.26 1 071 97.10 3 29 32.64 
Spiroplasma diminutum CUAS-1 2554235383 01/01/2014 Mosquito 945 296 890 0.25 858 96.40 3 29 27.75 
Spiroplasma mirum SMCA 2558860251 07/03/2014 Rabbit tick 1 132 608 1 422 0.29 1 386 97.47 3 33 51.76 
Spiroplasma sabaudiense Ar-1343 2558860238 07/03/2014 Mosquito 1 075 953 967 0.30 931 96.28 6 30 30.40 
Spiroplasma syrphidicola EA-1 2554235381 01/01/2014 Hoverfly 1 107 344 1 044 0.29 1 009 96.65 3 32 31.99 
Spiroplasma taiwanense CT-1 2561511192 23/03/2014 Mosquito 1 086 278 1 093 0.24 1 061 97.07 3 29 39.98 
Order: Mycoplasmatales               Family: Mycoplasmataceae                   Genus: Mycoplasma
Candidatus Mycoplasma 
haemolamae Purdue 2521172720 01/02/2013 Alpaca 756 845 961 0.39 925 96.25 3 33 65.87 
Mycoplasma agalactiae 5632 2540341079 19/09/2013   1 006 702 866 0.30 825 95.27 6 34 20.67 PG2 646564553 01/08/2010   1 006 702 854 0.30 813 95.20 6 34 43.09 
Mycoplasma arthritidis 158L3-1 642555141 01/12/2008 Human 820 453 666 0.31 631 94.74 3 32 34.38 
Mycoplasma bovis 
CQ-W70 2576861438   Cattle 948 516 816 0.29 778 95.34 4 34 16.42 
Donetta PG45 649633071 01/07/2011 Cattle 1 003 404 806 0.29 765 94.91 6 34 14.27 
HB0801 2521172704 01/02/2013 Cattle 991 702 849 0.29 809 95.29 6 34 13.90 
Hubei-1 650716062 01/12/2011 Cattle 948 121 839 0.29 801 95.47 4 34 35.40 
Mycoplasma bovoculi M165/69 2558860179 07/03/2014 Cattle 760 240 625 0.28 591 94.56 3 30 18.40 
Mycoplasma californicum ST-6 2576861462   Cattle 793 841 672 0.31 635 94.49 6 31 19.94 
Mycoplasma capricolum ATCC 27343 2606217281 10/03/2015 Goat 1 010 023 875 0.24 835 95.43 6 30 22.74 
Mycoplasma conjunctivae HRC/581 644736392 01/12/2009 Sheep 846 214 725 0.29 691 95.31 3 29 42.62 
Mycoplasma crocodyli MP145 646564554 01/08/2010 Crocodile 934 379 731 0.27 689 94.25 6 34 25.58 
Mycoplasma cynos C142 2540341156 19/09/2013 Dog 998 123 891 0.26 883 99.10 8 - 26.15 
Mycoplasma fermentans JER 648028044 01/01/2011 Human 977 524 838 0.27 797 95.11 5 36 35.68 M64 649633072 01/07/2011 Human 1 118 751 1 091 0.27 1 050 96.24 5 36 43.54 
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Species Strain IMG Genome ID  
Release 
Date Host Name 
Genome 
Size  
Gene 
Count  GC  
CDS 
Count  CDS % 
rRNA 
Count 
tRNA 
Count 
w/o function 
prediction % 
Mycoplasma gallisepticum 
  2517093027 06/09/2012   986 257 809 0.32 771 95.30 6 32 20.02 
CA06_2006.052-5-2P 2517093024 06/09/2012   976 412 801 0.32 763 95.26 6 32 19.85 
F 646862333 01/08/2010   977 612 795 0.31 756 95.09 7 32 25.53 
NC06_2006.080-5-2P 2518645544 04/12/2012 House finch 938 869 782 0.32 744 95.14 6 32 19.95 
NC08_2008.031-4-3P 2517093025 06/09/2012   926 650 777 0.32 739 95.11 6 32 19.95 
NC95_13295-2-2P 2518645562 04/12/2012   953 989 792 0.32 754 95.20 6 32 20.33 
NY01_2001.047-5-1P 2518645563 04/12/2012   965 525 798 0.32 760 95.24 6 32 20.18 
R(high) 646862334 01/08/2010   1 012 027 805 0.31 766 95.16 7 32 24.97 
R(low) 2606217644 10/03/2015   1 012 800 826 0.31 788 95.40 4 32 25.30 
S6 2531839059 23/08/2013 Chicken 929 411 757 0.31 720 95.11 4 33 20.74 
VA94_7994-1-7P 2518645561 04/12/2012   964 110 805 0.32 767 95.28 6 32 20.50 
WI01_2001.043-13-2P 2518645557 04/12/2012   939 844 784 0.32 746 95.15 6 32 20.28 
Mycoplasma genitalium 
G37 2606217665 10/03/2015 Human 580 076 563 0.32 521 92.54 3 36 17.76 
M2288 2540341178 19/09/2013 Human 579 558 545 0.32 506 92.84 3 36 14.31 
M2321 2512564088 31/01/2014 Human 579 977 588 0.32 547 93.03 3 36 20.41 
M6282 2540341080 19/09/2013 Human 579 504 523 0.32 484 92.54 3 36 14.72 
M6320 2540341081 19/09/2013 Human 579 796 548 0.32 509 92.88 3 36 14.23 
Mycoplasma haemocanis Illinois 2511231066 28/02/2012 Dog 919 992 1 190 0.35 1 156 97.14 3 31 71.60 
Mycoplasma haemofelis Langford 1 649633073 01/07/2011 Cat 1 147 259 1 580 0.39 1 545 97.78 3 31 79.49 Ohio2 651053045 01/12/2011   1 155 937 1 561 0.39 1 527 97.82 3 31 78.99 
Mycoplasma hominis PG21, ATCC 23114 646311946 01/04/2010 Human 665 445 563 0.27 523 92.90 7 33 33.04 
Mycoplasma hyopneumoniae 
168 650377960 01/07/2011 Pig 925 576 728 0.28 695 95.47 3 30 15.25 
168-L 2554235345 01/01/2014 Pig 921 093 726 0.28 693 95.45 3 30 27.55 
232 2606217661 10/03/2015   892 758 713 0.29 677 94.95 3 30 30.43 
7422 2554235315 01/01/2014 Pig 898 495 711 0.29 677 95.22 3 30 27.29 
7448 2606217470 10/03/2015 Pig 920 079 722 0.28 686 95.01 3 30 29.92 
J 2606217353 10/03/2015   897 405 728 0.29 690 94.78 3 30 29.95 
Mycoplasma hyorhinis 
DBS 1050 2554235454 01/01/2014   837 447 782 0.26 749 95.78 3 30 21.61 
GDL-1 2511231163 28/02/2012   837 480 740 0.26 707 95.54 3 30 28.38 
HUB-1 648028045 01/01/2011 Pig 839 615 687 0.26 654 95.20 3 30 23.44 
MCLD 2512047042 23/03/2012   829 709 811 0.26 778 95.93 3 30 27.37 
SK76 2519103106     836 897 786 0.26 753 95.80 3 30 21.88 
Mycoplasma leachii 99/014/6 651053046 01/12/2011 Cattle 1 017 232 942 0.24 905 96.07 6 31 6.48 PG50 649633074 01/07/2011 Cattle 1 008 951 922 0.24 882 95.66 6 30 25.27 
Mycoplasma mobile 163K 637000180 01/12/2006   777 079 669 0.25 633 94.62 3 28 9.27 163K 2606217309 10/03/2015   777 079 688 0.25 655 95.20 3 28 21.80 
Mycoplasma mycoides 
95010 650716063 01/12/2011   1 155 838 959 0.24 922 96.14 6 30 27.84 
GM12 646862335 01/08/2010   1 084 586 868 0.24 830 95.62 6 30 18.89 
GM12 646862336 01/08/2010   1 089 202 870 0.24 832 95.63 6 30 18.97 
Gladysdale 648231714 01/01/2011   1 193 808 1 134 0.24 1 095 96.56 6 30 25.93 
PG1 2606217549 10/03/2015   1 211 703 1 178 0.24 1 138 96.60 6 30 29.37 
Mycoplasma ovis Michigan 2558309058 26/02/2014   702 511 886 0.32 851 96.05 4 31 62.19 
Mycoplasma parvum Indiana 2554235465 01/01/2014   564 395 616 0.27 582 94.48 3 31 49.84 
Mycoplasma penetrans HF-2 2606217263 10/03/2015 Human 1 358 633 1 075 0.26 1 038 96.56 3 30 27.53 
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Species Strain IMG Genome ID  
Release 
Date Host Name 
Genome 
Size  
Gene 
Count  GC  
CDS 
Count  CDS % 
rRNA 
Count 
tRNA 
Count  
w/o function 
prediction % 
Mycoplasma pneumoniae 
309 2511231209 28/02/2012 Human 817 176 749 0.40 707 94.39 3 36 17.89 
FH 648231715 01/01/2011 Human 811 088 670 0.40 629 93.88 3 36 31.94 
M129-B7 2606217423 10/03/2015 Human 816 394 796 0.40 753 94.60 3 37 27.39 
M29 2597489969 08/12/2014 Human 857 799 837 0.40 794 94.86 3 37 27.24 
Mycoplasma pulmonis UAB CTIP 2606217467 10/03/2015   963 879 789 0.27 753 95.44 4 29 24.84 
Mycoplasma putrefaciens KS1 2511231058 28/02/2012 Goat 832 603 724 0.27 686 94.75 6 30 21.69 Mput9231 2540341179 19/09/2013   859 996 746 0.27 709 95.04 6 30 27.21 
Mycoplasma suis Illinois 650716064 01/12/2011 Pig 742 431 879 0.31 844 96.02 3 32 62.80 KI_3806 2511231073 28/02/2012 Pig 709 270 844 0.31 809 95.85 3 32 62.56 
Mycoplasma synoviae 53 2606217384 10/03/2015   799 476 736 0.28 695 94.43 4 34 27.72 
Mycoplasma wenyonii Massachusetts 2517093037 06/09/2012 Cattle 650 228 687 0.34 652 94.91 3 32 50.22 
Order: Mycoplasmatales               Family: Mycoplasmataceae                     Genus: Ureaplasma 
Ureaplasma parvum   641522658 01/08/2008 Human 751 679 642 0.25 609 94.86 6 27 30.69 ATCC 700970 2606217444 10/03/2015 Human 751 719 656 0.25 617 94.05 6 30 27.59 
Ureaplasma urealyticum Western 643348586 01/04/2009 Human 874 478 679 0.26 646 95.14 6 27 31.08 
 
Data was downloaded from Integrated Microbial Genomes (IMG) system (http://www.jgi.doe.gov/) on 25 June 2015 
 
Summary of the above genomes 
Order Family Genus Number 
of 
Species
Number 
of 
Genome*
Genome 
Size 
Gene 
Count 
GC CDS 
count 
CDS % rRNA 
Count 
tRNA 
Count 
w/o function 
prediction % 
Acholeplasmatales Acholeplasmataceae Acholeplasma 1  1  1 497  1 422 0.32 1 380 97.05 6 36 25.74 
  Phytoplasma Candidatus 5  6  570-960  518-1 155 0.21-0.28 479-1 114 92.47-96.45 6 27-35 23.58-45.97 
Entomoplasmatales Entomoplasmataceae Mesoplasma 1 2 793-825 721-768 0.27 682-733 94.59-95.44 6 29 19.00-20.05 
 Spiroplasmataceae Spiroplasma 8 8 945-1 175 890-1 422 0.24-0.30 858-1 386 96.28-97.47 3-6 29-33 27.75-51.76 
Mycoplasmatales Mycoplasmataceae  Mycoplasma 30 71 564-1 359 523-1 580 0.24-0.40 506-1 545 92.54-99.10 3-8 28-37 6.48-79.49 
  Ureaplasma 2 3 752-874 642-679 0.25-0.26 609-646 94.05-95.14 6 27-30 27.59-31.08 
Class: Mollicutes 47 91 564-1 497 518-1 580 0.21-0.40 479-1 545 92.47-99.10 3-8 27-37 6.48-79.49 
* In many cases more than one strain of the same species had a complete genome sequence available  
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Appendix 2 Supplementary tables and figures for Chapter 3 
Supplementary Table 2.1 Contigs generated by the GS de novo assembler arrange from longest to shortest* 
Contig Length (bp) Number of reads Contig Length (bp) Number of reads 
contig00239 39354 4190 contig00083 4229 558 
contig00095 31157 2304 contig00206 4137 341 
contig00059 26529 2537 contig00144 4125 216 
contig00408 25616 1634 contig00343 4099 233 
contig00350 24392 2473 contig00427 4059 251 
contig00132 21804 1480 contig00198 3922 325 
contig00135 21012 1729 contig00204 3897 256 
contig00160 20872 2102 contig00088 3768 202 
contig00061 17129 2026 contig00255 3753 170 
contig00166 15961 819 contig00020 3618 211 
contig00051 15263 1508 contig00267 3155 229 
contig00316 14165 808 contig00433 3153 159 
contig00311 14034 1003 contig00155 3089 190 
contig00116 13910 923 contig00222 2966 110 
contig00353 13542 915 contig00067 2955 177 
contig00034 13149 631 contig00118 2906 155 
contig00161 13130 1297 contig00465 2859 231 
contig00180 12250 1026 contig00200 2856 214 
contig00098 12239 1315 contig00077 2780 298 
contig00013 11983 922 contig00097 2750 124 
contig00163 10933 816 contig00091 2742 180 
contig00142 10406 1062 contig00019 2724 119 
contig00177 10160 1298 contig00371 2712 310 
contig00070 10116 861 contig00085 2663 168 
contig00285 9874 463 contig00004 2638 385 
contig00148 9719 637 contig00189 2614 370 
contig00389 9507 909 contig00196 2344 45 
contig00191 9482 1026 contig00092 2248 327 
contig00075 9466 531 contig00048 2201 69 
contig00009 8637 1062 contig00322 2191 176 
contig00058 8088 508 contig00209 2171 67 
contig00068 7993 702 contig00257 2092 81 
contig00159 7930 691 contig00169 2078 107 
contig00011 7663 540 contig00175 2060 150 
contig00046 7436 298 contig00219 1999 53 
contig00130 7434 708 contig00474 1981 121 
contig00450 7396 353 contig00165 1978 1054 
contig00056 6932 222 contig00221 1944 79 
contig00284 6856 475 contig00007 1938 59 
contig00151 6529 740 contig00245 1892 181 
contig00052 6515 329 contig00038 1884 67 
contig00050 6462 388 contig00187 1859 60 
contig00014 6425 745 contig00253 1845 138 
contig00117 6219 348 contig00317 1811 460 
contig00212 6173 251 contig00185 1796 111 
contig00152 6137 571 contig00030 1731 56 
contig00006 6028 268 contig00018 1719 42 
contig00031 5819 479 contig00054 1677 221 
contig00262 5683 327 contig00251 1658 49 
contig00274 5663 641 contig00261 1601 70 
contig00258 5545 157 contig00381 1576 276 
contig00218 5293 298 contig00352 1545 75 
contig00467 5147 528 contig00190 1532 235 
contig00002 4807 161 contig00210 1514 52 
contig00364 4675 241 contig00233 1476 103 
contig00199 4521 253 contig00005 1419 64 
contig00237 4423 277 contig00432 1349 294 
contig00178 4323 250 contig00125 1317 65 
contig00133 4272 353 contig00357 1312 63 
contig00220 4231 235 contig00032 1276 56 
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Contig Length (bp) Number of reads Contig Length (bp) Number of reads 
contig00081 1219 313 contig00482 444 68 
contig00354 1182 85 contig00057 440 7 
contig00036 1176 97 contig00229 439 12 
contig00359 1176 276 contig00250 437 6 
contig00269 1153 58 contig00044 426 6 
contig00129 1133 181 contig00137 424 137 
contig00039 1124 39 contig00410 422 39 
contig00053 1122 14 contig00265 421 40 
contig00291 1089 74 contig00275 419 23 
contig00468 1055 54 contig00028 410 8 
contig00043 1050 20 contig00485 409 24 
contig00033 1004 26 contig00197 405 148 
contig00292 977 141 contig00490 405 18 
contig00186 926 88 contig00402 404 127 
contig00248 910 17 contig00386 398 233 
contig00042 897 17 contig00012 392 15 
contig00379 881 38 contig00158 392 98 
contig00146 846 17 contig00066 390 212 
contig00045 806 12 contig00141 387 145 
contig00041 805 24 contig00451 373 16 
contig00035 797 4 contig00367 370 174 
contig00241 796 23 contig00404 369 286 
contig00214 786 22 contig00243 367 18 
contig00182 778 18 contig00242 361 11 
contig00349 769 137 contig00103 358 13 
contig00208 768 26 contig00211 356 130 
contig00195 750 42 contig00266 353 10 
contig00368 733 132 contig00476 344 78 
contig00089 727 46 contig00104 342 15 
contig00079 726 345 contig00029 331 3 
contig00240 719 28 contig00150 331 32 
contig00156 705 171 contig00145 327 12 
contig00188 696 49 contig00127 325 53 
contig00207 687 22 contig00162 324 9 
contig00121 657 50 contig00399 320 4 
contig00510 643 84 contig00437 315 137 
contig00064 621 262 contig00430 308 113 
contig00037 617 11 contig00139 305 132 
contig00082 614 143 contig00015 297 15 
contig00179 607 136 contig00181 297 10 
contig00026 589 67 contig00331 295 36 
contig00078 582 255 contig00010 290 51 
contig00306 570 19 contig00469 290 33 
contig00049 561 25 contig00710 281 103 
contig00140 556 71 contig00143 278 12 
contig00264 547 56 contig00297 276 12 
contig00157 546 157 contig00080 275 175 
contig00047 540 5 contig00246 270 7 
contig00124 527 139 contig00496 266 64 
contig00084 515 84 contig00409 265 471 
contig00023 504 30 contig00477 263 42 
contig00205 500 60 contig00380 256 7 
contig00183 492 19 contig00238 252 3 
contig00016 488 18 contig00471 251 102 
contig00120 488 24 contig00351 242 112 
contig00055 474 11 contig00090 240 51 
contig00217 469 44 contig00119 235 12 
contig00027 467 9 contig00147 231 12 
contig00236 465 47 contig00279 229 30 
contig00001 462 34 contig00230 222 2 
contig00390 459 116 contig00472 221 18 
contig00405 453 204 contig00065 215 182 
contig00247 444 12 contig00268 214 13 
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Contig Length (bp) Number of reads Contig Length (bp) Number of reads 
contig00231 198 2 contig00716 136 74 
contig00176 198 54 contig00303 134 7 
contig00069 195 202 contig00022 132 11 
contig00101 190 26 contig00428 132 51 
contig00366 189 151 contig00076 132 39 
contig00460 188 6 contig00107 129 2 
contig00416 186 649 contig00192 140 280 
contig00270 183 172 contig00713 140 17 
contig00213 182 27 contig00168 127 29 
contig00415 181 6 contig00003 126 10 
contig00363 176 9 contig00707 126 7 
contig00324 173 65 contig00310 122 16 
contig00108 166 1432 contig00733 120 115 
contig00374 166 39 contig00714 120 20 
contig00711 165 203 contig00479 119 124 
contig00588 164 814 contig00730 118 1142 
contig00466 164 99 contig00260 116 30 
contig00344 162 3 contig00294 116 10 
contig00223 159 7 contig00216 113 13 
contig00226 154 2 contig00300 112 10 
contig00228 151 14 contig00376 110 29 
contig00328 151 44 contig00319 110 9 
contig00184 151 77 contig00330 108 1723 
contig00346 150 25 contig00272 108 32 
contig00295 149 160 contig00340 108 61 
contig00735 148 370 contig00273 106 5 
contig00128 146 94 contig00280 105 16 
contig00301 146 11 contig00715 103 258 
contig00480 146 97 contig00024 102 25 
contig00734 144 19 contig00481 102 58 
contig00335 142 7 contig00123 101 19 
contig00235 141 110 contig00731 101 103 
contig00400 141 6 contig00017 100 5 
contig00040 140 3 contig00448 100 452 
* Contigs from the final assemble with 25.2 Mb of 454 data 
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Supplementary Table 2.2 List of the IGS and RAST annotate genes gene within the Ms03 draft genome 
IGS RAST  
Gene_id Common_name Sym
bol1 
GO terms2 fmin3 fmax3 S4 TIGR_roles Gene_id Function Subsystem Start5 Stop5 S4 
mnas_1 hypothetical protein   GO:0008150, 
GO:0003674, 
GO:0005575 
28 157 + Unknown: General           
mnas_2 endonuclease/Exonucl
ease/phosphatase 
family protein 
    270 2244 + Unknown: Enzymes of 
unknown specificity 
peg.214 Membrane nuclease, 
lipoprotein 
- none - 271 2244 + 
mnas_3 hypothetical protein   GO:0008150, 
GO:0003674, 
GO:0005575 
2191 2392 + Unknown: General      
        peg.215 hypothetical protein - none - 2406 2287 - 
mnas_4 hypothetical protein   GO:0008150, 
GO:0003674, 
GO:0005575 
2457 3255 + Unknown: General peg.216 hypothetical protein - none - 2458 3255 + 
mnas_5 putative lipoprotein   GO:0008150, 
GO:0003674, 
GO:0016020 
3284 6431 - Cell envelope: Other peg.217 hypothetical protein - none - 6431 3285 - 
mnas_6 metallo-beta-lactamase 
superfamily protein 
    6674 8564 + Unknown: General 
Hypothetical  
peg.218 Ribonuclease J1 
(endonuclease and 5’ 
exonuclease) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: Ribonucleases in 
Bacillus 
6675 8564 + 
mnas_7 M42 glutamyl 
aminopeptidase family 
protein 
    8572 9652 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.219 Endo-1,4-beta-glucanase - none - 8573 9652 + 
mnas_8 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
9672 9909 + Unknown: Conserved peg.220 M. genitalium predicted 
coding region MG335.1 
- none - 9673 9909 + 
mnas_9 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
10188 10656 + Unknown: General           
mnas_10 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
10657 10990 + Unknown: General peg.221 hypothetical protein - none - 10658 10990 + 
mnas_11 Putative potassium 
uptake protein KtrB 
ktrB   11069 12809 + Transport and binding 
proteins: Unknown 
substrate 
peg.222 Potassium uptake protein, 
integral membrane 
component, KtrB 
- none - 11124 12809 + 
mnas_12 trkA-C domain protein ktrA   12815 13490 + Unknown: General 
Hypothetical 
peg.223 Trk system potassium uptake 
protein TrkA 
Category: Potassium 
metabolism 
Subcategory: Potassium 
metabolism 
Subsystem: Potassium 
homeostasis 
12816 13490 + 
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mnas_13 DNA gyrase, A subunit 
(EC 5.99.1.3) 
gyrA GO:0003916,
GO:0003918,
GO:0006265,
GO:0009330 
13588 16267 - DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.224 DNA gyrase subunit A  
(EC 5.99.1.3) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA 
topoisomerases, Type II, ATP-
dependent 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Resistance to 
antibiotics and toxic compounds 
Subsystem: Resistance to 
fluoroquinolones 
Subsystem: Cell Division 
Subsystem including YidCD 
16267 13589 - 
mnas_14 ribosomal large subunit 
pseudouridine 
synthase B  
(EC 5.4.99.22) 
rluB GO:0003723,
GO:0006364,
GO:0001522,
GO:0009982 
16366 17083 - Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate,  
Unknown: Enzymes of 
unknown specificity 
peg.225 Ribosomal large subunit 
pseudouridine synthase B 
(EC 4.2.1.70) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA pseudouridine 
syntheses 
17083 16367 - 
mnas_15 nicotinate 
(nicotinamide) 
nucleotide 
adenylyltransferase 
(EC 2.7.7.18) 
nadD GO:0000309,
GO:0004515,
GO:0005737,
GO:0009435 
17082 18165 - Biosynthesis of 
cofactors, prosthetic 
groups, and carriers: 
Pyridine nucleotides 
peg.226 Nicotinate-nucleotide 
adenylyltransferase (EC 
2.7.7.18) / Hydrolase (HAD 
superfamily), YqeK 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: NAD and NADP 
Subsystem: NAD and NADP 
cofactor biosynthesis global 
18165 17083 - 
mnas_16 Damage-repair DNA 
polymerase IV  
(EC 2.7.7.7) 
dinB    18170 19400 - DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.227 DNA polymerase IV  
(EC 2.7.7.7) 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial 
19400 18171 - 
mnas_17 nifU-like N terminal 
domain protein 
    19399 19810 - Unknown: General 
Hypothetical  
peg.228 Putative iron-sulfur cluster 
assembly scaffold protein for 
SUF system, SufE2 
- none - 19810 19400 - 
mnas_18 aminotransferase 
class-V family protein 
    19799 20963 - Unknown: Enzymes of 
unknown specificity 
peg.229 Cysteine desulfurase  
(EC 2.8.1.7),  
SufS subfamily 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: mnm5U34 
biosynthesis bacteria 
 
Category: Amino Acids and 
Derivatives 
Subcategory: Alanine, serine, 
and glycine 
Subsystem: Alanine 
biosynthesis 
20963 19800 - 
mnas_19 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
20969 21491 - Unknown: General peg.230 hypothetical protein - none - 21368 20970 - 
mnas_20 nusB family protein     21471 21954 - Unclassified: Role 
category not yet 
assigned 
peg.231 Transcription termination 
protein NusB 
Category: RNA Metabolism 
Subcategory: Transcription 
Subsystem: Transcription 
factors bacterial 
21954 21472 - 
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mnas_21 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
22078 23686 - Cell envelope: Other peg.232 hypothetical protein - none - 23686 22079 - 
mnas_22 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
23764 24154 - Unknown: General peg.233 hypothetical protein - none - 24154 23765 - 
mnas_23 translation elongation 
factor P 
efp GO:0003746,
GO:0005737,
GO:0006414 
24304 24868 + Protein synthesis: 
Translation factors 
peg.234 Translation elongation factor 
P 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
elongation factors bacterial 
24305 24868 + 
mnas_24 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
24867 25179 + Unknown: General peg.235 hypothetical protein - none - 24868 25179 + 
mnas_25 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
25178 25508 + Unknown: General peg.236 Expressed protein - none - 25521 26450 + 
mnas_26 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
25520 26450 + Cell envelope: Other           
mnas_27 putative nicotinate 
phosphoribosyltransfer
ase 
  GO:0008152,
GO:0003824,
GO:0004516,
GO:0016757,
GO:0019363,
GO:0004514,
GO:0016740,
GO:0009435 
26439 27447 + Cellular processes: 
Other,  
Unknown: Enzymes of 
unknown specificity 
peg.237 Nicotinate 
phosphoribosyltransferase 
(EC 2.4.2.11) 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: NAD and NADP 
Subsystem: NAD and NADP 
cofactor biosynthesis global 
26440 27447 + 
mnas_28 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
27517 28297 + Unknown: General peg.238 Mobile element protein - none - 27518 28297 + 
mnas_29 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
28310 29933 - Unknown: General peg.239 hypothetical protein - none - 29933 28311 - 
mnas_30 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
29898 33624 - Cell envelope: Other peg.240 hypothetical protein - none - 33624 29899 - 
mnas_31 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
33705 35799 - Unknown: General peg.241 hypothetical protein - none - 35799 33706 - 
mnas_32 peptidase M60-like 
family protein 
    35900 37121 - Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.242 Integral membrane protein 
(Rhomboid family) 
- none - 37118 35901 - 
mnas_33 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
37086 38961 - Unknown: General peg.243 hypothetical protein - none - 38961 37087 - 
mnas_34 DNA methylase family 
protein 
    39414 40404 + DNA metabolism: 
Restriction/modification
peg.414 Type III restriction-
modification system 
methylation subunit  
(EC 2.1.1.72) 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: Restriction-
Modification System 
39496 40404 + 
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mnas_35 putative type III 
restricction-modification 
system: methylase 
  GO:0003677,
GO:0032775,
GO:0008170,
GO:0016740,
GO:0032259,
GO:0006306,
GO:0009007 
40506 40806 + Cellular processes: 
Other,  
Unknown: Enzymes of 
unknown specificity 
peg.415 Type III restriction-
modification system 
methylation subunit  
(EC 2.1.1.72) 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: Restriction-
Modification System 
40507 40806 + 
mnas_36 DEAD/DEAH box 
helicase family protein 
    40807 43450 + Unknown: Enzymes of 
unknown specificity 
peg.416 Type III restriction-
modification system DNA 
endonuclease res  
(EC 3.1.21.5) 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: Restriction-
Modification System 
40808 43450 + 
mnas_37 helix-turn-helix family 
protein 
    43698 44694 + Regulatory functions: 
DNA interactions 
peg.417 Sucrose operon repressor 
ScrR, LacI family 
- none - 43720 44694 + 
mnas_38 Putative potassium 
channel protein 
    44758 45874 + Transport and binding 
proteins: Cations and 
iron carrying 
compounds 
peg.418 putative potassium channel 
protein 
- none - 44759 45874 + 
mnas_39 putative endonuclease 
4 
  GO:0003677,
GO:0006281,
GO:0008270,
GO:0005622,
GO:0008833 
45866 46694 + Cellular processes: 
Other,  
Unknown: Enzymes of 
unknown specificity 
peg.419 Endonuclease IV  
(EC 3.1.21.2) 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial 
45867 46694 + 
mnas_40 ribosomal protein L33 rpmG GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
46776 46929 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.420 LSU ribosomal protein L33p 
@ LSU ribosomal protein 
L33p, zinc-dependent 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
46777 46929 + 
mnas_41 metallopeptidase M24 
family protein 
    46989 48051 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.421 Aminopeptidase YpdF (MP-, 
MA-, MS-, AP-, NP- specific) 
Category: Protein Metabolism 
Subcategory: Protein 
degradation 
Subsystem: Protein 
degradation 
46990 48051 + 
mnas_42 prolyl aminopeptidase 
(EC 3.4.11.5) 
pip GO:0016804,
GO:0030163 
48034 48985 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.422 Proline iminopeptidase  
(EC 3.4.11.5) 
- none - 48035 48985 + 
mnas_43 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
49099 49483 - Unknown: Conserved      
mnas_44 tRNA-Asn      49170  49245  +  rna.15 tRNA-Asn-GTT - none - 49171 49242 + 
mnas_45  tRNA-Glu    49251  49327 +   rna.16 tRNA-Glu-TTC - none - 49252 49324 + 
mnas_46 tRNA-Val      49332 49408  +   rna.17 tRNA-Val-TAC - none - 49333 49405 + 
mnas_47 tRNA-Thr      49409  49485 +   rna.18 tRNA-Thr-TGT - none - 49410 49482 + 
mnas_48 tRNA-Leu      49520 49604  +   rna.19 tRNA-Leu-TAG - none - 49521 49601 + 
mnas_49 ECF-type riboflavin 
transporter, S 
component family 
protein 
    49839 50841 + Transport and binding 
proteins: Unknown 
substrate 
peg.423 Substrate-specific component 
FolT of folate ECF transporter
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: Folate and 
pterines 
Subsystem: Folate biosynthesis
49840 50841 + 
mnas_50 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
50851 53320 + Unknown: General peg.424 oligopeptide ABC transporter 
ATP-binding protein 
- none - 50852 53320 + 
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mnas_51 high affinity transport 
system p37 family 
protein 
    53466 54666 + Transport and binding 
proteins: Unknown 
substrate 
peg.425 High affinity transport system 
protein p37 precursor 
- none - 53467 54666 + 
mnas_52 Phosphate/phosphonat
e ABC transporter, 
ATP-binding protein  
(EC 3.6.3.28) 
PhnC    54667 55396 + Transport and binding 
proteins: Unknown 
substrate 
peg.426 ABC transporter ATP-binding 
protein 
- none - 54668 55396 + 
mnas_53 binding--dependent 
transport system inner 
membrane component 
family protein 
    55490 57062 + Transport and binding 
proteins: Unknown 
substrate 
peg.427 Transport system permease 
protein p69 
- none - 55389 57062 + 
mnas_54 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
57342 57462 - Unknown: General peg.428 hypothetical protein - none - 57462 57343 - 
mnas_55 subtilase family protein     57637 60025 - Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.429 hypothetical protein - none - 60025 57638 - 
mnas_56 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
60033 61671 - Cell envelope: Other peg.430 hypothetical protein - none - 61671 60034 - 
mnas_57 RNA polymerase beta 
subunit 
    62087 64340 + Transcription: DNA-
dependent RNA 
polymerase 
peg.431 DNA-directed RNA 
polymerase beta subunit  
(EC 2.7.7.6) 
Category: RNA Metabolism 
Subcategory: Transcription 
Subsystem: RNA polymerase 
bacterial 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Invasion and 
intracellular resistance 
Subsystem: Mycobacterium 
virulence operon involved in 
DNA transcription 
62088 65722 + 
mnas_58 DNA-directed RNA 
polymerase subunit 
beta  
(EC 2.7.7.6) 
rpoB   64459 65722 + Transcription: DNA-
dependent RNA 
polymerase 
          
mnas_59 DNA-directed RNA 
polymerase, beta' 
subunit  
(EC 2.7.7.6) 
rpoC GO:0000345,
GO:0003899,
GO:0006350 
65714 70202 + Transcription: DNA-
dependent RNA 
polymerase 
peg.432 DNA-directed RNA 
polymerase beta’; subunit  
(EC 2.7.7.6) 
Category: RNA Metabolism 
Subcategory: Transcription 
Subsystem: RNA polymerase 
bacterial 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Invasion and 
intracellular resistance 
Subsystem: Mycobacterium 
virulence operon involved in 
DNA transcription 
65715 70202 + 
mnas_60 dUTPase family protein     70296 70599 + Unclassified: Role 
category not yet 
assigned 
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mnas_61 excinuclease ABC 
subunit A  
(EC 3.1.25.-) 
uvrA GO:0006289,
GO:0009380,
GO:0009381 
70611 73044 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.504 Excinuclease ABC subunit A Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
UvrABC system 
70873 73044 + 
mnas_62 HPr(Ser) 
kinase/phosphatase 
(EC 2.7.1.-) 
hprK GO:0004674,
GO:0009401,
GO:0016791 
73096 74038 + Regulatory functions: 
Protein interactions,  
Signal transduction: 
PTS 
peg.505 HPr kinase/phosphorylase 
(EC 2.7.1.-) (EC 2.7.4.-) 
Category: Regulation and Cell 
signaling 
Subcategory: no subcategory 
Subsystem: HPr catabolite 
repression system 
73097 74038 + 
mnas_63 prolipoprotein 
diacylglyceryl 
transferase  
(EC 2.4.99.-) 
lgt GO:0008961,
GO:0009249,
GO:0016021 
74039 75065 + Protein fate: Protein 
modification and repair 
peg.506 Prolipoprotein diacylglyceryl 
transferase  
(EC 2.4.99.-) 
Category: Protein Metabolism 
Subcategory: Protein 
processing and modification 
Subsystem: Lipoprotein 
Biosynthesis 
74040 75065 + 
mnas_64 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
75106 79135 - Unknown: General peg.507 DNA helicase - none - 79135 75107 - 
mnas_65 AAA domain protein     79229 83915 - Unknown: General 
Hypothetical  
peg.508 DNA helicase - none - 83915 79230 - 
mnas_66 thioredoxin reductase  
(EC 1.8.1.9) 
trxB GO:0019430,
GO:0050660,
GO:0005737,
GO:0004791 
84164 85091 + Cellular processes: 
Other,  
Unknown: Enzymes of 
unknown specificity 
peg.509 Thioredoxin reductase  
(EC 1.8.1.9) 
Category: Sulfur Metabolism 
Subcategory: no subcategory 
Subsystem: Thioredoxin-
disulfide reductase 
84165 85091 + 
mnas_67 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
85115 86762 - Cell envelope: Other peg.510 hypothetical protein - none - 86363 85116 - 
mnas_68 subtilase family protein     86745 89082 - Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.511 hypothetical protein - none - 89082 86746 - 
mnas_69 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
89097 90441 - Cell envelope: Other peg.512 hypothetical protein - none - 90441 89098 - 
mnas_70 Transposase, IS4 
family 
    90710 92354 - Mobile and 
extrachromosomal 
element functions: 
Transposon functions 
peg.513 Mobile element protein - none - 92354 90711 - 
mnas_71 DNA polymerase III, 
alpha subunit, Gram-
positive type  
(EC 2.7.7.7) 
polC GO:0003887,
GO:0006260,
GO:0009360 
92549 96941 - DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.514 DNA polymerase III alpha 
subunit  
(EC 2.7.7.7) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
96941 92550 - 
mnas_72 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
97267 98905 - Unknown: General peg.579 hypothetical protein - none - 98905 97268 - 
mnas_73 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
99049 104383 + Unknown: Conserved peg.580 FIG00834693: hypothetical 
protein 
- none - 99086 104383 + 
mnas_74 bacterial extracellular 
solute-binding protein 
oppA   104397 107490 + Transport and binding 
proteins: Unknown 
substrate 
peg.581 Oligopeptide ABC transporter, 
periplasmic oligopeptide-
binding protein OppA  
(TC 3.A.1.5.1) 
Category: Membrane Transport 
Subcategory: ABC transporters 
Subsystem: ABC transporter 
oligopeptide (TC 3.A.1.5.1)  
104398 107490 + 
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mnas_75 Oligopeptide ABC 
transporter, permease 
protein (OppB) 
oppB   107493 108549 + Transport and binding 
proteins: Unknown 
substrate 
peg.582 Oligopeptide transport system 
permease protein OppB  
(TC 3.A.1.5.1) 
Category: Membrane Transport 
Subcategory: ABC transporters 
Subsystem: ABC transporter 
oligopeptide (TC 3.A.1.5.1)  
107494 108549 + 
mnas_76 Oligopeptide ABC 
transporter, permease 
protein (OppC) 
oppC   108552 109635 + Transport and binding 
proteins: Unknown 
substrate 
peg.583 Oligopeptide transport system 
permease protein OppC  
(TC 3.A.1.5.1) 
Category: Membrane Transport 
Subcategory: ABC transporters 
Subsystem: ABC transporter 
oligopeptide (TC 3.A.1.5.1)  
108553 109635 + 
mnas_77 oligopeptide/dipeptide 
ATP-binding protein 
oppD GO:0005524,
GO:0009898,
GO:0015440,
GO:0015833,
GO:0043190 
109640 110849 + Transport and binding 
proteins: Amino acids, 
peptides and amines 
peg.584 Oligopeptide transport ATP-
binding protein OppD  
(TC 3.A.1.5.1) 
Category: Membrane Transport 
Subcategory: ABC transporters 
Subsystem: ABC transporter 
oligopeptide (TC 3.A.1.5.1)  
109641 110849 + 
mnas_78 Oligopeptide ABC 
transporter, ATP-
binding protein OppF 
OppF   110850 112182 + Transport and binding 
proteins: Unknown 
substrate 
peg.585 Oligopeptide transport ATP-
binding protein OppF  
(TC 3.A.1.5.1) 
Category: Membrane Transport 
Subcategory: ABC transporters 
Subsystem: ABC transporter 
oligopeptide (TC 3.A.1.5.1)  
110851 112182 + 
mnas_79 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
112196 112457 + Unknown: General peg.586 hypothetical protein - none - 112197 112457 + 
mnas_80 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
113305 114154 - Transport and binding 
proteins: Unknown 
substrate,  
Unknown: Enzymes of 
unknown specificity 
peg.587 TsaC protein (YrdC domain) 
required for 
threonylcarbamoyladenosine 
t(6)A37 modification in tRNA 
- none - 114154 113306 - 
mnas_81 archaeal ATPase 
family protein 
    114282 114936 - Unknown: General 
Hypothetical  
peg.588 hypothetical protein - none - 114936 114283 - 
mnas_82 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
115097 117698 - Unknown: Conserved peg.589 hypothetical protein - none - 117659 115098 - 
mnas_83 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
117790 118237 + Cell envelope: Other           
mnas_84 ATP synthase A chain 
family protein 
atpB   118238 119045 + Energy metabolism: 
ATP-proton motive 
force interconversion 
peg.590 ATP synthase F0 sector 
subunit a 
- none - 118239 119045 + 
mnas_85 ATP synthase F0, C 
subunit  
(EC 3.6.3.14) 
atpE GO:0000276,
GO:0015986,
GO:0045263,
GO:0045264,
GO:0046933 
119062 119380 + Energy metabolism: 
ATP-proton motive 
force interconversion 
peg.591 ATP synthase F0 sector 
subunit c 
- none - 119063 119380 + 
mnas_86 ATP synthase F0, B 
subunit  
(EC 3.6.3.14) 
atpF GO:0000276,
GO:0015986,
GO:0045263,
GO:0045264,
GO:0046933 
119389 119947 + Energy metabolism: 
ATP-proton motive 
force interconversion 
peg.592 ATP synthase F0 sector 
subunit b  
(EC 3.6.3.14) 
- none - 119405 119947 + 
mnas_87 ATP synthase F1, delta 
subunit  
(EC 3.6.3.14) 
atpH GO:0000275,
GO:0015986,
GO:0045261,
GO:0045262,
GO:0046933 
119962 120511 + Energy metabolism: 
ATP-proton motive 
force interconversion 
peg.593 ATP synthase delta chain  
(EC 3.6.3.14) 
- none - 119963 120511 + 
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mnas_88 ATP synthase F1, 
alpha subunit  
(EC 3.6.3.14) 
atpA GO:0000275,
GO:0015986,
GO:0045261,
GO:0045262,
GO:0046933 
120511 122092 + Energy metabolism: 
ATP-proton motive 
force interconversion 
peg.594 ATP synthase alpha chain 
(EC 3.6.3.14) 
- none - 120512 122092 + 
mnas_89 ATP synthase family 
protein 
atpG   122094 122820 + Energy metabolism: 
ATP-proton motive 
force interconversion 
          
mnas_90 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
122820 124143 - Unknown: General           
mnas_91 protein yebR yebR   124152 124599 - Unclassified: Role 
category not yet 
assigned 
peg.1 Free methionine-(R)-sulfoxide 
reductase, contains GAF 
domain 
- none - 124599 124153 - 
mnas_92 lysine--tRNA ligase  
(EC 6.1.1.6) 
lysS GO:0004824,
GO:0005737,
GO:0006430 
124659 126129 - Protein synthesis: 
tRNA aminoacylation 
peg.2 Lysyl-tRNA synthetase (class 
II)  
(EC 6.1.1.6) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Lys 
126129 124660 - 
mnas_93 ABC transporter family 
protein 
    126266 127307 - Transport and binding 
proteins: Unknown 
substrate 
peg.3 ABC transporter ATP-binding 
protein 
- none - 127307 126267 - 
mnas_94 Putative ABC 
transporter permease 
protein 
    127308 135783 - Transport and binding 
proteins: Unknown 
substrate 
peg.4 ABC transporter permease 
protein 
- none - 135783 127309 - 
mnas_95 ATP-dependent zinc 
metalloprotease FtsH 
domain protein  
(EC 3.4.24.-) 
ftsH GO:0004222,
GO:0005524,
GO:0043934,
GO:0006950,
GO:0030428,
GO:0030163,
GO:0006508,
GO:0051301,
GO:0016021,
GO:0017111,
GO:0008270,
GO:0005886,
GO:0007049 
136009 138019 - Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate, 
Cellular processes: 
Adaptations to atypical 
conditions,  
Protein fate: Other,  
Unknown: Enzymes of 
unknown specificity 
peg.5 Cell division protein FtsH  
(EC 3.4.24.-) 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: Folate and 
pterines 
Subsystem: Folate biosynthesis 
cluster 
Subsystem: Cell division-
ribosomal stress proteins cluster 
138019 136010 - 
mnas_96 tRNA(Ile)-lysidine 
synthetase  
(EC 6.3.4.-) 
tilS GO:0006400,
GO:0016879 
138132 138987 - Protein synthesis: 
tRNA and rRNA base 
modification 
peg.6 tRNA(Ile)-lysidine synthetase 
(EC 6.3.4.19) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: tRNA processing 
 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: Folate and 
pterines 
Subsystem: Folate biosynthesis 
cluster 
Subsystem: Cell division-
ribosomal stress proteins cluster 
138987 138133 - 
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mnas_97 peptidyl-tRNA 
hydrolase  
(EC 3.1.1.29) 
pth GO:0004045,
GO:0006412 
138986 139544 - Protein synthesis: 
Other 
peg.7 Peptidyl-tRNA hydrolase  
(EC 3.1.1.29) 
Category: Dormancy and 
Sporulation 
Subcategory: no subcategory 
Subsystem: Sporulation-
associated proteins with broader 
functions 
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
termination factors bacterial 
 
Subsystem: Cell division-
ribosomal stress proteins cluster 
139544 138987 - 
mnas_98 AAA domain protein     139551 141768 - Unknown: General 
Hypothetical  
peg.8 RecD-like DNA helicase YrrC Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial RecBCD pathway 
141768 139552 - 
mnas_99 chromosomal 
replication initiator 
protein DnaA 
dnaA GO:0003677,
GO:0003688,
GO:0005524,
GO:0006270,
GO:0006275 
142050 143460 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.9 Chromosomal replication 
initiator protein DnaA 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
 
Subsystem: Cell Division 
Subsystem including YidCD 
142051 143460 + 
mnas_100 DNA polymerase III 
beta subunit, central 
domain protein  
(EC 2.7.7.7) 
dnaN   143607 144738 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.10 DNA polymerase III beta 
subunit  
(EC 2.7.7.7) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
 
Subsystem: Cell Division 
Subsystem including YidCD 
143608 144738 + 
mnas_101 S4 domain protein     144739 144946 + Unknown: General 
Hypothetical  
peg.11 FIG002958: hypothetical 
protein 
Subsystem: DNA replication 
cluster 1 
144740 144946 + 
mnas_102 DNA methylase family 
protein 
    145044 146124 + DNA metabolism: 
Restriction/modification
peg.12 Adenine specific DNA 
methyltransferase (HINFIM) 
- none - 145045 146124 + 
mnas_103 putative type-2 
restriction enzyme HinfI 
  GO:0016787,
GO:0009036,
GO:0009307,
GO:0004519,
GO:0004518 
146116 146911 + Cellular processes: 
Other,  
Unknown: Enzymes of 
unknown specificity 
peg.13 Type II restriction enzyme 
HinfI  
(EC 3.1.21.4)  
(Endonuclease HinfI) (R.HinfI)
- none - 146117 146911 + 
mnas_104 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
146990 147200 + Cell envelope: Other peg.14 hypothetical protein - none - 147187 146957 - 
mnas_105 2,3-
bisphosphoglycerate-
independent 
phosphoglycerate 
mutase  
(EC 5.4.2.1) 
    147256 148009 + Unknown: Enzymes of 
unknown specificity 
peg.61 2,3-bisphosphoglycerate-
independent 
phosphoglycerate mutase 
(EC 5.4.2.1) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Glycolysis and 
Gluconeogenesis 
 
Category: Miscellaneous 
Subcategory: -no subcategory 
Subsystem: Phosphoglycerate 
mutase protein family 
147371 148009 + 
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mnas_106 integral membrane 
family protein 
    148120 149113 + Cell envelope: Other peg.62 hypothetical protein - none - 148121 149113 + 
mnas_107 D-lactate 
dehydrogenase  
(EC 1.1.1.28) 
ldhA GO:0008720,
GO:0006950,
GO:0009236,
GO:0051287,
GO:0008939 
149269 150307 + Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate,  
Cellular processes: 
Adaptations to atypical 
conditions,  
Unknown: Enzymes of 
unknown specificity 
peg.63 D-lactate dehydrogenase  
(EC 1.1.1.28) 
Category: Carbohydrates 
Subcategory: Fermentation 
Subsystem: Fermentations: 
Lactate 
149270 150307 + 
mnas_108 major intrinsic family 
protein 
    150299 151364 + Unclassified: Role 
category not yet 
assigned 
peg.64 Aquaporin Z Category: Stress Response 
Subcategory: Osmotic stress 
Subsystem: Osmoregulation  
150300 151364 + 
mnas_109 S1 RNA binding 
domain protein 
    151475 153614 + Unknown: General 
Hypothetical  
peg.65 Transcription accessory 
protein (S1 RNA-binding 
domain) 
Category: RNA Metabolism 
Subcategory: Transcription 
Subsystem: Transcription 
factors bacterial 
Subsystem: Cell division-
ribosomal stress proteins cluster 
151476 153614 + 
mnas_110 tRNA-Gln      153820 153745  -   rna.3 tRNA-Gln-TTG - none - 153820 153749 - 
mnas_111  tRNA-Tyr      153909 153825 -   rna.4 tRNA-Tyr-GTA - none - 153909 153829 - 
mnas_112 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
154014 154989 + Cell envelope: Other peg.66 hypothetical protein - none - 154015 154989 + 
mnas_113 ribulose-phosphate 3 
epimerase family 
protein 
    155012 155678 - Unknown: Enzymes of 
unknown specificity 
peg.67 Ribulose-phosphate 3-
epimerase  
(EC 5.1.3.1) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Pentose phosphate 
pathway 
Subsystem: Conserved gene 
cluster associated with Met-
tRNA formyltransferase 
155678 155013 - 
mnas_114 ribosome small 
subunit-dependent 
GTPase A  
(EC 3.6.-.-) 
rsgA GO:0005525,
GO:0006412,
GO:0043022 
155677 156526 - Protein synthesis: 
Translation factors 
peg.68 Ribosome small subunit-
stimulated GTPase EngC 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
156526 155678 - 
mnas_115 phosphotransferase 
enzyme family protein 
    156525 157521 - Unknown: Enzymes of 
unknown specificity 
peg.69 Serine/threonine protein 
kinase PrkC, regulator of 
stationary phase 
Subsystem: Conserved gene 
cluster associated with Met-
tRNA formyltransferase 
157521 156526 - 
mnas_116 phosphatase 2C family 
protein 
    157507 158287 - Unknown: Enzymes of 
unknown specificity 
peg.70 Protein serine/threonine 
phosphatase PrpC, regulation 
of stationary phase 
Subsystem: Conserved gene 
cluster associated with Met-
tRNA formyltransferase 
158287 157508 - 
mnas_117 guanylate kinase  
(EC 2.7.4.8) 
gmk GO:0004385,
GO:0015949 
158276 158891 - Purines, pyrimidines, 
nucleosides, and 
nucleotides: Nucleotide 
and nucleoside 
interconversions 
peg.71 Guanylate kinase  
(EC 2.7.4.8) 
Category: Nucleosides and 
Nucleotides 
Subcategory: Purines 
Subsystem: Purine conversions
158891 158277 - 
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mnas_118 tRNA 
pseudouridine(55) 
synthase  
(EC 5.4.99.25) 
truB GO:0004730,
GO:0006400,
GO:0016870 
159005 159848 + Protein synthesis: 
tRNA and rRNA base 
modification 
peg.72 tRNA pseudouridine synthase 
B  
(EC 4.2.1.70) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA pseudouridine 
syntheses 
Subsystem: tRNA processing 
 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: Riboflavin, FMN, 
FAD 
Subsystem: Riboflavin, FMN 
and FAD metabolism in plants 
159006 159848 + 
mnas_119 HAD hydrolase, IIB 
family protein 
  GO:0008152,
GO:0016787 
159847 160666 + Unknown: Enzymes of 
unknown specificity 
peg.73 FIG00834275: hypothetical 
protein 
- none - 159848 160666 + 
mnas_120 FAD synthetase family 
protein 
    160665 161508 + Unknown: Enzymes of 
unknown specificity 
peg.74 Riboflavin kinase  
(EC 2.7.1.26) / FMN 
adenylyltransferase  
(EC 2.7.7.2) 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: Riboflavin, FMN, 
FAD 
Subsystem: Riboflavin, FMN 
and FAD metabolism in plants 
Subsystem: Riboflavin, FMN 
and FAD metabolism in plants 
Subsystem: Riboflavin to FAD 
Subsystem: Riboflavin to FAD 
Subsystem: Riboflavin, FMN 
and FAD metabolism 
Subsystem: Riboflavin, FMN 
and FAD metabolism 
160666 161508 + 
mnas_121 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
161659 164827 + Cell envelope: Other peg.75 no similarity found Pfscan: 
pos. 16-26 PS00013 | 
PROKAR_LIPOPROTEIN 
Prokaryotic membrane 
lipoprotein lipid attachment 
site 
- none - 161660 164827 + 
mnas_122 ribosomal protein S15 rpsO GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
164971 165238 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.76 SSU ribosomal protein S15p 
(S13e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
164972 165238 + 
mnas_123 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
165357 165678 + Unknown: General peg.77 hypothetical protein - none - 165358 165678 + 
mnas_124 DAK2 domain fusion 
YloV family protein 
    165670 167311 + Unknown: General 
Hypothetical  
peg.78 Dihydroxyacetone kinase 
family protein 
Category: Fatty Acids, Lipids, 
and Isoprenoids 
Subcategory: Phospholipids 
Subsystem: Glycerolipid and 
Glycerophospholipid Metabolism 
in Bacteria 
165671 167311 + 
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mnas_125 fatty acid/phospholipid 
synthesis protein PlsX 
plsX GO:0003824,
GO:0008610 
167310 168321 + Fatty acid and 
phospholipid 
metabolism: 
Biosynthesis 
peg.79 Phosphate:acyl-ACP 
acyltransferase PlsX 
Category: Fatty Acids, Lipids, 
and Isoprenoids 
Subcategory: Phospholipids 
Subsystem: Glycerolipid and 
Glycerophospholipid Metabolism 
in Bacteria 
167311 168321 + 
mnas_126 ribonuclease III  
(EC 3.1.26.3) 
rnc GO:0004525,
GO:0006396 
168313 169006 + Transcription: RNA 
processing 
peg.80 Ribonuclease III  
(EC 3.1.26.3) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA processing 
and degradation, bacterial 
168314 169006 + 
mnas_127 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
169088 169754 - Unknown: General           
mnas_128 tRNA sulfurtransferase 
ThiI  
(EC 2.8.1.4) 
thiI GO:0003824,
GO:0006400,
GO:0009228 
169746 170895 - Biosynthesis of 
cofactors, prosthetic 
groups, and carriers: 
Thiamine,  
Protein synthesis: 
tRNA and rRNA base 
modification 
peg.118 tRNA S(4)U 4-thiouridine 
synthase (former ThiI) 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: Cofactors, 
Vitamins, Prosthetic Groups, 
Pigments - no subcategory 
Subsystem: Thiamin 
biosynthesis 
170895 169747 - 
mnas_129 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
170884 172480 - Unknown: General peg.119 DNA double-strand break 
repair Rad50 ATPase 
- none - 172480 170885 - 
mnas_130 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
172691 173186 + Unknown: General peg.120 hypothetical protein - none - 172584 173186 + 
mnas_131 HAD hydrolase, IIB 
family protein 
  GO:0008152,
GO:0016787 
173197 174184 - Unknown: Enzymes of 
unknown specificity 
peg.121 Hydrolase (HAD superfamily) - none - 174184 173198 - 
mnas_132 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
174240 174702 + Unknown: Conserved peg.122 predicted coding region - none - 174241 174702 + 
mnas_133 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
174701 175199 + Unknown: Conserved peg.123 hypothetical protein - none - 174994 174794 - 
                peg.124 hypothetical protein - none - 175032 175199 + 
mnas_134 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
175182 175566 + Unknown: Conserved peg.125 Expressed protein - none - 175183 175566 + 
mnas_135 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
176098 176542 + Unknown: General peg.126 hypothetical protein - none - 176099 176542 + 
mnas_136 nusA-like KH domain 
protein 
    176549 178202 + Unknown: General 
Hypothetical  
peg.127 Transcription termination 
protein NusA 
Category: RNA Metabolism 
Subcategory: Transcription 
Subsystem: Transcription 
factors bacterial 
Subsystem: NusA-TFII Cluster 
176550 178202 + 
mnas_137 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
178185 178473 + Unknown: Conserved peg.128 hypothetical protein - none - 178186 178473 + 
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mnas_138 translation initiation 
factor IF-2 
infB GO:0003743,
GO:0005737,
GO:0006413 
178456 179602 + Protein synthesis: 
Translation factors 
peg.129 Translation initiation factor 2 Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
initiation factors bacterial 
Subsystem: NusA-TFII Cluster 
178457 180291 + 
mnas_139 translation-initiation 
factor 2 family protein 
    179643 180291 + Protein synthesis: 
Translation factors,  
Disrupted reading 
frame: NULL 
          
mnas_140 adenine 
phosphoribosyltransfer
ase  
(EC 2.4.2.7) 
apt GO:0003999,
GO:0005737,
GO:0006166 
180290 180797 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Salvage of 
nucleosides and 
nucleotides 
peg.130 Adenine 
phosphoribosyltransferase 
(EC 2.4.2.7) 
Category: Nucleosides and 
Nucleotides 
Subcategory: Purines 
Subsystem: Purine conversions
180291 180797 + 
mnas_141 ribosomal protein L1 rplA GO:0000311,
GO:0003735,
GO:0006412,
GO:0022625 
180893 181589 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.131 LSU ribosomal protein L1p 
(L10Ae) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
 
181589 180894 - 
mnas_142 ribosomal protein L11 rplK GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
181588 182179 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.132 LSU ribosomal protein L11p 
(L12e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
 
Subsystem: LSU ribosomal 
proteins cluster 
182179 181589 - 
mnas_143 LMP repeated region 
family protein 
    182519 183395 + Unclassified: Role 
category not yet 
assigned 
peg.133 VlhA.4.04 - none - 182520 183395 + 
mnas_144 Putative Beta-
galactosidase 
    183431 186473 - Unknown: General 
Hypothetical  
peg.134 Beta-galactosidase  
(EC 3.2.1.23) 
Category: Carbohydrates 
Subcategory: Di- and 
oligosaccharides 
Subsystem: Lactose utilization 
 
Category: Sulfur Metabolism 
Subcategory: no subcategory 
Subsystem: 
Galactosylceramide and 
Sulfatide metabolism 
186473 183432 - 
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mnas_145 beta-galactosidase 
domain protein  
(EC 3.2.1.23 
bgaA
2 
GO:0016020,
GO:0008152,
GO:0003824,
GO:0016798,
GO:0009986,
GO:0043169,
GO:0004553,
GO:0016787,
GO:0004565,
GO:0005618,
GO:0005975 
186593 186770 - Energy metabolism: 
Sugars, 
Transport and binding 
proteins: Unknown 
substrate, 
Disrupted reading 
frame: NULL, 
Unknown: Enzymes of 
unknown specificity 
peg.135 hypothetical protein - none - 186770 186594 - 
mnas_146 beta-galactosidase 
domain protein  
(EC 3.2.1.23) 
bgaA GO:0016020,
GO:0008152,
GO:0003824,
GO:0016798,
GO:0009986,
GO:0043169,
GO:0004553,
GO:0016787,
GO:0004565,
GO:0005618,
GO:0005975 
186883 187102 - Energy metabolism: 
Sugars, 
Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
peg.136 Beta-galactosidase  
(EC 3.2.1.23) 
Category: Carbohydrates 
Subcategory: Di- and 
oligosaccharides 
Subsystem: Lactose utilization 
 
Category: Sulfur Metabolism 
Subcategory: no subcategory 
Subsystem: 
Galactosylceramide and 
Sulfatide metabolism 
187102 186884 - 
mnas_147 glycosyl hydrolases 
family 2, sugar binding 
domain protein 
    187112 189515 - Unknown: Enzymes of 
unknown specificity 
peg.137 Beta-galactosidase  
(EC 3.2.1.23) 
Category: Carbohydrates 
Subcategory: Di- and 
oligosaccharides 
Subsystem: Lactose utilization 
 
Category: Sulfur Metabolism 
Subcategory: no subcategory 
Subsystem: 
Galactosylceramide and 
Sulfatide metabolism 
189515 187113 - 
mnas_148 ABC transporter family 
protein 
    189740 190124 - Transport and binding 
proteins: Unknown 
substrate 
peg.138 Lipid A export ATP-
binding/permease protein 
MsbA 
- none - 190100 189741 - 
mnas_149 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
190132 190285 - Unknown: General           
mnas_150 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
190495 200602 + Unknown: General peg.157 Putative peptidoglycan bound 
protein (LPXTG motif) 
Lmo1799 homolog 
- none - 190496 200602 + 
mnas_151 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
200893 204526 + Unknown: General peg.158 Exonuclease SbcC Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial 
200894 204526 + 
mnas_152 type I restriction-
modification system, M 
subunit  
(EC 2.1.1.72) 
hsdM GO:0006306,
GO:0009007,
GO:0009307,
GO:0015666 
204706 205987 + DNA metabolism: 
Restriction/modification
peg.159 Type I restriction-modification 
system, DNA-
methyltransferase subunit M 
(EC 2.1.1.72) 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: Type I Restriction-
Modification 
Subsystem: Restriction-
Modification System 
204707 206292 + 
mnas_153 N-6 DNA Methylase 
family protein 
    205944 206292 + Unknown: Enzymes of 
unknown specificity 
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mnas_154 type I restriction 
modification DNA 
specificity domain 
protein 
    206314 207580 + DNA metabolism: 
Restriction/modification
peg.160 Type I restriction-modification 
system, specificity subunit S 
(EC 3.1.21.3) 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: Type I Restriction-
Modification 
Subsystem: Restriction-
Modification System 
206315 207580 + 
mnas_155 type I restriction 
modification DNA 
specificity domain 
protein 
    207533 208235 + DNA metabolism: 
Restriction/modification
peg.161 Type I restriction-modification 
system, specificity subunit S 
(EC 3.1.21.3) 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: Type I Restriction-
Modification 
Subsystem: Restriction-
Modification System 
207534 208235 + 
mnas_156 type I site-specific 
deoxyribonuclease, 
HsdR family protein 
(EC 3.1.21.3) 
hsdR GO:0009035,
GO:0009307,
GO:0019812 
208238 211040 + DNA metabolism: 
Restriction/modification
          
mnas_157 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
211050 212709 + Unknown: General peg.182 massive surface protein MspF - none - 211366 212709 + 
mnas_158 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
212867 212987 + Unknown: General peg.183 hypothetical protein - none - 212868 212987 + 
mnas_159 DNA polymerase III, 
subunit gamma and tau 
(EC 2.7.7.7) 
dnaX GO:0003887,
GO:0006260,
GO:0009360 
213184 215344 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.184 DNA polymerase III subunits 
gamma and tau  
(EC 2.7.7.7) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
 
Subcategory: DNA uptake, 
competence 
Subsystem: DNA processing 
cluster 
213185 215344 + 
mnas_160 DNA-binding protein, 
YbaB/EbfC family 
  GO:0003677,
GO:0005737,
GO:0008150 
215353 215638 + Unknown: Conserved peg.185 FIG000557: hypothetical 
protein co-occurring with 
RecR 
Category: DNA Metabolism 
Subcategory: DNA uptake, 
competence 
Subsystem: DNA processing 
cluster 
215354 215638 + 
mnas_161 recR family protein     215637 216222 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.186 Recombination protein RecR Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
 
Subcategory: DNA uptake, 
competence 
Subsystem: DNA processing 
cluster 
215638 216222 + 
mnas_162 thymidylate kinase  
(EC 2.7.4.9) 
tmk GO:0004798,
GO:0015949 
216239 216896 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Nucleotide 
and nucleoside 
interconversions 
peg.187 Thymidylate kinase  
(EC 2.7.4.9) 
- none - 216240 216896 + 
mnas_163 Putative DNA 
polymerase III, delta' 
subunit  
(EC 2.7.7.7) 
holB   216882 217782 + Unknown: General 
Hypothetical  
peg.188 DNA polymerase III delta 
prime subunit  
(EC 2.7.7.7) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
216883 217782 + 
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mnas_164 tetrapyrrole 
(Corrin/Porphyrin) 
Methylases family 
protein 
    217774 218506 + Unknown: Enzymes of 
unknown specificity 
peg.189 rRNA small subunit 
methyltransferase I 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: 16S rRNA 
modification within P site of 
ribosome 
 
Category: Stress Response 
Subcategory: Heat shock 
Subsystem: Heat shock dnaK 
gene cluster extended 
217775 218506 + 
mnas_165 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
218495 219779 + Unknown: General peg.190 hypothetical protein - none - 218496 219779 + 
mnas_166 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
219800 220277 - Unknown: Conserved peg.191 Protein yjgK - none - 220277 219801 - 
mnas_167 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
220343 222005 - Unknown: Conserved peg.192 Chromosome partition protein 
smc 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: DNA structural 
proteins, bacterial 
222005 220344 - 
mnas_168 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
222372 222588 + Unknown: General peg.193 hypothetical protein - none - 222373 222588 + 
mnas_169 cytidylyltransferase 
family protein 
    222687 223755 - Fatty acid and 
phospholipid 
metabolism: 
Biosynthesis 
peg.194 Phosphatidate 
cytidylyltransferase  
(EC 2.7.7.41) 
Category: Fatty Acids, Lipids, 
and Isoprenoids 
Subcategory: Phospholipids 
Subsystem: Glycerolipid and 
Glycerophospholipid Metabolism 
in Bacteria 
223755 222688 - 
mnas_170 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
224286 225714 - Unknown: General peg.195 hypothetical protein - none - 225714 224287 - 
mnas_171 subtilase family protein     225911 227657 - Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.196 hypothetical protein - none - 227513 225912 - 
mnas_172 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
227599 228199 - Unknown: General peg.197 hypothetical protein - none - 228175 227600 - 
mnas_173 DNA topoisomerase 
family protein 
    228205 229624 - DNA metabolism: DNA 
replication, 
recombination, and 
repair 
          
mnas_174 ribosomal protein S6 rpsF GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
229809 230271 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.244 SSU ribosomal protein S6p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
229867 230271 + 
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mnas_175 single-stranded DNA-
binding family protein 
ssb GO:0003697,
GO:0006260,
GO:0006281,
GO:0006310,
GO:0006350 
230304 230943 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.245 Single-stranded DNA-binding 
protein 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial 
230305 230943 + 
mnas_176 ribosomal protein S18 rpsR GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
231029 231233 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.246 SSU ribosomal protein S18p 
@ SSU ribosomal protein 
S18p, zinc-independent 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
Subsystem: Ribosome SSU 
bacterial 
231030 231233 + 
mnas_177 tRNA (guanine-N(7)-)-
methyltransferase  
(EC 2.1.1.33) 
trmB GO:0006400,
GO:0008176 
231282 231891 - Protein synthesis: 
tRNA and rRNA base 
modification 
peg.247 tRNA (guanine46-N7-)-
methyltransferase  
(EC 2.1.1.33) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation 
231891 231283 - 
mnas_178 RNA 
methyltransferase, 
RsmD family  
(EC 2.1.1.-) 
  GO:0008168,
GO:0031167 
231951 232497 + Unknown: Enzymes of 
unknown specificity 
peg.248 16S rRNA (guanine(966)-
N(2))-methyltransferase  
(EC 2.1.1.171) ## SSU rRNA 
m(2)G966 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation 
231952 232497 + 
mnas_179 23S rRNA (uracil-5-)-
methyltransferase 
RumA  
(EC 2.1.1.-) 
rumA GO:0000154,
GO:0008649 
232484 233780 + Protein synthesis: 
tRNA and rRNA base 
modification 
peg.249 RNA methyltransferase, TrmA 
family 
- none - 232485 233780 + 
mnas_180 glycosyl transferase 2 
family protein 
    234006 235026 + Cell envelope: 
Biosynthesis and 
degradation of surface 
polysaccharides and 
lipopolysaccharides 
peg.250 Glycosyltransferase - none - 234007 235026 + 
mnas_181 RDD family protein     235025 235646 +   peg.251 predicted coding region - none - 235026 235646 + 
mnas_182 uvrD/REP helicase N-
terminal domain protein 
    235648 237832 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.252 ATP-dependent DNA helicase 
UvrD/PcrA 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial UvrD and related 
helicases 
235649 237832 + 
mnas_183 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
237834 239493 + Unknown: General peg.253 predicted coding region - none - 237835 239493 + 
mnas_184 EDD, DegV family 
domain protein 
  GO:0005575,
GO:0008150,
GO:0016740 
239605 240448 + Unknown: General 
Hypothetical  
peg.254 FIG00836191: hypothetical 
protein 
- none - 239456 240448 + 
mnas_185 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
240447 240690 + Unknown: General peg.255 hypothetical protein - none - 240448 240690 + 
mnas_186 CDP-diacylglycerol--
glycerol-3-phosphate 3-
phosphatidyltransferas
e  
(EC 2.7.8.5) 
pgsA GO:0008444,
GO:0008654 
240741 241395 - Fatty acid and 
phospholipid 
metabolism: 
Biosynthesis 
peg.256 CDP-diacylglycerol--glycerol-
3-phosphate 3-
phosphatidyltransferase  
(EC 2.7.8.5) 
Category: Fatty Acids, Lipids, 
and Isoprenoids 
Subcategory: Phospholipids 
Subsystem: Glycerolipid and 
Glycerophospholipid Metabolism 
in Bacteria 
241395 240742 - 
mnas_187 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
241378 241942 - Unknown: General peg.257 hypothetical protein - none - 241942 241379 - 
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mnas_188 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
241950 242274 - Unknown: Conserved peg.258 hypothetical protein - none - 242274 241951 - 
mnas_189 magnesium transporter mgtE GO:0015095,
GO:0015693 
242282 243617 - Transport and binding 
proteins: Cations and 
iron carrying 
compounds 
peg.259 Mg/Co/Ni transporter MgtE / 
CBS domain 
Category: Membrane Transport 
Subcategory: Cation 
transporters 
Subsystem: Magnesium 
transport 
243617 242283 - 
mnas_190 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
243694 243784 - Unknown: General           
mnas_191 disA bacterial 
checkpoint controller 
nucleotide-binding 
family protein 
    243785 244196 - Unclassified: Role 
category not yet 
assigned 
          
mnas_192 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
244214 244547 + Unknown: General peg.277 hypothetical protein - none - 244296 244547 + 
mnas_193 tRNA-Arg      244829 244752 -   rna.11 tRNA-Arg-TCT - none - 244829 244756 - 
mnas_194 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
245280 248232 + Unknown: General peg.278 Predicted cell-wall-anchored 
protein SasA (LPXTG motif) 
- none - 245281 248232 + 
mnas_195 GDSL-like 
Lipase/Acylhydrolase 
family protein 
    248502 258885 + Unknown: Enzymes of 
unknown specificity 
peg.279 hypothetical protein - none - 248524 258885 + 
mnas_196 cation transporting 
ATPase, family protein 
    258959 259481 - Transport and binding 
proteins: Unknown 
substrate 
peg.280 Lead, cadmium, zinc and 
mercury transporting ATPase 
(EC 3.6.3.3) (EC 3.6.3.5); 
Copper-translocating P-type 
ATPase  
(EC 3.6.3.4) 
Category: Membrane Transport 
Subcategory: Cation 
transporters 
Subsystem: Copper Transport 
System 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Resistance to 
antibiotics and toxic compounds 
Subsystem: Copper 
homeostasis 
259481 258960 - 
mnas_197 recombination O N 
terminal family protein 
    259497 259776 - Unclassified: Role 
category not yet 
assigned 
          
mnas_198 chaperone protein 
DnaJ 
dnaJ GO:0005515,
GO:0006457,
GO:0009408 
259848 260949 + Protein fate: Protein 
folding and stabilization
peg.291 Chaperone protein DnaJ Category: Protein Metabolism 
Subcategory: Protein folding 
Subsystem: Protein chaperones
 
Category: Stress Response 
Subcategory: Heat shock 
Subsystem: Heat shock dnaK 
gene cluster extended 
259849 260949 + 
mnas_199 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
260949 261324 + Unknown: Conserved peg.292 FIG000605: protein co-
occurring with transport 
systems (COG1739) 
- none - 260950 261324 + 
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mnas_200 cytosol aminopeptidase 
family, catalytic domain 
protein 
    261323 262694 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.293 Cytosol aminopeptidase 
PepA  
(EC 3.4.11.1) 
Category: Protein Metabolism 
Subcategory: Protein 
degradation 
Subsystem: Aminopeptidases 
(EC 3.4.11.-) 
261324 262694 + 
mnas_201 cytosol aminopeptidase 
family, catalytic domain 
protein 
    262702 264076 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.294 Cytosol aminopeptidase 
PepA  
(EC 3.4.11.1) 
Category: Protein Metabolism 
Subcategory: Protein 
degradation 
Subsystem: Aminopeptidases 
(EC 3.4.11.-) 
262703 264076 + 
mnas_202 peptidase S41 family 
protein 
    264139 266107 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.295 hypothetical protein - none - 264140 266107 + 
mnas_203 endonuclease I family 
protein 
    266153 267725 - Unknown: Enzymes of 
unknown specificity 
peg.296 Endonuclease I - none - 267725 266154 - 
mnas_204 HAD hydrolase, IIB 
family protein 
  GO:0008152,
GO:0016787 
267833 268661 - Unknown: Enzymes of 
unknown specificity 
peg.297 hypothetical protein - none - 268661 267834 - 
mnas_205 calcineurin-like 
phosphoesterase 
family protein 
    268775 271316 + Unknown: Enzymes of 
unknown specificity 
peg.299 5’-nucleotidase  
(EC 3.1.3.5) 
Category: Nucleosides and 
Nucleotides 
Subcategory: Purines 
Subsystem: Purine conversions
268959 271316 + 
                peg.298 hypothetical protein - none - 268999 268877 - 
mnas_206 ribosomal protein S12 rpsL GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
271479 271890 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.300 SSU ribosomal protein S12p 
(S23e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Invasion and 
intracellular resistance 
Subsystem: Mycobacterium 
virulence operon involved in 
protein synthesis (SSU 
ribosomal proteins) 
271480 271890 + 
mnas_207 ribosomal protein S7 rpsG GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
271950 272421 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.301 SSU ribosomal protein S7p 
(S5e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Invasion and 
intracellular resistance 
Subsystem: Mycobacterium 
virulence operon involved in 
protein synthesis (SSU 
ribosomal proteins) 
271951 272421 + 
mnas_208 translation elongation 
factor G 
fusA GO:0003746,
GO:0006414 
272433 273702 + Protein synthesis: 
Translation factors 
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mnas_209 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
273712 274435 + Unknown: General peg.308 hypothetical protein - none - 273743 274435 + 
                peg.309 hypothetical protein - none - 274609 274761 + 
mnas_210 preprotein translocase, 
SecE subunit 
secE GO:0005887,
GO:0015450,
GO:0043952 
274760 275003 + Protein fate:Protein and 
peptide secretion and 
trafficking 
peg.310 Preprotein translocase 
subunit SecE  
(TC 3.A.5.1.1) 
Subsystem: LSU ribosomal 
proteins cluster 
274761 275003 + 
mnas_211 KOW motif family 
protein 
    275027 275633 + Unclassified: Role 
category not yet 
assigned 
peg.311 Transcription antitermination 
protein NusG 
Category: RNA Metabolism 
Subcategory: Transcription 
Subsystem: Transcription 
factors bacterial 
Subsystem: LSU ribosomal 
proteins cluster  
275028 275633 + 
mnas_212 ABC-2 type transporter 
family protein 
    275685 276825 - Transport and binding 
proteins: Unknown 
substrate 
peg.312 ABC transporter, permease 
protein 
- none - 276825 275686 - 
mnas_213 ABC transporter family 
protein 
    276805 277750 - Transport and binding 
proteins: Unknown 
substrate 
peg.313 Methionine ABC transporter 
ATP-binding protein 
- none - 277750 276806 - 
mnas_214 tRNA-Trp      277866  277792 -   rna.13 tRNA-Trp-CCA - none - 277866 277796 - 
mnas_215 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
278060 278345 + Cell envelope: Other peg.314 hypothetical protein - none - 278061 278345 + 
mnas_216 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
278507 278636 + Unknown: General peg.315 hypothetical protein - none - 278508 278636 + 
mnas_217 50S ribosome-binding 
GTPase family protein 
    278781 279882 - Unknown: General 
Hypothetical  
peg.316 GTP-binding and nucleic 
acid-binding protein YchF 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
279882 278782 - 
mnas_218 HNH endonuclease 
family protein 
    279918 281205 - Unclassified: Role 
category not yet 
assigned 
peg.317 hypothetical protein - none - 281205 279919 - 
mnas_219 adenine-specific 
methyltransferase 
EcoRI family protein 
    281191 281860 - Unknown: Enzymes of 
unknown specificity 
peg.318 Phage protein - none - 281860 281192 - 
mnas_220 DNA (cytosine-5-)-
methyltransferase 
family protein  
(EC 2.1.1.37) 
dcm GO:0003886,
GO:0006304 
282059 283031 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.319 DNA-cytosine 
methyltransferase  
(EC 2.1.1.37) 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial 
282060 283031 + 
mnas_221 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
283064 283388 + Unknown: General peg.320 hypothetical protein - none - 283065 283388 + 
mnas_222 fic/DOC family protein     283395 284010 + Unclassified: Role 
category not yet 
assigned 
peg.321 hypothetical protein - none - 283396 284010 + 
mnas_223 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
284169 285819 + Unknown: General peg.322 predicted coding region - none - 284170 285819 + 
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mnas_224 histidine--tRNA ligase 
(EC 6.1.1.21) 
hisS GO:0004821,
GO:0005737,
GO:0006427 
285808 287191 + Protein synthesis: 
tRNA aminoacylation 
peg.323 Histidyl-tRNA synthetase  
(EC 6.1.1.21) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, His 
285809 287191 + 
mnas_225 OB-fold nucleic acid 
binding domain protein 
    287201 287780 + Unknown: General 
Hypothetical  
          
mnas_226 hemolysin C domain 
protein 
hlyC GO:0050660,
GO:0003824,
GO:0055114 
287782 288106 + Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
peg.333 hypothetical protein - none - 287891 288106 + 
mnas_227 Probable 
spermidine/putrescine/
ABC transporter 
substrate 
potD GO:0008150,
GO:0003674,
GO:0005575 
288456 290397 + Unknown: General peg.334 Probable 
spermidine/putrescine 
substrate binding protein in 
Mollicutes 
- none - 288508 290397 + 
mnas_228 ribosomal protein S20 rpsT GO:0000312,
GO:0003735,
GO:0006412,
GO:0022627 
290447 290708 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.335 SSU ribosomal protein S20p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
290448 290708 + 
mnas_229 thymidine kinase  
(EC 2.7.1.21) 
tdk GO:0046872,
GO:0005524,
GO:0006260,
GO:0004797,
GO:0005737 
290785 291346 - Cellular processes: 
Other, 
Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
peg.336 Thymidine kinase  
(EC 2.7.1.21) 
- none - 291346 290786 - 
mnas_230 sporulation Regulator 
WhiA C terminal 
domain protein 
    291364 292240 - Unknown: Conserved peg.337 FIG001886: Cytoplasmic 
hypothetical protein 
- none - 292231 291365 - 
mnas_231 translation initiation 
factor IF-3 
infC GO:0003743,
GO:0006413 
292734 293247 + Protein synthesis: 
Translation factors 
peg.338 Translation initiation factor 3 Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
initiation factors bacterial 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Invasion and 
intracellular resistance 
Subsystem: Mycobacterium 
virulence operon involved in 
protein synthesis (LSU 
ribosomal proteins) 
292735 293247 + 
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mnas_232 ribosomal protein L35 rpmI GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
293227 293416 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.339 LSU ribosomal protein L35p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Invasion and 
intracellular resistance 
Subsystem: Mycobacterium 
virulence operon involved in 
protein synthesis (LSU 
ribosomal proteins) 
293228 293416 + 
mnas_233 ribosomal protein L20 rplT GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
293473 293827 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.340 LSU ribosomal protein L20p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Invasion and 
intracellular resistance 
Subsystem: Mycobacterium 
virulence operon involved in 
protein synthesis (LSU 
ribosomal proteins) 
293474 293827 + 
mnas_234 DHHA1 domain protein     294264 295239 - Unknown: General 
Hypothetical  
peg.341 FIG146085: 3’-to-5’ 
oligoribonuclease A, Bacillus 
type 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA processing 
and degradation, bacterial 
295239 294265 - 
mnas_235 DHHA1 domain protein     295238 296201 - Unknown: General 
Hypothetical  
peg.342 FIG146085: 3’-to-5’ 
oligoribonuclease A, Bacillus 
type 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA processing 
and degradation, bacterial 
296201 295239 - 
mnas_236 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
296202 297330 - Unknown: General peg.343 hypothetical protein - none - 297330 296203 - 
mnas_237 HAD super, subIIIB 
family protein 
    297495 298860 + Unknown: Enzymes of 
unknown specificity 
peg.344 Multiple banded antigen - none - 297496 298860 + 
mnas_238 branched-chain amino 
acid transport system / 
permease component 
family protein 
    298946 299903 - Transport and binding 
proteins: Other 
peg.345 Unspecified monosaccharide 
ABC transport system, 
permease component 2 
- none - 299903 298947 - 
mnas_239 Putative sugar ABC 
transporter permease 
protein 
    299902 301714 - Transport and binding 
proteins: Other 
peg.346 Sugar ABC transporter, 
permease protein 
- none - 301636 299903 - 
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mnas_240 spermidine/putrescine 
ABC transporter 
permease PotB domain 
protein 
potB GO:0006810,
GO:0016021,
GO:0005886,
GO:0005215 
301718 302042 - Transport and binding 
proteins: Unknown 
substrate 
          
mnas_241 putative 
permidine/putrescine 
transport system ATP-
binding protein  
(EC 3.6.3.31) 
potA   302025 302700 - Transport and binding 
proteins: Unknown 
substrate 
peg.353 Putrescine transport ATP-
binding protein PotA  
(TC 3.A.1.11.1) 
- none - 303408 302026 - 
mnas_242 putative 
spermidine/putrescine 
import ATP-binding 
protein PotA 
  GO:0006810,
GO:0005524,
GO:0016820,
GO:0016787,
GO:0000166,
GO:0006200,
GO:0043190,
GO:0005886,
GO:0015417,
GO:0016887,
GO:0005215 
302678 303149 - Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate,  
Disrupted reading 
frame: NULL,  
Unknown: Enzymes of 
unknown specificity 
          
mnas_243 spermidine/putrescine 
import ATP-binding 
PotA domain protein 
(EC 3.6.3.31) 
potA GO:0006810,
GO:0005524,
GO:0016820,
GO:0016787,
GO:0000166,
GO:0006200,
GO:0017111,
GO:0043190,
GO:0005886,
GO:0015417,
GO:0016887,
GO:0005215 
303195 303408 - Cellular processes: 
Other, Transport and 
binding proteins:  
Unknown substrate,  
Disrupted reading 
frame: NULL,  
Unknown: Enzymes of 
unknown specificity 
          
mnas_244 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
303450 303588 - Unknown: General peg.354 hypothetical protein - none - 303588 303451 - 
mnas_245 DNA polymerase III, 
alpha subunit  
(EC 2.7.7.7) 
dnaE GO:0003887,
GO:0006260,
GO:0009360 
303755 306668 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.355 DNA polymerase III alpha 
subunit  
(EC 2.7.7.7) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
303756 306668 + 
mnas_246 Putative DNA 
polymerase I  
(EC 2.7.7.7) 
    306660 307536 + DNA metabolism: 
Degradation of DNA 
peg.356 DNA polymerase I  
(EC 2.7.7.7) 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA Repair Base 
Excision 
Subcategory: DNA replication 
Subsystem: DNA-replication 
306661 307536 + 
mnas_247 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
307811 308810 + Unknown: General peg.357 Helicase loader DnaB - none - 307812 308810 + 
mnas_248 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
308877 309813 + Unknown: General peg.358 Putative DNA helicase - none - 308878 309813 + 
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mnas_249 methionyl-tRNA 
formyltransferase  
(EC 2.1.2.9) 
fmt GO:0004479,
GO:0005737,
GO:0006431 
309803 310640 + Protein synthesis: 
tRNA aminoacylation 
peg.359 Methionyl-tRNA 
formyltransferase  
(EC 2.1.2.9) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
initiation factors bacterial 
Subsystem: Conserved gene 
cluster associated with Met-
tRNA formyltransferase 
309804 310640 + 
mnas_250 glyceraldehyde-3-
phosphate 
dehydrogenase, type I 
(EC 1.2.1.-) 
gap GO:0006094,
GO:0006096,
GO:0008943,
GO:0019682 
310772 311777 + Energy metabolism: 
Glycolysis/gluconeogen
esis 
peg.360 NAD-dependent 
glyceraldehyde-3-phosphate 
dehydrogenase  
(EC 1.2.1.12) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Glycolysis and 
Gluconeogenesis 
310773 311777 + 
mnas_251 tRNA uridine 5-
carboxymethylaminom
ethyl modification 
enzyme GidA 
gidA GO:0006400,
GO:0016740 
311865 313701 + Protein synthesis: 
tRNA and rRNA base 
modification 
peg.361 tRNA uridine 5-
carboxymethylaminomethyl 
modification enzyme GidA 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: mnm5U34 
biosynthesis bacteria 
Subsystem: Cell Division 
Subsystem including YidCD 
Subsystem: RNA modification 
and chromosome partitioning 
cluster  
311866 313701 + 
mnas_252 putative type II DNA 
modification enzyme 
  GO:0003677,
GO:0008168,
GO:0016740,
GO:0032259 
313720 314827 + Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate,  
Unknown: Enzymes of 
unknown specificity 
peg.362 putative type II DNA 
modification enzyme 
(methyltransferase) 
- none - 313721 314827 + 
mnas_253 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
314816 315296 + Unknown: General           
mnas_254 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
315304 315889 + Unknown: General peg.367 hypothetical protein - none - 315338 315889 + 
mnas_255 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
315891 316371 + Unknown: General peg.368 Phage excisionase - none - 3158141 316371 + 
mnas_256 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
316382 316541 - Unknown: General peg.369 hypothetical protein - none - 316541 316383 - 
mnas_257 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
316542 316881 - Unknown: General peg.370 hypothetical protein - none - 316881 316543 - 
mnas_258 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
316897 318844 - Unknown: General peg.371 massive surface protein 
MspJ’; 
- none - 318727 316898 - 
mnas_259 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
318845 320141 - Unknown: General peg.372 Phage protein - none - 320141 318846 - 
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mnas_260 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
320145 321108 - Unknown: General peg.373 Phage protein - none - 321108 320146 - 
mnas_261 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
321122 321608 - Unknown: General peg.374 Phage protein - none - 321608 321123 - 
mnas_262 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
321649 323716 - Unknown: General peg.375 Phage protein - none - 323716 321650 - 
mnas_263 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
323690 324881 - Unknown: General peg.376 Phage protein - none - 324881 323691 - 
mnas_264 putative marRP     324867 326547 - Unclassified: Role 
category not yet 
assigned 
peg.377 MarRP - none - 326547 324868 - 
mnas_265 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
326551 327529 - Unknown: General peg.378 hypothetical protein - none - 327529 326552 - 
mnas_266 dnaB-like helicase C 
terminal domain protein 
    327515 328475 - Unknown: General 
Hypothetical  
peg.379 Replicative DNA helicase 
(DnaB)  
(EC 3.6.4.12) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
328106 327516 - 
mnas_267 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
328489 329512 + Unknown: General peg.382 hypothetical protein - none - 328703 329512 + 
mnas_268 glycine--tRNA ligase 
(EC 6.1.1.14) 
glyS GO:0004820,
GO:0006426,
GO:0009345 
329639 330980 + Protein synthesis: 
tRNA aminoacylation 
peg.383 Glycyl-tRNA synthetase (EC 
6.1.1.14) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Gly 
329616 330980 + 
mnas_269 DNA primase  
(EC 2.7.7.-) 
dnaG GO:0003896,
GO:0006269 
331007 332948 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.384 DNA primase  
(EC 2.7.7.-) 
Category: Cell Division and Cell 
Cycle 
Subcategory: no subcategory 
Subsystem: Macromolecular 
synthesis operon 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
331008 332948 + 
mnas_270 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
332950 333211 + Unknown: General peg.385 hypothetical protein - none - 332951 333211 + 
mnas_271 RNA polymerase sigma 
factor, sigma-70 family 
protein 
rpoD   333300 334452 + Transcription: DNA-
dependent RNA 
polymerase 
peg.386 RNA polymerase sigma factor 
RpoD 
Category: RNA Metabolism 
Subcategory: Transcription 
Subsystem: Transcription 
initiation, bacterial sigma factors 
 
Category: Cell Division and Cell 
Cycle 
Subcategory: no subcategory 
Subsystem: Macromolecular 
synthesis operon 
333301 334452 + 
mnas_272 NIF3 family protein     334459 335239 + Unclassified: Role 
category not yet 
assigned 
peg.387 UPF0135 protein Bsu YqfO - none - 334460 335239 + 
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mnas_273 AAA ATPase, central 
region 
  GO:0005524,
GO:0017111 
335501 336722 + Transport and binding 
proteins: Unknown 
substrate,  
Unknown: Enzymes of 
unknown specificity 
peg.388 ATPase, AAA family - none - 335502 336722 + 
mnas_274 phenylalanine--tRNA 
ligase, alpha subunit 
(EC 6.1.1.20) 
pheS GO:0004826,
GO:0006432,
GO:0009328 
336721 337675 + Protein synthesis: 
tRNA aminoacylation 
peg.389 Phenylalanyl-tRNA 
synthetase alpha chain  
(EC 6.1.1.20) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Phe 
336722 337675 + 
mnas_275 uracil DNA glycosylase 
superfamily protein 
    337664 337904 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.390 Uracil-DNA glycosylase, 
family 1 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: Uracil-DNA 
glycosylase 
Subsystem: DNA Repair Base 
Excision 
337665 338322 + 
mnas_276 uracil DNA glycosylase 
superfamily protein 
    337980 338322 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
          
mnas_277 tRNA synthetase B5 
domain protein 
  GO:0004826,
GO:0006432 
338330 340490 + Protein synthesis: 
tRNA aminoacylation 
peg.391 Phenylalanyl-tRNA 
synthetase beta chain  
(EC 6.1.1.20) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Phe 
338331 340490 + 
mnas_278 serine 
hydroxymethyltransfera
se  
(EC 2.1.2.1) 
glyA   340489 341647 + Surface structures: 
Serine family,  
Biosynthesis of 
cofactors, prosthetic 
groups, and carriers: 
Folic acid,  
Purines, pyrimidines, 
nucleosides, and 
nucleotides: Nucleotide 
and nucleoside 
interconversions 
          
mnas_279 hsp70 family protein     341651 342440 - Protein fate: Protein 
folding and stabilization
          
mnas_280 grpE family protein     342528 343383 - Protein fate: Protein 
folding and stabilization
peg.393 Heat shock protein GrpE Category: Protein Metabolism 
Subcategory: Protein folding 
Subsystem: Protein chaperones
 
Category: Stress Response 
Subcategory: Heat shock 
Subsystem: Heat shock dnaK 
gene cluster extended 
343383 342529 - 
mnas_281 hrcA C terminal domain 
protein 
    343397 344435 - Unknown: General 
Hypothetical  
peg.394 Heat-inducible transcription 
repressor HrcA 
Category: Stress Response 
Subcategory: Heat shock 
Subsystem: Heat shock dnaK 
gene cluster extended 
344435 343398 - 
mnas_282 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
344704 346750 + Cell envelope: Other peg.395 massive surface protein 
MspC 
- none - 344705 346750 + 
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mnas_283 phosphocarrier protein 
HPr  
(EC 2.7.11.-) 
ptsH GO:0006355,
GO:0016301,
GO:0006351,
GO:0005351,
GO:0009401,
GO:0005737 
346838 347102 - Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate,  
Signal transduction: 
PTS,  
Unknown: Enzymes of 
unknown specificity 
peg.396 Phosphotransferase system, 
phosphocarrier protein HPr 
Category: Regulation and Cell 
signaling 
Subcategory: no subcategory 
Subsystem: HPr catabolite 
repression system 
347102 346839 - 
mnas_284 phospholipase D family 
protein 
    347174 348692 - Fatty acid and 
phospholipid 
metabolism: 
Degradation 
peg.397 Cardiolipin synthetase  
(EC 2.7.8.-) 
Category: Fatty Acids, Lipids, 
and Isoprenoids 
Subcategory: Phospholipids 
Subsystem: Cardiolipin 
synthesis 
Subsystem: Glycerolipid and 
Glycerophospholipid Metabolism 
in Bacteria 
348692 347175 - 
mnas_285 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
348732 348978 - Unknown: Conserved peg.398 hypothetical protein - none - 348978 348733 - 
mnas_286 Putative ribose-5-
phosphate isomerase 
(EC 5.3.1.6) 
    348980 349421 - Unknown: Enzymes of 
unknown specificity 
peg.399 Ribose 5-phosphate 
isomerase B  
(EC 5.3.1.6) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Pentose phosphate 
pathway 
349421 348981 - 
mnas_287 ABC transporter family 
protein 
    349525 351553 + Transport and binding 
proteins: Unknown 
substrate 
peg.400 ABC transporter atp-binding 
and permease protein (MDR 
homolog) 
- none - 349526 351553 + 
mnas_288 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
351584 351914 + Unknown: General peg.401 hypothetical protein - none - 351600 351914 + 
mnas_289 putative rRNA 
maturation factor YbeY 
  GO:0008150,
GO:0046872 
351954 352437 + Unknown: Conserved peg.402 Metal-dependent hydrolase 
YbeY, involved in rRNA 
and/or ribosome maturation 
and assembly 
- none - 351955 352437 + 
mnas_290 cytidine deaminase 
(EC 3.5.4.5) 
cdd GO:0004126,
GO:0005737,
GO:0008655 
352423 352822 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Salvage of 
nucleosides and 
nucleotides 
peg.403 Cytidine deaminase  
(EC 3.5.4.5) 
- none - 352424 352822 + 
mnas_291 GTP-binding protein 
Era 
era GO:0003924,
GO:0005525,
GO:0019843,
GO:0042254,
GO:0043022 
352823 353726 + Cellular processes: Cell 
division,  
Regulatory functions: 
RNA interactions 
peg.404 GTP-binding protein Era Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
352824 353726 + 
mnas_292 putative SPOUT 
methyltransferase 
family protein 
    353767 353929 - Unknown: Enzymes of 
unknown specificity 
          
mnas_293 ATP synthase 
alpha/beta family, 
nucleotide-binding 
domain protein 
    353957 354818 + Unknown: Enzymes of 
unknown specificity 
peg.405 ATP synthase alpha chain 
(EC 3.6.3.14) 
- none - 353958 354818 + 
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mnas_294 ATP synthase F1, beta 
subunit  
(EC 3.6.3.14) 
atpD GO:0000275,
GO:0015986,
GO:0045261,
GO:0045262,
GO:0046933 
354817 356179 + Energy metabolism: 
ATP-proton motive 
force interconversion 
peg.406 ATP synthase beta chain  
(EC 3.6.3.14) 
- none - 354818 356179 + 
mnas_295 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
356190 358470 + Unknown: Conserved peg.407 Prolipoprotein - none - 356191 358470 + 
mnas_296 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
358513 360538 - Cell envelope: Other peg.408 massive surface protein 
MspG 
- none - 360538 358514 - 
mnas_297 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
360673 362746 + Unknown: Conserved peg.409 FIG00833989: hypothetical 
protein 
- none - 360674 362746 + 
mnas_298 phosphotransferase 
enzyme family protein 
    362821 363574 + Unknown: Enzymes of 
unknown specificity 
peg.410 Choline kinase family - none - 362822 363574 + 
mnas_299 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
363701 363899 + Unknown: General peg.411 hypothetical protein - none - 363717 363899 + 
mnas_300 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
363888 364953 + Cell envelope: Other peg.412 hypothetical protein - none - 363889 364953 + 
mnas_301 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
365046 366111 + Cell envelope: Other peg.413 hypothetical protein - none - 365047 366111 + 
mnas_302 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
366212 366557 - Cell envelope: Other           
mnas_303 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
366761 368090 - Cell envelope: Other peg.433 hypothetical protein - none - 368090 366762 - 
mnas_304 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
368166 377586 + Unknown: General peg.434 Putative peptidoglycan bound 
protein (LPXTG motif) 
Lmo1799 homolog 
- none - 368242 377586 + 
mnas_305 ribonuclease HII family 
protein 
    378227 378746 - Transcription: 
Degradation of RNA 
          
mnas_306 phosphorylase 
superfamily protein 
    377758 378235 + Unclassified: Role 
category not yet 
assigned 
peg.435 HMP-PP hydrolase (pyridoxal 
phosphatase) Cof, detected in 
genetic screen for thiamin 
metabolic genes 
(PMID:15292217) 
- none - 379658 378750 - 
mnas_307 HAD hydrolase, IIB 
family protein 
  GO:0008152,
GO:0016787 
378749 379658 - Unknown: Enzymes of 
unknown specificity 
peg.436 Dihydrofolate reductase  
(EC 1.5.1.3) 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: Folate and 
pterines 
Subsystem: Folate biosynthesis
380268 379741 - 
mnas_308 dihydrofolate reductase 
family protein 
    379740 380268 - Biosynthesis of 
cofactors, prosthetic 
groups, and carriers: 
Folic acid 
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mnas_309 UMP kinase  
(EC 2.7.4.22) 
pyrH GO:0015949,
GO:0033862 
380436 381156 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Nucleotide 
and nucleoside 
interconversions 
peg.437 Uridine monophosphate 
kinase  
(EC 2.7.4.22) 
Subsystem: Ribosome 
recycling related cluster 
380437 381156 + 
mnas_310 ribosome recycling 
factor 
frr GO:0005737,
GO:0006412,
GO:0008135 
381155 381707 + Protein synthesis: 
Translation factors 
peg.438 Ribosome recycling factor Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
termination factors bacterial 
Subsystem: Ribosome 
recycling related cluster, 
381156 381707 + 
mnas_311 tRNA modification 
GTPase TrmE  
(EC 3.6.-.-) 
trmE GO:0003924,
GO:0006400 
381748 383146 + Protein synthesis: 
tRNA and rRNA base 
modification 
peg.439 GTPase and tRNA-U34 5-
formylation enzyme TrmE 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: mnm5U34 
biosynthesis bacteria 
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
Subsystem: Cell Division 
Subsystem including YidCD 
Subsystem: RNA modification 
and chromosome partitioning 
cluster 
Subsystem: RNA modification 
cluster 
381749 383146 + 
mnas_312 tatD related DNase 
family protein 
    383147 383942 + Unknown: Enzymes of 
unknown specificity 
peg.440 Putative deoxyribonuclease 
YcfH 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: YcfH 
383148 383942 + 
mnas_313 dimethyladenosine 
transferase  
(EC 2.1.1.-) 
ksgA GO:0000154,
GO:0000179 
383941 384724 + Protein synthesis: 
tRNA and rRNA base 
modification 
peg.441 SSU rRNA (adenine(1518)-
N(6)/adenine(1519)-N(6))-
dimethyltransferase  
(EC 2.1.1.182) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation 
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome 
biogenesis bacterial 
383942 384724 + 
mnas_314 HIT domain protein     384750 385098 - Unknown: Enzymes of 
unknown specificity 
peg.442 HIT-family hydrolase protein - none - 385098 384751 - 
mnas_315 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
385097 386327 - Unknown: General peg.443 P60-like lipoprotein - none - 386327 385098 - 
mnas_316 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
386326 388534 - Unknown: General peg.444 M. hominis p80-related 
protein 
- none - 388534 386327 - 
mnas_317 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
388650 389151 + Unknown: General peg.445 hypothetical protein - none - 388615 389151 + 
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mnas_318 recF/RecN/SMC N 
terminal domain protein 
    389204 391247 + Cellular processes: Cell 
division 
peg.446 Chromosome partition protein 
smc 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: DNA structural 
proteins, bacterial 
389790 391247 + 
mnas_319 GTP-binding protein 
LepA  
(EC 3.6.5.-) 
lepA GO:0005525 391496 393299 + Unknown: General 
Hypothetical  
peg.447 Translation elongation factor 
LepA 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
elongation factors bacterial 
 
Category: Stress Response 
Subcategory: Heat shock 
Subsystem: Heat shock dnaK 
gene cluster extended  
391497 393299 + 
mnas_320 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
393377 395834 - Unknown: Conserved peg.448 hypothetical protein - none - 395783 393378 - 
mnas_321 peptidase M13 family 
protein 
    396052 397960 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.449 Neutral endopeptidase O  
(EC 3.4.24.-) 
- none - 396053 397960 + 
mnas_322 OB-fold nucleic acid 
binding domain protein 
    399642 400500 - Unknown: General 
Hypothetical  
          
mnas_323 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
398311 399646 + Unknown: General           
mnas_324 virulence factor BrkB 
family protein 
    400523 401621 - Unclassified: Role 
category not yet 
assigned 
peg.450 FIG00835188: hypothetical 
protein 
- none - 401621 400524 - 
mnas_325 aspartyl/glutamyl-
tRNA(Asn/Gln) 
amidotransferase, B 
subunit  
(EC 6.3.5.-) 
gatB GO:0006424,
GO:0030956,
GO:0050567 
401604 403026 - Protein synthesis: 
tRNA aminoacylation 
peg.451 Aspartyl-tRNA(Asn) 
amidotransferase subunit B 
(EC 6.3.5.6) @ Glutamyl-
tRNA(Gln) amidotransferase 
subunit B  
(EC 6.3.5.7) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Asp and Asn; 
Subsystem: tRNA 
aminoacylation, Glu and Gln 
403026 401605 - 
mnas_326 amidase family protein     403027 404350 - Unknown: Enzymes of 
unknown specificity 
peg.452 Aspartyl-tRNA(Asn) 
amidotransferase subunit A 
(EC 6.3.5.6) @ Glutamyl-
tRNA(Gln) amidotransferase 
subunit A  
(EC 6.3.5.7) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Asp and Asn 
Subsystem: tRNA 
aminoacylation, Glu and Gln 
404350 403028 - 
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mnas_327 glu-tRNAGln 
amidotransferase C 
subunit 
    404349 404652 - Protein synthesis: 
tRNA aminoacylation 
peg.453 Aspartyl-tRNA(Asn) 
amidotransferase subunit C 
(EC 6.3.5.6) @ Glutamyl-
tRNA(Gln) amidotransferase 
subunit C  
(EC 6.3.5.7) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Asp and Asn 
 
Subsystem: tRNA 
aminoacylation, Glu and Gln 
404652 404350 - 
mnas_328 RNA pseudouridylate 
synthase family protein 
    404658 405534 - Protein synthesis: 
tRNA and rRNA base 
modification 
peg.454 Ribosomal large subunit 
pseudouridine synthase C 
(EC 4.2.1.70) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA pseudouridine 
syntheses 
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome 
biogenesis bacterial 
405534 404659 - 
mnas_329 segregation and 
condensation protein B 
scpB GO:0005515,
GO:0007059,
GO:0030261 
405576 406152 - Cellular processes: Cell 
division,  
DNA metabolism: 
Chromosome-
associated proteins 
peg.455 Segregation and 
condensation protein B 
CBSS-314276.3.peg.1499 406152 405577 - 
mnas_330 segregation and 
condensation protein A 
scpA   406141 406906 - Cellular processes: Cell 
division,  
DNA metabolism: 
Chromosome-
associated proteins 
peg.456 Segregation and 
condensation protein A 
CBSS-314276.3.peg.1499 406906 406142 - 
mnas_331 Putative 1-acyl-sn-
glycerol-3-phosphate 
acyltransferase  
(EC 2.3.1.51) 
plsC   406895 407666 - Unknown: Enzymes of 
unknown specificity 
peg.457 1-acyl-sn-glycerol-3-
phosphate acyltransferase 
(EC 2.3.1.51) 
Category: Fatty Acids, Lipids, 
and Isoprenoids 
Subcategory: Phospholipids 
Subsystem: Glycerolipid and 
Glycerophospholipid Metabolism 
in Bacteria 
407666 406896 - 
mnas_332 phosphopantetheine--
transferase domain 
protein 
    407658 408033 - Protein fate: Protein 
modification and repair 
peg.458 Holo-[acyl-carrier protein] 
synthase  
(EC 2.7.8.7) 
- none - 407985 407659 - 
mnas_333 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
408072 409734 - Unknown: General peg.459 hypothetical protein - none - 409734 408073 - 
mnas_334 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
410384 419783 - Unknown: General peg.460 glycosyl hydrolase, family 
31/fibronectin type III domain 
protein 
- none - 419759 410385 - 
mnas_335 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
419994 420525 + Unknown: General peg.461 unknown; predicted coding 
region 
- none - 420022 420525 + 
mnas_336 transcription elongation 
factor GreA domain 
protein 
greA GO:0003711,
GO:0006354 
420668 421184 + Transcription: 
Transcription factors 
peg.462 Transcription elongation 
factor GreA 
Category: RNA Metabolism 
Subcategory: Transcription 
Subsystem: Transcription 
factors bacterial 
420669 421184 + 
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mnas_337 deoxynucleoside 
kinase family protein 
    421303 421960 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Nucleotide 
and nucleoside 
interconversions 
peg.463 Deoxyadenosine kinase (EC 
2.7.1.76) / Deoxyguanosine 
kinase  
(EC 2.7.1.113) 
Category: Nucleosides and 
Nucleotides 
Subcategory: Purines 
Subsystem: Purine conversions  
Subsystem: Purine conversions
421304 421960 + 
mnas_338 hypoxanthine 
phosphoribosyltransfer
ase  
(EC 2.4.2.8) 
hpt GO:0004422,
GO:0006166 
421965 422574 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Salvage of 
nucleosides and 
nucleotides 
peg.464 Hypoxanthine-guanine 
phosphoribosyltransferase 
(EC 2.4.2.8) 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: Folate and 
pterines 
Subsystem: Folate biosynthesis 
cluster 
 
Category: Nucleosides and 
Nucleotides 
Subcategory: Purines 
Subsystem: Purine conversions
Subsystem: Cell division-
ribosomal stress proteins cluster 
421966 422574 + 
mnas_339 preprotein translocase, 
SecA subunit 
secA GO:0009898,
GO:0015450,
GO:0016887,
GO:0043952 
422797 425623 + Protein fate:Protein and 
peptide secretion and 
trafficking 
peg.465 Protein export cytoplasm 
protein SecA ATPase RNA 
helicase  
(TC 3.A.5.1.1) 
- none - 422798 425623 + 
mnas_340 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
425653 426412 + Unknown: General peg.466 hypothetical protein - none - 425654 426412 + 
mnas_341 ABC transporter family 
protein 
    426586 428206 + Transport and binding 
proteins: Unknown 
substrate 
peg.467 ABC transporter ATP-binding 
protein uup 
- none - 426587 428206 + 
mnas_342 RNA 
methyltransferase, 
RsmE family protein 
(EC 2.1.1.-) 
  GO:0016436,
GO:0031167 
428205 428886 + Unknown: Conserved peg.468 Ribosomal RNA small subunit 
methyltransferase E  
(EC 2.1.1.-) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation 
 
Category: Stress Response 
Subcategory: Heat shock 
Subsystem: Heat shock dnaK 
gene cluster extended 
428206 428886 + 
mnas_343 ribosomal protein L13 rplM GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
429035 429470 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.469 LSU ribosomal protein L13p 
(L13Ae) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
429036 429470 + 
mnas_344 30S ribosomal protein 
S9 
rpsI GO:0005840,
GO:0006412,
GO:0003735 
429469 429862 + Cellular processes: 
Other 
peg.470 SSU ribosomal protein S9p 
(S16e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
429470 429862 + 
mnas_345 mycoplasma 
MG185/MG260 family 
protein 
    429892 431416 - Unclassified: Role 
category not yet 
assigned 
peg.471 hypothetical protein - none - 430488 430892 + 
                peg.472 hypothetical protein - none - 431106 431438 + 
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mnas_346 antibiotic biosynthesis 
monooxygenase family 
protein 
    431616 431901 - Cellular processes: 
Toxin production and 
resistance 
peg.473 hypothetical protein - none - 431901 431617 - 
mnas_347 methionine--tRNA 
ligase domain protein 
(EC 6.1.1.10) 
metG GO:0005524,
GO:0000166,
GO:0004825,
GO:0006431,
GO:0005737,
GO:0016874 
431917 432442 - Cellular processes: 
Other, Transport and 
binding proteins: 
Unknown substrate, 
Unknown: Enzymes of 
unknown specificity 
peg.474 Methionyl-tRNA synthetase 
(EC 6.1.1.10) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Met 
433472 431918 - 
mnas_348 methionine--tRNA 
ligase  
(EC 6.1.1.10) 
metG GO:0004825,
GO:0005737,
GO:0006431 
432401 433472 - Protein synthesis: 
tRNA aminoacylation 
          
mnas_349 conserved hypothetical 
95 family protein 
    433474 434278 - Unclassified: Role 
category not yet 
assigned 
peg.475 tRNA (adenine37-N(6))-
methyltransferase TrmN6  
(EC 2.1.1.223) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation  
434278 433475 - 
mnas_350 ribonuclease R  
(EC 3.1.13.1) 
rnr GO:0006401,
GO:0008997 
434243 436445 - Transcription: 
Degradation of RNA 
peg.476 3'-to-5' exoribonuclease 
RNase R  
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA processing 
and degradation, bacterial 
436445 434244 - 
mnas_351 preprotein translocase, 
SecG subunit 
secG GO:0005887,
GO:0015450,
GO:0043952 
436455 436695 - Protein fate:Protein and 
peptide secretion and 
trafficking 
peg.477 hypothetical protein - none - 436695 436456 - 
mnas_352 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
437093 439496 + Unknown: General peg.478 hypothetical protein - none - 437094 439496 + 
mnas_353 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
439555 439645 - Unknown: General           
mnas_354 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
439651 441286 - Unknown: General peg.479 hypothetical protein - none - 441313 441984 + 
mnas_355 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
441312 441984 + Cell envelope: Other           
mnas_356 tyrosine--tRNA ligase 
(EC 6.1.1.1) 
tyrS GO:0004831,
GO:0005737,
GO:0006437 
442022 443264 - Protein synthesis: 
tRNA aminoacylation 
peg.480 Tyrosyl-tRNA synthetase  
(EC 6.1.1.1) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Tyr 
443264 442023 - 
mnas_357 putative tRNA binding 
domain protein 
    443266 443875 - Unknown: General 
Hypothetical  
peg.481 Phenylalanyl-tRNA 
synthetase domain protein 
(Bsu YtpR) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Phe 
443875 443267 - 
mnas_358 EDD, DegV family 
domain protein 
  GO:0005575,
GO:0008150,
GO:0016740 
443900 444767 + Unknown: General 
Hypothetical  
peg.482 hypothetical protein - none - 443997 444767 + 
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mnas_359 tRNA 
threonylcarbamoyl 
adenosine modification 
protein YjeE 
  GO:0005737,
GO:0006400,
GO:0016887 
444760 445147 + Unknown: Conserved peg.483 TsaE protein, required for 
threonylcarbamoyladenosine 
t(6)A37 formation in tRNA 
Category: Cell Wall and 
Capsule 
Subcategory: no subcategory 
Subsystem: YjeE 
444761 445147 + 
mnas_360 tRNA 
threonylcarbamoyl 
adenosine modification 
protein YeaZ 
yeaZ   445156 445717 + Transport and binding 
proteins: Cations and 
iron carrying 
compounds 
peg.484 TsaB protein, required for 
threonylcarbamoyladenosine 
(t(6)A) formation in tRNA 
Category: Cell Division and Cell 
Cycle 
Subcategory: no subcategory 
Subsystem: YgjD and YeaZ 
 
Category: Cell Wall and 
Capsule 
Subcategory: no subcategory 
Subsystem: YjeE 
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome 
biogenesis bacterial 
Subsystem: Bacterial RNA-
metabolizing Zn-dependent 
hydrolases 
Subsystem: Conserved gene 
cluster associated with Met-
tRNA formyltransferase 
445157 445717 + 
mnas_361 tRNA 
threonylcarbamoyl 
adenosine modification 
protein YgjD 
    445716 446646 + Transport and binding 
proteins: Cations and 
iron carrying 
compounds 
peg.485 TsaD/Kae1/Qri7 protein, 
required for 
threonylcarbamoyladenosine 
t(6)A37 formation in tRNA 
Category: Cell Division and Cell 
Cycle 
Subcategory: no subcategory 
Subsystem: YgjD and YeaZ 
Subsystem: Macromolecular 
synthesis operon 
Subsystem: Bacterial RNA-
metabolizing Zn-dependent 
hydrolases 
Subsystem: Conserved gene 
cluster associated with Met-
tRNA formyltransferase 
445717 446646 + 
mnas_362 type I restriction 
modification DNA 
specificity domain 
protein 
    446816 448133 + DNA metabolism: 
Restriction/modification
peg.486 Type I restriction-modification 
system, specificity subunit S 
(EC 3.1.21.3) 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: Type I Restriction-
Modification 
Subsystem: Restriction-
Modification System 
446817 448133 + 
mnas_363 type I restriction 
modification DNA 
specificity domain 
protein 
    448080 448788 + DNA metabolism: 
Restriction/modification
peg.487 Type I restriction-modification 
system, specificity subunit S 
(EC 3.1.21.3) 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: Type I Restriction-
Modification 
Subsystem: Restriction-
Modification System 
448372 448788 + 
mnas_364 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
449190 449838 - Unknown: General peg.488 hypothetical protein - none - 449375 449872 + 
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mnas_365 type III restriction-
modification system 
methylation subunit 
domain protein  
(EC 2.1.1.72) 
sthIM GO:0003677,
GO:0032775,
GO:0008170,
GO:0016740,
GO:0032259,
GO:0006306,
GO:0009007 
448982 449198 + Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate,  
Unknown: Enzymes of 
unknown specificity 
          
mnas_366 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
450101 452267 - Unknown: General peg.489 hypothetical protein - none - 452267 450102 - 
mnas_367 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
452547 454830 - Unknown: General peg.490 VlhA.5.03 - none - 454830 452548 - 
                peg.491 hypothetical protein - none - 454832 454975 + 
mnas_368 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
455138 457310 - Unknown: General peg.492 VlhA.4.08 - none - 457010 455139 - 
mnas_369 ribosomal protein L19 rplS GO:0000311,
GO:0003735,
GO:0006412,
GO:0022625 
457336 457693 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.493 LSU ribosomal protein L19p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
457693 457337 - 
mnas_370 tRNA (guanine(37)-
N(1))-
methyltransferase 
trmD GO:0006400,
GO:0009019 
457682 458390 - Protein synthesis: 
tRNA and rRNA base 
modification 
peg.494 tRNA (Guanine37-N1) -
methyltransferase  
(EC 2.1.1.31) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation 
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome 
biogenesis bacterial 
458390 457683 - 
mnas_371 ribosomal protein S16 rpsP GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
458389 458638 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.495 SSU ribosomal protein S16p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
458638 458390 - 
mnas_372 RNA 2'-O ribose 
methyltransferase 
substrate binding family 
protein 
    458750 459512 - Protein synthesis: 
tRNA and rRNA base 
modification 
peg.496 23S rRNA (guanosine-2’;-O-) 
-methyltransferase rlmB  
(EC 2.1.1.-) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation 
459512 458751 - 
mnas_373 cysteine--tRNA ligase 
(EC 6.1.1.16) 
cysS GO:0004817,
GO:0006423 
459540 460776 - Protein synthesis: 
tRNA aminoacylation 
peg.497 Cysteinyl-tRNA synthetase 
(EC 6.1.1.16) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Cys 
460692 459541 - 
mnas_374 arginine--tRNA ligase 
(EC 6.1.1.19) 
argS GO:0004814,
GO:0005737,
GO:0006420 
460892 462548 + Protein synthesis: 
tRNA aminoacylation 
peg.498 Arginyl-tRNA synthetase  
(EC 6.1.1.19) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Arg 
460893 462548 + 
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mnas_375 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
462561 462825 + Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate 
peg.499 hypothetical protein - none - 462562 462825 + 
mnas_376 fructose-1,6-
bisphosphate aldolase, 
class II  
(EC 4.1.2.13) 
fba GO:0004332,
GO:0006096 
462826 463696 + Energy metabolism: 
Glycolysis/gluconeogen
esis 
peg.500 Fructose-bisphosphate 
aldolase class II  
(EC 4.1.2.13) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Glycolysis and 
Gluconeogenesis 
462827 463696 + 
mnas_377 eco57I restriction-
modification methylase 
family protein 
    463734 464700 + DNA metabolism: 
Restriction/modification
peg.501 Transcriptional regulator - none - 463735 464700 + 
mnas_378 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
464822 465893 + Unknown: General 
Hypothetical  
peg.502 Thermonuclease family 
protein 
- none - 464823 465893 + 
mnas_379 DNA gyrase subunit B 
(EC 5.99.1.3) 
gyrB    465983 467939 + DNA metabolism: 
Other 
peg.503 DNA gyrase subunit B  
(EC 5.99.1.3) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA 
topoisomerases, Type II, ATP-
dependent 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Resistance to 
antibiotics and toxic compounds 
Subsystem: Resistance to 
fluoroquinolones 
Subsystem: Cell Division 
Subsystem including YidCD 
465984 467931 + 
mnas_380 tetrahydrofolate 
dehydrogenase/cyclohy
drolase, NAD(P)-
binding domain protein 
    468061 468208 - Biosynthesis of 
cofactors, prosthetic 
groups, and carriers: 
Folic acid 
          
mnas_381 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
468224 476891 + Unknown: General peg.515 hypothetical protein - none - 473356 472508 - 
                peg.516 hypothetical protein - none - 474529 473522 - 
                peg.517 hypothetical protein - none - 475507 474623 - 
                peg.518 hypothetical protein - none - 476803 476126 - 
mnas_382 ribosomal protein L15 rplO GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
477052 477487 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.519 LSU ribosomal protein L15p 
(L27Ae) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
477487 477053 - 
mnas_383 ribosomal protein S5 rpsE GO:0000312,
GO:0003735,
GO:0006412,
GO:0022627 
477491 478136 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.520 SSU ribosomal protein S5p 
(S2e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
478136 477492 - 
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mnas_384 ribosomal protein L18 rplR GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
478135 478486 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.521 LSU ribosomal protein L18p 
(L5e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
478486 478136 - 
mnas_385 ribosomal protein L6 rplF GO:0003735,
GO:0006412,
GO:0019843,
GO:0022625 
478510 479050 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.522 LSU ribosomal protein L6p 
(L9e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
479050 478511 - 
mnas_386 ribosomal S8 family 
protein 
    479060 479456 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.523 SSU ribosomal protein S8p 
(S15Ae) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
479456 479061 - 
mnas_387 30S ribosomal protein 
S14 type Z 
rpsZ GO:0005840,
GO:0046872,
GO:0006412,
GO:0003735,
GO:0019843 
479455 479641 - Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate 
peg.524 SSU ribosomal protein S14p 
(S29e) @ SSU ribosomal 
protein S14p (S29e), zinc-
dependent 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
Subsystem: Ribosome SSU 
bacterial 
479641 479456 - 
mnas_388 50S ribosomal protein 
L5 
rplE GO:0005840,
GO:0006412,
GO:0000049,
GO:0003735,
GO:0019843 
479640 480186 - Cellular processes: 
Other 
peg.525 LSU ribosomal protein L5p 
(L11e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
480186 479641 - 
mnas_389 ribosomal protein L24 rplX GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
480187 480520 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.526 LSU ribosomal protein L24p 
(L26e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
480520 480188 - 
mnas_390 ribosomal protein L14 rplN GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
480538 480904 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.527 LSU ribosomal protein L14p 
(L23e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
480904 480539 - 
mnas_391 30S ribosomal protein 
S17 
rpsQ GO:0003735,
GO:0006412,
GO:0022627 
480903 481173 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.528 SSU ribosomal protein S17p 
(S11e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
481173 480904 - 
mnas_392 ribosomal protein L29 rpmC GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
481172 481364 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.529 LSU ribosomal protein L29p 
(L35e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
481364 481146 - 
mnas_393 ribosomal protein L16 rplP GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
481363 481789 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.530 LSU ribosomal protein L16p 
(L10e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
481789 481364 - 
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mnas_394 ribosomal protein S3 rpsC GO:0000312,
GO:0003735,
GO:0006412,
GO:0022627 
481788 482442 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.531 SSU ribosomal protein S3p 
(S3e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
482442 481789 - 
mnas_395 ribosomal protein L22 rplV GO:0000311,
GO:0003735,
GO:0006412,
GO:0022625 
482443 482779 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.532 LSU ribosomal protein L22p 
(L17e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
482779 482444 - 
mnas_396 ribosomal protein S19 rpsS GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
482778 483057 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.533 SSU ribosomal protein S19p 
(S15e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
483057 482779 - 
mnas_397 ribosomal protein L2 rplB GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
483056 483902 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.534 LSU ribosomal protein L2p 
(L8e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
483902 483057 - 
mnas_398 50S ribosomal L23 
domain protein 
rplW GO:0005840,
GO:0000166,
GO:0006412,
GO:0003735,
GO:0019843 
484016 484490 - Cellular processes: 
Other 
peg.535 LSU ribosomal protein L23p 
(L23Ae) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
484490 484017 - 
mnas_399 ribosomal L4/L1 family 
protein 
    484489 484780 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.536 LSU ribosomal protein L4p 
(L1e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
484780 484490 - 
mnas_400 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
485007 486828 - Unknown: General           
mnas_401 DNA topoisomerase 4 
subunit A  
(EC 5.99.1.-) 
parC GO:0005524,
GO:0003918,
GO:0005694,
GO:0006265,
GO:0003700 
487275 489867 + Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate,  
Transcription: 
Transcription factors,  
Unknown: Enzymes of 
unknown specificity 
peg.537 Topoisomerase IV subunit A 
(EC 5.99.1.-) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA 
topoisomerases, Type II, ATP-
dependent 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Resistance to 
antibiotics and toxic compounds 
Subsystem: Resistance to 
fluoroquinolones 
487276 489867 + 
mnas_402 DNA (cytosine-5-)-
methyltransferase 
family protein  
(EC 2.1.1.37) 
dcm GO:0003886,
GO:0006304 
490036 490495 + DNA metabolism: DNA 
replication, 
recombination, and 
repair, 
Disrupted reading 
frame: NULL 
peg.538 DNA-cytosine 
methyltransferase  
(EC 2.1.1.37) 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial 
490037 490495 + 
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mnas_403 putative cytosine-
specific 
methyltransferase 
  GO:0003677,
GO:0009307,
GO:0008168,
GO:0006306,
GO:0003886,
GO:0016740,
GO:0032259 
490518 490869 + Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate, Unknown: 
Enzymes of unknown 
specificity 
peg.539 DNA-cytosine 
methyltransferase 
- none - 490519 490869 + 
mnas_404 type-2 restriction 
enzyme DpnII  
(EC 3.1.21.4) 
dpnB GO:0003677,
GO:0009307,
GO:0009036 
491431 492319 - Cellular processes: 
Other, Transport and 
binding proteins: 
Unknown substrate, 
Unknown: Enzymes of 
unknown specificity 
peg.540 Type II restriction enzyme 
MjaIII  
(EC 3.1.21.4) 
- none - 492319 491432 - 
mnas_405 modification methylase 
DpnIIA  
(EC 2.1.1.72) 
dpnM GO:0009307,
GO:0009007,
GO:0003676 
492319 493036 - Cellular processes: 
Other, Transport and 
binding proteins: 
Unknown substrate, 
Unknown: Enzymes of 
unknown specificity 
peg.541 DNA adenine methylase  
(EC 2.1.1.72) 
- none - 492877 492320 - 
mnas_406 ABC transporter 
transmembrane region 
family protein 
    493036 493804 - Transport and binding 
proteins: Unknown 
substrate 
peg.542 Lipid A export ATP-
binding/permease protein 
MsbA 
- none - 495533 493788 - 
mnas_407 ABC transporter family 
protein 
    493787 495533 - Transport and binding 
proteins: Unknown 
substrate 
          
mnas_408 bacterial regulatory , 
arsR family protein 
    495532 495898 - Regulatory functions: 
DNA interactions 
peg.543 arsenical resistance operon 
repressor family protein 
- none - 495898 495533 - 
mnas_409 AAA domain protein     495979 500236 - Unknown: General 
Hypothetical  
peg.544 Apolipoprotein N-
acyltransferase (EC 2.3.1.-) in 
lipid-linked oligosaccharide 
synthesis cluster 
- none - 500236 495980 - 
mnas_410 Putative PTS system 
glucose-specific 
enzyme IIB component 
  GO:0008150,
GO:0003674,
GO:0005575 
500247 500607 - Transport and binding 
proteins: Unknown 
substrate, 
 Signal transduction: 
PTS, Unknown: 
Enzymes of unknown 
specificity 
peg.545 PTS system glucose-specific 
enzyme IIB component 
- none - 500607 500248 - 
mnas_411 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
500832 501000 - Unknown: General           
mnas_412 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
501010 501196 - Unknown: General           
mnas_413 oligoendopeptidase F 
(EC 3.4.24.-) 
pepF GO:0004222,
GO:0006508 
502226 504056 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.546 Oligoendopeptidase F  
(EC 3.4.24.-) 
- none - 502227 504056 + 
mnas_414 oligopeptide ABC 
transporter substrate-
binding protein 
oppA GO:0008150,
GO:0003674,
GO:0005575 
504068 507935 + Transport and binding 
proteins: Unknown 
substrate 
peg.547 Lipoprotein - none - 504069 507935 + 
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mnas_415 Oligopeptide ABC 
transporter, permease 
protein OppB 
oppB   507946 508705 + Transport and binding 
proteins: Unknown 
substrate 
          
mnas_416 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
508709 509093 - Unknown: General           
mnas_417 terminase-like family 
protein 
    509193 511155 - Unclassified: Role 
category not yet 
assigned 
peg.548 Phage terminase, large 
subunit 
Category: Phage packaging 
machinPhages, Prophages, 
Transposable elements, 
Plasmids 
Subcategory: Phages, 
Prophages 
Subsystem: Phage packaging 
machineryery 
511155 509194 - 
mnas_418 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
511154 511388 - Unknown: General peg.549 hypothetical protein - none - 511388 511155 - 
mnas_419 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
511389 511728 - Unknown: General peg.550 hypothetical protein - none - 511728 511390 - 
mnas_420 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
511714 511939 - Unknown: General peg.551 hypothetical protein - none - 511939 511715 - 
mnas_421 phage Mu F like family 
protein 
    511931 512765 - Mobile and 
extrachromosomal 
element functions: 
Prophage functions 
peg.552 Phage protein - none - 512765 511932 - 
mnas_422 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
512764 514513 - Unknown: General peg.553 DNA polymerase B region - none - 514513 512765 - 
mnas_423 thymidylate kinase  
(EC 2.7.4.9) 
tmk GO:0004798,
GO:0015949 
514514 515099 - Purines, pyrimidines, 
nucleosides, and 
nucleotides: Nucleotide 
and nucleoside 
interconversions 
peg.554 Thymidylate kinase  
(EC 2.7.4.9) 
- none - 515099 514515 - 
mnas_424 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
515100 515457 - Unknown: General peg.555 hypothetical protein - none - 515457 515101 - 
mnas_425 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
515485 515980 - Unknown: General           
mnas_426 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
515981 516137 - Unknown: General peg.556 hypothetical protein - none - 516125 515982 - 
mnas_427 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
516185 520046 + Unknown: General peg.557 hypothetical protein - none - 516249 520046 + 
mnas_428 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
520183 521065 - Cell envelope: Other peg.558 hypothetical protein - none - 521065 520184 - 
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mnas_429 excinuclease ABC 
subunit B  
(EC 3.1.25.-) 
uvrB GO:0006289,
GO:0009380,
GO:0009381 
521216 523220 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.559 Excinuclease ABC subunit B Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
UvrABC system 
521217 523220 + 
mnas_430 excinuclease ABC 
subunit A domain 
protein 
uvrA GO:0003677,
GO:0005524,
GO:0009432,
GO:0005737,
GO:0006289,
GO:0009380,
GO:0046872,
GO:0009381,
GO:0016887 
523209 523647 + Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate,  
Unknown: Enzymes of 
unknown specificity 
          
mnas_431 ribosome biogenesis 
GTP-binding protein 
YlqF 
ylqF GO:0003924,
GO:0005525,
GO:0005737,
GO:0042254 
523647 524412 - Unclassified: Role 
category not yet 
assigned 
          
mnas_432 divIVA domain protein     524401 524668 - Unknown: General 
Hypothetical  
peg.560 hypothetical protein - none - 524668 524402 - 
mnas_433 RNA 2'-O ribose 
methyltransferase 
substrate binding family 
protein 
    524670 525402 - Protein synthesis: 
tRNA and rRNA base 
modification 
peg.561 FIG011178: rRNA methylase Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation 
525402 524671 - 
mnas_434 spoU rRNA Methylase 
family protein 
    525385 525922 - Protein synthesis: 
tRNA and rRNA base 
modification 
peg.562 tRNA (cytidine(34)-2’;-O)-
methyltransferase  
(EC 2.1.1.207) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation 
525922 525386 - 
mnas_435 translation elongation 
factor Tu 
tuf GO:0003746,
GO:0006414 
525991 527179 - Protein synthesis: 
Translation factors 
peg.563 Translation elongation factor 
Tu 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
Subsystem: Translation 
elongation factors bacterial 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Invasion and 
intracellular resistance 
Subsystem: Mycobacterium 
virulence operon involved in 
protein synthesis (SSU 
ribosomal proteins)  
527179 525992 - 
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mnas_436 xylulose-5-phosphate 
phosphoketolase (EC 
4.1.2.9) 
xpkA GO:0005975,
GO:0050193 
527686 530062 + Energy metabolism: 
Sugars,  
Unknown: Enzymes of 
unknown specificity 
peg.564 Xylulose-5-phosphate 
phosphoketolase (EC 4.1.2.9) 
@ Fructose-6-phosphate 
phosphoketolase (EC 
4.1.2.22) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Pentose phosphate 
pathway 
Subsystem: Pentose phosphate 
pathway 
Subcategory: Fermentation 
Subsystem: Fermentations: 
Lactate 
Subsystem: Fermentations: 
Lactate 
527687 530062 + 
mnas_437 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
531075 531387 - Unknown: Conserved           
mnas_438 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
530223 531087 + Unknown: General           
mnas_439 AAA domain protein     531412 532342 - Unknown: General 
Hypothetical  
peg.565 hypothetical protein - none - 532342 531413 - 
mnas_440 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
532325 532718 - Unknown: Conserved peg.566 hypothetical protein - none - 532718 532326 - 
mnas_441 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
532727 533117 - Unknown: General peg.567 hypothetical protein - none - 533117 532728 - 
mnas_442 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
533203 533617 - Unknown: General peg.568 hypothetical protein - none - 533581 533204 - 
mnas_443 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
533558 533714 - Unknown: General peg.569 hypothetical protein - none - 533714 533559 - 
mnas_444 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
533985 534894 - Unknown: General peg.570 hypothetical protein - none - 534894 533986 - 
mnas_445 inosine-uridine 
preferring nucleoside 
hydrolase family 
protein 
    534886 535915 - Purines, pyrimidines, 
nucleosides, and 
nucleotides: Salvage of 
nucleosides and 
nucleotides 
peg.571 preQ1-regulated inosine-
uridine nucleoside hydrolase 
(EC 3.2.2.1) 
Category: Nucleosides and 
Nucleotides 
Subcategory: Purines 
Subsystem: Purine conversions
535915 534887 - 
mnas_446 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
535916 536267 - Unknown: General peg.572 hypothetical protein - none - 536267 535917 - 
mnas_447 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
536259 536577 - Unknown: General           
mnas_448 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
536730 536910 - Unknown: General peg.573 hypothetical protein - none - 536910 536731 - 
mnas_449 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
537104 538043 - Unknown: Conserved peg.574 hypothetical protein - none - 537986 537105 - 
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mnas_450 trigger factor  
(EC 5.2.1.8) 
tig GO:0003755,
GO:0005854,
GO:0051082,
GO:0051083 
538059 539262 + Protein fate: Protein 
folding and stabilization
          
mnas_451 papain cysteine 
protease family protein 
    539360 540677 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.575 Aminopeptidase C  
(EC 3.4.22.40) 
Category: Protein Metabolism 
Subcategory: Protein 
degradation 
Subsystem: Protein 
degradation 
539361 540677 + 
mnas_452 tRNA (5-
methylaminomethyl-2-
thiouridylate)-
methyltransferase  
(EC 2.1.1.61) 
trmU GO:0004808,
GO:0005737,
GO:0006396 
540686 541802 + Protein synthesis: 
tRNA and rRNA base 
modification 
peg.576 tRNA-specific 2-thiouridylase 
MnmA 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA methylation 
540687 541802 + 
mnas_453 alanine--tRNA ligase 
(EC 6.1.1.7) 
alaS GO:0004813,
GO:0005737,
GO:0006419 
541809 544434 + Protein synthesis: 
tRNA aminoacylation 
peg.577 Alanyl-tRNA synthetase  
(EC 6.1.1.7) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Ala 
541810 544434 + 
mnas_454 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
544421 544847 + Unknown: Conserved peg.578 Putative Holliday junction 
resolvase YqgF 
- none - 544422 544847 + 
mnas_455 phosphatidylinositol-
specific phospholipase 
C, X domain protein 
    544947 546894 + Unknown: General 
Hypothetical  
peg.595 Phosphatidylinositol-specific 
phospholipase C  
(EC 4.6.1.13) 
Category: Phage packaging 
machinPhages, Prophages, 
Transposable elements, 
Plasmids 
Subcategory: Pathogenicity 
islands 
Subsystem: Listeria 
Pathogenicity Island LIPI-1 
extended 
545065 546894 + 
mnas_456 lipoassociated domain 
protein 
    546869 550376 + Unknown: General 
Hypothetical  
peg.596 hypothetical protein - none - 546870 550376 + 
mnas_457 Aspartate--tRNA ligase 
(EC 6.1.1.12) 
    550450 551500 - Unknown: Enzymes of 
unknown specificity 
peg.597 Aspartyl-tRNA synthetase 
(EC 6.1.1.12) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Asp and Asn 
551428 550451 - 
mnas_458 Glutamyl-tRNA 
synthetase  
(EC 6.1.1.17) 
  GO:0004818 551508 552183 - Unknown: Enzymes of 
unknown specificity 
          
mnas_459 tRNA-Lys      552267  552343 +   rna.20 tRNA-Lys-CTT - none - 552268 552340 + 
mnas_460 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
552533 553844 + Unknown: Conserved peg.598 FIG00834982: hypothetical 
protein 
- none - 552534 553844 + 
mnas_461 tRNA-Thr      554066  553992 -   rna.21 tRNA-Thr-CGT - none - 554066 553996 - 
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
Appendix 2  
188 
 
IGS RAST  
Gene_id Common_name Sym
bol1 
GO terms2 fmin3 fmax3 S4 TIGR_roles Gene_id Function Subsystem Start5 Stop5 S4 
mnas_462 ssrA-binding protein smpB GO:0003723,
GO:0006450 
554439 554877 - Protein synthesis: 
Other 
peg.599 tmRNA-binding protein SmpB Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
termination factors bacterial 
 
Category: Stress Response 
Subcategory: Heat shock 
Subsystem: Heat shock dnaK 
gene cluster extended 
554877 554440 - 
mnas_463 valine--tRNA ligase 
(EC 6.1.1.9) 
valS GO:0004832,
GO:0005737,
GO:0006438 
555014 557501 + Protein synthesis: 
tRNA aminoacylation 
peg.600 Valyl-tRNA synthetase  
(EC 6.1.1.9) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Val 
555015 557501 + 
mnas_464 tetrahydrofolate 
dehydrogenase/cyclohy
drolase, catalytic 
domain protein 
    557485 558055 + Biosynthesis of 
cofactors, prosthetic 
groups, and carriers: 
Folic acid 
          
mnas_465 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
558059 564545 - Unknown: General peg.601 hypothetical protein - none - 558124 559089 + 
                peg.602 hypothetical protein - none - 559465 560025 + 
mnas_466 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
564553 565924 - Unknown: General           
mnas_467 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
565946 567257 - Unknown: General peg.603 hypothetical protein - none - 567257 565947 - 
mnas_468 DJ-1/PfpI family protein     567420 567987 - Unclassified: Role 
category not yet 
assigned 
peg.604 hypothetical protein - none - 567987 567421 - 
mnas_469 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
567986 569000 - Cell envelope: Other peg.605 hypothetical protein - none - 569000 567987 - 
mnas_470 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
569002 570289 - Unknown: General peg.606 hypothetical protein - none - 570289 569003 - 
mnas_471 peptide deformylase 
(EC 3.5.1.88) 
def GO:0006464,
GO:0042586 
570303 570861 - Protein fate: Protein 
modification and repair 
peg.607 Peptide deformylase  
(EC 3.5.1.88) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
termination factors bacterial 
Subsystem: Bacterial RNA-
metabolizing Zn-dependent 
hydrolases 
Subsystem: Conserved gene 
cluster associated with Met-
tRNA formyltransferase 
570798 570304 - 
mnas_472 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
571010 571736 - Unknown: Conserved           
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mnas_473 putative Replicative 
DNA helicase  
(EC 3.6.1.-) 
dnaB   571777 573238 - Unknown: General 
Hypothetical  
peg.608 Replicative DNA helicase  
(EC 3.6.1.-) 
- none - 573238 571778 - 
mnas_474 ribosomal protein L9 rplI GO:0000311,
GO:0003735,
GO:0006412,
GO:0022625 
573224 573686 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.609 LSU ribosomal protein L9p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
573686 573225 - 
mnas_475 DHHA1 domain protein     573687 575673 - Unknown: General 
Hypothetical  
peg.610 Phosphoesterase, DHH 
family protein 
- none - 575673 573688 - 
mnas_476 ZIP Zinc transporter 
family protein 
    575782 576790 - Transport and binding 
proteins: Cations and 
iron carrying 
compounds 
peg.611 hypothetical protein - none - 576790 575783 - 
mnas_477 transcriptional regulator 
family protein 
    576789 577263 - Transcription: 
Transcription factors 
peg.612 FIG000859: hypothetical 
protein YebC 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: Riboflavin, FMN, 
FAD 
Subsystem: Riboflavin, FMN 
and FAD metabolism in plants 
 
Category: DNA Metabolism 
Subcategory: DNA 
recombination 
Subsystem: RuvABC plus a 
hypothetical 
577215 576790 - 
mnas_478 Spermidine/putrescine/
ABC transporter 
substrate binding 
protein 
potD GO:0016020 577279 579238 + Transport and binding 
proteins: Unknown 
substrate 
peg.613 Probable 
spermidine/putrescine 
substrate binding protein in 
Mollicutes 
- none - 577451 579238 + 
mnas_479 ribosome-binding factor 
A 
rbfA GO:0006396,
GO:0019843 
579306 579648 + Transcription: RNA 
processing 
peg.614 Ribosome-binding factor A Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
initiation factors bacterial 
 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA processing 
and degradation, bacterial 
Subsystem: NusA-TFII Cluster 
579307 579648 + 
mnas_480 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
579843 580533 + Unknown: General peg.615 hypothetical protein - none - 579844 580533 + 
mnas_481 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
580729 581755 + Unknown: General peg.616 hypothetical protein - none - 580730 581755 + 
mnas_482 methionine 
adenosyltransferase 
(EC 2.5.1.6) 
metK GO:0004478,
GO:0006556 
581907 583050 + Central intermediary 
metabolism: Other 
peg.617 S-adenosylmethionine 
synthetase  
(EC 2.5.1.6) 
- none - 581908 583050 + 
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mnas_483 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
583101 583230 + Unknown: General peg.618 hypothetical protein - none - 583102 583230 + 
mnas_484 ATP-dependent 
protease La  
(EC 3.4.21.53) 
lon GO:0004252,
GO:0006508,
GO:0008846 
583478 586061 - Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
          
mnas_485 leucine--tRNA ligase 
(EC 6.1.1.4) 
leuS GO:0004823,
GO:0005737,
GO:0006429 
586071 588402 - Protein synthesis: 
tRNA aminoacylation, 
Disrupted reading 
frame: NULL 
peg.619 Leucyl-tRNA synthetase  
(EC 6.1.1.4) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Leu 
588402 586072 - 
mnas_486 NAD+ synthetase  
(EC 6.3.1.5) 
nadE GO:0005737,
GO:0008795,
GO:0009435 
588691 589474 + Biosynthesis of 
cofactors, prosthetic 
groups, and carriers: 
Pyridine nucleotides 
peg.620 NAD synthetase  
(EC 6.3.1.5) 
Category: Cofactors, Vitamins, 
Prosthetic Groups, Pigments 
Subcategory: NAD and NADP 
Subsystem: NAD and NADP 
cofactor biosynthesis global 
588692 589474 + 
mnas_487 transcriptional regulator 
family protein 
    589488 589659 + Transcription: 
Transcription factors 
          
mnas_488 putative sn-glycerol-3-
phosphate ABC 
transporter, ATP-
binding protein 
ugpC GO:0008150,
GO:0003674,
GO:0005575 
589659 591540 + Transport and binding 
proteins: Unknown 
substrate,  
Unknown: Enzymes of 
unknown specificity 
peg.621 Multiple sugar ABC 
transporter, ATP-binding 
protein 
- none - 589912 591540 + 
mnas_489 putative sn-glycerol-3-
phosphate transport 
system permease 
protein 
ugpA GO:0008150,
GO:0003674,
GO:0016020 
591529 592576 + Cell envelope: Other peg.622 N-Acetyl-D-glucosamine ABC 
transport system, permease 
protein 
- none - 591530 592576 + 
mnas_490 ABC transporter 
permease protein ugpE 
ugpE   592520 593543 + Transport and binding 
proteins: Unknown 
substrate 
peg.623 ABC transporter permease 
protein 
- none - 592554 593543 + 
mnas_491 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
593545 593821 + Unknown: General peg.624 hypothetical protein - none - 593546 593821 + 
mnas_492 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
593823 595719 + Unknown: General           
mnas_493 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
595725 596658 + Unknown: General peg.625 hypothetical protein - none - 595786 596658 + 
mnas_494 tRNA-Gly      597015 596941  -   rna.22 tRNA-Gly-TCC - none - 597015 596945 - 
mnas_495 tRNA-Arg     597174 597097  -   rna.23 tRNA-Arg-ACG - none - 597174 597101 - 
mnas_496 tRNA-Cys      597257  597182  -   rna.24 tRNA-Cys-GCA - none - 597257 597186 - 
mnas_497 modification methylase 
BanI  
(EC 2.1.1.37) 
banI
M 
GO:0003677,
GO:0009307,
GO:0003886 
597393 598746 + Cellular processes: 
Other,  
Transport and binding 
proteins: Unknown 
substrate,  
Unknown: Enzymes of 
unknown specificity 
peg.626 DNA-cytosine 
methyltransferase (EC 
2.1.1.37) 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial 
597394 598746 + 
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mnas_498 endonuclease/Exonucl
ease/phosphatase 
family protein 
    598815 599928 - Unknown: Enzymes of 
unknown specificity 
peg.627 membrane nuclease - none - 599928 598816 - 
mnas_499 aspartate-ammonia 
ligase  
(EC 6.3.1.1) 
asnA    599974 600955 - Unclassified: Role 
category not yet 
assigned 
peg.628 Aspartate--ammonia ligase 
(EC 6.3.1.1) 
Category: Amino Acids and 
Derivatives 
Subcategory: Glutamine, 
glutamate, aspartate, 
asparagine; ammonia 
assimilation 
Subsystem: Glutamine, 
Glutamate, Aspartate and 
Asparagine Biosynthesis 
600955 599975 - 
mnas_500 smr domain protein     600962 601280 - Unknown: General 
Hypothetical  
peg.629 unknown; predicted coding 
region 
- none - 601280 600963 - 
mnas_501 isochorismatase family 
protein 
    601267 601564 - Unknown: Enzymes of 
unknown specificity 
peg.630 hypothetical protein - none - 601450 601268 - 
mnas_502 putative hydrolase   GO:0016787 601570 602803 - Unknown: Enzymes of 
unknown specificity 
          
mnas_503 putative hydrolase 
domain protein 
  GO:0016787 602847 603048 - Unknown: Enzymes of 
unknown specificity 
peg.631 Ribonuclease J2 
(endoribonuclease in RNA 
processing) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: Ribonucleases in 
Bacillus 
Subsystem: Bacterial RNA-
metabolizing Zn-dependent 
hydrolases 
603048 602848 - 
mnas_504 pyruvate kinase  
(EC 2.7.1.40) 
pyk GO:0004743,
GO:0005737,
GO:0006096 
603175 604609 - Energy metabolism: 
Glycolysis/gluconeogen
esis 
peg.632 Pyruvate kinase (EC 2.7.1.40) Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Pyruvate 
metabolism I: anaplerotic 
reactions, PEP 
Subsystem: Glycolysis and 
Gluconeogenesis;  
604609 603176 - 
mnas_505 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
604675 605578 - Unknown: General peg.633 hypothetical protein - none - 605578 604676 - 
mnas_506 ribosome biogenesis 
GTP-binding protein 
YsxC 
ysxC GO:0003924,
GO:0005525,
GO:0005737,
GO:0042254,
GO:0043022 
605567 606158 - Unclassified: Role 
category not yet 
assigned 
peg.634 GTP-binding protein EngB Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
606158 605568 - 
mnas_507 acetate kinase 
(EC 2.7.2.1) 
ackA GO:0005737,
GO:0006083,
GO:0006113,
GO:0008776 
606159 607281 - Energy metabolism: 
Fermentation 
peg.635 Acetate kinase  
(EC 2.7.2.1) 
Category: Carbohydrates 
Subcategory: Fermentation 
Subsystem: Fermentations: 
Lactate 
607185 606160 - 
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mnas_508 hsp70 family protein     607297 607717 + Protein fate: Protein 
folding and stabilization
peg.15 Chaperone protein DnaK Category: Protein Metabolism 
Subcategory: Protein folding 
Subsystem: Protein chaperones
 
Category: Stress Response 
Subcategory: Heat shock 
Subsystem: Heat shock dnaK 
gene cluster extended 
607388 607717 + 
mnas_509 phosphoglucose 
isomerase family 
protein 
    607836 609141 + Energy metabolism: 
Pentose phosphate 
pathway 
peg.16 Glucose-6-phosphate 
isomerase  
(EC 5.3.1.9) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Glycolysis and 
Gluconeogenesis 
607837 609141 + 
mnas_510 RNA pseudouridylate 
synthase family protein 
    609140 609644 + Protein synthesis: 
tRNA and rRNA base 
modification 
peg.17 Ribosomal small subunit 
pseudouridine synthase A 
(EC 4.2.1.70) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA pseudouridine 
syntheses 
609141 609865 + 
mnas_511 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
609709 609865 + Unknown: General           
mnas_512 neisseria meningitidis 
TspB family protein 
    609854 611543 + Unclassified: Role 
category not yet 
assigned 
peg.18 hypothetical lipoprotein - none - 609855 611543 + 
mnas_513 Phosphopentomutase 
(EC 5.4.2.7) 
deoB GO:0006139,
GO:0008973 
611597 612788 - Purines, pyrimidines, 
nucleosides, and 
nucleotides: Other 
peg.19 Phosphopentomutase (EC 
5.4.2.7) 
- none - 612788 611598 - 
mnas_514 dUTPase family protein     613000 613219 + Unclassified: Role 
category not yet 
assigned 
peg.20 hypothetical protein - none - 613070 613219 + 
mnas_515 tRNA-Leu      613243 613327 +   rna.1 tRNA-Leu-CAA - none - 613244 613324 + 
mnas_516 ahpC/TSA family 
protein 
    613365 613863 + Cellular processes: 
Detoxification, Cellular 
processes: Adaptations 
to atypical conditions 
peg.21 Thiol peroxidase, Tpx-type 
(EC 1.11.1.15) 
Category: Sulfur Metabolism 
Subcategory: no subcategory 
Subsystem: Thioredoxin-
disulfide reductase 
613366 613863 + 
mnas_517 aminopeptidase 
domain protein  
(EC 3.4.11.-) 
celM
2 
GO:0004177,
GO:0016787 
613864 614053 + Unknown: Enzymes of 
unknown specificity 
peg.22 hypothetical protein - none - 613865 614053 + 
mnas_518 M42 glutamyl 
aminopeptidase family 
protein 
    614052 614949 + Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.23 Endo-1,4-beta-glucanase - none - 614068 614949 + 
mnas_519 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
615080 615446 + Unknown: Conserved peg.24 hypothetical protein - none - 615210 615446 + 
mnas_520 NUDIX domain protein     615484 615934 - Unknown: Enzymes of 
unknown specificity 
peg.25 MutT/nudix family protein - none - 615934 615485 - 
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mnas_521 ribosomal protein S2 rpsB GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
616187 617054 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.26 SSU ribosomal protein S2p 
(SAe) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
Subsystem: Ribosome 
recycling related cluster 
616188 617054 + 
mnas_522 translation elongation 
factor Ts 
tsf GO:0003746,
GO:0006414 
617095 617974 + Protein synthesis: 
Translation factors 
peg.27 Translation elongation factor 
Ts 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
elongation factors bacterial 
Subsystem: Ribosome 
recycling related cluster 
617096 617974 + 
mnas_523 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
618098 61Gener
al 
Unknow
n9 
+ Cell envelope: Other           
mnas_524 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
618594 622437 + Unknown: General peg.28 Siderophore-mediated iron 
transport protein 
- none - 618595 622437 + 
mnas_525 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
622451 623906 + Cell envelope: Other           
mnas_526 chromate transporter 
family protein 
    623910 624492 + Transport and binding 
proteins: Anions 
peg.29 Chromate transport protein - none - 623947 624492 + 
mnas_527 chromate transporter 
family protein 
    624491 625139 + Transport and binding 
proteins: Anions 
peg.30 chromate ion transporter 
(CHR) family, putative 
- none - 624492 625139 + 
mnas_528 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
625754 626051 + Unknown: General peg.31 hypothetical protein - none - 625863 626051 + 
                peg.32 putative - none - 626843 627547 + 
mnas_529 eco57I restriction-
modification methylase 
family protein 
    627536 628559 - DNA metabolism: 
Restriction/modification
peg.33 N6 adenine-specific DNA 
methyltransferase, N12 class 
- none - 628559 627537 - 
mnas_530 putative restriction 
endonuclease Hpy8I 
  GO:0004519 626842 627547 + Unknown: Enzymes of 
unknown specificity 
          
mnas_531 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
628740 629073 - Unknown: General peg.34 hypothetical protein - none - 628992 628741 - 
mnas_532 anticodon binding 
domain protein 
    629093 629480 + Unknown: General 
Hypothetical  
peg.35 Threonyl-tRNA synthetase 
(EC 6.1.1.3) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Thr 
629127 629480 + 
mnas_533 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
629472 630051 + Unknown: General peg.36 hypothetical protein - none - 629473 630051 + 
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mnas_534 PTS system, 
glucose/glucosamine/b
eta-glucoside-specific 
(EC 2.7.1.69) 
    630093 630882 - Unknown: Enzymes of 
unknown specificity 
peg.37 PTS system, N-
acetylglucosamine-specific 
IIA component (EC 2.7.1.69) / 
PTS system, N-
acetylglucosamine-specific 
IIB component (EC 2.7.1.69) / 
PTS system, N-
acetylglucosamine-specific 
IIC component (EC 2.7.1.69) 
- none - 630882 630094 - 
mnas_535 ribosomal protein 
L7/L12 
rplL GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
631037 631409 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.38 LSU ribosomal protein L7/L12 
(P1/P2) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
 
Subsystem: LSU ribosomal 
proteins cluster 
631409 631038 - 
mnas_536 50S ribosomal protein 
L10 
rplJ GO:0005840,
GO:0042254,
GO:0006412,
GO:0006950,
GO:0003735 
631440 631938 - Cellular processes: 
Other,  
Cellular processes: 
Adaptations to atypical 
conditions 
peg.39 LSU ribosomal protein L10p 
(P0) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
 
Subsystem: LSU ribosomal 
proteins cluster
631938 631441 - 
mnas_537 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
632180 632645 - Unknown: General peg.40 hypothetical protein - none - 632609 632181 - 
mnas_538 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
632629 633916 - Unknown: General peg.41 Sialidase NanB  
(EC 3.2.1.18) 
- none - 633445 632630 - 
mnas_539 ruvA, C-terminal 
domain protein 
    633980 634598 + Unknown: General 
Hypothetical  
peg.42 Holliday junction DNA 
helicase RuvA 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
Subcategory: DNA 
recombination 
Subsystem: RuvABC plus a 
hypothetical 
633981 634598 + 
mnas_540 holliday junction DNA 
helicase RuvB  
(EC 3.6.4.12) 
ruvB GO:0006310,
GO:0009378,
GO:0009379 
634572 635526 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.43 Holliday junction DNA 
helicase RuvB 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
Subcategory: DNA 
recombination 
Subsystem: RuvABC plus a 
hypothetical 
634573 635526 + 
mnas_541 export membrane 
protein SecF 
secF GO:0015450,
GO:0031522,
GO:0043952 
635590 638176 + Protein fate:Protein and 
peptide secretion and 
trafficking 
peg.44 Protein-export membrane 
protein SecD  
(TC 3.A.5.1.1) / Protein-
export membrane protein 
SecF  
(TC 3.A.5.1.1) 
- none - 635591 638176 + 
mnas_542 GIY-YIG catalytic 
domain protein 
    638639 639758 - DNA metabolism: 
Restriction/modification
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mnas_543 recombination U family 
protein 
    638276 638639 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
          
mnas_544 NADPH-dependent 
FMN reductase family 
protein 
    639818 640409 - Energy metabolism: 
Electron transport 
peg.45 FMN-dependent NADH-
azoreductase 
- none - 640409 639819 - 
mnas_545 NADPH-dependent 
FMN reductase family 
protein 
    640414 641005 - Energy metabolism: 
Electron transport 
peg.46 FMN-dependent NADH-
azoreductase 
- none - 641005 640415 - 
mnas_546 tRNA-Ser      641317 641408  +   rna.2 tRNA-Pseudo-GCT - none - 641318 641405 + 
mnas_547 triose-phosphate 
isomerase  
(EC 5.3.1.1) 
tpiA GO:0004807,
GO:0006096 
641493 642237 + Energy metabolism: 
Glycolysis/gluconeogen
esis 
peg.47 Triosephosphate isomerase 
(EC 5.3.1.1) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Glycolysis and 
Gluconeogenesis 
641494 642237 + 
mnas_548 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
643188 644022 - Unknown: General           
mnas_549 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
642223 643192 + Unknown: General           
mnas_550 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
644182 644398 + Unknown: Conserved peg.48 FIG00837018: hypothetical 
protein 
- none - 644183 644398 + 
mnas_551 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
644504 645458 - Unknown: General peg.49 predicted coding region - none - 645458 644505 - 
mnas_552 pseudouridine 
synthase, RluA family 
protein  
(EC 5.4.99.-) 
  GO:0001522,
GO:0009451,
GO:0009982 
645458 646388 - Protein synthesis: 
tRNA and rRNA base 
modification 
peg.50 Ribosomal large subunit 
pseudouridine synthase D 
(EC 4.2.1.70) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: RNA pseudouridine 
syntheses  
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome 
biogenesis bacterial 
646388 645459 - 
mnas_553 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
646482 646980 - Unknown: Conserved peg.51 hypothetical protein - none - 646980 646483 - 
mnas_554 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
646955 647645 - Unknown: Conserved peg.52 hypothetical protein - none - 647264 646956 - 
mnas_555 zinc finger found in 
FPG and IleRS family 
protein 
    647663 648242 + Unclassified: Role 
category not yet 
assigned 
peg.53 Isoleucyl-tRNA synthetase 
(EC 6.1.1.5) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Ile 
647673 648242 + 
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mnas_556 signal peptidase 
(SPase) II family 
protein 
    648250 648964 + Protein fate:Protein and 
peptide secretion and 
trafficking 
peg.54 Lipoprotein signal peptidase 
(EC 3.4.23.36) 
Category: Protein Metabolism 
Subcategory: Protein 
processing and modification 
Subsystem: Signal peptidase 
 
Subsystem: Lipoprotein 
Biosynthesis 
648251 648964 + 
mnas_557 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
649069 650386 + Unknown: Conserved peg.55 Conserved expressed protein - none - 649070 650386 + 
mnas_558 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
650471 650714 + Unknown: General peg.56 hypothetical protein - none - 650472 650714 + 
mnas_559 ribosomal protein L21 rplU GO:0000311,
GO:0003735,
GO:0006412,
GO:0022625 
650820 651120 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.57 LSU ribosomal protein L21p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
 
650821 651120 + 
mnas_560 ribosomal protein L27 rpmA GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
651127 651388 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.58 LSU ribosomal protein L27p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
651128 651388 + 
mnas_561 DNA recombination-
mediator A family 
protein 
    651448 652006 - Unclassified: Role 
category not yet 
assigned 
peg.59 SMF family protein, DNA 
processing chain A (dprA) 
- none - 651943 651449 - 
mnas_562 integrase core domain 
protein 
    652014 652500 - Unknown: General 
Hypothetical  
          
mnas_563 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
652676 652895 - Unknown: General           
mnas_564 ABC transporter family 
protein 
    653065 654874 + Transport and binding 
proteins: Unknown 
substrate 
peg.60 FIG00836097: hypothetical 
protein 
- none - 653066 654874 + 
mnas_565 ABC transporter 
transmembrane region 
family protein 
    654882 656322 + Transport and binding 
proteins: Unknown 
substrate 
          
mnas_566 large-conductance 
mechanosensitive 
channel, MscL family 
protein 
    656550 656955 - Transport and binding 
proteins: Unknown 
substrate 
peg.81 Large-conductance 
mechanosensitive channel 
Category: Potassium 
metabolism 
Subcategory: Potassium 
metabolism 
Subsystem: Potassium 
homeostasis 
656955 656551 - 
mnas_567 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
657185 658805 + Unknown: General peg.82 hypothetical protein - none - 657186 658805 + 
mnas_568 ribosomal protein S4 rpsD GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
659041 659641 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.83 SSU ribosomal protein S4p 
(S9e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
659042 659641 + 
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mnas_569 ribosomal protein L31 rpmE GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
659658 659868 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.84 LSU ribosomal protein L31p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
659659 659868 + 
mnas_570 uvrC Helix-hairpin-helix 
N-terminal family 
protein 
    660055 660577 - Unclassified: Role 
category not yet 
assigned 
peg.85 Excinuclease ABC subunit C Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
UvrABC system 
660394 660056 - 
mnas_571 DNA polymerase III, 
delta subunit 
holA   660635 661577 - DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.86 DNA polymerase III delta 
subunit  
(EC 2.7.7.7) 
Category: DNA Metabolism 
Subcategory: DNA replication 
Subsystem: DNA-replication 
661577 660636 - 
mnas_572 comEC/Rec2-related 
domain protein 
    661589 662885 - Unknown: General 
Hypothetical  
peg.87 hypothetical protein - none - 662885 661590 - 
mnas_573 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
662905 663325 - Unknown: General peg.88 hypothetical protein - none - 663364 662906 - 
mnas_574 uracil 
phosphoribosyltransfer
ase  
(EC 2.4.2.9) 
upp GO:0004845,
GO:0008655 
664082 664712 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Salvage of 
nucleosides and 
nucleotides 
peg.89 Uracil 
phosphoribosyltransferase 
(EC 2.4.2.9) 
- none - 664083 664712 + 
mnas_575 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
664860 665001 + Unknown: General           
mnas_576 Oligopeptide ABC 
transporter system, 
permeaseprotein 
(OppC) 
OppC   665000 666362 + Transport and binding 
proteins: Unknown 
substrate 
peg.90 Oligopeptide transport system 
permease protein OppC  
(TC 3.A.1.5.1) 
Category: Membrane Transport 
Subcategory: ABC transporters 
Subsystem: ABC transporter 
oligopeptide (TC 3.A.1.5.1)  
665001 666362 + 
mnas_577 Oligopeptide ABC 
transporter, ATP-
binding protein OppD 
oppD GO:0005524,
GO:0009898,
GO:0015440,
GO:0015833,
GO:0043190 
666374 667421 + Transport and binding 
proteins: Amino acids, 
peptides and amines 
peg.91 Oligopeptide transport ATP-
binding protein OppD  
(TC 3.A.1.5.1) 
Category: Membrane Transport 
Subcategory: ABC transporters 
Subsystem: ABC transporter 
oligopeptide (TC 3.A.1.5.1)  
666375 667421 + 
mnas_578 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
669019 669571 - Unknown: Conserved           
mnas_579 ABC superfamily ATP 
binding cassette 
transporter, ABC 
domain protein  
(EC 3.6.3.24) 
nikE GO:0005524,
GO:0016787,
GO:0000166,
GO:0017111,
GO:0006200,
GO:0015833,
GO:0015413,
GO:0016887 
667413 669027 + Cellular processes: 
Other, 
Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
          
mnas_580 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
669549 670995 - Cell envelope: Other peg.92 FIG065159: hypothetical 2 
cooccurring with ATP 
synthase chains 
- none - 670995 669550 - 
mnas_581 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
671013 673176 - Unknown: General peg.93 Siderophore-mediated iron 
transport protein 
- none - 673047 671014 - 
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mnas_582 5s_rRNA     673329  673226 -   rna.5 5S RNA - none - 673333 673227 - 
mnas_583 60Kd inner membrane 
family protein 
    673412 675431 - Cell envelope: Other peg.94 Inner membrane protein 
translocase component YidC, 
long form 
Subsystem: Cell Division 
Subsystem including YidCD 
 
Subsystem: RNA modification 
cluster 
675395 673413 - 
mnas_584 ribonuclease P protein 
component  
(EC 3.1.26.5) 
rnpA GO:0004526,
GO:0006396 
675381 675720 - Transcription: RNA 
processing 
peg.95 Ribonuclease P protein 
component  
(EC 3.1.26.5) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: tRNA processing 
Subsystem: Cell Division 
Subsystem including YidCD 
Subsystem: RNA modification 
cluster 
675720 675382 - 
mnas_585 ribosomal protein L34 rpmH GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
675734 675881 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.96 LSU ribosomal protein L34p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
Subsystem: Cell Division 
Subsystem including YidCD 
Subsystem: RNA modification 
cluster 
675881 675735 - 
mnas_586 serine--tRNA ligase 
(EC 6.1.1.11) 
serS GO:0004828,
GO:0005737,
GO:0006434 
676092 677319 + Protein synthesis: 
tRNA aminoacylation 
          
mnas_587 preprotein translocase, 
SecY subunit 
secY GO:0005887,
GO:0015450,
GO:0043952 
677514 678822 + Protein fate:Protein and 
peptide secretion and 
trafficking 
peg.97 Preprotein translocase secY 
subunit  
(TC 3.A.5.1.1) 
- none - 677533 678822 + 
mnas_588 adenylate kinase  
(EC 2.7.4.3) 
adk   678815 679481 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Nucleotide 
and nucleoside 
interconversions 
peg.98 Adenylate kinase  
(EC 2.7.4.3) 
Category: Nucleosides and 
Nucleotides 
Subcategory: Purines 
Subsystem: Purine conversions
678816 679481 + 
mnas_589 methionine 
aminopeptidase, type I 
(EC 3.4.11.18) 
map GO:0004239,
GO:0006464 
679496 680267 + Protein fate: Protein 
modification and repair 
peg.99 Methionine aminopeptidase 
(EC 3.4.11.18) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
termination factors bacterial 
679515 680267 + 
mnas_590 translation initiation 
factor IF-1 
infA GO:0003743,
GO:0006413 
680267 680483 + Protein synthesis: 
Translation factors 
peg.100 Translation initiation factor 1 Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
initiation factors bacterial 
680268 680483 + 
mnas_591 ribosomal protein L36 rpmJ GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
680497 680611 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.101 LSU ribosomal protein L36p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
680498 680611 + 
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mnas_592 30S ribosomal protein 
S13 
rpsM GO:0003735,
GO:0006412,
GO:0022627 
680645 681011 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.102 SSU ribosomal protein S13p 
(S18e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
680646 681011 + 
mnas_593 ribosomal S11 family 
protein 
    681117 681414 + Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.103 SSU ribosomal protein S11p 
(S14e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
681018 681224 + 
mnas_594 PQ loop repeat family 
protein 
    681803 682541 + Unclassified: Role 
category not yet 
assigned 
peg.104 predicted coding region - none - 681804 682541 + 
mnas_595 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
683097 684696 - Unknown: General peg.105 hypothetical protein - none - 684771 683098 - 
mnas_596 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
684727 685366 - Unknown: General peg.106 hypothetical protein - none - 685339 684728 - 
mnas_597 phosphoglycerate 
kinase  
(EC 2.7.2.3) 
  GO:0004618 685368 686469 - Energy metabolism: 
Glycolysis/gluconeogen
esis 
          
mnas_598 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
686587 687697 - Unknown: General peg.107 hypothetical protein - none - 687697 686588 - 
mnas_599 lemA family protein     687732 688386 - Unclassified: Role 
category not yet 
assigned 
peg.108 LemA PROTEIN - none - 688386 687733 - 
mnas_600 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
688508 689003 - Unknown: General peg.109 hypothetical protein - none - 689003 688509 - 
mnas_601 Oligopeptide ABC 
transporter, ATP-
binding protein OppF 
oppF   688995 689301 - Transport and binding 
proteins: Unknown 
substrate 
peg.110 Oligopeptide ABC transporter 
ATP-binding protein 
- none - 689271 688996 - 
mnas_602 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
689313 690792 + Unknown: General peg.111 predicted coding region - none - 689443 690792 + 
mnas_603 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
690809 691469 + Unknown: Conserved peg.112 Cysteinyl-tRNA synthetase 
related protein 
CBSS-261594.1.peg.788 690810 691469 + 
mnas_604 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
691558 692149 - Unknown: General peg.113 hypothetical protein - none - 692149 691559 - 
mnas_605 sigma-70, region 4 
family protein 
    692240 692465 - Unclassified: Role 
category not yet 
assigned 
peg.114 hypothetical protein - none - 692450 692241 - 
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mnas_606 signal recognition 
particle-docking protein 
FtsY 
ftsY GO:0003924,
GO:0005047,
GO:0009306 
692457 693084 - Protein fate:Protein and 
peptide secretion and 
trafficking 
peg.115 Signal recognition particle 
receptor protein FtsY (=alpha 
subunit)  
(TC 3.A.5.1.1) 
Category: Membrane Transport 
Subcategory: Protein 
translocation across cytoplasmic 
membrane 
Subsystem: Bacterial signal 
recognition particle (SRP) 
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
693084 692458 - 
mnas_607 DNA ligase, NAD-
dependent  
(EC 6.5.1.2) 
ligA GO:0003911,
GO:0006260,
GO:0006281,
GO:0006310 
693519 695565 - DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.116 DNA ligase  
(EC 6.5.1.2) 
Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA Repair Base 
Excision 
695565 693520 - 
mnas_608 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
695711 696842 + Unknown: General peg.117 hypothetical protein - none - 695712 696842 + 
mnas_609 phage integrase family 
protein 
    696894 697806 - DNA metabolism: DNA 
replication, 
recombination, and 
repair,  
Mobile and 
extrachromosomal 
element functions: 
Prophage functions 
          
mnas_610 collagen triple helix 
repeat family protein 
    698876 699716 + Unclassified: Role 
category not yet 
assigned 
peg.139 Phage tail fiber protein Category: Phage packaging 
machinPhages, Prophages, 
Transposable elements, 
Plasmids 
Subcategory: Phages, 
Prophages 
Subsystem: Phage tail fiber 
proteins 
698877 699716 + 
mnas_611 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
699772 700552 + Unknown: General           
mnas_612 peptidase M60-like 
family protein 
    700552 701815 - Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
          
mnas_613 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
701851 703735 - Unknown: General peg.140 hypothetical protein - none - 703507 701852 - 
mnas_614 ATP synthase 
alpha/beta family, 
nucleotide-binding 
domain protein  
(EC 3.6.3.14) 
atpA   703767 704628 + Energy metabolism: 
ATP-proton motive 
force interconversion 
peg.141 ATP synthase alpha chain 
(EC 3.6.3.14) 
- none - 703768 704628 + 
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mnas_615 ATP synthase F1, beta 
subunit  
(EC 3.6.3.14) 
atpD GO:0000275,
GO:0015986,
GO:0045261,
GO:0045262,
GO:0046933 
704627 705989 + Energy metabolism: 
ATP-proton motive 
force interconversion 
peg.142 ATP synthase beta chain  
(EC 3.6.3.14) 
- none - 704628 705989 + 
mnas_616 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
706000 706936 + Unknown: Conserved           
mnas_617 metalloenzyme 
superfamily protein 
    706936 707713 - Unclassified: Role 
category not yet 
assigned 
          
mnas_618 protein-(glutamine-N5) 
methyltransferase, 
release factor-specific 
(EC 2.1.1.-) 
prmC GO:0006412,
GO:0008757,
GO:0018364 
707723 708449 - Unknown: Enzymes of 
unknown specificity 
peg.143 Protein-N(5)-glutamine 
methyltransferase PrmC, 
methylates polypeptide chain 
release factors RF1 and RF2 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
termination factors bacterial 
708449 707724 - 
mnas_619 peptide chain release 
factor 1 
prfA GO:0003747,
GO:0006415 
708448 709513 - Protein synthesis: 
Translation factors 
peg.144 Peptide chain release factor 1 Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
termination factors bacterial 
709513 708449 - 
mnas_620 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
709608 710049 - Cell envelope: Other peg.145 Amino acid permease - none - 709983 709609 - 
mnas_621 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
710069 710993 + Cell envelope: Other peg.146 hypothetical protein - none - 710163 710993 + 
mnas_622 signal recognition 
particle protein 
ffh GO:0003924,
GO:0005048,
GO:0009306,
GO:0048501 
711337 712693 + Protein fate:Protein and 
peptide secretion and 
trafficking 
peg.147 Signal recognition particle, 
subunit Ffh SRP54  
(TC 3.A.5.1.1) 
Category: Membrane Transport 
Subcategory: Protein 
translocation across cytoplasmic 
membrane 
Subsystem: Bacterial signal 
recognition particle (SRP) 
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
711383 712693 + 
mnas_623 tRNA-Thr      712768 712843 +   rna.6 tRNA-Thr-GGT - none - 712769 712840 + 
mnas_624 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
713229 716046 - Unknown: General peg.148 contains gram positive anchor 
domain 
- none - 715617 713230 - 
mnas_625 mraW methylase family 
protein 
    716062 716491 + Unknown: Enzymes of 
unknown specificity 
peg.149 rRNA small subunit 
methyltransferase H 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: 16S rRNA 
modification within P site of 
ribosome 
716285 716491 + 
mnas_626 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
716507 717770 + Unknown: General peg.150 hypothetical protein - none - 716676 717770 + 
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mnas_627 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
717769 718930 + Unknown: General peg.151 hypothetical protein - none - 717770 718930 + 
mnas_628 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
719004 719304 + Unknown: General           
mnas_629 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
719294 721619 + Unknown: General peg.152 FIG057547: hypothetical 
cooccurring with ATP 
synthase chains 
- none - 719295 721619 + 
mnas_630 Putative ATP synthase 
alpha chain domain 
protein 
  GO:0045261,
GO:0015986,
GO:0016787,
GO:0005524,
GO:0046933,
GO:0046961 
721618 721891 + Cellular processes: 
Other, 
Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
          
mnas_631 obg family GTPase 
CgtA 
cgtA GO:0005525,
GO:0042254 
722034 723309 - Protein synthesis: 
Other 
peg.153 GTP-binding protein Obg Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
723309 722035 - 
mnas_632 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
723422 724283 + Unknown: General peg.154 hypothetical protein - none - 723423 724283 + 
mnas_633 bacterial DNA-binding 
family protein 
    724369 724666 + DNA metabolism: 
Chromosome-
associated proteins 
peg.155 Integration host factor 
alpha/beta 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: DNA structural 
proteins, bacterial 
724370 724666 + 
mnas_634 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
724789 725398 + Unknown: General peg.156 hypothetical protein - none - 724829 725398 + 
mnas_635 tRNA-His      725837 725913 +   rna.7 tRNA-His-GTG - none - 725838 725910 + 
mnas_636 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
726121 727603 + Cell envelope: Other           
mnas_637 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
727607 728645 + Unknown: General peg.162 hypothetical protein - none - 727860 728645 + 
mnas_638 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
728684 730373 - Unknown: General peg.163 hypothetical protein - none - 730286 728685 - 
mnas_639 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
730389 730800 + Cell envelope: Other peg.164 hypothetical protein - none - 730546 730800 + 
mnas_640 proline--tRNA ligase 
(EC 6.1.1.15) 
proS GO:0004827,
GO:0006433 
730877 732368 + Protein synthesis: 
tRNA aminoacylation 
peg.165 Prolyl-tRNA synthetase  
(EC 6.1.1.15), 
archaeal/eukaryal type 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Pro 
730911 732368 + 
mnas_641 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
732586 733084 + Unknown: General peg.166 hypothetical protein - none - 732587 733084 + 
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mnas_642 16s_rRNA   733261 734756 
+   rna.8 Small Subunit Ribosomal 
RNA; ssuRNA; SSU rRNA 
- none - 733282 734818 + 
                rna.9 Large Subunit Ribosomal 
RNA; lsuRNA; LSU rRNA 
- none - 735059 735903 + 
mnas_643 Putative ATP synthase 
alpha chain domain 
protein 
  GO:0045261,
GO:0015986,
GO:0016787,
GO:0005524,
GO:0046933,
GO:0046961 
735919 736192 - Cellular processes: 
Other, 
Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
          
mnas_644 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
736191 738369 - Unknown: General peg.167 FIG057547: hypothetical 
cooccurring with ATP 
synthase chains 
- none - 738369 736192 - 
mnas_645 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
738359 738659 - Unknown: General           
mnas_646 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
738677 738941 + Unknown: General peg.168 hypothetical protein - none - 738747 738941 + 
mnas_647 cytidylate kinase  
(EC 2.7.4.14) 
cmk GO:0004127,
GO:0015949 
738992 739673 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Nucleotide 
and nucleoside 
interconversions 
peg.169 Cytidylate kinase  
(EC 2.7.4.25) 
- none - 738993 739673 + 
mnas_648 ribosome-associated 
GTPase EngA 
engA GO:0003924,
GO:0005525,
GO:0005737,
GO:0042254,
GO:0043022 
739665 740979 + Unclassified: Role 
category not yet 
assigned 
peg.170 GTP-binding protein EngA Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
739666 740979 + 
mnas_649 ribosomal protein L28 rpmB GO:0000311,
GO:0003735,
GO:0006412,
GO:0022625 
741085 741277 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.171 LSU ribosomal protein L28p 
@ LSU ribosomal protein 
L28p, zinc-independent 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
741277 741086 - 
mnas_650 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
741374 744044 + Unknown: General           
mnas_651 energy-coupling factor 
transporter ATP-
binding EcfA 1 domain 
protein  
(EC 3.6.3.-) 
ecfA1 GO:0006810,
GO:0016787,
GO:0005524,
GO:0000166,
GO:0006200,
GO:0005886,
GO:0016887 
744048 744384 + Cellular processes: 
Other, 
Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
peg.172 ATPase component of 
general energizing module of 
ECF transporters 
- none - 744082 744384 + 
mnas_652 energy-coupling factor 
transporter ATP-
binding protein EcfA2 
(EC 3.6.3.-) 
ecfA2 GO:0006824,
GO:0016820,
GO:0005524,
GO:0005886,
GO:0016887 
744374 745718 + Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
peg.173 ATPase component of 
general energizing module of 
ECF transporters 
- none - 744375 745718 + 
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mnas_653 energy-coupling factor 
transporter 
transmembrane protein 
EcfT 
ecfT GO:0015087,
GO:0016021,
GO:0009236,
GO:0005886 
745717 746698 + Cellular processes: 
Other, 
Transport and binding 
proteins: Unknown 
substrate 
          
                peg.175 hypothetical protein - none - 748105 748272 + 
mnas_654 putative membrane 
protein 
  GO:0008150,
GO:0003674,
GO:0016020 
746762 748139 - Cell envelope: Other peg.174 Unspecified monosaccharide 
ABC transport system, ATP-
binding protein 
- none - 748139 746763 - 
mnas_655 Putative Sugar ABC 
transporter ATP-
binding protein 
mglA   748233 749064 - Transport and binding 
proteins: Unknown 
substrate 
peg.176 Unspecified monosaccharide 
ABC transport system, ATP-
binding protein 
- none - 748917 748234 - 
mnas_656 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
749080 750265 + Unknown: General peg.177 hypothetical protein - none - 749207 750265 + 
mnas_657 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
750251 750698 + Unknown: General peg.178 hypothetical protein - none - 750252 750698 + 
mnas_658 phosphopantetheine 
attachment site family 
protein 
    750705 750924 + Unclassified: Role 
category not yet 
assigned 
peg.179 hypothetical protein - none - 750706 750924 + 
mnas_659 tRNA-SeC      750949 751024 +   rna.10 tRNA-SeC-TCA - none - 750950 751021 + 
mnas_660 basic membrane family 
protein 
    751354 752332 - Cell envelope: Other           
mnas_661 NAD-dependent 
glycerol-3-phosphate 
dehydrogenase  
(EC 1.1.1.94) 
    751067 751358 + Energy metabolism: 
Other 
          
mnas_662 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
752542 752701 - Unknown: General peg.180 hypothetical protein - none - 752701 752543 - 
mnas_663 inorganic 
pyrophosphatase 
family protein 
    752851 753406 - Central intermediary 
metabolism: 
Phosphorus 
compounds 
peg.181 Inorganic pyrophosphatase 
(EC 3.6.1.1) 
Category: Phosphorus 
Metabolism 
Subcategory: no subcategory 
Subsystem: Phosphate 
metabolism 
753406 752852 - 
mnas_664 ribosomal protein L32 rpmF GO:0000315,
GO:0003735,
GO:0006412,
GO:0022625 
753660 753861 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.198 LSU ribosomal protein L32p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
753861 753661 - 
                peg.199 FIG007079: UPF0348 protein 
family 
- none - 754166 755134 + 
mnas_665 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
755123 755810 - Unknown: General peg.200 hypothetical protein - none - 755651 755124 - 
mnas_666 cytidyltransferase-like 
domain protein 
    754165 755134 + Unknown: Enzymes of 
unknown specificity 
          
mnas_667 PD-(D/E)XK nuclease 
superfamily protein 
    755814 756633 - Unclassified: Role 
category not yet 
assigned 
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mnas_668 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
756656 757046 - Unknown: General peg.201 hypothetical protein - none - 757046 756657 - 
mnas_669 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
757164 757398 - Unknown: General peg.202 hypothetical protein - none - 757398 757165 - 
mnas_670 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
757502 758021 - Unknown: General peg.203 hypothetical protein - none - 757916 757503 - 
mnas_671 pyrimidine-nucleoside 
phosphorylase family 
protein  
(EC 2.4.2.2) 
pdp GO:0006213,
GO:0016154 
758052 759222 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Other 
peg.204 Pyrimidine-nucleoside 
phosphorylase  
(EC 2.4.2.2) 
- none - 758053 759222 + 
mnas_672 deoxyribose-phosphate 
aldolase  
(EC 4.1.2.4) 
deoC GO:0004139,
GO:0009264 
759247 759577 + Purines, pyrimidines, 
nucleosides, and 
nucleotides: Other, 
Energy metabolism: 
Other 
peg.205 Deoxyribose-phosphate 
aldolase  
(EC 4.1.2.4) 
- none - 759248 759911 + 
mnas_673 deoC/LacD aldolase 
family protein 
    759674 759911 + Unknown: Enzymes of 
unknown specificity 
          
mnas_674 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
760153 760660 - Unknown: General           
mnas_675 cof-like hydrolase 
family protein 
  GO:0008152,
GO:0016787 
760876 761701 - Unknown: Enzymes of 
unknown specificity 
peg.206 Hydrolase (HAD superfamily) - none - 761701 760877 - 
mnas_676 TM2 domain protein     761891 762110 + Unknown: General 
Hypothetical  
peg.207 hypothetical protein - none - 761892 762110 + 
mnas_677 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
762151 762259 - Unknown: General           
mnas_678 isoleucine--tRNA ligase 
(EC 6.1.1.5) 
ileS GO:0004822,
GO:0005737,
GO:0006428 
762331 764371 + Protein synthesis: 
tRNA aminoacylation 
          
mnas_679 50S ribosomal protein 
L3 
rplC   764427 765093 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.208 LSU ribosomal protein L3p 
(L3e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
765226 764428 - 
mnas_680 putative lSU ribosomal 
protein L3P 
  GO:0005840,
GO:0006412,
GO:0005622,
GO:0003735 
765061 765226 - Cellular processes: 
Other 
          
mnas_681 ribosomal protein S10 rpsJ GO:0000314,
GO:0003735,
GO:0006412,
GO:0022627 
765261 765570 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.209 SSU ribosomal protein S10p 
(S20e) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome SSU 
bacterial 
765570 765262 - 
mnas_682 thioredoxin family 
protein 
    765767 766109 - Energy metabolism: 
Electron transport 
peg.210 Possible periplasmic 
thiredoxin 
- none - 766109 765768 - 
mnas_683 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
766186 766390 - Unknown: Conserved           
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mnas_684 threonyl and Alanyl 
tRNA synthetase 
second additional 
domain protein 
    766394 767297 - Protein synthesis: 
tRNA aminoacylation 
          
mnas_685 tryptophan--tRNA 
ligase  
(EC 6.1.1.2) 
trpS GO:0004830,
GO:0005737,
GO:0006436 
767304 768297 - Protein synthesis: 
tRNA aminoacylation 
peg.211 Tryptophanyl-tRNA 
synthetase  
(EC 6.1.1.2) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Trp 
768297 767305 - 
mnas_686 DNA gyrase B subunit, 
carboxyl terminus 
family protein  
(EC 5.99.1.-) 
gyrB1   76Gener
al 
Unknown
9 
770429 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
          
mnas_687 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
770437 772243 + Unknown: General peg.212 VlhA.4.04 - none - 770516 772243 + 
mnas_688 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
772296 772401 - Unknown: General           
mnas_689 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
772405 772546 - Unknown: General peg.213 hypothetical protein - none - 774263 772632 - 
mnas_690 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
772487 772619 - Unknown: General           
mnas_691 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
772631 774263 - Unknown: General           
mnas_692 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
774391 775252 + Unknown: General peg.260 hypothetical protein - none - 774809 775252 + 
mnas_693 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
775500 775953 + Unknown: General peg.261 hypothetical protein - none - 775501 775953 + 
mnas_694 glycerol-3-phosphate 
acyltransferase family 
protein 
    776321 776816 + Unknown: Enzymes of 
unknown specificity 
peg.262 Acyl-phosphate:glycerol-3-
phosphate O-acyltransferase 
PlsY 
Category: Fatty Acids, Lipids, 
and Isoprenoids 
Subcategory: Phospholipids 
Subsystem: Glycerolipid and 
Glycerophospholipid Metabolism 
in Bacteria 
776343 776816 + 
mnas_695 phosphopyruvate 
hydratase  
(EC 4.2.1.11) 
eno GO:0004634,
GO:0006096 
776Gene
ral 
Unknown
778227 - Energy metabolism: 
Glycolysis/gluconeogen
esis 
peg.263 Enolase  
(EC 4.2.1.11) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Glycolysis and 
Gluconeogenesis 
778014 776857 - 
mnas_696 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
778276 779878 - Unknown: General peg.264 hypothetical protein - none - 779878 778277 - 
mnas_697 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
779858 780122 - Unknown: General peg.265 hypothetical protein - none - 780104 779859 - 
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mnas_698 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
780243 782001 - Unknown: General peg.266 hypothetical protein - none - 781524 780244 - 
mnas_699 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
782015 782402 + Unknown: General peg.267 hypothetical protein - none - 782067 782402 + 
mnas_700 Putative glucose-6-
phosphate isomerase 
(EC 5.3.1.9) 
  GO:0004347 782379 783636 + Energy metabolism: 
Pentose phosphate 
pathway 
peg.268 Glucose-6-phosphate 
isomerase  
(EC 5.3.1.9) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Glycolysis and 
Gluconeogenesis 
782380 783636 + 
mnas_701 multidrug resistance 
ABC superfamily ATP 
binding cassette 
transporter, membrane 
domain protein  
(EC 3.6.3.42) 
ndvA GO:0006810,
GO:0055085,
GO:0015441,
GO:0005524,
GO:0016787,
GO:0000166,
GO:0006200,
GO:0017111,
GO:0016021,
GO:0016887 
783659 783848 - Cellular processes: 
Other, 
Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
          
mnas_702 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
783858 784389 - Unknown: General           
mnas_703 DNA (cytosine-5-)-
methyltransferase 
family protein  
(EC 2.1.1.37) 
dcm GO:0003886,
GO:0006304 
784390 785557 - DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.269 CPG DNA methylase - none - 785557 784391 - 
mnas_704 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
785842 786892 + Unknown: General peg.270 hypothetical protein - none - 785843 786892 + 
mnas_705 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
786891 787461 + Unknown: General           
mnas_706 protein RecA recA GO:0003677,
GO:0005737,
GO:0006281,
GO:0006310,
GO:0008094,
GO:0009432 
787461 788181 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
peg.271 RecA protein Category: DNA Metabolism 
Subcategory: DNA repair 
Subsystem: DNA repair, 
bacterial 
Subcategory: DNA replication 
Subsystem: DNA-replication 
787684 788181 + 
mnas_707 ymdB-like family 
protein 
    788238 789069 + Unclassified: Role 
category not yet 
assigned 
peg.272 FIG006542: Phosphoesterase - none - 788239 789069 + 
mnas_708 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
789218 789437 + Unknown: General peg.273 hypothetical protein - none - 789437 789775 + 
mnas_709 phage holin family 
protein 
    789436 789775 + Unclassified: Role 
category not yet 
assigned 
          
mnas_710 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
789764 790073 + Unknown: General peg.274 hypothetical protein - none - 789765 790073 + 
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mnas_711 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
790023 790494 + Unknown: General peg.275 hypothetical protein - none - 790024 790494 + 
mnas_712 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
790502 790925 + Unknown: General           
                peg.276 hypothetical protein - none - 790997 791128 + 
mnas_713 HAD ATPase, P-type, 
IC family protein  
(EC 3.6.3.-) 
    791145 792615 + Unclassified: Role 
category not yet 
assigned 
          
mnas_714 ribosomal protein L17 rplQ GO:0003735,
GO:0005762,
GO:0006412,
GO:0022625 
792787 793150 - Protein synthesis: 
Ribosomal proteins: 
synthesis and 
modification 
peg.281 LSU ribosomal protein L17p Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Ribosome LSU 
bacterial 
793150 792788 - 
mnas_715 DNA-directed RNA 
polymerase, alpha 
subunit  
(EC 2.7.7.6) 
rpoA GO:0000345,
GO:0003899,
GO:0006350 
793151 794198 - Transcription: DNA-
dependent RNA 
polymerase 
peg.282 DNA-directed RNA 
polymerase alpha subunit 
(EC 2.7.7.6) 
Category: RNA Metabolism 
Subcategory: Transcription 
Subsystem: RNA polymerase 
bacterial 
794198 793152 - 
mnas_716 DNA methylase family 
protein 
    794260 795649 + DNA metabolism: 
Restriction/modification
peg.283 Type III restriction-
modification system 
methylation subunit  
(EC 2.1.1.72) 
Category: DNA Metabolism 
Subcategory: no subcategory 
Subsystem: Restriction-
Modification System 
794339 795649 + 
mnas_717 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
795658 795868 + Unknown: General           
mnas_718 peptidase S41 family 
protein 
    795892 797401 - Protein fate: 
Degradation of 
proteins, peptides, and 
glycopeptides 
peg.284 hypothetical protein - none - 797401 795893 - 
mnas_719 ribonuclease HII family 
protein 
    797530 798136 - Transcription: 
Degradation of RNA 
peg.285 Ribonuclease HII  
(EC 3.1.26.4) 
Category: RNA Metabolism 
Subcategory: RNA processing 
and modification  
Subsystem: Ribonucleases in 
Bacillus 
Subsystem: Ribonuclease H;  
 
Subsystem: Conserved gene 
cluster associated with Met-
tRNA formyltransferase 
798136 797531 - 
mnas_720 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
798711 799005 - Unknown: General peg.286 hypothetical protein - none - 798188 798715 + 
mnas_721 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
798187 798715 + Unknown: General           
mnas_722 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
799009 800440 - Unknown: Conserved peg.287 hypothetical protein - none - 800082 800477 + 
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mnas_723 16S rRNA 
(guanine(527)-N(7))-
methyltransferase GidB 
(EC 2.1.1.170) 
gidB GO:0005575,
GO:0008168,
GO:0031167,
GO:0046118 
800563 801184 - Unknown: Enzymes of 
unknown specificity 
          
mnas_724 ribose-phosphate 
diphosphokinase family 
protein  
(EC 2.7.6.1) 
prs GO:0004749,
GO:0009152 
801185 802067 - Purines, pyrimidines, 
nucleosides, and 
nucleotides: Purine 
ribonucleotide 
biosynthesis 
          
mnas_725 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
802075 802666 - Cell envelope: Other peg.288 Ribose-phosphate 
pyrophosphokinase  
(EC 2.7.6.1) 
Category: Carbohydrates 
Subcategory: Central 
carbohydrate metabolism 
Subsystem: Pentose phosphate 
pathway 
802034 801186 - 
mnas_726 mycoplasma lipo, C-
terminal region family 
protein 
    802737 803526 - Unclassified: Role 
category not yet 
assigned 
peg.289 hypothetical protein - none - 803019 802738 - 
mnas_727 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
803538 804915 + Unknown: General           
mnas_728 elongation factor G, 
domain IV family 
protein 
    804927 805773 + Unknown: General 
Hypothetical  
peg.290 Translation elongation factor 
G 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Universal GTPases
 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: Translation 
elongation factors bacterial 
Subsystem: Translation 
elongation factor G family 
 
Category: Virulence, Disease 
and Defense 
Subcategory: Invasion and 
intracellular resistance 
Subsystem: Mycobacterium 
virulence operon involved in 
protein synthesis (SSU 
ribosomal proteins) 
805033 805773 + 
mnas_729 recA bacterial DNA 
recombination family 
protein 
    805892 806276 + DNA metabolism: DNA 
replication, 
recombination, and 
repair 
          
mnas_730 23s_rRNA   811845 806381 -   rna.12 Large Subunit Ribosomal 
RNA; lsuRNA; LSU rRNA 
- none - 807600 806382 - 
mnas_731 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
806553 806925 - Unknown: Conserved           
mnas_732 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
807620 808544 - Unknown: General           
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
Appendix 2  
210 
 
IGS RAST  
Gene_id Common_name Sym
bol1 
GO terms2 fmin3 fmax3 S4 TIGR_roles Gene_id Function Subsystem Start5 Stop5 S4 
mnas_733 aromatic cluster 
surface family protein 
    808932 809841 - Cell envelope: Surface 
structures 
          
mnas_734 aromatic cluster 
surface family protein 
    809840 810179 - Cell envelope: Surface 
structures 
          
mnas_735 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
810195 811104 + Unknown: Conserved peg.302 Prolipoprotein - none - 810415 811104 + 
mnas_736 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
811876 812617 + Unknown: Conserved           
mnas_737 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
812621 812828 + Unknown: General peg.303 hypothetical protein - none - 812649 812828 + 
mnas_738 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
812839 813313 + Unknown: General peg.304 hypothetical protein - none - 812840 813313 + 
mnas_739 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
813351 813825 + Cell envelope: Other           
mnas_740 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
813829 814135 - Unknown: General           
mnas_741 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
814137 814308 - Unknown: General           
mnas_742 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
814352 814664 - Unknown: General peg.305 hypothetical protein - none - 814664 814353 - 
mnas_743 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
814670 815006 - Unknown: General           
mnas_744 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
816183 817335 - Unknown: General           
mnas_745 GA module family 
protein 
    815024 816191 + Unclassified: Role 
category not yet 
assigned 
          
mnas_746 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
817339 817936 - Unknown: Conserved           
mnas_747 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
818071 818410 - Unknown: General peg.306 hypothetical protein - none - 818410 818072 - 
mnas_748 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
818497 818941 - Unknown: General           
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mnas_749 tRNA synthetases 
class I (E and Q), 
catalytic domain protein 
    818933 819605 - Unknown: Enzymes of 
unknown specificity 
peg.307 Glutamyl-tRNA synthetase 
(EC 6.1.1.17) @ Glutamyl-
tRNA(Gln) synthetase  
(EC 6.1.1.24) 
Category: Protein Metabolism 
Subcategory: Protein 
biosynthesis 
Subsystem: tRNA 
aminoacylation, Glu and Gln  
 
Subsystem: tRNA 
aminoacylation, Glu and Gln 
819605 818934 - 
mnas_750 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
819636 820374 + Unknown: General 
Hypothetical  
peg.324 hypothetical protein - none - 820240 820374 + 
mnas_751 sn-glycerol-3-
phosphate ABC 
transporter, ATP-
binding UgpC domain 
protein  
(EC 3.6.3.20) 
ugpC GO:0006810,
GO:0005524,
GO:0016820,
GO:0016787,
GO:0000166,
GO:0006200,
GO:0017111,
GO:0015430,
GO:0043190,
GO:0016887,
GO:0005215 
820488 820725 + Cellular processes: 
Other, 
Transport and binding 
proteins: Unknown 
substrate, 
Unknown: Enzymes of 
unknown specificity 
          
mnas_752 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
820725 821136 + Unknown: General peg.325 hypothetical protein - none - 820783 821136 + 
mnas_753 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
821150 821807 + Unknown: Conserved           
mnas_754 AAA domain protein     822073 822688 - Unknown: General 
Hypothetical  
          
mnas_755 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
821906 822095 + Unknown: General peg.326 hypothetical protein - none - 821907 822095 + 
                peg.327 hypothetical protein - none - 822709 822074 - 
mnas_756 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
822839 823850 - Unknown: General           
mnas_757 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
823852 824059 - Unknown: General           
mnas_758 HNH endonuclease 
family protein 
    824147 824810 - Unclassified: Role 
category not yet 
assigned 
peg.328 hypothetical protein - none - 824612 824148 - 
mnas_759 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
824814 825372 - Unknown: General           
mnas_760 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
825376 825760 - Unknown: General peg.329 hypothetical protein - none - 825673 825377 - 
mnas_761 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
825764 825875 - Unknown: General peg.330 hypothetical protein - none - 826290 825877 - 
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mnas_762 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
825876 826290 - Unknown: General           
mnas_763 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
826289 826691 - Unknown: Conserved peg.331 hypothetical protein - none - 826541 826290 - 
mnas_764 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
826724 827606 - Unknown: General peg.332 hypothetical protein - none - 827492 826725 - 
mnas_765 ATP synthase F1, beta 
subunit  
(EC 3.6.3.14) 
atpD GO:0000275,
GO:0015986,
GO:0045261,
GO:0045262,
GO:0046933 
827622 828504 + Energy metabolism: 
ATP-proton motive 
force interconversion 
          
mnas_766 ATP synthase F1, 
epsilon subunit  
(EC 3.6.3.14) 
atpC GO:0000275,
GO:0015986,
GO:0045261,
GO:0045262,
GO:0046933 
829415 829835 - Energy metabolism: 
ATP-proton motive 
force interconversion 
peg.347 ATP synthase epsilon chain 
(EC 3.6.3.14) 
- none - 829835 829416 - 
mnas_767 ATP synthase subunit 
beta  
(EC 3.6.3.14) 
atpD   829837 830173 - Energy metabolism: 
ATP-proton motive 
force interconversion 
          
mnas_768 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
831020 831707 + Unknown: General peg.348 hypothetical protein - none - 831378 831707 + 
mnas_769 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
831706 831844 + Unknown: General           
mnas_770 Spermidine/putrescine 
ABC transporter 
permease protein PotB 
PotB   831867 832221 + Transport and binding 
proteins: Unknown 
substrate 
peg.349 Spermidine Putrescine ABC 
transporter permease 
component PotB  
(TC 3.A.1.11.1) 
- none - 831868 832221 + 
mnas_771 spermidine/putrescine 
transport system 
permease PotC domain 
protein 
potC GO:0016020,
GO:0006810,
GO:0005215 
832213 832666 + Transport and binding 
proteins: Unknown 
substrate 
          
mnas_772 telomere recombination 
family protein 
    832846 833314 - Unclassified: Role 
category not yet 
assigned 
peg.350 TsaC protein (YrdC domain) 
required for 
threonylcarbamoyladenosine 
t(6)A37 modification in tRNA 
- none - 833314 832847 - 
mnas_773 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
833387 833480 + Unknown: General           
mnas_774 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
833705 834293 + Unknown: General           
mnas_775 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
834607 834718 - Unknown: General           
mnas_776 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
835093 835480 - Unknown: General           
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mnas_777 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
834821 835097 + Unknown: General           
mnas_778 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
835442 835871 - Unknown: General peg.351 hypothetical protein - none - 835706 835443 - 
mnas_779 NAD-dependent 
glycerol-3-phosphate 
dehydrogenase family 
protein 
    835906 836638 - Energy metabolism: 
Other 
peg.352 Glycerol-3-phosphate 
dehydrogenase [NAD(P)+] 
(EC 1.1.1.94) 
Category: Fatty Acids, Lipids, 
and Isoprenoids 
Subcategory: Phospholipids 
Subsystem: Glycerolipid and 
Glycerophospholipid Metabolism 
in Bacteria 
836626 835907 - 
mnas_780 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
836648 837320 - Unknown: General           
mnas_781 ABC transporter family 
protein 
    837407 838070 - Transport and binding 
proteins: Unknown 
substrate 
          
mnas_782 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
838173 838920 - Unknown: General           
mnas_783 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
838920 839268 - Unknown: Conserved           
mnas_784 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
839749 840229 - Unknown: General peg.363 hypothetical protein - none - 839887 839750 - 
mnas_785 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
840222 840393 - Unknown: General peg.364 hypothetical protein - none - 840375 840223 - 
mnas_786 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
840405 840531 + Unknown: General           
mnas_787 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
840530 840986 + Unknown: General peg.365 hypothetical protein - none - 840531 840986 + 
mnas_788 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
841116 841809 - Unknown: General           
mnas_789 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
840960 841128 + Unknown: General           
mnas_790 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
841821 842451 + Unknown: General peg.366 hypothetical protein - none - 841870 842451 + 
mnas_791 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
843153 843459 - Unknown: General           
mnas_792 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
842500 843157 + Unknown: General           
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IGS RAST  
Gene_id Common_name Sym
bol1 
GO terms2 fmin3 fmax3 S4 TIGR_roles Gene_id Function Subsystem Start5 Stop5 S4 
mnas_793 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
843442 843796 - Unknown: General           
mnas_794 putative lipoprotein   GO:0008150,
GO:0003674,
GO:0016020 
843802 844339 - Cell envelope: Other           
mnas_795 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
844342 844444 - Unknown: General           
mnas_796 hsp70 family protein     844464 845103 + Protein fate: Protein 
folding and stabilization
          
mnas_797 amino acid permease 
family protein 
    845105 845720 + Transport and binding 
proteins: Unknown 
substrate 
peg.380 hypothetical protein - none - 845404 845204 - 
mnas_798 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
845724 846330 - Unknown: General           
mnas_799 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
846342 846549 - Unknown: General           
mnas_800 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
847090 847447 + Unknown: Conserved peg.381 hypothetical protein - none - 847091 847447 + 
mnas_801 conserved hypothetical 
protein 
  GO:0008150,
GO:0003674,
GO:0005575 
847595 848141 + Unknown: Conserved           
mnas_802 ABC transporter family 
protein 
    848720 849290 - Transport and binding 
proteins: Unknown 
substrate 
          
mnas_803 recF/RecN/SMC N 
terminal domain protein 
    848141 848720 + Cellular processes: Cell 
division 
          
mnas_804 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
849882 850437 + Unknown: General           
mnas_805 hypothetical protein   GO:0008150,
GO:0003674,
GO:0005575 
850671 850980 - Unknown: General peg.392 hypothetical protein - none - 850869 850672 - 
                rna.14 Large Subunit Ribosomal 
RNA; lsuRNA; LSU rRNA 
- none - 851512 851009 - 
mnas_806 Putative oligopeptide 
ABC transporter, ATP-
binding protein OppF 
C-terminal 
    851524 852058 - Transport and binding 
proteins: Unknown 
substrate 
          
1.  Gene symbol                                                                                             2.  Gene Ontology terms                                                                     
3.  The start and stop condon positions (location include stop codon)          4.  DNA strand (+ or -) on which the predicted gene is located                    
5.  The start and stop codon postions (location include stop codon) 
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Supplementary Table 2.3 Ribosomal RNAs found within the IGS and RAST annotations of the Ms03 draft genome 
 IGS RAST
 RNA_ID Location  Size 
(nt) 
RNA_ID Description  Location  Size (nt) 
5s_rRNA  mnas_582  673329-673226  103 rna.5 5S RNA 673333-673227 107 
16s_rRNA  mnas_642  733261-734756  1495 rna.8 
Small Subunit Ribosomal 
RNA; ssuRNA; SSU 
rRNA 
733282-734818 1537
    rna.9 Large Subunit Ribosomal RNA; lsuRNA; LSU rRNA 735059-735903 845 
23s_rRNA mnas_730  811845-806381 5464 rna.12 Large Subunit Ribosomal RNA; lsuRNA; LSU rRNA 807600-806382 1219
    rna.14 Large Subunit Ribosomal RNA; lsuRNA; LSU rRNA 851512-851009 504 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2.4 The transfer RNAs found within the IGS and RAST annotations of the Ms03 draft genome 
aa 
IGS RAST
Gene_ID RNA Location Size (nt) RNA_ID RNA Location 
Size 
(nt) 
Ala No annotation tRNA 
Arg mnas_193 tRNA-Arg 244829-244752 77 rna.11 tRNA-Arg-TCT 244829-244756 74 mnas_495 tRNA-Arg 597174-597097 77 rna.23 tRNA-Arg-ACG 597174-597101 74 
Asn mnas_44 tRNA-Asn 49170-49245 75 rna.15 tRNA-Asn-GTT 49171-49242 72 
Asp No annotation tRNA 
Cys mnas_496 tRNA-Cys 597257-597182 75 rna.24 tRNA-Cys-GCA 597257-597186 72 
Gln mnas_110 tRNA-Gln 153820-153745 75 rna.3 tRNA-Gln-TTG 153820-153749 72 
Glu mnas_45 tRNA-Glu 49251-49327 76 rna.16 tRNA-Glu-TTC 49252-49324 73 
Gly mnas_494 tRNA-Gly 597015-596941 74 rna.22 tRNA-Gly-TCC 597015-596945 71 
His mnas_635 tRNA-His 725837-725913 76 rna.7 tRNA-His-GTG 725838-725910 73 
Ile No annotation tRNA 
Leu mnas_48 tRNA-Leu 49520-49604 84 rna.19 tRNA-Leu-TAG 49521-49601 81 mnas_515 tRNA-Leu 613243-613327 84 rna.1 tRNA-Leu-CAA 613244-613324 81 
Lys mnas_459 tRNA-Lys 552267-552343 76 rna.20 tRNA-Lys-CTT 552268-552340 73 
Met No annotation tRNA 
Phe No annotation tRNA 
Pro No annotation tRNA 
Ser mnas_546 tRNA-Ser 641317-641408 91 rna.2 tRNA-Pseudo-GCT 641318-641405 88 mnas_659 tRNA-SeC 750949-751024 75 rna.10 tRNA-SeC-TCA 750950-751021 72 
Thr 
mnas_47 tRNA-Thr 49409-49485 76 rna.18 tRNA-Thr-TGT 49410-49482 73 
mnas_461 tRNA-Thr 554066-553992 74 rna.21 tRNA-Thr-CGT 554066-553996 71 
mnas_623 tRNA-Thr 712768-712843 75 rna.6 tRNA-Thr-GGT 712769-712840 72 
Trp mnas_214 tRNA-Trp 77866-77792 74 rna.13 tRNA-Trp-CCA 277866-277796 71 
Tyr mnas_111 tRNA-Tyr 153909-153825 84 rna.4 tRNA-Tyr-GTA 153909-153829 81 
Val mnas_46 tRNA-Val 49332-49408 76 rna.17 tRNA-Val-TAC 49333-49405 73 
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Supplementary Table 2.5 DNA replication genes found within the IGS and RAST annotations of the Ms03 draft 
genome 
EC 
IGS RAST 
Gene_id Gene name  Gene symbol Gene_id Gene name  
2.7.7.- mnas_269 DNA primase dnaG peg.384 DNA primase 
2.7.7.7 mnas_71 DNA polymerase III, alpha subunit, Gram-positive type polC peg.514 DNA polymerase III alpha subunit  
2.7.7.7  mnas_100 DNA polymerase III beta subunit, central domain protein dnaN peg.10
 DNA polymerase III beta subunit  
2.7.7.7 mnas_159  DNA polymerase III, subunit gamma and tau dnaX peg.184 
DNA polymerase III subunits 
gamma and tau  
2.7.7.7  mnas_163 Putative DNA polymerase III, delta' subunit holB peg.188  
DNA polymerase III delta prime 
subunit  
2.7.7.7 mnas_245 DNA polymerase III, alpha subunit dnaE peg.355 DNA polymerase III alpha subunit  
2.7.7.7 mnas_571 DNA polymerase III, delta subunit holA peg.86  DNA polymerase III delta subunit  
2.7.7.7 mnas_246* Putative DNA polymerase I  peg.356* DNA polymerase I  
3.1.26.4 mnas_719# Ribonuclease HII family protein   peg.285# Ribonuclease HII 
3.6.1.-  mnas_473  Putative replicative DNA helicase  dnaB peg.608 Replicative DNA helicase  
3.6.4.12 mnas_266  DnaB-like helicase C terminal domain protein   peg.379 Replicative DNA helicase (DnaB)  
6.5.1.2 mnas_607$ DNA ligase, NAD-dependent ligA peg.116$ DNA ligase  
- mnas_175 Single-stranded DNA-binding family protein ssb peg.245 
Single-stranded DNA-binding 
protein 
- mnas_99 Chromosomal replication initiator protein DnaA  dnaA peg.9 
Chromosomal replication initiator 
protein DnaA  
* Correspond to the DpoI of DNA polymerase I in Figure 3.5  
# Correspond to the RNaseHII in Figure 3.5  
$ Correspond to the Lig of DNA ligase in Figure 3.5 
 
 
Supplementary Table 2.6 Purine metabolism genes found within the IGS and RAST annotations of the Ms03 draft 
genome 
EC 
IGS RAST 
Gene_id Gene name  Gene symbol Gene_id Gene name  
2.4.2.7   mnas_140 Adenine 
phosphoribosyltransferase   
apt peg.130 Adenine 
phosphoribosyltransferase 
2.4.2.8   mnas_338* Hypoxanthine 
phosphoribosyltransferase   
hpt peg.464* Hypoxanthine-guanine 
phosphoribosyltransferase  
2.7.1.40# mnas_504 Pyruvate kinase pyk peg.632 Pyruvate kinase  
2.7.1.113 
2.7.1.76 
mnas_337 Deoxynucleoside kinase family 
protein 
 peg.463 Deoxyadenosine kinase (EC 
2.7.1.76) / Deoxyguanosine 
kinase (EC 2.7.1.113) 
2.7.4.3 mnas_588$ Adenylate kinase family protein adk peg.98$  Adenylate kinase 
2.7.4.8 mnas_117 Guanylate kinase gmk peg.71 Guanylate kinase  
2.7.6.1 mnas_724∆  Ribose-phosphate 
diphosphokinase family protein  
prs peg.288∆  Ribose-phosphate 
pyrophosphokinase 
3.1.3.5 mnas_205 Calcineurin-like phosphoesterase 
family protein 
 peg.299 5'-nucleotidase 
3.2.2.1 mnas_445 Inosine-uridine preferring 
nucleoside hydrolase family 
protein 
 peg.571 preQ1-regulated inosine-
uridine nucleoside hydrolase  
5.4.2.7 mnas_513£∆  Phosphopentomutase deoB peg.19£∆  Phosphopentomutase  
* Enzyme number for reverse reaction is EC 2.4.2.22 
# Part of glycolysis 
$ Enzyme number for reverse reaction is EC 2.7.4.11 
∆ Part of Pentose phosphate pathway 
£ Enzyme number for reverse reaction is EC 5.4.2.2
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Supplementary Table 2.7 Pyrimidine metabolism genes found within the IGS and RAST annotations of the Ms03 draft 
genome 
EC 
IGS RAST 
Gene_id Gene name  Gene symbol Gene_id Gene name  
1.8.1.9 mnas_66 Yhioredoxin reductase trxB peg.509 Thioredoxin reductase 
2.4.2.2 ⌂ mnas_671θ  Pyrimidine-nucleoside phosphorylase family protein pdp peg.204
θ Pyrimidine-nucleoside phosphorylase 
2.4.2.9 mnas_574 Uracil phosphoribosyltransferase upp peg.89 Uracil phosphoribosyltransferase 
2.7.1.21 mnas_229 Thymidine kinase tdk   peg.336  Thymidine kinase  
2.7.4.9 mnas_423 Thymidylate kinase tmk peg.554 Thymidylate kinase 
2.7.4.9 mnas_162 Thymidylate kinase tmk peg.187 Thymidylate kinase 
2.7.4.22 mnas_309 UMP kinase pyrH peg.437 Uridine monophosphate kinase 
2.7.4.14Ω mnas_647 Cytidylate kinase cmk peg.169 Cytidylate kinase (EC 2.7.4.25Ω) 
4.2.1.70 mnas_14 
Ribosomal large subunit 
pseudouridine synthase B (EC 
5.4.99.22) 
rluB peg.225 Ribosomal large subunit pseudouridine synthase B  
4.2.1.70 mnas_118 tRNA pseudouridine(55) synthase (EC 5.4.99.25) truB  peg.72 
tRNA pseudouridine synthase B 
(EC 4.2.1.70)  
4.2.1.70 mnas_328 RNA pseudouridylate synthase family protein   peg.454 
Ribosomal large subunit 
pseudouridine synthase C (EC 
4.2.1.70)  
4.2.1.70 mnas_552 Pseudouridine synthase, RluA family protein (EC 5.4.99.-)   peg.50 
Ribosomal large subunit 
pseudouridine synthase D (EC 
4.2.1.70)  
4.2.1.70 mnas_510 RNA pseudouridylate synthase family protein   peg.17  
Ribosomal small subunit 
pseudouridine synthase A (EC 
4.2.1.70) 
3.1.3.5 mnas_205 Calcineurin-like phosphoesterase family protein  peg.299
¥ 5'-nucleotidase 
3.5.4.5♦  mnas_290  Cytidine deaminase  cdd peg.403 Cytidine deaminase  
* Part of glycolysis 
$Enzyme number for reverse reaction is EC 2.7.4.11 
∆ Part of Pentose phosphate pathway 
¥Part of Purine metabolise  
θ Enzyme number for reverse reaction is EC 2.4.2.3 
Ω The eukaryotic enzyme EC 2.7.4.14 is a bifunctional enzyme that catalyses the phosphorylation of both CMP and UMP with similar 
efficiency (dCMP can also act as acceptor). Different from the monofunctional prokaryotic enzymes EC 2.7.4.25, (d)CMP kinase and EC 
2.7.4.22, UMP kinase.  
⌂This enzyme can accept both the ribonucleoside uridine (EC 2.4.2.3) and the 2'-deoxyribonucleosides 2'-deoxyuridine (EC 2.4.2.3) and 
thymidine (EC 2.4.2.4). Formally known as EC 2.4.2.23.  
♦ Enzyme number for reverse reaction is EC 3.5.4.14
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Supplementary Table 2.8 RNA polymerase genes found within the IGS and RAST annotations of the Ms03 draft 
genome 
EC 
IGS RAST 
Gene_id Gene name  Gene symbol Gene_id Gene name  
- mnas_271  RNA polymerase sigma factor, 
sigma-70 family protein  
rpoD peg.386 RNA polymerase sigma 
factor RpoD 
2.7.7.6 mnas_715  DNA-directed RNA polymerase, 
alpha subunit  
rpoA peg.282 DNA-directed RNA 
polymerase alpha subunit 
2.7.7.6 mnas_59  DNA-directed RNA polymerase, 
beta' subunit 
rpoC peg.432  DNA-directed RNA 
polymerase beta' subunit 
2.7.7.6 mnas_57* 
mnas_58* 
RNA polymerase beta subunit 
rpoB 
rpoB peg.431* DNA-directed RNA 
polymerase beta subunit 
* The ORF of mnas_57 and mnas_58 from 64459 to 65722 and 65714 to 70202, respectively. The ORF of peg.431 are from 62088 to 
65722 and therefore include both mnas_57 and mnas_58 
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Supplementary Table 2.9 Ribosomal genes found within the IGS and RAST annotations of the Ms03 draft genome 
IGS RAST 
Gene_id Gene name  Gene symbol Gene_id Gene name  
mnas_40 ribosomal protein L33 rpmG peg.420 LSU ribosomal protein L33p  
mnas_122   ribosomal protein S15 rpsO peg.76 SSU ribosomal protein S15p (S13e) 
mnas_141 ribosomal protein L1 rplA peg.131 LSU ribosomal protein L1p (L10Ae) 
mnas_142 ribosomal protein L11 rplK peg.132 LSU ribosomal protein L11p (L12e) 
mnas_174 ribosomal protein S6 rpsF  peg.244 SSU ribosomal protein S6p 
mnas_176 ribosomal protein S18 rpsR peg.246 
SSU ribosomal protein S18p @ SSU 
ribosomal protein S18p, zinc-
independent 
mnas_206 ribosomal protein S12 rpsL peg.300 SSU ribosomal protein S12p (S23e) 
mnas_207 ribosomal protein S7 rpsG peg.301 SSU ribosomal protein S7p (S5e) 
mnas_228 ribosomal protein S20 rpsT peg.335 SSU ribosomal protein S20p 
mnas_232 ribosomal protein L35 rpmI peg.339 LSU ribosomal protein L35p 
mnas_233 ribosomal protein L20 rplT peg.340 LSU ribosomal protein L20p 
mnas_343 ribosomal protein L13 rplM peg.469 LSU ribosomal protein L13p (L13Ae) 
mnas_344 30S ribosomal protein S9 rpsI  peg.470 SSU ribosomal protein S9p (S16e) 
mnas_369 ribosomal protein L19 rplS peg.493 LSU ribosomal protein L19p  
mnas_371 ribosomal protein S16 rpsP  peg.495 SSU ribosomal protein S16p 
mnas_382 ribosomal protein L15 rplO peg.519 LSU ribosomal protein L15p (L27Ae) 
mnas_383 ribosomal protein S5 rpsE peg.520 SSU ribosomal protein S5p (S2e) 
mnas_384 ribosomal protein L18 rplR  peg.521 LSU ribosomal protein L18p (L5e) 
mnas_385 ribosomal protein L6   rplF  peg.522 LSU ribosomal protein L6p (L9e) 
mnas_386 ribosomal S8 family protein  peg.523 SSU ribosomal protein S8p (S15Ae) 
mnas_387 30S ribosomal protein S14 type Z rpsZ  peg.524 
SSU ribosomal protein S14p (S29e) 
@ SSU ribosomal protein S14p 
(S29e), zinc-dependent  
mnas_388 50S ribosomal protein L5 rplE  peg.525 LSU ribosomal protein L5p (L11e)  
mnas_389 ribosomal protein L24 rplX peg.526 LSU ribosomal protein L24p (L26e) 
mnas_390 ribosomal protein L14 rplN peg.527 LSU ribosomal protein L14p (L23e) 
mnas_391 30S ribosomal protein S17 rpsQ peg.528 SSU ribosomal protein S17p (S11e) 
mnas_392 ribosomal protein L29 rpmC peg.529 LSU ribosomal protein L29p (L35e) 
mnas_393 ribosomal protein L16 rplP peg.530 LSU ribosomal protein L16p (L10e) 
mnas_394 ribosomal protein S3 rpsC peg.531 SSU ribosomal protein S3p (S3e) 
mnas_395 ribosomal protein L22 rplV peg.532 LSU ribosomal protein L22p (L17e) 
mnas_396 ribosomal protein S19 rpsS  peg.533 SSU ribosomal protein S19p (S15e) 
mnas_397 ribosomal protein L2 rplB peg.534 LSU ribosomal protein L2p (L8e) 
mnas_398 50S ribosomal L23 domain protein rplW  peg.535 LSU ribosomal protein L23p (L23Ae)  
mnas_399 ribosomal L4/L1 family protein  peg.536 LSU ribosomal protein L4p (L1e) 
mnas_474 ribosomal protein L9 rplI peg.609 LSU ribosomal protein L9p 
mnas_521 ribosomal protein S2 rpsB peg.26 SSU ribosomal protein S2p (SAe) 
mnas_535 ribosomal protein L7/L12 rplL peg.38 LSU ribosomal protein L7/L12 (P1/P2)
mnas_536 50S ribosomal protein L10 rplJ  peg.39 LSU ribosomal protein L10p (P0) 
mnas_559 ribosomal protein L21 rplU peg.57 LSU ribosomal protein L21p 
mnas_560 ribosomal protein L27 rpmA peg.58 LSU ribosomal protein L27p 
mnas_568   ribosomal protein S4 rpsD peg.83 SSU ribosomal protein S4p (S9e) 
mnas_569 ribosomal protein L31 rpmE peg.84 LSU ribosomal protein L31p 
mnas_585 ribosomal protein L34 rpmH peg.96 LSU ribosomal protein L34p 
mnas_591 ribosomal protein L36 rpmJ peg.101 LSU ribosomal protein L36p 
mnas_592 30S ribosomal protein S13 rpsM peg.102 SSU ribosomal protein S13p (S18e) 
mnas_593 ribosomal S11 family protein   peg.103 SSU ribosomal protein S11p (S14e) 
mnas_649 ribosomal protein L28 rpmB peg.171 LSU ribosomal protein L28p  
mnas_664 ribosomal protein L32 rpmF peg.198 LSU ribosomal protein L32p 
mnas_679 50S ribosomal protein L3 rplC peg.208 LSU ribosomal protein L3p (L3e) 
mnas_681 ribosomal protein S10 rpsJ peg.209  SSU ribosomal protein S10p (S20e) 
mnas_714 ribosomal protein L17 rplQ peg.281 LSU ribosomal protein L17p 
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Supplementary Table 2.10 The aminoacyl-tRNA biosynthesis genes found within the IGS and RAST annotations of 
the Ms03 draft genome 
EC IGS RAST  
Gene name Gene id Gene name Gene id 
2.1.2.9 methionyl-tRNA formyltransferase mnas_249  Methionyl-tRNA formyltransferase peg.359 
6.1.1.1 tyrosine--tRNA ligase mnas_356  Tyrosyl-tRNA synthetase  peg.480 
6.1.1.2 tryptophan--tRNA ligase mnas_685  Tryptophanyl-tRNA synthetase  peg.211 
6.1.1.3 
threonyl and Alanyl tRNA 
synthetase second additional 
domain protein 
mnas_684  
Threonyl-tRNA synthetase  peg.35 
6.1.1.4 leucine--tRNA ligase mnas_485  Leucyl-tRNA synthetase  peg.619 
6.1.1.5 isoleucine--tRNA ligase mnas_678  Isoleucyl-tRNA synthetase  peg.53 
6.1.1.6 lysine--tRNA ligase mnas_92  Lysyl-tRNA synthetase (class II)  peg.2 
6.1.1.7 alanine--tRNA ligase mnas_453  Alanyl-tRNA synthetase peg.577 
6.1.1.9 valine--tRNA ligase mnas_463  Valyl-tRNA synthetase  peg.600 
6.1.1.10 methionine--tRNA ligase mnas_348  Methionyl-tRNA synthetase  peg.474 
6.1.1.11 serine--tRNA ligase mnas_586    
6.1.1.12 aspartate--tRNA ligase mnas_457 Aspartyl-tRNA synthetase  peg.597 
6.1.1.14 glycine--tRNA ligase mnas_268  Glycyl-tRNA synthetase peg.383 
6.1.1.15 proline--tRNA ligase mnas_640  Prolyl-tRNA synthetase  peg.165 
6.1.1.16 cysteine--tRNA ligase mnas_373  Cysteinyl-tRNA synthetase  peg.497 
6.1.1.17 glutamyl-tRNA synthetase  mnas_458 Glutamyl-tRNA synthetase  peg.307 
6.1.1.19 arginine--tRNA ligase mnas_374  Arginyl-tRNA synthetase  peg.498 
6.1.1.20 
phenylalanine--tRNA ligase, alpha 
subunit mnas_274  
Phenylalanyl-tRNA synthetase alpha 
chain  
peg.389 
tRNA synthetase B5 domain 
protein mnas_277  
Phenylalanyl-tRNA synthetase domain 
protein (Bsu YtpR) 
peg.391 
Phenylalanyl-tRNA synthetase beta 
chain  
peg.481 
6.1.1.21 histidine--tRNA ligase  mnas_224  Histidyl-tRNA synthetase  peg.323 
6.1.1.24 tRNA synthetases class I (E and Q), catalytic domain protein  
mnas_749 Glutamyl-tRNA(Gln) synthetase peg.307 
6.3.5.6 glu-tRNAGln amidotransferase C subunit mnas_327  
Aspartyl-tRNA(Asn) amidotransferase 
subunit A  
peg.452 
Aspartyl-tRNA(Asn) amidotransferase 
subunit B  
peg.451 
Aspartyl-tRNA(Asn) amidotransferase 
subunit C 
peg.453 
6.3.5.7 aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase, B subunit mnas_325  
Glutamyl-tRNA(Gln) amidotransferase 
subunit A 
peg.452 
Glutamyl-tRNA(Gln) amidotransferase 
subunit B 
peg.451 
Glutamyl-tRNA(Gln) amidotransferase 
subunit C  
peg.453 
 
  
Stellenbosch University  https://scholar.sun.ac.za
Appendix 2  
221 
 
Supplementary Table 2.11 Glycolysis / gluconeogenesis genes found within the IGS and RAST annotations of the 
Ms03 draft genome 
IGS RAST 
EC Gene_id Gene name  
Gene 
symb
ol 
Gene_id Gene name  
1.2.1.12 mnas_250# Glyceraldehyde-3-phosphate dehydrogenase, type I gap peg.360
# NAD-dependent glyceraldehyde-3-phosphate dehydrogenase 
2.7.1.40 mnas_504 Pyruvate kinase pyk peg.632 Pyruvate kinase 
2.7.1.69  mnas_534 
PTS system, 
glucose/glucosamine/beta-
glucoside-specific 
- peg.37 
PTS system, N-acetylglucosamine-
specific IIA component / PTS 
system, N-acetylglucosamine-
specific IIB component / PTS 
system, N-acetylglucosamine-
specific IIC component 
2.7.2.3 mnas_597 Phosphoglycerate kinase -   
4.1.2.13 mnas_376 Fructose-1,6-bisphosphate aldolase, class II fba peg.500 
Fructose-bisphosphate aldolase 
class II 
4.2.1.11 mnas_695 Phosphopyruvate hydratase eno peg.263 Enolase 
5.3.1.1 mnas_547 Triose-phosphate isomerase tpiA peg.47 Triosephosphate isomerise 
5.3.1.9 mnas_509 Phosphoglucose isomerase family protein  peg.16 Glucose-6-phosphate isomerise 
5.3.1.9  mnas_700  Putative glucose-6-phosphate isomerase - peg.268 Glucose-6-phosphate isomerise 
5.4.2.1  mnas_105 
2,3-bisphosphoglycerate-
independent phosphoglycerate 
mutase 
- peg.61 
2,3-bisphosphoglycerate-
independent phosphoglycerate 
mutase 
#Enzyme number for reverse reaction is EC 1.2.1.59
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Supplementary Table 2.12 Pentose phosphate pathway 
EC IGS RAST 
Gene_id Gene name  Gene symbol Gene_id Gene name  
2.7.6.1 mnas_724 ribose-phosphate diphosphokinase family protein prs peg.288 
Ribose-phosphate 
pyrophosphokinase 
4.1.2.4 mnas_672 deoxyribose-phosphate aldolase deoC peg.205 
Deoxyribose-phosphate 
aldolase   
4.1.2.9 mnas_436 xylulose-5-phosphate phosphoketolase xpkA peg.564 
Xylulose-5-phosphate 
phosphoketolase / Fructose-
6-phosphate phosphoketolase 
4.1.2.13* mnas_376 Fructose-1,6-bisphosphate aldolase, class II fba peg.500 
Fructose-bisphosphate 
aldolase class II  
5.1.3.1 mnas_113 Ribulose-phosphate 3 epimerase family protein - peg.67 
Ribulose-phosphate 3-
epimerase  
5.4.2.7 mnas_513# Phosphopentomutase  deoB peg.19# Phosphopentomutase  
5.3.1.6  mnas_286 Putative ribose-5-phosphate isomerase  - peg.399 
Ribose 5-phosphate 
isomerase B  
5.3.1.9* mnas_509 Phosphoglucose isomerase family protein  peg.16 
Glucose-6-phosphate 
isomerise 
5.3.1.9* mnas_700  Putative glucose-6-phosphate isomerase - peg.268 
Glucose-6-phosphate 
isomerase  
*Part of glycolysis 
# Enzyme number for reverse reaction is 5.4.2.2 
 
 
 
 
 
Supplementary Table 2.13 Pyruvate metabolism 
EC 
IGS RAST 
Gene_id Gene name  Gene symbol Gene_id Gene name  
1.1.1.28  mnas_107 D-lactate dehydrogenase   ldhA peg.63 D-lactate dehydrogenase  
2.7.2.1 mnas_507 Acetate kinase  ackA peg.635 Acetate kinase 
2.7.1.40*  mnas_504 Pyruvate kinase pyk peg.632 Pyruvate kinase  
*Part of glycolysis 
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Supplementary Table 2.14 Membrane associated, substrate-binding and transport proteins in the Ms03 draft genome.  
IGS RAST
Gene_id Gene name  Gene symbol Gene_id Gene name  
Putative potassium uptake (ktrB/ktrA) 
mnas_11 Putative potassium uptake protein KtrB ktrB peg.222  Potassium uptake protein, integral 
membrane component, KtrB 
mnas_12 TrkA-C domain protein ktrA  peg.223 Trk system potassium uptake protein TrkA 
Magnesium (channel-type mechanism) 
mnas_189 Magnesium transporter mgtE  peg.259 Mg/Co/Ni transporter MgtE / CBS domain  
Putative cation transporting P-type ATPase (Copper, Lead, cadmium, zinc and mercury) 
mnas_196 Cation transporting ATPase, family 
protein 
 peg.280 Lead, cadmium, zinc and mercury 
transporting ATPase (EC 3.6.3.3) (EC 
3.6.3.5); Copper-translocating P-type 
ATPase (EC 3.6.3.4) 259481-258960 
Phosphoenolpyruvate-dependent sugar phosphotransferase system 
mnas_283 phosphocarrier protein HPr (EC 7.11.-) ptsH peg.396 Phosphotransferase system, 
phosphocarrier protein HPr 
mnas_410 Putative PTS system glucose-specific 
enzyme IIB component 
 peg.545 PTS system glucose-specific enzyme IIB 
component 
mnas_62 HPr(Ser) kinase/phosphatase (EC 2.7.1.- 
) 
hprK peg.505 HPr kinase/phosphorylase (EC 2.7.1.-) (EC 
2.7.4.-) 
mnas_534 PTS system, glucose/glucosamine/beta-
glucoside-specific (EC 2.7.1.69) 
 peg.37 PTS system, N-acetylglucosamine-specific 
IIA component (EC 2.7.1.69) / PTS system, 
N-acetylglucosamine-specific IIB 
component (EC 2.7.1.69) / PTS system, N-
acetylglucosamine-specific IIC component 
(EC 2.7.1.69) 
Putative energy-coupling factor transporter 
mnas_651 Energy-coupling factor transporter ATP-
binding EcfA1 domain protein (EC 3.6.3.-
) 
ecfA1 peg.172 ATPase component of general energizing 
module of ECF transporters 
mnas_652 Energy-coupling factor transporter ATP-
binding protein EcfA2 (EC 3.6.3.-) 
ecfA2 peg.173 ATPase component of general energizing 
module of ECF transporters 
mnas_653 energy-coupling factor transporter 
transmembrane protein EcfT 
ecfT   
mnas_49 ECF-type riboflavin transporter, S 
component family protein  
 peg.423 Substrate-specific component FolT of 
folate ECF transporter 
Putative spermidine/putrescine ABC transporter permease 
mnas_227 Probable spermidine/putrescine/ABC 
transporter substrate 
potD  peg.334 Probable spermidine/putrescine substrate 
binding protein in Mollicutes  
mnas_240 Spermidine/putrescine ABC transporter 
permease PotB domain protein  
potB   
mnas_241 Putative spermidine/putrescine transport 
system ATP-binding protein (EC 
3.6.3.31)  
potA   
mnas_242 Putative spermidine/putrescine import 
ATP-binding protein 
potA   
mnas_243 Spermidine/putrescine import ATP-
binding PotA domain protein (EC 
3.6.3.31)  
potA   
mnas_478 Spermidine/putrescine/ABC transporter 
substrate binding protein 
potD peg.613 Probable spermidine/putrescine substrate 
binding protein in Mollicutes  
mnas_770 Spermidine/putrescine ABC transporter 
permease protein PotB 
potB peg.349 Spermidine Putrescine ABC transporter 
permease component PotB (TC 3.A.1.11.1) 
mnas_771 Spermidine/putrescine transport system 
permease PotC domain protein 
potC   
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IGS RAST 
Gene_id Gene name  Gene symbol Gene_id Gene name  
Putative glycerol-3-phosphate ABC transporter 
mnas_488 Putative sn-glycerol-3-phosphate ABC 
transporter, ATP-binding protein 
ugpC peg.621 Multiple sugar ABC transporter, ATP-
binding protein 
mnas_489 Putative sn-glycerol-3-phosphate 
transport system permease protein 
ugpA  peg.622 N-Acetyl-D-glucosamine ABC transport 
system, permease protein 
mnas_490 ABC transporter permease protein ugpE  ugpE peg.623 ABC transporter permease protein 
mnas_751 sn-glycerol-3-phosphate ABC transporter, 
ATP-binding UgpC domain protein 
ugpC   
p37 transport system 
mnas_51 High affinity transport system p37 family 
protein  
 peg.425 High affinity transport system protein p37 
precursor 
mnas_52 Phosphate/phosphonate ABC 
transporter, ATP-binding protein (EC 
3.6.3.28) 
PhnC peg.426 ABC transporter ATP-binding protein 
mnas_53 Binding-dependent transport system 
inner membrane component family 
protein 
 peg.427 Transport system permease protein p69 
Oligopeptide permease ABC transporter 
mnas_50  Hypothetical protein  peg.424 Oligopeptide ABC transporter ATP-binding 
protein  
mnas_74 Bacterial extracellular solute-binding 
protein 
oppA peg.581 Oligopeptide ABC transporter, periplasmic 
oligopeptide-binding protein OppA (TC 
3.A.1.5.1) 
mnas_75 Oligopeptide ABC transporter, permease 
protein (OppB) 
oppB peg.582 Oligopeptide transport system permease 
protein OppB (TC 3.A.1.5.1) 
mnas_76  Oligopeptide ABC transporter, permease 
protein (OppC)  
oppC peg.583 Oligopeptide transport system permease 
protein OppC (TC 3.A.1.5.1) 
mnas_77 Oligopeptide/dipeptide ATP-binding 
protein 
oppD  peg.584 Oligopeptide transport ATP-binding protein 
OppD (TC 3.A.1.5.1) 
mnas_78 Oligopeptide ABC transporter, ATP-
binding protein OppF 
oppF peg.585 Oligopeptide transport ATP-binding protein 
OppF (TC 3.A.1.5.1) 
mnas_414 Oligopeptide ABC transporter substrate-
binding protein 
oppA  peg.547 Lipoprotein 
mnas_415 Oligopeptide ABC transporter, permease 
protein OppB 
oppB   
mnas_576 Oligopeptide ABC transporter system, 
permease protein OppC 
oppC peg.90 Oligopeptide transport system permease 
protein OppC (TC 3.A.1.5.1) 
mnas_577 Oligopeptide ABC transporter, ATP-
binding protein OppD 
oppD peg.91 Oligopeptide transport ATP-binding protein 
OppD  
mnas_601 Oligopeptide ABC transporter, ATP-
binding protein OppF 
oppF peg.110 Oligopeptide ABC transporter ATP-binding 
protein 
mnas_806 Putative oligopeptide ABC transporter, 
ATP-binding protein OppF C-terminal 
   
Putative Lipid A export 
mnas_148 ABC transporter family protein  peg.138 Lipid A export ATP-binding/permease 
protein MsbA 
mnas_407  ABC transporter family protein   peg.542 Lipid A export ATP-binding/permease 
protein MsbA 
Membrane protein with beta galactosidase activity 
mnas_144 Putative Beta-galactosidase   peg.134 Beta-galactosidase (EC 3.2.1.23) 
mnas_145 Beta-galactosidase domain protein (EC 
3.2.1.23) 
bgaA2 peg.135 hypothetical protein 
mnas_146 Beta-galactosidase domain protein (EC 
3.2.1.23) 
bgaA peg.136 Beta-galactosidase (EC 3.2.1.23) 
mnas_147 Glycosyl hydrolases family 2, sugar 
binding domain protein  
 peg.137 Beta-galactosidase (EC 3.2.1.23) 
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IGS RAST 
Gene_id Gene name  Gene symbol Gene_id Gene name  
Hypothetical membrane, peripheral, transport and putative ABC transporters 
mnas_476 ZIP Zinc transporter family protein   peg.611 hypothetical protein 
mnas_199    conserved hypothetical protein   peg.292 FIG000605: protein co-occurring with 
transport systems (COG1739)  
mnas_226 hemolysin C domain protein hlyC peg.333 Hypothetical protein 
mnas_797 amino acid permease family protein    
mnas_107  D-lactate dehydrogenase (EC 1.1.1.28) ldhA mnas_10
7 
D-lactate dehydrogenase  
mnas_401 DNA topoisomerase 4 subunit A (EC 
5.99.1.-) 
parC peg.537 Topoisomerase IV subunit A (EC 5.99.1.-) 
mnas_239 Putative sugar ABC transporter permease 
protein  
 peg.345 Unspecified monosaccharide ABC 
transport system, permease component 2 
   peg.346 Sugar ABC transporter, permease protein  
mnas_93 ABC transporter family protein  peg.3 ABC transporter ATP-binding protein 
mnas_94 Putative ABC transporter permease 
protein  
 peg.4 ABC transporter permease protein 
mnas_701 Multidrug resistance ABC superfamily ATP 
binding cassette transporter, membrane 
domain protein (EC 3.6.3.42)  
ndvA   
mnas_273 AAA ATPase, central region  peg.388 ATPase, AAA family 
mnas_212 ABC-2 type transporter family protein  peg.312 ABC transporter, permease protein 
mnas_213 ABC transporter family protein   peg.313 Methionine ABC transporter ATP-binding 
protein 
mnas_287 ABC transporter family protein  peg.400 ABC transporter ATP-binding and 
permease protein (MDR homolog) 
mnas_341 ABC transporter family protein  peg.467 ABC transporter ATP-binding protein uup 
mnas_406 ABC transporter transmembrane region 
family protein 
   
mnas_565 ABC transporter transmembrane region 
family protein  
   
mnas_564 ABC transporter family protein  peg.60 FIG00836097: hypothetical protein 
mnas_781 ABC transporter family protein    
mnas_802 ABC transporter family protein    
mnas_654 putative membrane protein   peg.174 Unspecified monosaccharide ABC 
transport system, ATP-binding protein 
748139-746763 
mnas_579 ABC superfamily ATP binding cassette 
transporter, ABC domain protein (EC 
3.6.3.24) 
nikE   
mnas_655 Putative Sugar ABC transporter ATP-
binding protein 
mglA peg.176 Unspecified monosaccharide ABC 
transport system, ATP-binding protein 
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Supplementary Table 2.15 The InterPro results of the Ms03 Opp proteins.  
OppA 
(1288) 
Protein family membership: None predicted 
InterPro Domains: None predicted 
GO term prediction 
Biological Process: None predicted 
Molecular Function: None predicted 
Cellular Component: None predicted 
Signature matches 
Program Motif/domain Regions 
PROSITE  PS51257 (PROKAR_LIPOPROTEIN) 1-23 
COILS  Coil 68-103, 158-224, 249-284 
PHOBIUS SIGNAL_PEPTIDE 1-20 
 SIGNAL_PEPTIDE_C_REGION 17-20 
 SIGNAL_PEPTIDE_H_REGION 5-16 
 SIGNAL_PEPTIDE_N_REGION 1-4 
 Non_Cytoplasmic_Domains 21-1288 
OppA2 
(1030) 
Protein family membership: ABC-type oligopeptide transport system, solute-binding component, 
Mycoplasmataceae, predicted (IPR016880) 
InterPro Domains: Solute-binding protein family 5 domain (IPR000914) 
GO term prediction 
Biological Process: None predicted 
Molecular Function: None predicted 
Cellular Component: None predicted 
Signature matches 
Program Motif/domain Regions 
PIR PIRSF028335 (ABC_oligopep_OppA_prd) 2-1030 
Pfam PF00496 (SBP_bac_5) 191-710 
GENE3D CATH Superfamily: G3DSA:3.10.105.10  617-749 
PROSITE  PS51257 (PROKAR_LIPOPROTEIN) 1-27 
PHOBIUS SIGNAL_PEPTIDE 1-27 
 SIGNAL_PEPTIDE_C_REGION 20-27 
 SIGNAL_PEPTIDE_H_REGION 8-19 
 SIGNAL_PEPTIDE_N_REGION 1-7 
SUPERFAMILY SSF53850:Periplasmic binding protein-like II  391-589, 632-776 
COILS  Coil 784-805 
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OppB 
(387) 
Protein family membership: None predicted 
InterPro Domains: ABC transporter type 1, transmembrane domain MetI-like (IPR000515) 
GO term prediction 
Biological Process: GO:0006810 transport 
Molecular Function: GO:0005215 transporter activity 
Cellular Component: GO:0016020 membrane 
Signature matches 
Program Motif/domain Regions 
Pfam  PF00528: BPD_transp_1 150-353 
PROSITE  PS50928: ABC_TM1  132-341 
GENE3D  CATH Superfamily: G3DSA:1.10.3720.10 126-346 
SUPERFAMILY SSF161098: MetI-like 126-336 
PANTHER   PTHR30465 : Peptide transport system 
permease protein 
1-359 
 PTHR30465:SF0: Oligopeptide Transport 
System Permease Protein OppB 
1-359 
PHOBIUS Cytoplasmic_Domains 1-8, 160-170, 235-279, 349-387 
Non_Cytoplasmic_Domains 31-133, 196-214, 303-321 
Transmembrane_Domains  9-30, 134-159, 171-195, 215-234, 
280-302, 322-348 
TMHMM  TMhelix  9-30, 136-158, 171-193, 218-240, 
280-302, 322-344 
OppB2 
(351) 
Protein family membership: None predicted 
InterPro Domains: ABC transporter type 1, transmembrane domain MetI-like (IPR000515) 
GO term prediction 
Biological Process: GO:0006810 transport 
Molecular Function: None predicted 
Cellular Component: GO:0016020 membrane 
Signature matches 
Program Motif/domain Regions 
Pfam  PF00528: BPD_transp_1 157-348 
PROSITE  PS50928: ABC_TM1  139-335 
GENE3D  CATH Superfamily: G3DSA:1.10.3720.10 134-344 
SUPERFAMILY SSF161098: MetI-like 133-348 
PANTHER   PTHR30465 : Peptide transport system 
permease protein 
27-350 
 PTHR30465:SF0: Oligopeptide Transport 
System Permease Protein OppB 
27-350 
PHOBIUS Cytoplasmic_Domains 1-52, 166-176, 233-269, 399-351 
Non_Cytoplasmic_Domains 73-142, 202-212, 297-315 
Transmembrane_Domains  53-71, 143-165, 177-201, 213-232, 
270-296, 316-338 
TMHMM  TMhelix  53-75, 142-164, 176-198, 213-235, 
270-292, 317-339 
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OppC  
(453) 
Protein family membership: None predicted
InterPro Domains: Oligopeptide transport permease C-like, N- terminal domain (IPR025966) 
                                ABC transporter type 1, transmembrane domain MetI-like (IPR000515) 
GO term prediction 
Biological Process: GO:0006810 transport 
Molecular Function: None predicted 
Cellular Component: GO:0016020 membrane 
Signature matches: 
Program Motif/domain Regions 
Pfam   PF12911: OppC_N 40-82 
 PF00528: BPD_transp_1 267-450 
PROSITE  PS50928: ABC_TM1 253-438 
SUPERFAMILY  SSF161098: MetI-like family 244-431 
PANTHER   PTHR30465: Peptide Transport System 
Permease Protein 
25-448 
 PTHR30465:SF2 : Dipeptide transport 
system permease protein dppc-related  
25-448 
PHOBIUS   Cytoplasmic_Domain 1-49, 277-287, 337-374, 442-453 
 Non_Cytoplasmic_Domain 74-251, 311-375, 396-417 
 Transmembrane 50-73, 252-276, 288-310, 316-336, 
375-395, 418-441 
TMHMM  TMhelix   50-72, 255-277, 289-311, 315-337, 
371-393, 419-441 
Opp2C  
(360) 
Protein family membership: None Predicted 
InterPro Domains: Oligopeptide transport permease C-like, N- terminal domain (IPR025966) 
                                ABC transporter type 1, transmembrane domain MetI-like (IPR000515) 
GO term prediction 
Biological Process: GO:0006810 transport 
Molecular Function: None predicted 
Cellular Component: GO:0016020 membrane 
Signature matches: 
Program Motif/domain Regions
Pfam   PF12911: OppC_N 84-132
 PF00528: BPD_transp_1 181-354 
PROSITE  PS50928: ABC_TM1 163-349 
SUPERFAMILY  SSF161098: MetI-like family 156-342 
GENE3D   G3DSA:1.10.3720.10  154-357 
PANTHER   PTHR30465: Peptide Transport System 
Permease Protein 
68-356 
 PTHR30465:SF2 : Dipeptide transport system 
permease protein dppc-related  
68-356 
PHOBIUS   Cytoplasmic_Domain 1-95, 189-199, 245-276, 353-360 
 Non_Cytoplasmic_Domain 118-164, 220-224, 308-326 
 Transmembrane 96-117, 165-188, 200-219, 225-244, 
277-307, 327-352 
TMHMM  TMhelix   96-118, 165-187. 199-221, 225-244, 
273-295, 330-352 
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OppD 
(348) 
Protein family membership: None predicted. 
InterPro Domains: P-loop containing nucleoside triphosphate hydrolase (IPR027417) 
AAA+ ATPase domain (IPR003593) 
ABC transporter-like (IPR003439) 
Oligopeptide/dipeptide ABC transporter, C- terminal (IPR013563) 
Oligopeptide/dipeptide ABC transporter, ATP-binding protein, C-terminal (IPR010066) 
GO term prediction 
Biological Process:  GO:0015833 peptide transport  
Molecular Function: GO:0000166 nucleotide binding  
GO:0005524 ATP binding  
GO:0015197 peptide transporter activity  
GO:0016887 ATPase activity  
Cellular Component: GO:0016020 membrane 
Signature matches: 
Program Motif/domain Regions 
Pfam  PF00005: ABC_tran 27-187 
 PF08352: oligo_HPY 239-300 
PROSITE PS50893: ABC_TRANSPORTER_2 8-260 
GENE3D   G3DSA: 3.40.50.300 2-263 
SUPERFAMILY SSF52540: P-loop containing nucleoside triphosphate 
hydrolases 
34-310 
PANTHER    PTHR24220: FAMILY NOT NAMED 1-321 
 PTHR24220:SF177: D,D-DIPEPTIDE TRANSPORT ATP-
BINDING PROTEIN DDPD-RELATED  
1-321 
TIGRFAMs TIGR01727 237-320 
SMART SM00382 (AAA) 35-237 
OppD2 
(402) 
Protein family membership: None predicted. 
InterPro Domains: P-loop containing nucleoside triphosphate hydrolase (IPR027417) 
AAA+ ATPase domain (IPR003593) 
ABC transporter-like (IPR003439) 
Oligopeptide/dipeptide ABC transporter, C- terminal (IPR013563) 
Oligopeptide/dipeptide ABC transporter, ATP-binding protein, C-terminal (IPR010066) 
GO term prediction 
Biological Process:  GO:0015833 peptide transport  
Molecular Function: GO:0000166 nucleotide binding  
GO:0005524 ATP binding  
GO:0015197 peptide transporter activity  
GO:0016887 ATPase activity  
Cellular Component: GO:0016020 membrane 
Signature matches: 
Program Motif/domain Regions 
Pfam  PF00005: ABC_tran 80-239 
 PF08352: oligo_HPY 291-352 
PROSITE PS00211: ABC_TRANSPORTER_1 212-226 
 PS50893: ABC_TRANSPORTER_2 58-312 
GENE3D   G3DSA: 3.40.50.300 58-312 
SUPERFAMILY SSF52540: P-loop containing nucleoside triphosphate 
hydrolases 
62-310 
PANTHER    PTHR24220: FAMILY NOT NAMED 57-388 
 PTHR24220:SF177: D,D-dipeptide transport ATP-binding 
protein ddpD-related  
57-388 
TIGRFAMs TIGR01727: oligo_HPY  289-371 
SMART SM00382 (AAA) 87-297 
Stellenbosch University  https://scholar.sun.ac.za
Appendix 2  
230 
 
OppF 
(795) 
Protein family membership: None predicted. 
InterPro Domains: P-loop containing nucleoside triphosphate hydrolase (IPR027417) 
AAA+ ATPase domain (IPR003593) 
ABC transporter-like (IPR003439) 
Oligopeptide/dipeptide ABC transporter, C- terminal (IPR013563) 
GO term prediction 
Biological Process:  GO:0015833 peptide transport  
Molecular Function: GO:0000166 nucleotide binding  
GO:0005524 ATP binding  
GO:0016887 ATPase activity  
GO:0017111 nucleoside-triphosphatase activity  
Cellular Component: None predicted. 
Signature matches 
Program Motif/domain Regions 
Pfam  PF00005: ABC_tran 26-127, 594-660 
 PF08352: oligo_HPY 711-743 
PROSITE PS50893: ABC_TRANSPORTER_2 6-732 
 PS00211: ABC_TRANSPORTER_1 632-646 
GENE3D G3DSA: 3.40.50.300 2-127, 610-735 
SUPERFAMILY SSF52540: P-loop containing nucleoside triphosphate  
hydrolases 
4-126, 596-723 
PANTHER PTHR24220: FAMILY NOT NAMED 1-744 
 PTHR24220:SF214: D,D-DIPEPTIDE TRANSPORT ATP-
BINDING PROTEIN DDPF-RELATED  
1-744 
SMART SM00382: AAA 34-709 
COILS  Coil 394-419,441-462, 
470-491 
OppF2 
(443) 
Protein family membership: None predicted. 
InterPro Domains: P-loop containing nucleoside triphosphate hydrolase (IPR027417) 
AAA+ ATPase domain (IPR003593) 
ABC transporter-like (IPR003439) 
Oligopeptide/dipeptide ABC transporter, C- terminal (IPR013563) 
GO term prediction 
Biological Process:  GO:0015833 peptide transport  
Molecular Function: GO:0000166 nucleotide binding  
GO:0005524 ATP binding  
GO:0016887 ATPase activity  
Cellular Component: None predicted. 
Signature matches 
Program Motif/domain Regions 
Pfam  PF00005: ABC_tran 64-312 
 PF08352: oligo_HPY 364-396 
PROSITE PS50893: ABC_TRANSPORTER_2 45-385 
 PS00211: ABC_TRANSPORTER_1 285-299 
GENE3D G3DSA: 3.40.50.300 44-162, 249-395 
SUPERFAMILY SSF52540: P-loop containing nucleoside triphosphate  
hydrolases 
46-367 
PANTHER PTHR24220: FAMILY NOT NAMED 44-394 
 PTHR24220:SF336: D,D-DIPEPTIDE TRANSPORT ATP-
BINDING PROTEIN DDPF-RELATED  
44-394 
SMART SM00382: AAA 71-362 
COILS  Coil 234-258 
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Supplementary Figure 2.1 Alanine, aspartate and glutamate metabolism in Ms03. The enzymes coloured in green 
were annotated in both RAST and IGS analyses while the enzymes in white were not annotated in Ms03 draft 
genome annotations. In the M. synoviae 53 genome no enzymes were annotated for this pathway. The schematic 
was downloaded from metabolic analysis in RAST and adapted to include the Ms03 IGS annotated proteins as well 
as the KEGG pathway of the M. synoviae 53. This schematic represents the KEGG reference pathway 00250. 
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Supplementary Figure 2.2 Glycine, serine and theonine metabolism in Ms03. The enzymes coloured in green were 
annotated in both RAST and IGS analyses, enzymes in yellow were only annotated in IGS analyses while the 
enzymes in white were not annotated in Ms03 draft genome annotations. Annotated enzymes of the complete 
M. synoviae 53 genome are indicated with red boxes. The schematic was downloaded from metabolic analysis in 
RAST and adapted to include the Ms03 IGS annotated proteins as well as the KEGG pathway of the M. synoviae 53 
(msy00270). This schematic represents the KEGG reference pathway 00270.  
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Supplementary Figure 2.3 Cysteine and methionine metabolism in Ms03. The enzymes coloured in green were 
annotated in both RAST and IGS analyses while the enzymes in white were not annotated in Ms03 draft genome 
annotations. Annotated enzymes of the complete M. synoviae 53 genome are indicated with red boxes. The 
schematic was downloaded from metabolic analysis in RAST and adapted to include the Ms03 IGS annotated 
proteins as well as the KEGG pathway of the M. synoviae 53 (msy00270). This schematic represents the KEGG 
reference pathway 00270. 
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Supplementary Figure 2.4 Arginine and proline metabolism in Ms03. The enzymes coloured in green were annotated in both RAST and IGS analyses while the 
enzymes in white were not annotated in Ms03 draft genome annotations. In the M. synoviae 53 genome no enzymes were annotated for this pathway. The 
schematic was downloaded from metabolic analysis in RAST and adapted to include the Ms03 IGS annotated proteins. This schematic represents the KEGG 
reference pathway 00330. 
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Appendix 3 Supplementary tables and figures for Chapter 4 
Supplementary Table 1 Inventory of the opp operons within the mycoplasma genomes used for analyses 
Species Abbr NCBI nr Annotation opp operons (genomic location1) 
Candidatus Mycoplasma 
haemolamae str. Purdue  MHPL NC_018219.1 ND    
  
Candidatus Mycoplasma 
haemominutum 'Birmingham 1' MHM  NC_021007.1 ND    
  
M. agalactiae MAGa NC_013948.1 oppA
2BCDF 
(39649-34950) B 
MAGa10903, oppBCDF 
(115992-124849) A 
  
M. agalactiae PG2 MAG NC_009497.1 oppA
2BCDF 
(40944-32960) B 
MAG10003, oppBCDF 
(112247-121103) A 
  
M. alligatoris A21JP2 MALL NZ_ADNC00000000.1 
MALL_06603-0664 
(contig: ADNC01000007.1, 
22108-31018) 
A 
MALL_00072-0011 
(contig: ADNC01000018.1, 2432-
10724) 
B1
MALL_00202-0024  
(contig: ADNC01000020.1, 7011-
14606) 
B2 
M. arthritidis 158L3-1 MARTH NC_011025.1 MARTH_orf403
2, oppB1C1DF 
(366708-357886)  A   
  
M. bovis Hubei-1 MMB NC_015725.1 oppA1
2B1C1D1F1 
(40995-32981) B 
oppA23B2C2D2F2 
(121202-127178) A 
  
M. bovis PG45 MBOVPG45 NC_014760.1 
MBOVPG45_00372, oppB, 
MBOVPG45_0035, oppDF 
(39666-31652) 
B MBOVPG45_0112
3-0116 
(119020-127881) A 
  
M. capricolum subsp. 
capricolum ATCC 27343 MCAP NC_007633.1 
MCAP_01162-0120 
(138537-146357) B 
MCAP_0161-0164, MCAP_01652 
(195862-204849) C 
  
M. conjunctivae HRC/581 MCJ NC_012806.1 
MCJ_0023703, oppBCD-1F 
(220854-229281) A 
oppB-1C-1D-1F-1, 2 genes4, 
MCJ_0044402 
(490827-506717) 
B 
  
M. crocodyli MP145 MCRO NC_014014.1 oppA
2B-1C-1D-1F-1 
(389928-399020) B 
MCRO_06183, oppB-2C-2D-2F-2 
(726278-717361) A 
  
M. fermentans JER MFE NC_014552.1 MFE_02290
3, oppB1C1D1F3 
(245804-254675) A 
oppA2B2C2D2F4 
(197036-205524) B 
  
M. fermentans M64 MfeM64YM NC_014921.1 
oppA2B-1C-1D-1F-1 
(213463-221843) B 
MfeM64YM_02813, oppB-2C-2D-2F-2 
(282323-291194) A 
  
M. gallisepticum str. R(low) MGA NC_004829.2 
MGA_02263, 5, 
dpp/oppBb_1Ba_1C_1D_1F_1 
(721805-716646) 
A oppA
2, dpp/oppB_2C_3D_2F_2 
(724918-717083) B 
  
M. gallisepticum str. R(high) MGAH CP001872.1 
MGAH_02263, 5, dppB, 
MGAH_0221a, 0221b, dppDF 
(716475-707492) 
A oppA_2
2
, dppBCDF11 
(724747-716912) B 
  
M. gallisepticum str. F MGF CP001873.1 MGF_2297
3, 5, dppBCDF
(389898-398879) A 
oppA_22, dppBCDF 
(381626-389461) B 
  
M. genitalium G37 MG NC_000908.2 
OppBCDF
(99383-109206) 
MG_3213,5  (400119-402923) 
A   
  
M. haemocanis  str. Illinois  MHC NC_016638.1 ND      
M. haemofelis str. Langford 1  HF1 NC_014970.1 ND       
M. hominis ATCC 23114 MHO NC_013511.1 oppA
3BCDF 
(178627-187638) A   
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Species Abbr NCBI nr Annotation opp operons (genomic location1) 
M. hyopneumoniae 232 mhp NC_006360.1 oppBCDF, gene
6, mhp1642
(192435-206054) B 
mhp5023, oppBCDF 
(633310-624928) A 
  
M. hyopneumoniae 7448 MHP7448 NC_007332.1 
oppB-1C-1DF-1, gene6, 
MHP7448_02172 
(243270-256889) 
B MHP7448_0505
3, oppBCD-1F 
(670413-662031) A 
  
M. hyopneumoniae J MHJ NC_007295.1 
oppB-1C-1D-1F-1, gene6, 
MHJ_02132 
(235856-249475) 
B MHJ_0502
3, oppBCDF 
(647232- 638850) A 
  
M. hyorhinis HUB-1 MHR NC_014448.1 oppBCDF, gene
6, MHR_03572 
(467543-451680) B 
MHR_06393, oppBCDF 
(786329-777920) A 
  
M. iowae 695  GUU NZ_AGFP00000000.1 
GUU_028282, 02833, 02838, 
02843, 02848 
(contig: AGFP01000029.1, 
7327-16111) 
A 
 
 
  
M. leachii PG50 17 MSB NC_014751.1 MSB_A0161
2,0162-165 
(180561-188377) B 
MSB_A0212-0215, MSB_A02162
(244151- 253117) C 
  
M. mobile 163K MMOB NC_006908.1 MMOB4520
3, oppBC, pgk, oppF  
(564402-554792) A 
    
M. mycoides subsp. capri LC 
str. 95010 MLC NC_015431.1 
oppBCDFA2
(205424-214429) C 
oppA2BCDF 
(1029320-1021513) B 
  
M. mycoides subsp. mycoides 
SC str. PG1 MSC BX293980.2 
oppBCDFA2
(210699-219713) C 
oppA2BCDF 
(1097481-1105303) B  
 
M. ovis str. Michigan  OVS NC_023062.1 ND      
M. parvum str. Indiana PRV NC_022575.1 ND      
M. penetrans HF-2 MYPE NC_004432.1 
MYPE55603, 5, oppBCDF
(709149-700280) A1
oppBCDF 
(1183321-1176983) 
MYPE7570-MYPE76203, 5 
(993492-1008762) 
A2
  
M. pneumoniae 309 MPNA NC_016807.1 
oppBCDF,  
(264311-270394)  
MPNA45603, 5  
(553754-556771) 
A 
 
 
  
M. pneumoniae M129 MPN NC_000912.1 
oppB, amiD, oppDF 
(265910-271993)  
MPN4563, 5 (555398-558415) 
A 
 
 
  
M. pulmonis UAB CTIP MYPU NC_002771.1 MYPU_2820
2, oppBCDF  
(327933-336205) A 
oppBCDF, gene6, MYPU_41502
(485792-500096) B 
  
M. putrefaciens KS1 MPUT NC_015946.1 oppBCDFA
3
(745676-736919) C 
    
 M. suis str. Illinois  MSU NC_015155.1 ND      
M. synoviae 53 MS53 NC_007294.1 
oppBC, MS53_0186, oppD7, 2 
genes4, MS53_01903  
(199080-213247) 
B 
MS53_03493, oppB-1C-1D-1F-1 
(401341-392438) A 
  
M. nasistruthionis sp. nov str. 
Ms03 Ms03 
KM410300 
KM410301 oppA
3BCDF A oppA22B2C2D2F2 B   
Mycoplasma sp. Ms02 Ms02 KM410302 KM410304 oppA
3BCDF A B2C2F2D2, 3 genes, oppA22 B  
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Species Abbr NCBI nr Annotation opp operons (genomic location1) 
M. struthionis sp. nov. str. 
Ms01 Ms01 KM410303 oppA
3BCDF A    
M. wenyonii str. 
Massachusetts WEN NC_018149.1 ND    
 
1 From the start codon of the first gene to the stop codon of the last gene 
2 Conserve domain found in NCBI BLAST search 
3 No putative conserve domain found in NCBI BLAST 
4 Two genes are located between oppBCDF and the putative oppA, both located on the same strand, transcribe unidirectional and code for hypothetical proteins 
5 oppA gene identified with two PSI-BLAST iterations 
6 Gene is located between oppBCDF and the putative oppA, located on the same strand, transcribe unidirectional and codes for a hypothetical protein 
7 Note the order of genes BCFD 
8 Three genes are located between oppBCDF and the putative oppA, both located on the same strand, transcribe unidirectional and code for hypothetical proteins 
ND No opp operon was identified with in the genome 
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Supplementary Table 2 Annotated opp genes that are located within single or incomplete opp operon  
Species Abbr NCBI nr opp genes Location  
M. agalactiae MAGa NC_013948.1 oppB  598047-598982 
M. agalactiae PG2 MAG NC_009497.1 oppB  548505-549440 
M. arthritidis 158L3-1 MARTH NC_011025.1 oppB2C2 656656-654525 
M. bovis Hubei-1 MMB NC_015725.1 oppB3  613224-614159 
M. fermentans JER MFE NC_014552.1 oppF pseudo  oppB3C3  
341222-343764 
722489-720386 
M. fermentans M64 MfeM64YM NC_014921.1 oppF3  oppB-3C2 
352166-354709 
799513-797410 
M. hominis ATCC 23114 MHO NC_013511.1 oppBC  210656-212795 
M. mobile 163K MMOB NC_006908.1 oppF 212201-214753 
M. mycoides subsp. mycoides SC str. PG1 MSC BX293980.2 oppF  oppF 
1112073-1113035 
1121742-1122701 
Total  
OppB 3  
OppBC 4  
OppF 5  
 16  
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Supplementary Table 3 PSORTb, PRED-LIPO, SignalP and InterPro results for mycoplasma OppA proteins 
OppA Type A protein Size PSORT PRED-LIPO SignalP 4.1 
InterPro 
Prosite Family Domains Region Unintegrated signatures Region GO term 
GUU_02828 832 Unknown LIPO Y -     G3DSA:3.40.190.10 317-480  
G3DSA:3.90.76.10 173-288 
PD024071 609-648 
SSF53850  172-270, 319-506, 555-658 
MAG1000 959 Unknown LIPO Y  -         
MAGa1090  959 Extracellular LIPO Y  -        
MALL_0660 949 Unknown LIPO Y PS51257 (1-27)       
MARTH_orf403 918 Unknown LIPO Y PS51257 (1-31)    G3DSA:3.90.76.10 174-224  
MBOVPG45_0112 961 Unknown LIPO Y -       
MCJ_002370  955 Extracellular Membrane Y PS51257 (1-25)       
MCRO_0618  940 Unknown SIGNAL Y PS51257 (1-28) 
PS00387 (172-178) 
   G3DSA:3.90.76.10 213-269  
MfeM64YM_0281 929 Unknown LIPO Y PS51257 (1-29)       
MFE_02290  928 Unknown LIPO Y PS51257 (1-29)        
MGAH_0226 897 Cytoplasmic
Membrane 
LIPO Y PS51257 (1-28)       
MGA_0226 897 Cytoplasmic
Membrane 
LIPO Y PS51257 (1-28)       
MGF_2297 897 Cytoplasmic
Membrane 
LIPO Y PS51257 (1-28)       
MG_321 934 Extracellular LIPO Y PS51257 (1-25)    G3DSA:3.90.76.10 162-356  
PD024071 664-934  
SSF53850 165-302, 335-373 
MHJ_0502 926 Unknown SIGNAL Y - IPR017012 PIRSF032899 1-926    
MHO_OppA  961 Unknown SIGNAL Y PS51257 (1-28) IPR017012 PIRSF032899 1-960 G3DSA:3.90.76.10 192-237  
MHP7448_0505 938 Cytoplasmic
Membrane 
LIPO Y - IPR017012 PIRSF032899 1-926     
mhp502  938 Unknown SIGNAL Y - IPR017012 PIRSF032899 1-926    
MHR_0639  946 Unknown LIPO Y PS51257 (1-24)       
MMB_OppA2  961 Unknown LIPO Y -       
MMOB4520  955 Unknown SIGNAL Y - IPR017012  PIRSF032899 1-955     
MPN456 1005 Unknown LIPO Y PS51257 (1-25)    G3DSA:3.90.76.10 167-224, 274-373  
PD024071 698-1003  
SSF53850 167-228, 268-326, 356-409  
MPNA4560  1005 Unknown LIPO Y PS51257 (1-25)    G3DSA:3.90.76.10 167-224, 274-373  
PD024071 698-1003 
SSF53850 167-233, 279-319, 354-414 
Ms01_OppA  942 Unknown LIPO Y PS51257 (1-27)       
Ms02_OppA  998 Unknown LIPO Y PS51257 (1-28)    G3DSA:3.90.76.10 192-213, 245-292  
Ms03_OppA  1288 Unknown LIPO Y PS51257 (1-23)       
MS53_0349  991 Unknown LIPO Y PS51257 (1-26)       
MYPE5560 847 Unknown SIGNAL Y -    PD024071 129-158  
MYPE7580/MYPE7570* 982 Extracellular SIGNAL Y PS51257 (1-26)    PD024071 494-769   
MYPE7590 972 Extracellular LIPO Y PS51257 (1-26)    PD024071 694-969  
MYPE7600 965 Extracellular SIGNAL Y PS51257 (1-26)    PD024071 690-963  
MYPE7610 1010 Extracellular LIPO Y PS51257 (1-35)     PD024071 720-1008   
MYPE7620 990 Extracellular LIPO Y PS51257 (1-26)    PD024071 697-988  
MYPU_2820 876 Unknown LIPO Y - IPR017012  PIRSF032899  2-876    
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OppA Type B Protein Size PSORT PRED-LIPO SignalP 4.1 
InterPro 
Prosite Family Domains Region Unintegrated signatures Region GO terms 
MAGa_OppA  983 Unknown LIPO Y  - IPR016880  PIRSF028335  1-982 G3DSA:3.10.105.10 576-640, 683-813, 894-938 GO:0006810 
GO:0005215 IPR000914 437-798 SSF53850 437-639, 681-804, 892-946 
MAG_OppA  982 Unknown LIPO Y  - IPR016880 PIRSF028335  1-982 G3DSA:3.10.105.10 576-640, 683-813, 894-938 GO:0006810 
GO:0005215 IPR000914 437-798 SSF53850 437-651, 698-796 
MALL_0007 938 Unknown LIPO Y PS51257 (1-25) IPR016880 PIRSF028335 1-937 G3DSA:3.10.105.10 559-616, 657-787, 852-896 GO:0006810 
GO:0005215 IPR000914 464-772 G3DSA:3.90.76.10 136-204 
SSF53850 443-615, 655-778, 854-906 
MALL_0020 991 Unknown LIPO Y PS51257 (1-24) IPR016880  PIRSF028335 1-991 G3DSA:3.10.105.10 510-567, 606-737, 905-949 GO:0006810 
GO:0005215 IPR000914 360-700 SSF53850 348-578, 621-729 
MBOVPG45_0037 983 Unknown LIPO Y - IPR016880 PIRSF028335 1-982 G3DSA:3.10.105.10 576-640, 683-813, 894-938 GO:0006810 
GO:0005215 IPR000914 437-798 SSF53850 437-639, 678-804, 892-947 
MCAP_0116 984 Unknown SIGNAL Y - IPR016880 PIRSF028335 1-984 G3DSA:3.10.105.10 583-647, 688-818, 896-940 GO:0006810 
GO:0005215 IPR000914 444-803 SSF53850 444-646, 683-809, 898-949 
MCJ_004440 888 Unknown LIPO Y PS51257 (1-21) IPR016880  PIRSF028335 1-888 G3DSA:3.10.105.10 482-539, 580-716, 580-716 GO:0006810 
GO:000521 IPR000914 146-677 G3DSA:3.90.76.10 147-235 
SSF53850 144-197, 337-538, 582-727 
MCRO_OppA 950 Unknown LIPO Y PS51257 (1-26) IPR016880 PIRSF028335 1-949 G3DSA:3.10.105.10 571-628, 669-799, 864-908 GO:0006810 
GO:0005215 IPR000914 476-784 SSF53850 456-627, 667-829 
MfeM64YM_OppA 935 Unknown LIPO Y PS51257 (1-26) IPR016880 PIRSF028335  1-935 G3DSA:3.10.105.10 547-604, 644-774, 853-893 GO:0006810 
GO:0005215 IPR000914 426-757 SSF53850 405-603, 639-774 
MFE_OppA 935 Unknown LIPO Y PS51257 (1-26) IPR016880 PIRSF028335 1-935 G3DSA:3.10.105.10 547-604, 644-774, 853-893 GO:0006810 
GO:0005215 IPR000914 426-757 SSF53850 405-603, 639-774 
MGAH_OppA_2  1034 Cytoplasmic
Membrane 
LIPO Y PS51257 (1-26) IPR016880 PIRSF028335 1-1034 G3DSA:3.10.105.10 524-581, 620-751, 948-992 GO:0006810 
GO:0005215 IPR000914 382-716 SSF53850 382-592, 635-779 
MGA_OppA 1034 Cytoplasmic
Membrane 
LIPO Y PS51257 (1-26) IPRO16880 PIRSF028335 1-1034 G3DSA:3.10.105.10 524-581, 620-751, 948-992 GO:0006810 
GO:0005215 IPR000914 382-716 SSF53850 382-592, 635-779 
MGF_OppA_2  1034 Cytoplasmic
Membrane 
LIPO Y PS51257 (1-26) IPR016880 PIRSF028335 1-1034 G3DSA:3.10.105.10 524-581, 620-751, 948-992 GO:0006810 
GO:0005215 IPR000914 382-716 SSF53850 382-592, 635-807 
MHJ_0213  889 Cytoplasmic
Membrane 
LIPO Y - IPR016880 PIRSF028335  1-889 G3DSA:3.10.105.10 482-539, 580-715, 805-849 GO:0006810 
GO:0005215 IPR000914 159-678 SSF53850 361-538, 582-740 
MHP7448_0217 889 Unknown LIPO Y - IPR016880  PIRSF028335 1-889 G3DSA:3.10.105.10 482-539, 580-715, 805-849 GO:0006810 
GO:0005215 IPR000914 159-679 SSF53850 361-538, 582-738 
mhp164  892 Unknown LIPO Y PS51257 (1-24) IPR016880 PIRSF028335 1-892 G3DSA:3.10.105.10 485-542, 583-718, 808-852 GO:0006810 
GO:0005215 IPR000914 162-682 SSF53850 364-541, 585-740 
MHR_0357  901 Unknown LIPO Y PS51257 (1-25) IPR016880 PIRSF028335  1-901 G3DSA:3.10.105.10 494-551, 595-724, 816-860 GO:0006810 
GO:0005215 IPR000914 348-710 G3DSA:3.90.76.10  159-214, 340-370 
SSF53850 154-207, 349-550, 593-735 
MLC_OppA  985 Unknown SIGNAL N - IPR016880 PIRSF028335 1-985 G3DSA:3.10.105.10 584-648, 689-819, 896-941  GO:0006810 
GO:0005215 IPR000914 446-804 SSF53850 445-647, 684-810 
MMB_OppA1  982 Unknown LIPO Y - IPR016880 PIRSF028335 1-982 G3DSA:3.10.105.10 576-640, 683-813, 894-938 GO:0006810 
GO:0005215 IPR000914 437-798 SSF53850 437-639, 678-804, 892-947 
Ms02_OppA2  895 Unknown LIPO Y PS51257 (1-28) IPR016880 PIRSF028335 1-895 G3DSA:3.10.105.10 512-569, 614-744, 809-853 GO:0006810 
GO:0005215 IPR000914 374-729 SSF53850 374-568, 612-735, 794-863 
Ms03_OppA2 1030 Unknown LIPO Y PS51257 (1-27) IPR016880 PIRSF028335 1-1030 G3DSA:3.10.105.10 521-578, 617-749, 783-794  GO:0006810 
GO:0005215 IPR000914 191-710 SSF53850 391-589, 632-776 
MS53_0190 894 Unknown LIPO Y -  IPR000914 367-722 G3DSA:3.10.105.10 511-568, 611-741, 805-849 GO:0006810 
GO:0005215 G3DSA:3.90.76.10  158-212  
SSF53850 371-567, 607-732, 805-858 
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OppA Type B protein Size PSORT PRED-LIPO SignalP 4.1 
InterPro 
Prosite Family Domains Region Unintegrated signatures Region GO terms 
MSB_A0161  985 Unknown SIGNAL N - IPR016880 PIRSF028335 1-985 G3DSA:3.10.105.10 584-648, 689-819, 896-941 GO:0006810 
GO:0005215 IPR000914 445-804 SSF53850 445-647, 684-810 
MSC_OppA 985 Unknown SIGNAL N - IPR016880 PIRSF028335 1-985 G3DSA:3.10.105.10 584-648, 689-819, 894-941 GO:0006810 
GO:0005215 IPR000914 445-804 SSF53850 445-647, 684-810 
MYPU_4150  904 Cytoplasmic
Membrane 
LIPO Y PS51257 (1-23) IPR016880  PIRSF028335 1-903 G3DSA:3.10.105.10 494-551, 596-725, 811-859 GO:0006810 
GO:0005215 IPR000914 346-711 G3DSA:3.90.76.10  163-214, 339-371 
SSF53850 171-207, 171-207, 611-751 
OppA Type C protein Size PSORT PRED-LIPO SignalP 4.1 
InterPro 
Prosite Family Domains Region Unintegrated signatures Region GO terms 
MCAP_0165 1035 Unknown LIPO Y PS51257 (1-24)  IPR000914  85-550 G3DSA:3.10.105.10 791-853 GO:0006810 
GO:0005215 G3DSA:3.40.190.10 278-430 
G3DSA:3.90.76.10  76-161, 247-277 
SSF53850  43-157, 243-430 
MLC_OppA 1044 Extracellular LIPO Y  PS51257 (1-24)  IPR000914 330-540 G3DSA:3.10.105.10 802-903 GO:0006810 
GO:0005215 Code: 3.40.190.10 288-440 
G3DSA:3.90.76.10  76-158, 253-287 
SSF53850  43-158, 252-438 
MPUT_OppA 966 Unknown LIPO Y PS51257 (1-24)  
PS01040 (90-112) 
 IPR000914  85-435 G3DSA:3.10.105.10 757-876 GO:0006810 
GO:0005215 G3DSA:3.40.190.10 271-435 
G3DSA:3.90.76.10 74-161, 243-270 
SSF53850  47-156, 236-435 
MSB_A0216 1031 Extracellular LIPO Y PS51257 (1-24)  IPR000914 325-497 G3DSA:3.10.105.10 798-888 GO:0006810 
GO:0005215 G3DSA:3.40.190.10 287-443 
G3DSA:3.90.76.10  76-161, 252-286 
SSF53850  42-148, 245-446 
MSC_OppA 1047 Extracellular LIPO Y PS51257 (1-24)  IPR000914  330-540 G3DSA:3.10.105.10 805-859 GO:0006810 
GO:0005215 G3DSA:3.40.190.10 288-440 
G3DSA:3.90.76.10  76-161, 252-287 
SSF53850 43-158, 252-438 
* Open reading frame MYPE7570 and MYPE7580 represent the complete copy of one OppA protein 
G3DSA:3.10.105.10: CATH Classification, Class 3: Alpha Beta, Architecture 3.10: Roll, Topology 3.10.105: Dipeptide-binding Protein; domain 3, Homologous Superfamily 3.10.105.10: Dipeptide-binding Protein; domain 3 
G3DSA:3.40.190.10: CATH Classification, Class 3: Alpha Beta, Architecture 3.40: 3-Layer(aba) Sandwich, Topology 3.40.190: D-Maltodextrin-Binding Protein; domain 2, Homologous Superfamily 3.40.190.10: Periplasmic 
binding protein-like II 
G3DSA:3.90.76.10: CATH Classification, Class 3: Alpha Beta, Architecture 3.90: Alpha-Beta Complex, Topology 3.90.76: Dipeptide-binding Protein; domain 1, Homologous Superfamily 3.90.76.10: Dipeptide-binding Protein; 
domain 1 
GO:0006810 transport: Biological Process 
GO:0005215 transporter activity: Molecular Function 
IPR000914: Pfam PF00496, Bacterial extracellular solute-binding proteins, family 5  
IPR016880: InterPro, ABC-type oligopeptide transport system, solute-binding component, Mycoplasmataceae, predicted 
IPR017012: InterPro family, Uncharacterised conserved protein UCP032899 (PIRSF032899), lipoprotein  
PD024071: ProDom family, lipoprotein related to MG321 
PIRSF028335: Protein information Resource, ABC-type oligopeptide transport system, solute-binding component, Mycoplasmataceae type 
PIRSF032899: Protein Information Resource, uncharacterized conserved lipoprotein  
PS00387: Prosite, PPASE, Inorganic pyrophosphatase signature  
PS01040: Prosite, SBP_BACTERIAL_5 Bacterial extracellular solute-binding proteins, family 5 signature 
PS51257: Prosite, PROKAR_LIPOPROTEIN, Prokaryotic membrane lipoprotein lipid attachment site 
SSF53850: SCOP Classification, Class: Alpha and beta proteins (a/b) [51349], Fold: Periplasmic binding protein-like II [53849], Superfamily: Periplasmic binding protein-like II [53850] 
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Supplementary Table 4 MEME motifs in Type A, B and C OppA proteins 
Motif Motif 1A Motif 2A Motif 3A Motif 4A Motif 5A Motif 6A 
Size of motif 29 41 41 29 32 41 
E-value 1.0e-280 3.3e-339 8.2e-157 2.0e-155 5.3e-151 1.2e-193 
GUU_02828 624-652 162-202 247-287 - 447-478 203-243 
MAG1000 762-790 205-245 - 678-706 - - 
MAGa1090 762-790 205-245 - 678-706 - - 
MALL_0660 754-782 209-249 - 672-700 - - 
MARTH_orf403 711-739 161-201 - 628-656 - 203-243 
MBOVPG45_0112 762-790 205-245 - 678-706 - - 
MCJ_002370 702-730 162-202 - 620-648 - 204-244 
MCRO_0618 746-774 203-243 - 665-693 555-586 - 
MfeM64YM_0281 730-758 174-214 859-899 645-673 - 392-432 
MFE_02290 730-758 174-214 859-899 645-673 - 392-432 
MGAH_0226 134-162 458-498 570-610 - 796-827 499-539 
MGA_0226 134-162 458-498 570-610 - 796-827 499-539 
MGF_2297 134-162 458-498 570-610 - 796-827 499-539 
MG_321 687-715 154-194 271-311 - 473-504 201-241 
MHJ_0502 698-726 159-199 - 616-644 516-547 201-241 
MHO_OppA 736-764 179-219 - 651-679 - - 
MHP7448_0505 698-726 159-199 - 616-644 516-547 201-241 
mhp502 698-726 159-199 - 616-644 516-547 201-241 
MHR_0639 720-748 167-207 - 637-665 - - 
MMB_OppA2 762-790 205-245 - 678-706 - - 
MMOB4520 754-782 173-213 - 673-701 - 215-255 
MPN456 721-749 159-199 288-328 - 490-521 207-247 
MPNA4560 721-749 159-199 288-328 - 490-521 207-247 
Ms01_OppA 730-758 174-214 - 645-673 - - 
Ms02_OppA 794-822 232-272 - 711-739 - - 
Ms03_OppA 1073-1101 534-574 - 994-1022 - - 
MS53_0349 752-780 184-224 - 673-701 - 267-307 
MYPE5560 134-162 419-459 529-569 - 741-772 460-500 
MYPE7570/MYPE7580* 499-527 6-46 118-158 - 327-358 47-87 
MYPE7590 699-727 208-248 317-357 - 527-588 329-289 
MYPE7600 695-723 207-247 315-355 - 524-555 248-288 
MYPE7610 738-766 232-272 349-389 - 557-588 273-313 
MYPE7620 717-745 221-261 333-373 - 543-574 262-302 
MYPU_2820 692-720 165-205 - 609-637 502-533 - 
Motif Motif 1B Motif 2B Motif 3B Motif 4B Motif 5B Motif 6B 
Size 85 49 43 62 55 56 
E-value 2.2e-1119 2.1e-710 3.0e-640 5.3e-723 1.2e-613 1.2e-623 
MAGa_OppA 503-587 607-655 909-951 664-725 148-202 727-782 
MAG_OppA 503-587 607-655 909-951 664-725 148-202 727-782 
MALL_0007 486-570 583-631 867-909 638-699 141-195 701-756 
MALL_0020 437-521 534-582 920-962 587-648 163-217 650-705 
MBOVPG45_0037 503-587 607-655 909-951 664-725 148-202 727-782 
MCAP_0116 510-594 614-662 911-953 669-730 152-206 732-787 
MCJ_004440 409-493 506-554 820-862 565-626 140-194 627-682 
MCRO_OppA 498-582 595-643 879-921 650-711 153-207 713-768 
MfeM64YM_OppA 474-558 571-619 864-906 625-686 141-195 688-743 
MFE_OppA 474-558 571-619 864-906 625-686 141-195 688-743 
MGAH_OppA_2 451-535 548-596 963-1005 601-662 172-226 664-719 
MGA_OppA 451-535 548-596 963-1005 601-662 172-226 664-719 
MGF_OppA_2 451-535 548-596 963-1005 601-662 172-226 664-719 
MHJ_0213 409-493 506-554 820-862 565-626 139-193 627-682 
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Motif Motif 1B Motif 2B Motif 3B Motif 4B Motif 5B Motif 6B 
MHP7448_0217 409-493 506-554 820-862 565-626 139-193 627-682 
mhp164 412-496 509-557 823-865 568-629 142-196 630-685 
MHR_0357 421-505 518-566 834-874 576-637 151-205 638-693 
MLC_OppA 511-595 615-663 912-954 670-731 153-207 735-788 
MMB_OppA1 503-587 607-655 909-951 664-725 148-202 727-782 
Ms02_OppA2 439-523 536-584 824-866 595-656 144-198 658-713 
Ms03_OppA2 448-532 545-693 959-1001 592-653 171-225 661-716 
MS53_0190 438-522 535-583 820-862 592-653 149-203 655-710 
MSB_A0161 511-599 615-663 912-954 670-731 153-207 733-788 
MSC_OppA 511-595 615-663 912-954 670-731 153-207 733-788 
MYPU_4150 421-505 518-566 830-872 577-638 151-205 639-694 
Motif Motif 1C Motif 2C Motif 3C Motif 4C Motif 5C Motif 6C 
Size  100 100 100 74 100 57 
E-value 1.0e-184 2.8e-181 8.0e-160 5.7e-111 4.8e-119 4.7e-092 
MCAP_0165 72-171 275-374 745-844 884-957 453-552 1-57 
MLC_OppA 72-171 284-383 756-855 894-967 463-562 1-57 
MPUT_OppA 72-171 271-370 707-806 826-899 449-548 1-57 
MSB_A0216 72-171 283-382 751-850 880-953 461-560 1-57 
MSC_OppA 72-171 271-370 707-806 826-899 449-548 1-57 
* Open reading frame MYPE7570 and MYPE7580 represent the complete copy of one OppA protein 
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Supplementary Table 5 Regular expressions of the MEME motifs within Type A, B and C OppA protein  
Type A OppA 
Motif Regular expression  
Motif 1A [YW][FIY]xxG[TS]SP[LA]GFS[GS]W[SG][YP]DY[ND]G[IV]G[TS][GW][LIY][DE][GA]L[TIS]  
Motif 2A SINS[EK]xF[KQ][EKD]A[LI]KKA[KT]K[LYV]QFx[IV][DRK][KT][GDN][IV]KWV[DN][SN][KN]G[NEK]PTKYE[VS][VG][APK] 
Motif 3A F[TNR][FILV]Y[LIV][TK][KQS][PA][YF][PA][FY][TAL][FLM][GQS][MT][LFM][STK][KI][ES][YF][FL][AFT][AP][MLI]P[HY][T
W][NDH][PQT][KER][VI][KR][AN][IL][HKR][LI][GQS][SGK][GDQ][STAG][PD] 
Motif 4A [KQR]FK[SA][AP][KN]FKE[LI][KQ][AE]E[MV]KK[IL]LD[KE][FY]Y[QAK]DN[PKN]LG[PA]  
Motif 5A [MET][AR][KN][FI][LIF][YR][NQ][WS][NE]S[DEK][DE][SA][YRL][TI]IRA[GA]I[ANV][GN]LINWY[NQR]L[AS][LIQ][IV]  
Motif 6A D[FY]ER[GA][FIL]E[SI]Y[WY]L[AS][AS]SLGYNRNGYF[LI]DL[IL]GLD[FL]EKT[VA][GN]Y[TD]P[KS][SN]  
Type B OppA 
Motif Regular expression  
Motif 1B 
LGPQG[YS][LMI][LI]LSKN[PL][SN]Y[YF]S[AS][DE][KN]TI[SP][NE][KR]I[KR]I[FY]F[SA][SQ][DN]P[NE][ILT][NL][AS][AL][
LM][FY][DE]D[GK]YI[AS][AQ]T[RK]IPAIQQ[LN][AKR][YF]W[TAS][ND][KP]E[YT][RK][KQ][YF][ML][KN]K[SN][SQT]G[FY
]GTI[AG][LF][AQG][FL]NLD  
Motif 2B DLRNAIYY[AG]INR[DE][DE][ML]L[NK][IL]VG[WL][ND][SF]S[FY]PV[IT]TWTAFGQG[SK][ST]S[FDR]GD[ANP][LI]E[LIT][
FG]FD  
Motif 3B [KAE][EQ][GN]WT[EQ][QN][SK][VA]F[AG][IF]I[AG][AG][LF]EKI[IV]R[DE]AAP[VI][VI]PLMEVDT[YN]WEI[SNT]R[VI][GN
R]G  
Motif 4B [KD][TVD][GDK][KN][KN][KT][EAP][IF]P[VLI][QL]NY[SDN][HYF][IV][DNV]HL[SA]KS[YF][NK]FE[HAK][VT]DR[TK]D[KL][
GA][FY][DN][LP][KE][IVT]A[NKR][FKQ]Y[LM]D[RL]FK[AK]K[HY]P[ND][LV]K[KQS][VI]TL[KN][YF][IL]  
Motif 5B [ILN][QP][NT][NS][NGS]N[KN][IFV][QLMV][SA][ML][TN][IG]LLNDG[KA][SN][RK]WSN[GN]DEV[VT]A[DQ]D[YF]ID[AY][I
L][HL]YILD[LI][NS]T[GA]SQ[KR][LQ][TDV][NT][IL]LQ  
Motif 6B [NY]STDE[QH]Q[NK][AV][GA][IT][AG]L[QK]D[FA][ML][RS]KA[FT][NG]G[FY][ILV]NI[ED]IK[SG]LPE[NG][VI]YE[DS][FAR
][RI][TE]KG[EQ][FY]D[LI][IL]Y[RQK]NFD[AT]F  
Type C OppA 
Motif Regular expression  
Motif 1C 
LQD[VIT]L[LI][TA]V[ND][RKN]HD[HN][YF]EGALA[EL][YK]W[DK][HA][ND][KST][DN][KFS][DK][YHT]W[KS]F[RK][LI]RK
N[AI][YK]WT[KAR]IENGK[QA]V[KD][GK][DGP][LAQ]IT[GA][LKQ]D[IFLV]FNTFRYV[LF]NKNN[LR]ALT[TL][ED][HI][FW]
[LS][TS][NAK][FL][KA][HN][VA][PHN][QEK]L[MI][DEN]F[IL][ND]KLSDP  
Motif 2C YFE[ST][VI]ISYL[AS]FAP[IM]P[ED]I[AS][LV][FQL]Y[AV][NKQS]D[KS][DG]Q[VEGK][SY][NS][IK][YF]AGT[NAL]Y[GA]KP
[LS][GAE][KS][KQ]SGY[NE][GT][LM]WYSG[PA]Y[VI][IV][EDQ][DE]Y[FV][PS]G[SR]NLNL[TK][KR]NE[FH]Y[YF]NK[ED
Q][NK]V[YH]I[EH]K[IM][NL][YF]SY[VT]NK[AG]D[AP][AS][TS][RS]R  
Motif 3C [TI][IN]P[FG][LN][LS][NDS][PT][TG]G[AS][DS][DG][FY]K[IN][KY][IVL][AIQ][QR][FAL]F[GK][SAT]FN[YF]LVR[KN][HKF][
DGN][NSG][NGS]D[IM][DN]SP[FI]V[FI]D[IP][DY][KE]P[IG][DT][FAQ][SK][NAE]Y[LG][KE][EDLQ][LIRV]R[ADE][GS]K[Y
FS][GA][LI][AGM][AE][FI]GW[SA]PDY[DA]DPTNYL[AY]T[LV][KL]Y[GD]G[VA][YF][ED][HY]I[QM][SGN][WM][TDK]K[VL]
F  
Motif 4C [AH][YF][KAES][DEQ]LK[NDK][IA][LIT][QE][HF][FL][TS][NK]E[LV][TE][YEN][IV]D[EK]N[EK][ASTV][DE][IK][YK][KDE]R
YT[EQR]LA[KQ]LEN[YF][YL][TN]L[SA]SA[IL]IIPT[HY][TV][HR][LQE][AS][DE][TF]LP[SIT][IV]S[YF][VL]D[EQ][FL][ST][KI
][PS][TR][WF]P[TIS]  
Motif 5C R[TPV]RT[PA][EQ]EDSILNRA[LI]ALKS[LV]RI[LM][AT]R[YF][AV]LNRSLYAKF[YFH]SEA[RK]DG[NV][DN][RH]P[TV]S[T
S]QLRNTFTS[KQ]Y[VI]ST[FY][EN]D[DK][EKQS][HK][QKR]V[LIV]D[KE][DNS][SL][KGT][QDE][KT]VADYADFLAK[DN]Y
YDI[RT]KYDD[ND]  
Motif 6C MKK[VI]LG[ML]T[LT][LS][GT][SL][IL]IA[TS][AS][AS][AM][ST][AI]VSCS[VL][GR][IV][SGN][LP][DY]K[IL]L[NS]R[KR][NI]S[
ND]T[KT][VI][LY][RK][ED]L[TI][NT][YQ][SP][LI][AV][NT][LW]NS  
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Supplementary Table 6 A comparison of the conserved functional motifs in M. hominis with the postulated motifs in M. 
struthionis sp. nov. str. Ms01, Mycoplasma sp. Ms02 and M. nasistruthionis sp. nov. str. Ms03  
 
 
  
Sequence of the conserved motifs 
 
Signal peptidase II 
recognition site 
Oligopeptide binding 
site Walker B Walker A 
Consensus 
motif1, 2 (+4)-VAASC-(-1) (F/Y)X(L/I)RKGVK(W/F) RXXXGXXXLZZZZD GXXXXGKS/T 
Mho_OppA -LVAASC-28 197-FVIRKGVKW-205 737-RFDGVTGENLLAWSAD-752 869-GKDSSGKS-876 
Ms01_OppA -LVAAAC-28 192-YVLKDNLKW-200 732-INQGANGTRNVGWSYD-747 752-GSGYDGLS-759 
Ms02_OppA -SVAVSC-27 250-FRIRPEQVW-258 795-YWYSVSPARRGRWNYD-810 815-GTGRDGYS-822 
Ms03_OppA -ALALSC-28 552-FRVRPGHFW-560 1074-YWTGTSPFSLAGWGYD-1089 1094-GSGIDGYS-1101 
Percentage identity between the postulated and consensus motifs 
 
Signal peptidase II 
recognition site 
Oligopeptide binding 
site Walker B Walker A 
Mho_OppA 100% 100% 75% 100% 
Ms01_OppA 80% 50% 50% 75% 
Ms02_OppA 80% 50% 37.5% 75% 
Ms03_OppA 60% 50% 50% 75% 
Percentage identity and similarity of the Ms01, Ms02 and Ms03 motifs to that of M. hominis3
 
Signal peptidase II 
recognition site 
Oligopeptide binding 
site Walker B Walker A 
Ms01_OppA Identity:     5/6 (83.3%) 
Similarity: 6/6 (100.0%) 
Identity:     3/9 (33.3%) 
Similarity:  7/9 (77.8%) 
Identity:      5/16 (31.2%) 
Similarity:   6/16 (37.5%) 
Identity:      3/8 (37.5%) 
Similarity:   3/8 (37.5%) 
Ms02_OppA Identity:     4/6 (66.7%) 
Similarity:  4/6 (66.7%) 
Identity:     4/9 (44.4%) 
Similarity:  4/9 (44.4%) 
Identity:      3/16 (18.8%) 
Similarity:   6/16 (37.5%) 
Identity:      3/8 (37.5%) 
Similarity:   3/8 (37.5%) 
Ms03_OppA Identity:     3/6 (50.0%) 
Similarity:  4/6 (66.7%) 
Identity:     4/9 (44.4%) 
Similarity:  5/9 (55.6%) 
Identity:      4/16 (25.0%) 
Similarity:   7/16 (43.8%) 
Identity:      3/8 (37.5%) 
Similarity:   3/8 (37.5%) 
1 X represents any amino acids 
2 Z represents all hydrophobic amino acids 
3 Similarity and identity calculated with EMBOSS Stretcher Pairwise alignment (http://www.ebi.ac.uk/Tools/psa/emboss_stretcher/) using 
the BLOSUM62 matrix with a gap penalty of 10 and extension penalty of 0.5 
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Supplementary Figure 1 The opp operons of M. penetrans HF-2. Type A1 has the oppA gene next to the OppBCDF 
genes in a polycistronic unit while the Type A2 opp operon has 5 copies of oppA encoded by six open reading frames, 
MYPE7570-MYPE7620 that is located several hundreds of bases from the opp operon. MYPE7570 and MYPE7580 
represent a single copy of oppA. 
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Appendix 4 Sequencing data of Chapter 5 
Alignments of the Mycoplasma nasistruthionis sp. nov. str. Ms03 Type A oppA gene was done in BioEdit, as obtained by sequencing after each round of SDM modification 
and after each clone experiment.  
 
                               10        20        30        40        50        60        70        80        90       100       110       120       130       140             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                                            ATGAAAAAATGATGATTATTACCAGTAGCTAGTACAAGTTTAATTCTTCCAGCACTTGCCCTTTCATGTAAAAACACATCAAGCGAAAGAACTTTACACTTTTTATCTGAAAAA  
pGEM_oppA before SDM  GCGGCCGCGGGAATTCGATTACGCGT..................................................................................................................  
SDM1 Site 1, 2 & 10   GCGGCCGCGGGAATTCGATTACGCGT...........G..G...................................................................................................  
SDM2 Site 9, 13 & 14  GCGGCCGCGGGAATTCGATTACGCGT...........G..G...................................................................................................  
SDM3 Site 3 & 7       GCGGCCGCGGGAATTCGATTACGCGT...........G..G...................................................................................................  
SDM4 Site 4 & 12      GCGGCCGCGGGAATTCGATTACGCGT...........G..G...................................................................................................  
SDM5 Site 5 & 8       GCGGCCGCGGGAATTCGATTACGCGT...........G..G...................................................................................................  
SDM6 Site 6 & 16      GCGGCCGCGGGAATTCGATTACGCGT...........G..G...................................................................................................  
SDM7 Site 11 & 15     GCGGCCGCGGGAATTCGATTACGCGT...........G..G...................................................................................................  
pCI-neo_oppA          TAGGCTAGCCTCGAGAATTCACGCGT...........G..G...................................................................................................  
pGem_oppA BamBam      GCGGCCGCGGGAATTCGATTGGATCC...........G..G...................................................................................................  
VR1020_oppA           TCGTTTCGCCCAGCGGTACCGGATCC...........G..G...................................................................................................  
pGEM_oppA SalNot      GCGGCCGCGGGAATTCGATTGTCGAC...........G..G...................................................................................................  
VR1012_oppA           TCTTTTCTGCAGTCACCGTCGTCGAC...........G..G...................................................................................................  
pGEM_oppA BamNot      GCGGCCGCGGGAATTCGATTGGATCC...........G..G...................................................................................................  
pGEX_oppA             AATCGGATCTGGTTCCGCGTGGATCC...........G..G...................................................................................................  
 
                              150       160       170       180       190       200       210       220       230       240       250       260       270       280             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  CAAGTTGCTGAATATCAAGAAAAAGCTCAAGAATATTCAAAACAAGCATTAGCTTCACTTGCTGAATTTAATAAATACAGCAAACAAAAaCAACAATTAGAACAACAAGCTGATTTATTAATCTTTTCTTTACAAGACTT  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
  
Key
Start codon  
Stop codon 
SDM site  
BamIH restriction enzyme site 
MluI restriction enzyme site 
AccI restriction enzyme site 
SalI restriction enzyme site 
NotI restriction enzyme site 
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                              290       300       310       320       330       340       350       360       370       380       390       400       410       420             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  AAATTCAGACTTATTAGCTGCTAAAACAAAaTTATTTAACTTACAAGCTAAAAAAGAATTATTATCTTTAGCCCTTGCTTCTAGTGATTTTAGTCAATTACAAGACAAAGTTAAACAATATTCAAATTCAGAATTTAAAA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              430       440       450       460       470       480       490       500       510       520       530       540       550       560             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  TCCAAGATTTTTTAAATACTGAATTTAATAATTATTTAAATAAATCATATGGTGATGAACAAAACCACTTACCAACACTAAAACAACTAACAGACAGAGCTAAAAGTTTAGAAAGTAATTTAAACACACTAAAACAAACA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              570       580       590       600       610       620       630       640       650       660       670       680       690       700             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  TTAGATAATAAAAACATTAATTTAGCTTTATTAAAAGATAAAGCAAATAAAACAGAGCAAGAAAATGCCCAAATTACAGCGCTAGAAGCTGAAATTCAAGCATCAAAAGAACAACAAACAACAATTTCACAAGAATTAGA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
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                              710       720       730       740       750       760       770       780       790       800       810       820       830       840             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  TCAAAATTCTGAAACAATGGCTACAGTTCAGAATCATATTTACCAAGATTTAAAACAACAAGCAAATGATCAAAGTATGTTAGATGCCCAAATTGCACAACAAGAGCAATCAAATCAAGAAGTTCAACAACAAATCAACA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              850       860       870       880       890       900       910       920       930       940       950       960       970       980             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  CAAAACAACAAGAACTATCAACTAAAAAAGCTGAAATTAACAAACAAATCAGCGACCAAGGCTTAAATGAAAAAATTCAAAGTGCTTTTGATACTTATTCTAAGGCAACTGATGAACAAAGAAAATACAATGGTTTACTA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              990       1000      1010      1020      1030      1040      1050      1060      1070      1080      1090      1100      1110     1120             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  GTCCAAAATGACATTTCAGCTTATAGTTATTCAACTAAAGATGCTAATTTTGATGAAACAGGAGCTAATTCAGATCCTAAATATTTATCAAAACAAGAAGTCAATAAAATAGTTTTTCCTAATGACCCTTTTGTAAATTC  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
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                              1130      1140      1150      1160      1170      1180      1190      1200      1210      1220      1230      1240      1250     1260             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  ACCAGTTAGTGATAGTTTTGCTAAAAACGGTGTTTTCCAAATTGATACAAACTCACAATATTCACCTGGTTATGCTCCATTTGACAACACTGTAAGTTTTGGAAATCGTCAAGCTAATATTTCAGATACTGTTTCAATTT  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              1270      1280      1290      1300      1310      1320      1330      1340      1350      1360      1370      1380      1390     1400             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  CATTTGTTTCAGCTGAAAGAATAGGAAAAACAAAACTTAAAGCATCTGATAAGTGAGAATTAAATGAAAACGGTGTTCCTGTTAAAGTAAAAGTTGAAAACATTATTTCACCAACTGTTTTAAGATACAAATTAGAACTA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       .......................................................G....................................................................................  
SDM4 Site 4 & 12      .......................................................G....................................................................................  
SDM5 Site 5 & 8       .......................................................G....................................................................................  
SDM6 Site 6 & 16      .......................................................G....................................................................................  
SDM7 Site 11 & 15     .......................................................G....................................................................................  
pCI-neo_oppA          .......................................................G....................................................................................  
pGem_oppA BamBam      .......................................................G....................................................................................  
VR1020_oppA           .......................................................G....................................................................................  
pGEM_oppA SalNot      .......................................................G....................................................................................  
VR1012_oppA           .......................................................G....................................................................................  
pGEM_oppA BamNot      .......................................................G....................................................................................  
pGEX_oppA             .......................................................G....................................................................................  
 
                              1410      1420      1430      1440      1450      1460      1470      1480      1490      1500      1510      1520      1530      540             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  GCAGACGCAATTATTTTAAAAGTGCCTAATGAAAGCGGACAATTAGTAGAAATGGTTTTTGATTCAGATGATGCAGGATTAATTCCGGCACCAACTGAAGTTGTAGTTGAAGATAAATTAGACGAAAACGGAAACCCGGT  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
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                              1550      1560      1570      1580      1590      1600      1610      1620      1630      1640      1650      1660      1670     1680             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  ACTTGATGAAAACGGTCAAGTTGTTAAAGAAACAAACAAATACTTTGCCAGTGCTGAAGTTAGAAGATTTTCATCAAATCCTAAATCAATTAACTCACAGCATTTCTTTGATGTTTTAAATAAATCAACTGAACTTAAAT  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              1690      1700      1710      1720      1730      1740      1750      1760      1770      1780      1790      1800      1810     1820             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  TCAGAGTTAGACCAGGTCATTTCTGAACCGATGCTAAAGGAAATCGAACAAAATATCCAATAGTAGCAAAAGACTTCTATCTTGGATTATTAAGAACACAAATGTGAGACACACCTTATAGGCTATCACATGGTGGTTCA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      .........................G..................................................................................................................  
SDM5 Site 5 & 8       .........................G................................................................................G.................................  
SDM6 Site 6 & 16      .........................G................................................................................G.................................  
SDM7 Site 11 & 15     .........................G................................................................................G.................................  
pCI-neo_oppA          .........................G................................................................................G.................................  
pGem_oppA BamBam      .........................G................................................................................G.................................  
VR1020_oppA           .........................G................................................................................G.................................  
pGEM_oppA SalNot      .........................G................................................................................G.................................  
VR1012_oppA           .........................G................................................................................G.................................  
pGEM_oppA BamNot      .........................G................................................................................G.................................  
pGEX_oppA             .........................G................................................................................G.................................  
 
                              1830      1840      1850      1860      1870      1880      1890      1900      1910      1920      1930      1940      1950     1960             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  AGGGAAACAGATAATGATGTTAGAAGTATGCTAATTAATCCTGGGAGATTCTTAGACCCTAGAGCAAACTATGGAAATAAATATTTATTTTCATTATTTAATGTAAGTTTTGATGACTTATTAAAACCAGAAAAATCATT  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
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                              1970      1980      1990      2000      2010      2020      2030      2040      2050      2060      2070      2080      2090     2100             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  ATCAGAAGATGACAATTACACATACTTCACAATTCACAGAGAGGATGAAAGTGTTCCAATTACACAATTTGATAAAGTCCTTGAAAaTGTCTCTTCTTCATATGAATTTATTCCGGCACCTTCTGAATATATCATCAACA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              2110      2120      2130      2140      2150      2160      2170      2180      2190      2200      2210      2220      2230     2240             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  CTTCAAAAGCAAATGCTGAAACAGTAATTTCACAAAAAGATTTAAGTGATGCTCAACTCAAAGCAATCAAATCATCAATCCAAAATGCTAAAGGATTGGCTAAATTGAGTGGTATTTACTGATATGGACTTTCAGTTGAT  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      .........................................................................................................................G..................  
SDM7 Site 11 & 15     .........................................................................................................................G..................  
pCI-neo_oppA          .........................................................................................................................G..................  
pGem_oppA BamBam      .........................................................................................................................G..................  
VR1020_oppA           .........................................................................................................................G..................  
pGEM_oppA SalNot      .........................................................................................................................G..................  
VR1012_oppA           .........................................................................................................................G..................  
pGEM_oppA BamNot      .........................................................................................................................G..................  
pGEX_oppA             .........................................................................................................................G..................  
 
                              2250      2260      2270      2280      2290      2300      2310      2320      2330      2340      2350      2360      2370     2380             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  GATACTTTATATTCAGGTAAATACATCGGAGAAGACTTTAATCCAGACACATTAACAATTTCAACAGTAATTAATAAGAATTACTGAGACACAGAATATGTTAATGATTTAACAACAATTAAAAAATtCTCAAACAAAtA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ......................................................................................G.....................................................  
SDM4 Site 4 & 12      ......................................................................................G.....................................................  
SDM5 Site 5 & 8       ......................................................................................G.....................................................  
SDM6 Site 6 & 16      ......................................................................................G.....................................................  
SDM7 Site 11 & 15     ......................................................................................G.....................................................  
pCI-neo_oppA          ......................................................................................G.....................................................  
pGem_oppA BamBam      ......................................................................................G.....................................................  
VR1020_oppA           ......................................................................................G.....................................................  
pGEM_oppA SalNot      ......................................................................................G.....................................................  
VR1012_oppA           ......................................................................................G.....................................................  
pGEM_oppA BamNot      ......................................................................................G.....................................................  
pGEX_oppA             ......................................................................................G.....................................................  
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                              2390      2400      2410      2420      2430      2440      2450      2460      2470      2480      2490      2500      2510     2520             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  TGCTTCAGCACCAGTTGAACCAGCTACTTATTCAGaTTTATCATACTTCTCATAtCTTTCGGGACAAAAAGCCACATATCCATTTACAACCTTATCAAAAGCTAATAGAGATGCTGTAAATAAAGATCCTGAAGGATATG  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              2530      2540      2550      2560      2570      2580      2590      2600      2610      2620      2630      2640      2650     2660             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  GAATTGCTTATATTCGTGCTTTATCTAAAAACACATTAGTAAATACCTTCTTCTGATCAATTCTGCCAAAAGAAGGTAATTCAGCACCATATTACAATGATGAATATGCTTACACAATGTGAGGAATGTCAGCAGCAGAA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  .........................................................................................................................G..................  
SDM3 Site 3 & 7       .........................................................................................................................G..................  
SDM4 Site 4 & 12      .........................................................................................................................G..................  
SDM5 Site 5 & 8       .......................................................G.................................................................G..................  
SDM6 Site 6 & 16      .......................................................G.................................................................G..................  
SDM7 Site 11 & 15     .......................................................G.................................................................G..................  
pCI-neo_oppA          .......................................................G.................................................................G..................  
pGem_oppA BamBam      .......................................................G.................................................................G..................  
VR1020_oppA           .......................................................G.................................................................G..................  
pGEM_oppA SalNot      .......................................................G.................................................................G..................  
VR1012_oppA           .......................................................G.................................................................G..................  
pGEM_oppA BamNot      .......................................................G.................................................................G..................  
pGEX_oppA             .......................................................G.................................................................G..................  
 
                              2670      2680      2690      2700      2710      2720      2730      2740      2750      2760      2770      2780      2790     2800             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  TCAATTAGTACAAGTTCAAAAAATGCTATAAGAGAAGCAACCGCAGGAACTGGAGGAGAATTTAGAAGCATTTtAACAGCAGCTATTGACTGAAACTCAATCGCTTCAATTCAGCGTTCACCTCAACCGGTTAAACCTTG  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................G...............................................  
SDM2 Site 9, 13 & 14  ............................................................................................G...............................................  
SDM3 Site 3 & 7       ............................................................................................G...............................................  
SDM4 Site 4 & 12      ............................................................................................G...............................................  
SDM5 Site 5 & 8       ............................................................................................G...............................................  
SDM6 Site 6 & 16      ............................................................................................G...............................................  
SDM7 Site 11 & 15     ............................................................................................G...............................................  
pCI-neo_oppA          ............................................................................................G...............................................  
pGem_oppA BamBam      ............................................................................................G...............................................  
VR1020_oppA           ............................................................................................G...............................................  
pGEM_oppA SalNot      ............................................................................................G...............................................  
VR1012_oppA           ............................................................................................G...............................................  
pGEM_oppA BamNot      ............................................................................................G...............................................  
pGEX_oppA             ............................................................................................G...............................................  
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                              2810      2820      2830      2840      2850      2860      2870      2880      2890      2900      2910      2920      2930     2940             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  AATTACAGGATTGTCTCCTGACTCTAAAATTAATGAACAAAACGaCACAGAAACAACTGTTCCAAATAACTTAAGAGACAACAACGACTTAATTAATGCGGTTTTTGTTGTTGATTCAGAAACAGGACAAAGAGTTAACT  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     G...........................................................................................................................................  
pCI-neo_oppA          G...........................................................................................................................................  
pGem_oppA BamBam      G...........................................................................................................................................  
VR1020_oppA           G...........................................................................................................................................  
pGEM_oppA SalNot      G...........................................................................................................................................  
VR1012_oppA           G...........................................................................................................................................  
pGEM_oppA BamNot      G...........................................................................................................................................  
pGEX_oppA             G...........................................................................................................................................  
 
                              2950      2960      2970      2980      2990      3000      3010      3020      3030      3040      3050      3060      3070     3080             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  TTGGTGAACTGGGTTCATTAATTAAACCAAGTTTTACAAACAATGTTAACGTTTCAGCATCTGATGTTGCTAAATCAGTTGTTTATAGTCAATTACAAGAAAGAATGAAGAATTTATTAGACAGAGTTTATGCTAAGTTC  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              3090      3100      3110      3120      3130      3140      3150      3160      3170      3180      3190      3200      3210     3220             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  AACATTCCTTCAACTAACAAAATTAGTTTTGATATCTACTACAGATACTTAAACTACCCAGATCCAGTAATTAATGCTTTAGATTTAGTAATTGCTGCTTGAAACGGATTAGATCCAAGAATGAATGTAAACTTTGTTAA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      .....................................................................................................G......................................  
SDM5 Site 5 & 8       .....................................................................................................G......................................  
SDM6 Site 6 & 16      .....................................................................................................G......................................  
SDM7 Site 11 & 15     .....................................................................................................G......................................  
pCI-neo_oppA          .....................................................................................................G......................................  
pGem_oppA BamBam      .....................................................................................................G......................................  
VR1020_oppA           .....................................................................................................G......................................  
pGEM_oppA SalNot      .....................................................................................................G......................................  
VR1012_oppA           .....................................................................................................G......................................  
pGEM_oppA BamNot      .....................................................................................................G......................................  
pGEX_oppA             .....................................................................................................G......................................  
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                              3230      3240      3250      3260      3270      3280      3290      3300      3310      3320      3330      3340      3350     3360             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  ACCAACTACTGAACAATGAAGAAATTACTGAACAGGAACTTCTCCATTTTCACTAGCAGGTTGAGGTTATGACTACGATGGTATCGGTTCAGGAATTGATGgATATTCATTAAATGCCAAAATCATTCCAACATtATTtG  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ..................G...........G.............................................................................................................  
SDM3 Site 3 & 7       ..................G...........G.............................................................................................................  
SDM4 Site 4 & 12      ..................G...........G.............................................................................................................  
SDM5 Site 5 & 8       ..................G...........G.............................................................................................................  
SDM6 Site 6 & 16      ..................G...........G.............................................................................................................  
SDM7 Site 11 & 15     ..................G...........G................................G............................................................................  
pCI-neo_oppA          ..................G...........G................................G............................................................................  
pGem_oppA BamBam      ..................G...........G................................G............................................................................  
VR1020_oppA           ..................G...........G................................G............................................................................  
pGEM_oppA SalNot      ..................G...........G................................G............................................................................  
VR1012_oppA           ..................G...........G................................G............................................................................  
pGEM_oppA BamNot      ..................G...........G................................G............................................................................  
pGEX_oppA             ..................G...........G................................G............................................................................  
 
                              3370      3380      3390      3400      3410      3420      3430      3440      3450      3460      3470      3480      3490     3500             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  CCATAGTTGCTGATCCAGAATATGCAGCTAAAATGCAAAATCTTTATCCTCAACTATACAAAGCTGCTCAATATCTAAAaGAGTTTGTCCAAATGAATCGTTTCAGACCTTCAATTTCTCTTGATGACTTTACAAATAAA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              3510      3520      3530      3540      3550      3560      3570      3580      3590      3600      3610      3620      3630     3640             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  TTAACAAATTCAAATGTTCAAGATATAGAaCATTACTTTGGTTCATTCAAATATGAAAACGATGGATTTGTTGAATTATCAGCCGAAGAAGCTTCACAATATGTTGACATTAGTGTATTTAGTTCAAGATTCTGACTAAA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ......................................................................................................................................G.....  
SDM7 Site 11 & 15     ......................................................................................................................................G.....  
pCI-neo_oppA          ......................................................................................................................................G.....  
pGem_oppA BamBam      ......................................................................................................................................G.....  
VR1020_oppA           ......................................................................................................................................G.....  
pGEM_oppA SalNot      ......................................................................................................................................G.....  
VR1012_oppA           ......................................................................................................................................G.....  
pGEM_oppA BamNot      ......................................................................................................................................G.....  
pGEX_oppA             ......................................................................................................................................G.....  
 
  
Stellenbosch University  https://scholar.sun.ac.za
Stellenbosch University  https://scholar.sun.ac.za
Appendix 4  
256 
 
                              3650      3660      3670      3680      3690      3700      3710      3720      3730      3740      3750      3760      3770     3780             
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....| 
oppA                  CTATACAACATCACCAGTAATTGACGATCCACAAAATCCAGGTCAAAAGAAAATCATTGATCGTTTAGACTTAGTTGAATTAGCTCAAGAAGTGTCAAACTTAGCTGGCGCTATTCCAGACATTAATTTAGCAGTTTCAA  
pGEM_oppA before SDM  ............................................................................................................................................  
SDM1 Site 1, 2 & 10   ............................................................................................................................................  
SDM2 Site 9, 13 & 14  ............................................................................................................................................  
SDM3 Site 3 & 7       ............................................................................................................................................  
SDM4 Site 4 & 12      ............................................................................................................................................  
SDM5 Site 5 & 8       ............................................................................................................................................  
SDM6 Site 6 & 16      ............................................................................................................................................  
SDM7 Site 11 & 15     ............................................................................................................................................  
pCI-neo_oppA          ............................................................................................................................................  
pGem_oppA BamBam      ............................................................................................................................................  
VR1020_oppA           ............................................................................................................................................  
pGEM_oppA SalNot      ............................................................................................................................................  
VR1012_oppA           ............................................................................................................................................  
pGEM_oppA BamNot      ............................................................................................................................................  
pGEX_oppA             ............................................................................................................................................  
 
                              3790      3800      3810      3820      3830      3840      3850      3860      3870      3880      3890      3900      3910                  
                      ....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|.... 
oppA                  CACAAAAATATTCAAAAaCATTAATTAATCCAAATTACATCGTGCCTACAAACTTTTCAGACTATGATGATTTCCAAAGATATAGAACTGTAAACGGTGTAAGACCTAAATAG                            
pGEM_oppA before SDM  .................................................................................................................GTCGACAATCACTAGTGAATTCGCGG  
SDM1 Site 1, 2 & 10   .................................................................................................................GTCGACAATCACTAGTGAATTCGCGG  
SDM2 Site 9, 13 & 14  .................................................................................................................GTCGACAATCACTAGTGAATTCGCGG  
SDM3 Site 3 & 7       .................................................................................................................GTCGACAATCACTAGTGAATTCGCGG  
SDM4 Site 4 & 12      .................................................................................................................GTCGACAATCACTAGTGAATTCGCGG  
SDM5 Site 5 & 8       .................................................................................................................GTCGACAATCACTAGTGAATTCGCGG  
SDM6 Site 6 & 16      .................................................................................................................GTCGACAATCACTAGTGAATTCGCGG  
SDM7 Site 11 & 15     .................................................................................................................GTCGACAATCACTAGTGAATTCGCGG  
pCI-neo_oppA          .................................................................................................................GTCGACCCCGGGCGGCCGCTTCCCTT  
pGem_oppA BamBam      .................................................................................................................GGATCCAATCACTAGTGAATTCGCGG  
VR1020_oppA           .................................................................................................................GGATCCAGATCTGCTGTGCCTTCTAG  
pGEM_oppA SalNot      .................................................................................................................GCGGCCGCATAATCACTAGTGAATTC  
VR1012_oppA           .................................................................................................................GCGGCCGCTCTAGACCAGGCGCCTGG  
pGEM_oppA BamNot      .................................................................................................................GCGGCCGCATAATCACTAGTGAATTC  
pGEX_oppA             .................................................................................................................GCGGCCGCATCGTGACTGACTGACGA  
 
 
 
 
 Key 
Start codon  
Stop codon 
SDM site  
BamIH restriction enzyme site 
MluI restriction enzyme site 
AccI restriction enzyme site 
SalI restriction enzyme site 
NotI restriction enzyme site 
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Appendix 5 Supplementary tables and figures for Chapter 5 
Supplementary Table 5.1 The weight, mycoplasma infections and ELISA data of each ostrich in the vaccine trial  
Vaccine group  Ostrich 
number  
Weight Ostrich mycoplasma infections Average A260Week 0 Week 3 Week 0 Week 3
28/3/11 18/4/11 Ms01 Ms02 Ms03 Ms01 Ms02 Ms03 Mean Mean
pCI-neo_oppA 7689 42.4 42.4             0.556 0.436 
pCI-neo_oppA 7690 34.8 37.4             0.707 1.617 
pCI-neo_oppA 7692 37.8 40.4             0.511 0.950 
pCI-neo_oppA 7695 42.4 42.6             0.938 1.298 
pCI-neo_oppA 7696 48.6 50.0         +   0.632 2.697 
pCI-neo_oppA 7697 41.2 47.0             0.928 0.865 
pCI-neo_oppA 7698 47.6 38.4     +     + 0.842 0.916 
pCI-neo_oppA 7699 37.4 39.2         +   0.687 1.999 
pCI-neo_oppA 7701 36.6 33.8           + 1.028 1.092 
pCI-neo_oppA 7702 39.4 42.2           + 0.706 0.462 
pCI-neo_oppA 7703 38.8 42.0         +   1.574 1.646 
pCI-neo_oppA 7704 36.0 38.6         + + 1.372 1.689 
pCI-neo_oppA 7705 34.4 38.0           + 1.441 2.639 
pCI-neo_oppA 7706 31.6 29.2         + + 1.493 1.120 
pCI-neo_oppA 7707 42.4 45.8             0.557 0.518 
pCI-neo_oppA 7708 34.0 40.4           + 0.616 1.706 
pCI-neo_oppA 7709 47.6 52.0           + 0.441 0.728 
pCI-neo_oppA 7710 41.6 42.4   +       + 0.886 0.960 
pCI-neo_oppA 7711 38.0 -         + + 0.870 1.876 
pCI-neo_oppA 7712 38.0 39.8             1.215 1.888 
pCI-neo_oppA 7713 39.8 25.2           + 1.858 2.942 
pCI-neo_oppA 7714 33.0 38.4           + 1.295 1.426 
pCI-neo_oppA 7715 38.0 39.8             1.231 2.003 
pCI-neo_oppA 7717 35.8 36.4         + + 0.288 1.643 
pCI-neo_oppA 7718 36.0 35.4             0.779 1.258 
 Mean weight  38.9 39.9         0.938 1.455 
Total Ms01/02/03 Infected ostriches  0 1 1 0 7 13 
Total infected ostriches per week 2 16 
Total infected ostriches 16
VR1020_oppA 7720 29.4 32.4             0.848 1.476 
VR1020_oppA 7721 38.0 39.6             0.895 1.908 
VR1020_oppA 7722 33.8 35.8         +   0.675 2.779 
VR1020_oppA 7724 34.6 39.4             0.677 0.975 
VR1020_oppA 7725 30.6 37.2             1.441 0.977 
VR1020_oppA 7727 38.2 41.4             0.504 0.793 
VR1020_oppA 7728 33.0 32.6           + 0.881 0.857 
VR1020_oppA 7729 32.0 29.0           + 0.668 0.492 
VR1020_oppA 7730 40.2 42.8         +   1.481 2.696 
VR1020_oppA 7731 33.2 36.8             1.936 2.622 
VR1020_oppA 7732 32.6 37.8             1.722 1.369 
VR1020_oppA 7733 32.4 27.0             1.228 0.285 
VR1020_oppA 7736 31.8 38.6             0.834 2.312 
VR1020_oppA 7739 32.4 38.4         + + 0.446 0.934 
VR1020_oppA 7740 31.4 39.2             1.222 2.260 
VR1020_oppA 7741 35.2 37.8     +       1.841 3.029 
VR1020_oppA 7742 36.6 42.0             1.164 1.870 
VR1020_oppA 7744 33.4 34.6             1.397 2.726 
VR1020_oppA 7745 29.2 36.4   +     +   1.797 2.775 
VR1020_oppA 7746 30.8 35.8             0.808 1.016 
VR1020_oppA 7748 36.4 37.8             1.515 1.503 
 Mean weight  33.6 36.8 1.142 1.698
Total Ms01/02/03 Infected ostriches  0 1 1 0 4 3 
Total infected ostriches per week 2 6 
Total infected ostriches 7 
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Vaccine group  Ostrich 
number  
Weight Ostrich mycoplasma infections Average A260 
Week 0 Week 3 Week 0 Week 3 Week 0 Week 3 
28/3/11 18/4/11 Ms01 Ms02 Ms03 Ms01 Ms02 Ms03 28/3/11 18/4/11 
VR1012_oppA 7750 33.6 32.6   + +       1.173 2.375 
VR1012_oppA 7752 38.0 30.8   + +       1.031 0.729 
VR1012_oppA 7753 36.8 44.4     +   +   0.954 1.724 
VR1012_oppA 7754 39.6 39.0   +         2.702 3.003 
VR1012_oppA 7755 41.6 46.8   + +   +   1.524 1.129 
VR1012_oppA 7756 45.6 49.6   +   +     2.923 1.784 
VR1012_oppA 7757 44.4 45.6             0.762 0.642 
VR1012_oppA 7759 42.8 43.0   +         0.824 0.720 
VR1012_oppA 7760 43.4 31.6   +     +   0.406 0.586 
VR1012_oppA 7761 44.4 29.6   + + + + + 0.807 0.807 
VR1012_oppA 7762 36.2 35.4   + +   + + 0.679 1.044 
VR1012_oppA 7763 32.0 33.8   + + + + + 0.707 0.986 
VR1012_oppA 7765 31.0 35.8   + +       0.526 0.842 
VR1012_oppA 7767 27.8 30.6   + +       0.689 1.959 
VR1012_oppA 7768 26.8 27.6             1.576 1.242 
VR1012_oppA 7769 31.6 44.4   + +   + + 0.497 0.682 
VR1012_oppA 7771 30.0 25.4     +       1.556 1.342 
VR1012_oppA 7773 27.5 24.4   + +   +   0.001 1.096 
VR1012_oppA 7775 28.6 22.2   + +       0.950 0.767 
VR1012_oppA 7776 28.5 32.4   +     +   0.867 0.328 
VR1012_oppA 7777 27.6 28.8             0.475 0.937 
 Mean weight  35.1 34.9    1.030 1.177 
Total Ms01/02/03 Infected ostriches  0 16 13 3 9 4 
Total infected ostriches per week 18 10 
Total infected ostriches 18
Control 7779 28.0 34.6     +     + 0.816 1.374 
Control 7780 31.6 32.6   + +       1.010 0.852 
Control 7781 27.5 30.0   + +   +   0.410 1.102 
Control 7782 30.5 26.8             0.251 2.044 
Control 7783 29.6 32.6     +       0.510 0.291 
Control 7784 32.6 34.8   + +       0.806 0.611 
Control 7785 28.6 29.0   + +   +   0.643 0.787 
Control 7787 31.2 27.8   + +   +   0.311 0.511 
Control 7788 34.2 36.8   + +   +   0.342 0.618 
Control 7789 21.4 22.8   + +       0.854 0.632 
Control 7790 30.2 18.4   + +       0.215 0.536 
Control 7791 27.4 26.2     +       1.414 1.466 
Control 7792 29.2 31.0             2.276 0.638 
Control 7795 25.8 24.6     +   +   1.231 1.797 
Control 7797 26.0 27.4     +       1.965 1.967 
Control 7798 27.2 30.0   +         0.912 0.637 
Control 7799 30.4 34.4   + +       1.759 1.662 
Control 7800 23.6 24.2   + +       1.750 0.684 
Control 7802 27.6 26.0     +       1.434 1.018 
Control 7803 25.6 26.0   + +       1.646 0.965 
Control 7805 28.6 29.6   + +       1.057 0.999 
Control 7806 - 24.0   + +       1.464 0.461 
Control 7807 - 28.2   +         0.908 0.384 
 Mean weight  28.4 28.6 1.043 0.958
Total Ms01/02/03 Infected ostriches  0 15 19 0 5 1 
Total infected ostriches per week 21 6 
Total infected ostriches 21 
 
 
  
Stellenbosch University  https://scholar.sun.ac.za
Appendix 5  
259 
 
Supplementary Table 5.2 ANOVA analysis of the weight data  
Source df SS MS F-value Pr> F 
Treatment 3 3241.832 1080.611 24.72 0.0000 
Time 1 70.104 70.104 1.60 0.2071 
Treatment by time 3 129.612 43.204 0.99 0.3997 
Residual 172 7519.021 43.715   
Total 179 10960.569    
Df  Degrees of freedom 
SS Sum of squares 
MS Mean of SS 
 
 
 
 
 
 
 
Supplementary Table 5.3 ANOVA analysis of the ELISA data  
Source df SS MS F-value Pr> F 
Treatments 3 4.166 1.389 3.59 0.0149 
Time 1 3.611 3.611 9.33 0.0026 
Treatments by time 3 3.224 1.075 2.78 0.0428 
Residual 172 66.545 0.387   
Total 179 77.547    
Df  Degrees of freedom 
SS Sum of squares 
MS Mean of SS 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 5.1 Average weight of the ostriches vaccinated with three different DNA vaccines containing 
the mutated oppA gene of M. nasistruthionis sp. nov. strain Ms03. Vaccinated ostriches received a single DNA 
vaccine dose (100 μg/ml) at week 0 and the control group did not receive any vaccine. Statistical parameters are 
indicated.  
25
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Week 0 Week 3
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pCI-neo_oppA
VR1012_oppA
VR1020_oppA
ControlLSD treatment
df Pr> F 
Treatments 3 0.000 
Time 1 0.2071 
Treatments by time 3 0.3997 
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